<?xml version="1.0" encoding="UTF-8" ?>
<rss version="2.0"
	xmlns:excerpt="http://wordpress.org/export/1.2/excerpt/"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:wp="http://wordpress.org/export/1.2/"
>

<channel> 
	<title>Compass</title>
	<link>http://localhost/wordpress</link>
	<description>Blah blah</description>
	<pubDate>Sun, 07 Feb 2016 14:06:19 +0000</pubDate>
	<language>en-US</language>
	<wp:wxr_version>1.2</wp:wxr_version>
	<wp:base_site_url>http://localhost/wordpress</wp:base_site_url>
	<wp:base_blog_url>http://localhost/wordpress</wp:base_blog_url>

	<wp:author>
		<wp:author_id>5</wp:author_id>
		<wp:author_login><![CDATA[spoon]]></wp:author_login>
		<wp:author_email><![CDATA[georges.guigui@spoonconsulting.com]]></wp:author_email>
		<wp:author_display_name><![CDATA[spoon]]></wp:author_display_name>
		<wp:author_first_name><![CDATA[]]></wp:author_first_name>
		<wp:author_last_name><![CDATA[]]></wp:author_last_name>
	</wp:author>

	
			<item>

	<title>Cortendo AB to Start Ph3 for Endogenous Cushing's Syndrome</title>
	<pubDate>2013-04-30T19:02:58+02:00</pubDate>
	<wp:post_id>3940</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: NormoCort (COR-003), the single 2S,4R enantiomer of ketoconazole, is to enter Ph3 in January next year.<wbr> PE will assess reduction in urinary free cortisol.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Recruitment: approx.<wbr> 90 </div><div style="margin-bottom: 10px;">Location: USA </div><div style="margin-bottom: 10px;">Completion date: January 2016 </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">During 2012 both the FDA and EMA granted COR-003 Orphan Drug Designation.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">NormoCort has an issued patent in Europe (EP 1853266B1) and a similar patent has been filed in the US.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Biopharmaceutical company headquartered in Göteborg, Sweden.<wbr> </div><div style="margin-bottom: 10px;">Its stock is publicly traded on the NOTC-A-list (OTC) in Norway.<wbr> </div><div><A href="http://www.cortendo.com/">http:/<wbr>/<wbr>www.<wbr>cortendo.<wbr>com/<wbr></A> </div><!-- Comment details --><span style="font-weight: bold; font-style: italic;"><br>Comments</span><a name="Endocrinology7775c"></a><br><div style="border: 1px solid #AAA; background-color: #FFF; margin-left: 10px; padding: 5px;"><div style="margin-bottom: 10px;">Last week Cortendo announced the enrollment of the first EU patient in the SONICS trial.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Investigator Meetings</STRONG> </div><div style="margin-bottom: 10px;">Cortendo successfully completed its European Investigator meeting supporting SONICS held in Barcelona, Spain on July 17-18.<wbr>  More than 35 investigators/<wbr>study coordinators, including many of the world&rsquo;s leading Cushing&rsquo;s experts from 24 study sites, were in attendance and received training for the trial.<wbr> Based on the positive feedback from the meeting, Cortendo has gained further confidence that NormoCort (COR-003) has the potential to be an important future treatment option for patients afflicted with Cushing&rsquo;s Syndrome.<wbr> </div><div style="margin-bottom: 10px;">A second US Investigator meeting is also being planned for later this year.<wbr> </div><div style="margin-bottom: 10px;">Cortendo has also further strengthened its internal as well as external teams to support the study and to position the trial for an increased recruitment rate.<wbr> In July, Cortendo added both an experienced physician and internal Clinical Operations Director to the NormoCort development team.<wbr> Cortendo, working in concert with its CROs supporting the SONICS trial, now has a team of approximately 20 personnel on the NormoCort development program.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Study Sites</STRONG> </div><div>The company has previously communicated its plan to meet the recruitment goal by increasing the number of study sites from 38 to 45 worldwide.<wbr> The company is at various levels of activation with more than 30 study sites to date.<wbr> Therein, Cortendo expects a large proportion of the sites to be activated by the end of the third quarter this year and remains confident that essentially all sites will be open by the end of 2014.<wbr> </div></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20130431&edate=20130101&rec=7330">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-04-30T19:02:58+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-04-30T19:02:58+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category endocrinology > <![CDATA[Endocrinology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Lousy First Quarter 2013 for Pfizer</title>
	<pubDate>2013-04-30T18:42:56+02:00</pubDate>
	<wp:post_id>3941</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Sales were hurt by weak demand of Prevnar 13 vaccine, Pfizer's third-biggest product, and generic medicines.<wbr> Management reported sales rose only 5% in emerging market (17% in the prior quarter).<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><UL><LI>WW Sales for the quarter decreased to $189M (vs $195M 1Q:12).<wbr></LI>
<LI>US Sales for the quarter increased to $47M (vs $41M 1Q:12).<wbr></LI>
</UL> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10429_1_ScreenCapture1.jpg"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10429_3_ScreenCapture3.jpg"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10429_2_ScreenCapture2.jpg"> </div><div><EM>Source: Pfizer</EM> </div><!-- Comment details --><a name="pharmaworld10429attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10429_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(34,4 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10429_2_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(64,8 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10429_3_ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(55,3 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20130431&edate=20130101&rec=10429">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-04-30T18:42:56+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-04-30T18:42:56+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category pharma-news > <![CDATA[Pharma News]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>FDA Says Allergan's Juvéderm Voluma XC Effective</title>
	<pubDate>2013-04-30T18:19:30+02:00</pubDate>
	<wp:post_id>3942</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Reviewers for the U.<wbr>S Agency said the dermal filler was effective in correcting volume deficit in the middle of the face at 6 months of treatment.<wbr> </div><div style="margin-bottom: 10px;">The reviewers said that if the filler was approved, the company should be required to do a post-approval study to test the safety of a repeat treatment.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Hyaluronic acid dermal fillers provide a smooth, long-lasting correction of moderate to severe facial wrinkles and folds.<wbr> </div><div>See @<a href="http://www.allergan.com/products/medical_aesthetics/juvederm.htm" class="defaultlink" title="http://www.allergan.com/products/medical_aesthetics/juvederm.htm">allergan.com/<wbr>prod&hellip;</a> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20130431&edate=20130101&rec=6988">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-04-30T18:19:30+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-04-30T18:19:30+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Valeant & Actavis Merger On Hold</title>
	<pubDate>2013-04-30T13:05:55+02:00</pubDate>
	<wp:post_id>3943</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: The potential merger of Valeant and Actavis is put on hold as negotiations break down </div><div style="margin-bottom: 10px;">A proposed merger of Valeant Pharmaceuticals International Inc.<wbr> and Actavis Inc.<wbr> was put on hold after the two drugmakers failed to agree on terms of a deal that would have created a healthcare giant with a combined market value of $35 billion.<wbr>  It seems the talks started to unravel this week due to disagreements on the proposed terms.<wbr> </div><div style="margin-bottom: 10px;">Earlier this month, Valeant and Actavis announced a partnership to release a series of generic drugs, and resolved patent disputes around two others.<wbr> </div><div style="margin-bottom: 10px;">Valeant has aggressively built up its dermatology and aesthetics portfolio in the United States in the past year, acquiring about a dozen assets or smaller companies, most recently winning a short bidding war with Merz for Obagi Medical Products.<wbr> </div><div style="margin-bottom: 10px;">Actavis, the third-largest global generic drugmaker, is itself the product of a merger.<wbr> The company changed its name in January from Watson after buying Actavis as part of its strategy to expand in international markets and offer more specialty drugs.<wbr> </div><div>If the deal is revived, it would mark one of the biggest healthcare transactions of the year.<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20130431&edate=20130101&rec=10428">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-04-30T13:05:55+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-04-30T13:05:55+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category pharma-news > <![CDATA[Pharma News]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Oncologists Rally At High Priced Cancer Drugs</title>
	<pubDate>2013-04-30T12:48:38+02:00</pubDate>
	<wp:post_id>3944</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Oncologists lash out at Pharmaceutical companies over high priced cancer drugs and are asking for discussions to be held in order to help stop the spiralling cost of cancer care.<wbr> </div><div style="margin-bottom: 10px;">A group of over 100 top global Oncologist (all experts in CML) have recently published a paper in the journal <EM>Blood, </EM>detailing astronomical price levels for Chronic Myeloid Leukemia drugs launched in 2012<EM>.<wbr>   </EM> </div><div style="margin-bottom: 10px;">They stated &ldquo;<EM>Of the 12 drugs approved by the FDA for various cancer indications in 2012, 11 were priced above $100,000 per year&hellip;cancer drug prices have almost doubled from a decade ago, from an average of $5,000 per month to more than $10,000 per month.<wbr>"</EM> </div><div style="margin-bottom: 10px;">Breakdown of drug cost for recent CML approvals: </div><div style="margin-bottom: 10px;"><UL><LI>bosutinib (Pfizer's Bosulif) at about $118,000 per year
</LI>
<LI>ponatinib (Ariad's Iclusig) at $138,000 per year
</LI>
<LI>omacetaxine (Teva's Synribo at $28,000 for induction and $14,000 per maintenance course
</LI>
</UL> </div><div style="margin-bottom: 10px;">
A key question posed in the paper is one around ethics and morals in so much as w<EM>hat determines a morally justifiable 'just price' for a cancer drug?</EM>  The Oncologists believe that unjustifiable prices are preventing many patients from accessing lifesaving drugs.<wbr> </div><div style="margin-bottom: 10px;">The Oncologists also called Novartis' imatinib (Gleevec/<wbr>Glivec) into question, outlining its initial price of around $30,000 although following its huge success the cost in the US has since tripled, even though Novartis has recouped its investment many times over.<wbr> </div><div style="margin-bottom: 10px;">The group were keen to state they understand that the drugs should be reasonably priced so that the companies involved can maintain healthy profits but should not be &lsquo;profiteering&rsquo; from them; likening this behaviour to raising commodity prices after natural disasters.<wbr> </div><div style="margin-bottom: 10px;">The rationale for publishing this paper is basically a call-to-action and to begin regular dialogue with all parties concerned to address the reasons behind the high prices and help offer solutions to solve these problems.<wbr> </div><div style="margin-bottom: 10px;">The authors of the latest paper have likely been inspired by oncologists from the Memorial Sloan-Kettering Cancer Center in New York, who last year openly stated that they would not stock Sanofi's Zaltrap at its initial launch price, which was double that of Avastin (which had almost the exact response rates as Zaltrap).<wbr> Sanofi quickly started offering a 50% discount to the price of Zaltrap.<wbr> </div><div>It will be interesting to see if a power shift occurs where prescribers might have more of a hand in dictating prices.<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20130431&edate=20130101&rec=8920">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-04-30T12:48:38+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-04-30T12:48:38+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>re: Therapy Area Landscapes - A New Traction Service</title>
	<pubDate>2013-04-30T08:58:16+02:00</pubDate>
	<wp:post_id>3945</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="border-left: 2px solid #8B1010; padding: 0px 0px 5px 12px; margin-bottom: 3px;"><span style="font-size: 12px;"><DIV class="i" id="pharmaworld7400.04i">
<DIV class="ii" id="pharmaworld7400.04ii">Comment: We would like to introduce you to a new concept within Traction, the so called "Therapy Area Landscapes" (TAL) This area has been designed to provide you with a distilled overview of the competitive landscape in each of our specialised therapy areas.<wbr> The links, which can be accessed through one of the "Traction Short-Cuts" on the right hand side of the Traction screen, will in time provide access to a presentation on each topic area; a presentation that will be regularly updated with new intelligence as and when it is received.<wbr> The first slide presentation will be on the acromegaly therapy area, however.<wbr> we hope to be in a position to provide a number of other TALs within a matter of weeks.<wbr></DIV>
</DIV></span>&nbsp;<br></div><div style="margin-bottom: 10px;">Very good initiative to gather info per TA, can we envisage one for Short Stature ? </div><div>If yes, can we liaise with our medical colleagues (Bruno Fiorentino &amp; Robin Kingswell) and Brigitte Deschamps to see how we can organize /<wbr> contribute to this possible TAL.<wbr> </div><!-- Comment details --><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20130431&edate=20130101&rec=10425">Add a Comment on this Article</a><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10099">View thread  PharmaWorld10099: Therapy Area Landscapes (TALs)</a>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-04-30T08:58:16+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-04-30T08:58:16+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category pharma-news > <![CDATA[Pharma News]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>The Changing Face of Teva</title>
	<pubDate>2013-04-29T16:05:50+02:00</pubDate>
	<wp:post_id>3946</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Newly created group to utilise strong locally-led Generics presence to leverage Teva's globally-based Specialty offering </div><div style="margin-bottom: 10px;">Teva has announced the creation of a global specialty medicines group to work in line with its regional teams, to expand the company beyond its roots as a generic drug manufacturer.<wbr> </div><div style="margin-bottom: 10px;">Dr.<wbr> Levin stated, " <EM>it combines the strong local presence we have established in high-quality and accessible generics with our global scale and capabilities in specialty medicines and will work seamlessly with our regional generics teams.<wbr>.<wbr>.<wbr>they will complement each other and establish a single, differentiated Teva presence in the market&hellip;the creation of this group is a stepping stone in our strategy to optimize our commercialization, and it paves the path forward to make Teva the most indispensable medicines company for the world.<wbr>"</EM> </div><div style="margin-bottom: 10px;">Dr.<wbr> Rob Koremans is appointed President and CEO of Global Specialty Medicines Group.<wbr> He has previously held senior positions at Grunenthal and Sanofi.<wbr> </div><div style="margin-bottom: 10px;">Teva's branded businesses focus on various therapy areas including: CNS, oncology, pain, respiratory and women's health, as well as biologics.<wbr> </div><div>Source: ScripIntelligence </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20130431&edate=20130101&rec=10423">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-04-29T16:05:50+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-04-29T16:05:50+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category pharma-news > <![CDATA[Pharma News]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>FDA Alerts HCP and the Public on Fraudulent Versions of Botox</title>
	<pubDate>2013-04-29T15:57:07+02:00</pubDate>
	<wp:post_id>3947</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: The company selling the fraudulent versions of Botox goes by the names "online Botox Pharmacy", "onlinebotox.<wbr>com", and "onlinebotox".<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">- the outer carton displays the API as "Botulinum Toxin Tye A" </div><div style="margin-bottom: 10px;">- the lot numbers and exp dates on the outer carton and accompanying vial do not match </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6987_1_ScreenCapture1.jpg"> </div><!-- Comment details --><a name="neurology6987attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6987_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(25,1 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20130431&edate=20130101&rec=6987">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-04-29T15:57:07+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-04-29T15:57:07+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>re: Therapy Area Landscapes - A New Traction Service</title>
	<pubDate>2013-04-28T08:45:39+02:00</pubDate>
	<wp:post_id>3948</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="border-left: 2px solid #8B1010; padding: 0px 0px 5px 12px; margin-bottom: 3px;"><span style="font-weight: bold; font-size: 14px;">Therapy Area Landscapes (TALs)</span>&nbsp;<br><span style="font-size: 12px;"><DIV class="i" id="pharmaworld7400.04i">
<DIV class="ii" id="pharmaworld7400.04ii">Comment: We would like to introduce you to a new concept within Traction, the so called "Therapy Area Landscapes" (TAL) This area has been designed to provide you with a distilled overview of the competitive landscape in each of our specialised therapy areas.<wbr> The links, which can be accessed through one of the "Traction Short-Cuts" on the right hand side of the Traction screen, will in time provide access to a presentation on each topic area; a presentation that will be regularly updated with new intelligence as and when it is received.<wbr> The first slide presentation will be on the acromegaly therapy area, however.<wbr> we hope to be in a position to provide a number of other TALs within a matter of weeks.<wbr></DIV>
</DIV></span>&nbsp;&nbsp;<a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20130431&edate=20130101&rec=10099">...</a><br></div><div>Thanks a lot for compiling all this  information.<wbr> This will be really useful for the countries during the SP exercice.<wbr> </div><!-- Comment details --><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20130431&edate=20130101&rec=10421">Add a Comment on this Article</a><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10099">View thread  PharmaWorld10099: Therapy Area Landscapes (TALs)</a>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-04-28T08:45:39+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-04-28T08:45:39+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category pharma-news > <![CDATA[Pharma News]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Pfenex Agila JV to Develop Biosimilars</title>
	<pubDate>2013-04-26T20:34:21+02:00</pubDate>
	<wp:post_id>3949</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Pfenex and Agila Biotech, one of India's fastest growing manufacturers and exporters of branded and generic finished pharmaceutical dosage forms, have entered into a JV to develop, manufacture and commercialize an initial pipeline of 6 biosimilar products for the global market.<wbr> The lead product for the JV is Interferon beta-1b, a biosimilar to Betaseron®, indicated for relapsing-remitting and secondary-progressive forms of multiple sclerosis, commencing human clinical trials by Q4 2013.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Both parties will equally share in decision making regarding product development and commercialization, Agila Biotech will be a 51% equity stakeholder.<wbr> </div><div style="margin-bottom: 10px;">This multi-product joint venture combines Pfenex’s industry-leading expertise in strain engineering and process development with Agila Biotech’s biologics manufacturing and clinical development excellence.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Pfenex will assume primary responsibility for development of  an optimized production strain, process and analytical package for each product </div><div style="margin-bottom: 10px;">Agila Biotech will be responsible for pre-clinical and Phase 1 development, as well as cGMP manufacturing.<wbr> </div><div style="margin-bottom: 10px;">The joint venture will then progress the products through Phase 3 and into commercialization.<wbr> </div><div style="margin-bottom: 10px;">Manufacture of the collaboration products will be carried out at Agila Biotech’s state-of-the-art manufacturing facility being built with Bio-XCell at Nusajaya, Johor, Malaysia – a 160 acre site comprised of customized biotech facilities.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10420_1_ScreenCapture1.jpg"> </div><!-- Comment details --><a name="pharmaworld10420attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10420_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(50,4 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20130431&edate=20130101&rec=10420">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-04-26T20:34:21+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-04-26T20:34:21+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category pharma-news > <![CDATA[Pharma News]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Orion Reports 1Q:13 Results & Ongoing Negotiations to Partner its Androgen Receptor Antagonist</title>
	<pubDate>2013-04-26T18:47:47+02:00</pubDate>
	<wp:post_id>3950</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Development of androgen receptor antagonist (ODM-201) for treatment of advanced prostate cancer is in Phase II clinical trials undertaken jointly with Endo Pharmaceuticals.<wbr> Negotiations to find a suitable partner for markets outside Europe and North America are ongoing.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">- Orion has completed preclinical studies with <U>another androgen receptor antagonist</U> molecule and another alpha-2c adrenoceptor antagonist molecule.<wbr> Progress of these drug candidates into clinical trials will depend on the results of the ongoing androgen receptor antagonist and alpha-2c adrenoceptor antagonist clinical trials.<wbr> </div><div style="margin-bottom: 10px;">- Early projects in Preclinical studies include: – Prostate cancer, neuropathic pain, Parkinson’s disease and Alzheimer’s disease.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10415_2_ScreenCapture2.jpg"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10415_1_ScreenCapture1.jpg"> </div><!-- Comment details --><a name="pharmaworld10415attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10415_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(39,6 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10415_2_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(76,3 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20130431&edate=20130101&rec=10415">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-04-26T18:47:47+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-04-26T18:47:47+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category pharma-news > <![CDATA[Pharma News]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Mayoly Spindler to Start New Study for Bowel Cleansing</title>
	<pubDate>2013-04-26T18:23:27+02:00</pubDate>
	<wp:post_id>3951</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: The purpose of this Ph3 is to evaluate the efficacy and safety of sodium phosphate tablets compared to split dose of 4 liters of PEG used in adults for bowel cleansing prior to colonoscopy.<wbr> Approx 448 participants will be recruited in four hospitals in France.<wbr> PE will assess overall quality of bowel cleansing.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG><A href="http://clinicaltrials.gov/ct2/show/NCT01840553?recr=Open&amp;no_unk=Y&amp;phase=012&amp;fund=2&amp;rcv_s=03%2F26%2F2013&amp;rank=90"><STRONG></STRONG></A> </div><div style="margin-bottom: 10px;">Start date: May 2013 Completion dates: Oct 2013 - Nov 2013 </div><div style="margin-bottom: 10px;">Protocol </div><div><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_gastroenterology_1882_1_ScreenCapture1.jpg"> </div><!-- Comment details --><a name="gastroenterology1882attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_gastroenterology_1882_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(60,8 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20130431&edate=20130101&rec=1882">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-04-26T18:23:27+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-04-26T18:23:27+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category gastroenterology > <![CDATA[gastroenterology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Humira Sales Propel AbbVie in 1Q:13</title>
	<pubDate>2013-04-26T15:56:40+02:00</pubDate>
	<wp:post_id>3952</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Alongside the financial results for the quarter, management outlined that elagolix for fibroid is poised to advance to Ph2b in 1H:13, and Ph3 in 2014.<wbr> Analysts at Morgan Stanley reported that the drug could cannibalize some of Lupron sales.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Humira is currently the most important drug to Abbvie, generating more than half of company sales (first patent expirations in 2016).<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><UL><LI>Worldwide sales were $4.<wbr>329 billion in the first quarter, up 3.<wbr>7%.<wbr></LI>
<LI>Net income of $968 million in the first quarter, compared to $883 million when the business was part of Abbott.<wbr></LI>
</UL> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10411_2_ScreenCapture2.jpg"> </div><!-- Comment details --><a name="pharmaworld10411attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10411_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(14 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10411_2_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(55,1 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20130431&edate=20130101&rec=10411">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-04-26T15:56:40+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-04-26T15:56:40+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category pharma-news > <![CDATA[Pharma News]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>EU Regulators Recommended Approval of Xtandi</title>
	<pubDate>2013-04-26T15:21:47+02:00</pubDate>
	<wp:post_id>3953</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Astellas and <ORG value="NASDAQ-NMS:MDVN">Medivation have received a positive opinion from the European Medicines Agency's </ORG><ORG>Committee for Medicinal Products for Human Use</ORG> (CHMP), recommending <ORG>European Commission</ORG> (EC) approval for XTANDI<SUP>®</SUP> (enzalutamide) capsules.<wbr> </div><div style="margin-bottom: 10px;">Recommendations for marketing approval by the EMA's Committee for Medicinal Products for Human Use (CHMP) are normally endorsed by the European Commission within a couple of months.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">- approval last August.<wbr> </div><div><EM>Source: ThomsonOne; Astellas/<wbr>Medivation</EM> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20130431&edate=20130101&rec=8917">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-04-26T15:21:47+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-04-26T15:21:47+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>re: OPKO Health to Acquire PROLOR for $480M</title>
	<pubDate>2013-04-25T18:08:42+02:00</pubDate>
	<wp:post_id>3954</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="border-left: 2px solid #8B1010; padding: 0px 0px 5px 12px; margin-bottom: 3px;"><span style="font-weight: bold; font-size: 14px;">OPKO Health to Acquire PROLOR for $480M</span>&nbsp;<br><span style="font-size: 12px;">Comment: With the acquisition of PROLOR, OPKO will expand its portfolio of specialty drugs with 4 significant products in development (for GHD, Hemophilia, obesity and diabetes).<wbr></span>&nbsp;&nbsp;<a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20130431&edate=20130101&rec=7327">...</a><br></div><div>PROLOR most advanced product, hGH-GTP, is slated to start Phase III testing this quarter in adults with growth hormone deficiency (GHD).<wbr> It has successfully completed four clinical trials, including a Phase II trial in adults with growth hormone deficiency (GHD).<wbr> </div><!-- Comment details --><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20130431&edate=20130101&rec=7328">Add a Comment on this Article</a><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7327">View thread  Endocrinology7327: OPKO Health to Acquire PROLOR for $480M</a>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-04-25T18:08:42+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-04-25T18:08:42+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category endocrinology > <![CDATA[Endocrinology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>AstraZeneca 1Q:13 Revenues in Decline</title>
	<pubDate>2013-04-25T17:02:03+02:00</pubDate>
	<wp:post_id>3955</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Revenues was $6,385M, down 12% due to loss of exclusivity for Seroquel IR and Atacand in many markets, and for Crestor in Canada.<wbr> Emerging markets revenue increased by 9%, largely driven by a 21% increase in China.<wbr> Zoladex, Arimidex and Casodex revenue decreased by 8%, 33% and 13% respectively.<wbr> </div><div style="margin-bottom: 10px;">Management started the presentation with 3 Clear Priorities </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8915_1_ScreenCapture1.jpg"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8915_2_ScreenCapture2.jpg"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8915_3_ScreenCapture3.jpg"> </div><!-- Comment details --><a name="oncology8915attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8915_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(52,3 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8915_2_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(17 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8915_3_ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(42,6 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20130431&edate=20130101&rec=8915">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-04-25T17:02:03+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-04-25T17:02:03+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Analysts Report China Onco Market to Quadruple by 2023</title>
	<pubDate>2013-04-25T16:22:07+02:00</pubDate>
	<wp:post_id>3956</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: In the 40-page report from Morgan Stanley, it is expected the China oncology market to reach $20bn by 2023.<wbr> Chemotherapy is now the largest class of cancer drug with &gt;80% share in China.<wbr> However, targeted therapies like mAbs and small molecules are growing faster than the overall market and is estimated to take &gt;40% market share by 2023 (vs.<wbr> 18% currently).<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">In the report, Sinobiopharm, CSPC Pharm and Hengrui are cited as top picks of the cancer treatment players.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8911_1_ScreenCapture1.jpg"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Driven by increasing prevalence of cancer, better diagnostics, surging sales of existing molecular targeted therapies, new product launches and better insurance coverage.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Deteriorating environment, high prevalence of smokers, rising alcohol consumption, unhealthy lifestyle and aging population.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8911_2_ScreenCapture2.jpg"> </div><div><STRONG>FULL REPORT</STRONG> available on demand to Brigitte Deschamps </div><!-- Comment details --><a name="oncology8911attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8911_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(40,5 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8911_2_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(127,2 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20130431&edate=20130101&rec=8911">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-04-25T16:22:07+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-04-25T16:22:07+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Management Reported 'Remarkable' Quarter for Biogen Idec</title>
	<pubDate>2013-04-25T15:56:20+02:00</pubDate>
	<wp:post_id>3957</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: For the 1Q:13, total revenues was +10% to $1.<wbr>4 billion, and +12% to $1,09 billion for product revenues.<wbr> Cost of goods represented 9% of revenue, and R&amp;D expense 20%.<wbr> Management highlighted key event of the quarter being the launch of Tecfidera (relapsing forms of MS) in the US, the reacquisition from Elan of the full ownership of Tysabri, and the advance of its late-stage hemophilia drugs.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10409_4_ScreenCapture4.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10409_1_ScreenCapture1.jpg"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10409_2_ScreenCapture2.jpg"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10409_3_ScreenCapture3.jpg"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div><STRONG></STRONG> </div><!-- Comment details --><a name="pharmaworld10409attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10409_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(33,9 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10409_2_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(68,1 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10409_3_ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(59,6 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10409_4_ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(63 KB)<br>&nbsp;&nbsp;5.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10409_5_ScreenCapture5.jpg">ScreenCapture5.jpg</a>&nbsp;&nbsp;(105,5 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20130431&edate=20130101&rec=10409">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-04-25T15:56:20+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-04-25T15:56:20+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category pharma-news > <![CDATA[Pharma News]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Amgen's Q1 2013 Highlight's</title>
	<pubDate>2013-04-25T15:04:40+02:00</pubDate>
	<wp:post_id>3958</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;"><P style="TEXT-TRANSFORM: none; TEXT-INDENT: 0px; FONT: 12px/18px 'Lucida Grande', 'Helvetica Neue', Arial, Helvetica, sans-serif; WHITE-SPACE: normal; LETTER-SPACING: normal; COLOR: rgb(0,0,0); WORD-SPACING: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"></P> </div><div style="margin-bottom: 10px;"><P style="TEXT-TRANSFORM: none; TEXT-INDENT: 0px; FONT: 12px/18px 'Lucida Grande', 'Helvetica Neue', Arial, Helvetica, sans-serif; WHITE-SPACE: normal; LETTER-SPACING: normal; COLOR: rgb(0,0,0); WORD-SPACING: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"></P> </div><div style="margin-bottom: 10px;"><P style="TEXT-TRANSFORM: none; TEXT-INDENT: 0px; FONT: 12px/18px 'Lucida Grande', 'Helvetica Neue', Arial, Helvetica, sans-serif; WHITE-SPACE: normal; LETTER-SPACING: normal; COLOR: rgb(0,0,0); WORD-SPACING: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"></P> </div><div style="margin-bottom: 10px;"><P style="TEXT-TRANSFORM: none; TEXT-INDENT: 0px; FONT: 12px/18px 'Lucida Grande', 'Helvetica Neue', Arial, Helvetica, sans-serif; WHITE-SPACE: normal; LETTER-SPACING: normal; COLOR: rgb(0,0,0); WORD-SPACING: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"><SPAN style="LINE-HEIGHT: 1.5em"></SPAN></P> </div><div style="margin-bottom: 10px;"><P style="TEXT-TRANSFORM: none; TEXT-INDENT: 0px; FONT: 12px/18px 'Lucida Grande', 'Helvetica Neue', Arial, Helvetica, sans-serif; WHITE-SPACE: normal; LETTER-SPACING: normal; COLOR: rgb(0,0,0); WORD-SPACING: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"><STRONG></STRONG></P> </div><div style="margin-bottom: 10px;"><P style="TEXT-TRANSFORM: none; TEXT-INDENT: 0px; FONT: 12px/18px 'Lucida Grande', 'Helvetica Neue', Arial, Helvetica, sans-serif; WHITE-SPACE: normal; LETTER-SPACING: normal; COLOR: rgb(0,0,0); WORD-SPACING: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8910_1_ScreenCapture1.jpg"></P> </div><div style="margin-bottom: 10px;"><P style="TEXT-TRANSFORM: none; TEXT-INDENT: 0px; FONT: 12px/18px 'Lucida Grande', 'Helvetica Neue', Arial, Helvetica, sans-serif; WHITE-SPACE: normal; LETTER-SPACING: normal; COLOR: rgb(0,0,0); WORD-SPACING: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"></P> </div><div><P style="TEXT-TRANSFORM: none; TEXT-INDENT: 0px; FONT: 12px/18px 'Lucida Grande', 'Helvetica Neue', Arial, Helvetica, sans-serif; WHITE-SPACE: normal; LETTER-SPACING: normal; COLOR: rgb(0,0,0); WORD-SPACING: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px">, </P> </div><!-- Comment details --><a name="oncology8910attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8910_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(44,7 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20130431&edate=20130101&rec=8910">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-04-25T15:04:40+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-04-25T15:04:40+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Highlights of Leerink Swann's 1Q:13 Cosmetic Survey Results</title>
	<pubDate>2013-04-25T13:52:40+02:00</pubDate>
	<wp:post_id>3959</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: The survey polled 30 U.<wbr><WBR></WBR><WBR>S based dermatologists and 30 plastic surgeons.<wbr> Respondents still expect Botox to capture &gt;70%+ of the overall market in 2015.<wbr> Survey results suggest low share losses for Botox, modest gains for Xeomin, and flattening Dysport share.<wbr> Topical Botulinum Toxin, and Belotero (for fine lines correction) hold highest new product interest among Physicians.<wbr></WBR> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6984_1_ScreenCapture1.jpg"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6984_3_ScreenCapture3.jpg"> </div><div><STRONG></STRONG> </div><!-- Comment details --><a name="neurology6984attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6984_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(43,4 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6984_2_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(60,4 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6984_3_ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(69,9 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20130431&edate=20130101&rec=6984">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-04-25T13:52:40+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-04-25T13:52:40+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Anterios Financed Further Clinical Development of its Topical BoNT-A</title>
	<pubDate>2013-04-25T13:11:50+02:00</pubDate>
	<wp:post_id>3960</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: The company has reported closing $8.<wbr>5M in corporate financing.<wbr> Indications pursued for ANT-1207 include lateral canthal lines (LCL), hyperhidrosis and acne.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">ANT-1207 is a lotion that takes five to ten minutes to apply in the physician's office, where it is fully massaged into the skin.<wbr> </div><div style="margin-bottom: 10px;">ANT-1207 does not require reconstitution in the physician's office prior to use, making it convenient and time-saving for the physician and the physician's staff.<wbr> </div><div style="margin-bottom: 10px;">ANT-1207 incorporates a highly purified botulinum developed from Anterios' proprietary cell line of <I>C.<wbr> Botulinum Type A</I>.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div>Please see <a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20130431&edate=20130101&rec=6922" class="defaultlink">Neurology6922: Revance Therapeutics Secures Financing For PhIII BoNT-A Trials</a>.<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20130431&edate=20130101&rec=6981">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-04-25T13:11:50+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-04-25T13:11:50+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>OPKO Health to Acquire PROLOR for $480M</title>
	<pubDate>2013-04-24T18:38:14+02:00</pubDate>
	<wp:post_id>3961</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: With the acquisition of PROLOR, OPKO will expand its portfolio of specialty drugs with 4 significant products in development (for GHD, Hemophilia, obesity and diabetes).<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">$7.<wbr>00 per PROLOR shares </div><div style="margin-bottom: 10px;">Expected to close in H2:13.<wbr> </div><div style="margin-bottom: 10px;">Represents a 20% premium to PROLOR's Tuesday close on Amex of $5.<wbr>83.<wbr> </div><div style="margin-bottom: 10px;"><A href="http://www.opko.com/"><STRONG></STRONG></A><STRONG></STRONG> </div><div><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7327_1_ScreenCapture1.jpg"> </div><!-- Comment details --><span style="font-weight: bold; font-style: italic;"><br>Comments</span><a name="Endocrinology7328c"></a><br><div style="border: 1px solid #AAA; background-color: #FFF; margin-left: 10px; padding: 5px;"><div>PROLOR most advanced product, hGH-GTP, is slated to start Phase III testing this quarter in adults with growth hormone deficiency (GHD).<wbr> It has successfully completed four clinical trials, including a Phase II trial in adults with growth hormone deficiency (GHD).<wbr> </div></div><a name="endocrinology7327attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7327_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(78,7 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20130431&edate=20130101&rec=7327">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-04-24T18:38:14+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-04-24T18:38:14+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category endocrinology > <![CDATA[Endocrinology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>New Avenues to Treat Cancer</title>
	<pubDate>2013-04-24T18:24:07+02:00</pubDate>
	<wp:post_id>3962</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Small British company, <A href="http://www.advancedoncotherapy.com/">Advanced Oncotherapy </A>has acquired Adam, a CERN spin-off business developing new forms of radiotherapy to fight tumours.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Adam, was established in 2007 by CERN, the European Organisation for Nuclear Research, to build low-cost innovative accelerators for <A href="http://www.advancedoncotherapy.com/ONCprotonbeam.aspx">proton beam therapy </A>(PBT) and conventional radiotherapy.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">PBT can blast tumours without damage to surrounding tissue - a particular benefit when cancer occurs in the brain, spine or eyes.<wbr> </div><div style="margin-bottom: 10px;">Protons are fundamental particles found inside the atomic nucleus and can be focused much more accurately than X-rays.<wbr> The big problem is that the large accelerators needed to make them are very expensive, raising questions over cost-effectiveness.<wbr> </div><div>In future, scientists at CERN believe they can make them far more cheaply by using a new kind of linear accelerator.<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20130431&edate=20130101&rec=8909">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-04-24T18:24:07+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-04-24T18:24:07+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Novartis Announces New CFO Alongside Q1:13 Results</title>
	<pubDate>2013-04-24T18:12:43+02:00</pubDate>
	<wp:post_id>3963</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Harry Kirsch has been promoted CFO and will replace Jonathan Symonds, who will become an advisor to the CEO until the end of the year.<wbr> Novartis expects 2013 to be a year of transition.<wbr> It is counting on sales of new products, such as Afinitor and Gilenya, to help the decline of Diovan sales.<wbr> Emerging markets growth was lerd by China (+21%), India (+14%) and Russia (+33%).<wbr> Outlook for 2013 remains unchanged.<wbr> Selected slides are provided below.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Kirsch, 48, chief financial officer (CFO) of Novartis' pharmaceuticals unit who was previously CFO at Proctor &amp; Gamble's pharmaceutical business, had increased the division's core operating income in every quarter of 2011 and 2012 despite the loss of patents on top drugs.<wbr> </div><div style="margin-bottom: 10px;">To quote Joe Jimenez: " .<wbr>.<wbr>.<wbr> And one of the reasons why Harry got this job is his focus on productivity and also his execution skills.<wbr> Jon's brought a focus on productivity that we are absolutely going to continue, and Harry will continue in that tradition.<wbr> He's been able to generate margin improvement in the Pharma Division even at a time when they faced generic competition, so he'll be able to bring that to the entire group".<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10405_1_ScreenCapture1.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10405_2_ScreenCapture2.jpg"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10405_3_ScreenCapture3.jpg"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10405_4_ScreenCapture4.jpg"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><STRONG>Biosimilar or BLA pathway ?</STRONG> - Head of the Sandoz Division outlined " .<wbr>.<wbr>.<wbr> we plan on using whatever pathway makes the most sense for Novartis, be it the BLA pathway or the new biosimilar pathway.<wbr> And we'll make those decisions on a case-by-case basis".<wbr> </div><div><STRONG>Multiple Sclerosis</STRONG> - Management reported : " .<wbr>.<wbr>.<wbr> BAF312, follow-on to Gilenya being studied in secondary progressive MS which would be a whole new opportunity for us.<wbr> In addition, we are doing work to show that with an appropriate titration study that you can avoid a first dose observation period which we think would make this an attractive alternative to Gilenya.<wbr> I think you also asked me about how much more growth there can be ex-US for the brand.<wbr> And the answer is a lot.<wbr> We think ex-US will be a key driver of the expansion of this product.<wbr> There is still a lot of interferons and Copaxone to replace.<wbr> And I truly believe that an oral product will become a very, very attractive way to go.<wbr> We think the overall MS market worldwide could reach as much as $16 billion in a few years time and as much as half of that, maybe even a bit more, could be oral medicines".<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20130431&edate=20130101&rec=10405">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-04-24T18:12:43+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-04-24T18:12:43+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category pharma-news > <![CDATA[Pharma News]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Alliance agreement between Roche Genentech and French Institu Gustave Roussy</title>
	<pubDate>2013-04-24T16:26:47+02:00</pubDate>
	<wp:post_id>3964</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment  : The alliance objectives are related to the development of new molecules against the cancer and associated biomarkers, the increase of the number of clinical trials in exploratory phases (I and II).<wbr> The agreement is about 14 ongoing or ready to start trials.<wbr> </div><div style="margin-bottom: 10px;">"It is the first time we sign an agreement of this type outside the United States" said Stuart Lutzker, <SPAN style="line-height: 1.5em;">Vice President BioOncology Exploratory Clinical </SPAN><SPAN style="line-height: 1.5em;">Development of Genentech.<wbr> </SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="line-height: 1.5em;">"The main mission of the SITEP is to offer to the patients fast access to innovative, promising molecules, but which still not have a marketing authorization ", specifies Pr Jean-Charles Soria, SITEP manager.<wbr> For him, the exploratory trials are going to become " the pillar essential to the implementation of the personalized medicine ".<wbr></SPAN> </div><div><SPAN style="line-height: 1.5em;">See <a href="http://www.igr.fr/index.php?p_m=igrinter&amp;p_id=5519" class="defaultlink" title="http://www.igr.fr/index.php?p_m=igrinter&amp;amp;p_id=5519">igr.fr/<wbr>index.php?&hellip;</a></SPAN> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20130431&edate=20130101&rec=8908">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-04-24T16:26:47+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-04-24T16:26:47+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>FDA launches Patient Network website</title>
	<pubDate>2013-04-24T14:16:02+02:00</pubDate>
	<wp:post_id>3965</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment : FDA launched the Patient Network <A href="http://pub.biocentury.com/c.html?ufl=5&amp;rtr=on&amp;s=x8pb1d,1gjb1,7y8,c9ep,fnqe,7wh9,j795" target="_blank">website</A> through which the public can apply to become a patient representative, comment on FDA regulations, report adverse events and attend FDA webinars.<wbr> A calendar of FDA's public meetings is also available on the site </div><div style="margin-bottom: 10px;">Margaret A.<wbr> Hamburg, M.<wbr>D.<wbr>, FDA commissioner, noted that since the early 1990s, FDA has been working with patients and patient advocates to educate them about how medical products are developed and regulated.<wbr> Patient representatives also participate in FDA advisory meetings.<wbr> "When patients better understand the intricacies of how medical products are studied, reviewed, assessed and brought to market, their input will be that much more focused and valuable.<wbr> We hope, with the launch of this new web site, to expand the role of patients beyond the select group of patient representatives and to engage a wider audience of patients in new and broader ways.<wbr>" she added.<wbr> </div><div>See <a href="http://www.patientnetwork.fda.gov/" class="defaultlink" title="http://www.patientnetwork.fda.gov/">patientnetwork.fd&hellip;</a> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20130431&edate=20130101&rec=10404">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-04-24T14:16:02+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-04-24T14:16:02+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category pharma-news > <![CDATA[Pharma News]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Business Unit Set Up To Change At Roche</title>
	<pubDate>2013-04-23T17:14:28+02:00</pubDate>
	<wp:post_id>3966</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Roche to change Applied Science business structure and morph it into other Diagnostic Business Areas.<wbr> </div><div style="margin-bottom: 10px;">Roche today announced changes to the management and set-up of its life-science business.<wbr> The Applied Science Business Area will be dissolved and its portfolio of products integrated within Roche’s other Diagnostics Business Areas.<wbr> These measures have been taken to ensure sustained success in a fast-changing market environment.<wbr> </div><div style="margin-bottom: 10px;">The changes are expected to affect approximately 110 positions in Penzberg (Germany) and 60 positions in Branford (Connecticut, USA).<wbr> </div><div style="margin-bottom: 10px;">Following assessment of its sequencing R&amp;D portfolio: </div><div style="margin-bottom: 10px;"><UL><LI>Roche has decided to return the ISFET project for the development of a semiconductor-based sequencing system to DNA Electronics </LI>
<LI>Roche has also ended its partnership with IBM for the development of a nanopore-based </LI>
</UL> </div><div style="margin-bottom: 10px;">Applied Science was made up of two key product areas: polymerase chain reaction technology (PCR) and nucleic acid product lines (NAP) which now overlaps with the division’s Molecular Diagnostics and Professional Diagnostics Business Areas.<wbr> Roche’s Custom Biotech portfolio also faces the same issue.<wbr> </div><div style="margin-bottom: 10px;">To address this, Roche plans to implement the following organisational changes: </div><div><UL><LI>PCR technology and NAP will in future be managed by Roche Molecular Diagnostics.<wbr> This includes real-time PCR and nucleic acid purification platforms and reagents, as well as nucleic acid-related biochemical reagents.<wbr> </LI>
<LI>The Custom Biotech portfolio, which includes platforms and reagents that are more closely aligned with Roche’s clinical chemistry portfolio, will move to Roche Professional Diagnostics.<wbr> </LI>
<LI>A dedicated unit will be established to focus solely on sequencing.<wbr> This unit will be tasked with implementing a sequencing strategy from life-science research to clinical diagnostics, explore internal and external opportunities that can provide customers with differentiated products, and will also manage Roche’s existing sequencing business.<wbr> </LI>
<LI>As a consequence, the Applied Science business area will be dissolved as of the end of 2013.<wbr> </LI>
</UL> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20130431&edate=20130101&rec=10402">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-04-23T17:14:28+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-04-23T17:14:28+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category pharma-news > <![CDATA[Pharma News]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>GSK & Avalon Join Forces to Fund Start-Ups</title>
	<pubDate>2013-04-23T16:10:04+02:00</pubDate>
	<wp:post_id>3967</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;"><SPAN style="LINE-HEIGHT: 1.5em">Comment: GSK and Avalon to fund up to 10 start-ups which could turn into potential GSK acquisition targets.<wbr></SPAN> </div><div style="margin-bottom: 10px;">In a deal meant to address the lack of funding for early-stage biotechnology companies, GlaxoSmithKline has committed up to $465 million which has been bolstered by $30 million from Avalon Ventures to finance about 10 start-ups.<wbr> </div><div style="margin-bottom: 10px;">A joint committee, drawing on each companies individual expertise has been set up in order to review ‘start-up worthy’ technology identified by Avalon.<wbr> </div><div style="margin-bottom: 10px;">GSK will have an option to buy each funded company in return for pre-clinical and clinical milestone payments; and Avalon will retain ownership of any start-up that isn't acquired.<wbr> </div><div style="margin-bottom: 10px;">GSK stated that although Avalon is based in San Diego USA, they are looking for targets worldwide.<wbr> </div><div>The announcement has been welcomed by the biotech industry during this cash-strapped time; especially after the recently published statistics from the National Venture Capital Association and PricewaterhouseCoopers detailing that first-quarter 2013 venture financings for life science companies and first-time funding rounds for early-stage biotech and medical device firms plummeted during the first three quarters of the year.<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20130431&edate=20130101&rec=10400">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-04-23T16:10:04+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-04-23T16:10:04+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category pharma-news > <![CDATA[Pharma News]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Value of Dipraglurant Franchise Enhanced by New Patent</title>
	<pubDate>2013-04-23T13:33:54+02:00</pubDate>
	<wp:post_id>3968</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: The European Patent Office granted Addex a broad composition of matter patent (European patent, EP 1 765 795) covering dipraglurant and other mGlu5 negative allosteric modulators (NAM).<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Dipraglurant is currently in development for the treatment of levodopa-induced dyskinesia in Parkinson’s disease patients as well as rare forms of dystonia.<wbr> </div><div><EM>Source: Addex Pharm</EM> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20130431&edate=20130101&rec=6980">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-04-23T13:33:54+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-04-23T13:33:54+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>GPR17 Antagonists May Reverse Multiple Sclerosis Degeneration</title>
	<pubDate>2013-04-23T11:21:47+02:00</pubDate>
	<wp:post_id>3969</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Omeros’ proprietary GPR17 antagonists’ treatment may restore myelin and improve function in a MS mouse model.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Using a common mouse model for multiple sclerosis (experimental autoimmune encephalomyelitis, EAE), treatment with Omeros’ proprietary GPR17 antagonists improved function and previously disclosed that treatment generates mature oligodendrocytes which produce myelin.<wbr> </div><div style="margin-bottom: 10px;">These early preclinical results suggest Omeros' has discovered compounds which may reverse the disease process of multiple sclerosis.<wbr> If they can replicate this in the clinic, in our view it would be the first truly disease modifying (versus reducing inflammation and slowing progression) and could become a potentially curative treatment for MS.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div>It will probably take a couple of years to get into the clinic; however, Omeros could monetize GPR17 antagonists by out-licensing the program.<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20130431&edate=20130101&rec=6978">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-04-23T11:21:47+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-04-23T11:21:47+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Europe's regulator warns over risks of unauthorised stem cell therapies</title>
	<pubDate>2013-04-23T10:57:06+02:00</pubDate>
	<wp:post_id>3970</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment : Europe's regulator on Monday urged governments to ensure stem cell therapies are properly regulated, following the Italian government's decision to allow an unauthorised stem cell treatment to be used in critically ill patients.<wbr> </div><div style="margin-bottom: 10px;">In an official statement from the International Society for Stem Cell Research, of which he is the president, Nobel prizewinner Yamanaka is said to have explained that developments in Italy have raised concern in the scientific community.<wbr> The health minister has given special permission for patients with rare diseases to be treated with mesenchymal stem cells despite a lack of any clinical data about the therapy.<wbr> </div><div style="margin-bottom: 10px;">Scientific journal Nature has strongly criticised the Vatican and parliament for Italy's divergent policy on stem cell therapies.<wbr> Nature said that parliament should have taken expert advice before "deregulating" stem cell therapies.<wbr> </div><div style="margin-bottom: 10px;">In its statement, the EMA points out that rules introduced in 2007 ensure medicines involving stem cell therapy are subject to appropriate authorisation, supervisation and controls to reduce and manage risks.<wbr><BR>Protection of patients is at the core of the EMA's rules and quality and manufacturing rules are set out in good manufacturing practices (GMP) requirements, while security and control of stem cell mechanisms are governed by EU advanced therapy legislation, according to the statement.<wbr><BR><BR>Source : APM International, April 22 </div><div>See also this week' s Nature Editorial article : <BR><SPAN style="line-height: 1.5em;"><a href="http://www.nature.com/news/smoke-and-mirrors-1.12805" class="defaultlink" title="http://www.nature.com/news/smoke-and-mirrors-1.12805">nature.com/<wbr>news/<wbr>s&hellip;</a></SPAN> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20130431&edate=20130101&rec=10398">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-04-23T10:57:06+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-04-23T10:57:06+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category pharma-news > <![CDATA[Pharma News]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>European Commission hails progress on market access discussions</title>
	<pubDate>2013-04-23T10:17:40+02:00</pubDate>
	<wp:post_id>3971</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment : An European Commission group has produced a question and answer document providing information on the concept of biosimilars for patients, health professionals and pricing and reimbursement authorities.<wbr> The document is entitled <SPAN style="line-height: 1.5em;">"Consensus Information Paper 2013.<wbr> What you need to know about Biosimilar Medicinal Products"</SPAN> </div><div style="margin-bottom: 10px;">The project is part of the 'Process on Corporate Responsibility' in the field of Pharmaceuticals, launched in September 2010.<wbr><BR><SPAN style="line-height: 1.5em;">According to this </SPAN><A href="http://pub.biocentury.com/c.html?ufl=5&amp;rtr=on&amp;s=x8pb1d,1ggpn,7y8,jntb,k7ns,7wh9,j795" style="line-height: 1.5em;" target="_blank">report</A><SPAN style="line-height: 1.5em;"> , presented Tuesday at the BIO International Convention, biosimilars are increasing competition and helping to stabilize healthcare costs.<wbr> The report notes that as biosimilars volume has grown, reference products have maintained volume, but their sales have declined.<wbr> </SPAN> </div><div style="margin-bottom: 10px;">The document cites IMS data for the 12-month period ended June 2011 that show biosimilar sales had reached EUR 240 million ($313.<wbr>7 million), a 55% increase over the prior 12-month period.<wbr> Sales of reference products declined 7% and sales of off-patent biologics that have not been copied grew 2%.<wbr> The data include sales for the three classes of biosimilars available in the EU: recombinant human growth hormone (hGH), erythropoietin (EPO) and granulocyte-colony stimulating factor (G-CSF).<wbr> </div><div style="margin-bottom: 10px;"><SPAN style="line-height: 1.5em;">Work on market access was split into five sub-groups :</SPAN> </div><div style="margin-bottom: 10px;"><P style="padding-left: 30px;">A sub-group co-chaired by Belgium was working on a mechanism of coordinated access to orphan medical products<BR><SPAN style="line-height: 1.5em;">Another sub-group co-chaired by Slovenia discussed supply of drugs in small markets and <BR>a further sub-group discussing managed entry agreements for innovative medicines was co-chaired by Italy <BR></SPAN><SPAN style="line-height: 1.5em;">A UK-authored report on good governance for non-prescription drugs co-chaired by acknowledged the "significant role" these played in self-care.<wbr></SPAN><SPAN style="line-height: 1.5em;">A sub-group discussing market access for biosimilars co-chaired by Denmark was praised by branded pharma.<wbr></SPAN></P> </div><div style="margin-bottom: 10px;">Sources : APM International, April, 19; Biocentury Extra for Monday, April 22, 2013 </div><div>See <A href="http://ec.europa.eu/enterprise/sectors/healthcare/files/docs/biosimilars_report_en.pdf">http:/<wbr>/<wbr>ec.<wbr>europa.<wbr>eu/<wbr>enterprise/<wbr>sectors/<wbr>healthcare/<wbr>files/<wbr>docs/<wbr>biosimilars_report_en.<wbr>pdf</A> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20130431&edate=20130101&rec=10396">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-04-23T10:17:40+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-04-23T10:17:40+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category pharma-news > <![CDATA[Pharma News]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Specialist UK cancer R&D fund makes first investment in MPS1 inhibitors</title>
	<pubDate>2013-04-23T09:52:51+02:00</pubDate>
	<wp:post_id>3972</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment : Cancer Research Technology said in a statement that its 50 million pounds (58.<wbr>4 million euros) Pioneer Fund (CPF) made its first investment in a "promising" class of drugs called MPS1 inhibitors.<wbr> </div><div style="margin-bottom: 10px;"><SPAN style="line-height: 1.5em;">These belong to a family of proteins called mitotic checkpoint kinases, responsible for correctly organising cell division, which fuel growth of cancer when faulty and are present in many types of tumours, including breast and prostate.<wbr></SPAN> </div><div style="margin-bottom: 10px;">Cancer Research Technology is a UK fund, designed to bridge the gap between drug discovery and early stage clinical development.<wbr> Cancer Research UK has created the fund in partnership with the European Investment Fund and appointed Sixth Element Capital to manage it.<wbr> </div><div style="margin-bottom: 10px;">Source : APM, April 26 </div><div>See <A class="lienAPM" href="http://www.cancertechnology.co.uk/" target="_blank">www.<wbr>cancertechnology.<wbr>co.<wbr>uk/<wbr></A> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20130431&edate=20130101&rec=10393">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-04-23T09:52:51+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-04-23T09:52:51+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category pharma-news > <![CDATA[Pharma News]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Biosimilar Development Remains Challenging</title>
	<pubDate>2013-04-22T15:09:14+02:00</pubDate>
	<wp:post_id>3973</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;"><SPAN style="line-height: 1.5em;">Comment:  Another company may cancel its development programme for a biosimilar, highlighting the difficultly in developing and launching these products.<wbr></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="line-height: 1.5em;">The South Korea-based biotech Celltrion</SPAN><A href="http://www.fiercebiotech.com/tags/celltrion-0" style="line-height: 1.5em;"></A><SPAN style="line-height: 1.5em;"> has terminated the phase III trial of its biosimilar development candidate CT-P10, a copy of Roche&rsquo;s Rituxan.<wbr></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="line-height: 1.5em;">However, Celltrion and its partner H</SPAN>ospira<SPAN style="line-height: 1.5em;"> might only be delayed in their pursuit, as Celltrion has issued a statement saying that it plans to push ahead with late-stage development later in 2013, but gave no further explanation as to why they cancelled the trial.<wbr></SPAN> </div><div style="margin-bottom: 10px;">An RBC analyst commented "<EM>The biosimilar opportunity for Hospira has been a tenet of the bull thesis, as management has touted that Hospira has 11 biosimilar molecules under development that target $40 billion of branded value&hellip;if the trial was terminated due to complications, it would validate our view that developing biosimilars is very difficult and complex, and may not lead to scientific, regulatory, or commercial success.<wbr>"</EM> </div><div style="margin-bottom: 10px;">Teva and Samsung have also fallen by the wayside with their own development of a biosimilar Rituxan last year amid uncertainty in regulation in the U.<wbr>S.<wbr> and expensive development requirements.<wbr> As we know, the upfront investment for these programs can easily dwarf the expense of a small molecule generic before it hits the market.<wbr> </div><div style="margin-bottom: 10px;">This is just another story showing that to get a biosimilar to market, generics players must clear a gauntlet of regulatory, development, manufacturing and marketing obstacles.<wbr> </div><div>Sandoz and Boehringer Ingelheim are still in the game with their own independent Rituxan biosimilar programmes.<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20130431&edate=20130101&rec=10392">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-04-22T15:09:14+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-04-22T15:09:14+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category pharma-news > <![CDATA[Pharma News]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>AZ & BIND Therapeutics Announce Worldwide Development & Commercialisation Agreement For Cancer Nanomedicine</title>
	<pubDate>2013-04-22T12:58:58+02:00</pubDate>
	<wp:post_id>3974</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: AZ and BIND Therapeutics have entered into partnership, further cementing AZ position in personalised cancer treatments </div><div style="margin-bottom: 10px;">AstraZeneca and BIND Therapeutics announced today that they have entered into a strategic collaboration to develop and commercialise an Accurin&trade;, a targeted and programmable cancer nanomedicine from BIND&rsquo;s Medicinal Nanoengineering platform, based on a molecularly targeted kinase inhibitor developed and owned by AstraZeneca.<wbr> </div><div style="margin-bottom: 10px;">Susan Galbraith, Head of AstraZeneca&rsquo;s Oncology Innovative Medicines Unit stated &ldquo;Our oncology teams are actively exploring a range of platforms to deliver targeted therapies, with a strategic focus on unlocking the significant potential of nanoparticles in cancer treatment.<wbr> We view BIND&rsquo;s targeted nanomedicines as a leading technology in this field.<wbr>&rdquo; </div><div style="margin-bottom: 10px;">BIND develops Accurins that outperform conventional drugs by selectively accumulating in diseased tissues and cells.<wbr> The result is higher drug concentrations at the site of action with minimal off-target exposure, leading to markedly better efficacy and safety.<wbr> </div><div style="margin-bottom: 10px;">AstraZeneca has agreed to pay BIND upfront and pre-approval milestone fees of $69 million, plus $130 million in payments tied to regulatory and sales goals for the lead candidate.<wbr> </div><div style="margin-bottom: 10px;">BIND has had a busy 2013, teaming up with a number of big players including Pfizer and Amgen.<wbr> Bind also attracted an additional $20million from its investors to further fund Phase II work on its docetaxel-carrying nanotech drug, BIND-014.<wbr> </div><div>Currently, BIND is working in the areas of oncology, inflammatory diseases and cardiovascular disorders.<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20130431&edate=20130101&rec=8906">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-04-22T12:58:58+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-04-22T12:58:58+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Tekmira to Initiate POC Study of TKM-PLK1 in Previously Treated GI-NET</title>
	<pubDate>2013-04-19T19:17:24+02:00</pubDate>
	<wp:post_id>3975</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Tekmira reported Ph1 data at <A href="http://investor.tekmirapharm.com/releasedetail.cfm?ReleaseID=755333">AACR</A> showing treatment response among four of nine evaluable patients.<wbr> Two of the responsers had GI neuroendocrine tumours (GI-NET), prompting the company to plan a Ph2 trial in this indication in H2:13.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Tekmira has decided to initiate a Phase II study of TKM-PLK1 in previously treated GI-NET in H213.<wbr> </div><div style="margin-bottom: 10px;">While the response rate seen thus far in GI-NET is promising, the small sample size of just 2 patients renders any extrapolation of potential efficacy to a larger trial speculative, particularly as there is no hypothesis as yet as to why TKM-PLK1 may have a superior effect this group.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">TKM-PLK1 silences polo-like kinase 1 (PLK1) activity and is formulated to circulate beyond the liver.<wbr> </div><div style="margin-bottom: 10px;">Has been shown in pre-clinical animal studies to selectively kill cancer cells, while sparing normal cells in adjacent healthy tissue.<wbr> TKM-PLK1 targets PLK1 (polo-like kinase 1), a protein involved in tumor cell proliferation and a validated oncology target.<wbr> Inhibition of PLK1 expression prevents the tumor cell from completing cell division, resulting in cell cycle arrest and death of the cancer cell.<wbr> <BR> </div><div><EM>Source: Edison</EM> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20130431&edate=20130101&rec=7325">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-04-19T19:17:24+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-04-19T19:17:24+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category endocrinology > <![CDATA[Endocrinology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>EAP of Abiraterone + Prednisone for Asymptomatic or Mildly Symptomatic Patients With mCRPC</title>
	<pubDate>2013-04-19T18:45:12+02:00</pubDate>
	<wp:post_id>3976</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;"><DIV class="indent1" style="MARGIN-TOP: 3ex">
<DIV class="indent2" style="MARGIN-TOP: 2ex">
<DIV class="indent3">
<DIV class="body3">
<P style="MARGIN-TOP: 1ex; MARGIN-BOTTOM: 1ex">Comment: Approx.<wbr> 60 participants will be enrolled in this early access protocol (EAP) study.<wbr> The drug will be provided until the company obtains market authorization and reimbursement in the participant countries (Brazil and Colombia).<wbr></P></DIV></DIV></DIV></DIV> </div><div style="margin-bottom: 10px;"><STRONG></STRONG><A href="http://clinicaltrials.gov/ct2/show/NCT01834209?recr=Open&amp;no_unk=Y&amp;fund=2&amp;rcv_s=03%2F19%2F2013&amp;rank=24"><STRONG></STRONG></A> </div><div style="margin-bottom: 10px;">Start date April 2013 - Completion: September 2014 </div><div style="margin-bottom: 10px;"><P style="MARGIN-TOP: 1ex; MARGIN-BOTTOM: 1ex"><U>Protocol</U></P> </div><div><UL><LI>
Participants will receive abiraterone acetate 1000 mg daily plus prednisone or prednisolone 5 mg daily.<wbr> </LI>
<LI>
Treatment in 28-day cycles will continue until progression of clinical disease.<wbr></LI>
</UL> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20130431&edate=20130101&rec=8902">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-04-19T18:45:12+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-04-19T18:45:12+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Registration Trial of PTC's Ataluren for Nonsense Mutation Dystrophinopathy</title>
	<pubDate>2013-04-19T18:27:20+02:00</pubDate>
	<wp:post_id>3977</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: PE of this Ph3 will assess the effect of ataluren on ambulation in approx.<wbr> 220 patients (males) with the condition.<wbr> The effect of ataluren on physical function, quality of life, and activities of daily living will be evaluated.<wbr> This study will also provide additional information on the long-term safety of ataluren.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Dystrophinopathy is a disease continuum that includes Duchenne muscular dystrophy, which develops in boys.<wbr> </div><div style="margin-bottom: 10px;">It is caused by a mutation in the gene for dystrophin, a protein that is important for maintaining normal muscle structure and function.<wbr> Loss of dystrophin causes muscle fragility that leads to weakness and loss of walking ability.<wbr> </div><div style="margin-bottom: 10px;">A specific type of mutation, called a nonsense (premature stop codon) mutation is the cause of dystrophinopathy in approximately 10-15% of boys with the disease.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Principal Investigator: Brenda Wong, MD </div><div style="margin-bottom: 10px;">Start date: March 2013  Completion: June 2015 </div><div><EM>Source: clinicaltrials.<wbr>gov</EM> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20130431&edate=20130101&rec=6977">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-04-19T18:27:20+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-04-19T18:27:20+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Pluristem To Initiate PhI Rotator Cuff Study</title>
	<pubDate>2013-04-18T16:09:42+02:00</pubDate>
	<wp:post_id>3978</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Pluristem Therapeutics intends to expand its presence in the 
orthopaedic and sports medicine makret with plans to initiate a phI clinical 
trial to evaluate the safety and efficacyy of the local administration of PLX 
cell to patients suffering from tendon injuries.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Study Design</STRONG> </div><div style="margin-bottom: 10px;">The study planned will be a randomised, double-blind, placeob-controlled 
trial to evaluate the safety and efficacy of the local intr-tendon 
injections of of PLX cells to patients with rotator cuff injury requiring 
arthroscopic repair.<wbr> </div><div style="margin-bottom: 10px;">The hypothesis is that the PLX-PAD cells will improve the post-operative 
functional effectiveness of the rotator cuff.<wbr> The study will be undertaken in 30 
patients who will be followed up for 6 months.<wbr> </div><div style="margin-bottom: 10px;">Pluristem claims to have preclinical data illustrating the potential efficacy 
of PLK cell in tendon pathologies.<wbr> </div><div>Source: <A href="http://www.pluristem.com">www.<wbr>pluristem.<wbr>com</A> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20130431&edate=20130101&rec=6976">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-04-18T16:09:42+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-04-18T16:09:42+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Addex Plans To Move Into PhIIa With Dipraglurant For Dystonia</title>
	<pubDate>2013-04-18T16:00:39+02:00</pubDate>
	<wp:post_id>3979</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Based on further postive preclinical findings on top of some clinical data, Addex plans to move its mGLu5 allosteric modulator dipraglurant in phIIa development for the treatment of rare dystonia in the 1H2013.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>New Preclinical Data</STRONG> </div><div style="margin-bottom: 10px;">In a study conducted by Professor Antonio Pisani at the University of Rome, dipraglurant dose-dependently prevented that abnormal exicitatory effecct ovserved on brain slides of transgenic DYT1 mice ovreexpressing the human mutant TOR1A gene by decreasing pardoxical neuronal activity induced by the dopamine D2 receptor agonist quinpirole, thus normalising cholinergic over-activity.<wbr> These data combined with others have reinforced the view that mGLuR inhibition has potential to treat dystonia </div><div style="margin-bottom: 10px;"><STRONG>Adds to The Findings of Key Clinical Data</STRONG> </div><div style="margin-bottom: 10px;">Dipraglurant is an oral small molecule modulator that inhibits selectively the metabotropic glutamate receptor 5 a class C GPCR.<wbr> Data from a recent phIIa trial has shown that the drug met its primary endpoint from a safety and tolerability perspective and significantly reduced Parkinson's disease levodopa-induced dyskinesia.<wbr> Dipraglurant appears to reduce dystonia in addition to chorea the two major component of PD-LID.<wbr> </div><div>Source: <A href="http://www.addex.com">www.<wbr>addex.<wbr>com</A> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20130431&edate=20130101&rec=6974">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-04-18T16:00:39+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-04-18T16:00:39+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Daewoong Announces Russian Export Contract For Depot Leuprolide & Signals Its Global Ambition</title>
	<pubDate>2013-04-17T18:04:28+02:00</pubDate>
	<wp:post_id>3980</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Korean company Daewoong has announced the signing of an export 
contract with Russian company Pharm-Sintez for the commercialisation of Luphere 
3.<wbr>75mg Depot injection for the treatment of prostate cancer &amp; endometriosis.<wbr> 
Plans for internationalisation of the product elsewhere are also ongoing.<wbr> </div><div style="margin-bottom: 10px;">Pharm-Sintez, a well established Russian pharmaceutical company plans to 
complete local registration trials with the product and then commercialise 
the product from 2015 onwards.<wbr> Daewoong's expectation is that it will sell over 
$15m of product over a 5 year period in the CIS area.<wbr> It estimates that the 
current market size for such products is around $90m.<wbr> </div><div style="margin-bottom: 10px;">In the press statement Seo Jong Won Head of Global Business Unit noted that 
Luphere is preparing for entering into America, Japan, Europe &amp; Central 
&amp; South America with visible outcomes expected next year.<wbr> </div><div>Source: <A href="http://www.daewoong.co.kr">www.<wbr>daewoong.<wbr>co.<wbr>kr</A> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20130431&edate=20130101&rec=8901">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-04-17T18:04:28+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-04-17T18:04:28+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Nymox Drug Has An Attractive Safety Profile In BPH patrients - Implications For Prostate Cancer Therapy</title>
	<pubDate>2013-04-17T14:50:39+02:00</pubDate>
	<wp:post_id>3981</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Nymox Pharmaceuticals has reported positive findings from its phIII 
programme in bening prostatic hyperplasia demonstrating that its drug NX-1207 
has no detectable effect on key male structures involved in sexual function.<wbr> 
These findings are also of potential interest in the context of the ongoing 
development of the drug for localised prostate cancer.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>What does the data show?</STRONG> </div><div style="margin-bottom: 10px;">The new data demonstrates that NX-1207 is highly selective and sparing of 
prostatic nerves.<wbr> In over 1000 patients in clinical trials who have received 
NX-1207 there has been no  evidence of clinical secular problems related to 
the drug.<wbr> </div><div style="margin-bottom: 10px;">Current BPH treatments tend to be non-selective with the end-results being 
improved urinary function at the cost of lost sexual function.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Efficacy profile is also attractive</STRONG> </div><div style="margin-bottom: 10px;">The drug has successfully completed a series of blinded controlled 
mutli-centre trials where a single dose of NX-1207 has been found to produce an 
average symptomatic improvement double that seen with other BPH therapies 
without causing sexual or cardiovascular side-effects.<wbr> Recordatti has European 
commercialisation rights to the BPH indication.<wbr> </div><div>Source: <A href="http://www.nymox.com">www.<wbr>nymox.<wbr>com</A> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20130431&edate=20130101&rec=8900">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-04-17T14:50:39+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-04-17T14:50:39+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Zytiga Receives Second Positive Verdict in Germany</title>
	<pubDate>2013-04-16T22:14:42+02:00</pubDate>
	<wp:post_id>3982</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Zytiga was assessed in its recently approved indication of metastatic castration-resistant, androgen-independent prostate cancer before chemotherapy, in combination with prednisone.<wbr> The Federal Joint Committee (G-BA) identified watchful waiting as its appropriate comparator therapy – although it was decided to maintain the conventional androgen-deprivation therapy (hormone-blocking medicines), or a combination of androgen-blocking drugs and a non-steroidal anti-androgen.<wbr> </div><div style="margin-bottom: 10px;">Based on the trial data submitted (trial COU-AA-302), IQWiG noted that there was a strong indication of a significant additional benefit, as the length of time of treatment before disease progression was considerably longer in the Zytiga arm, noting also that life expectancy was longer by a median of five months, and severe pain occurred later in the Zytiga arm.<wbr> </div><div style="margin-bottom: 10px;">However, it also noted that quality-of-life data and data on side effects were not admissible.<wbr> Overall, however, an indication of considerable added benefit was highlighted.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">The likelihood is that Zytiga – which received its label extension from the European Commission in December 2012 – will be granted a fairly high added benefit rating by the G-BA,.<wbr> This is a very positive development for J&amp;J, which has also seen the National Institute for Health and Care Excellence in the United Kingdom recently recommend Zytiga in this new indication.<wbr> </div><div><EM>Source: Global Insight</EM> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20130431&edate=20130101&rec=8899">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-04-16T22:14:42+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-04-16T22:14:42+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>J&J Reports Strong 1st Quarter Zytiga Sales</title>
	<pubDate>2013-04-16T18:28:19+02:00</pubDate>
	<wp:post_id>3983</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: <SPAN lang="EN-US" style="FONT-FAMILY: 'Arial','sans-serif'; FONT-SIZE: 10pt; mso-bidi-font-size: 12.0pt; mso-fareast-font-family: 'Times New Roman'; mso-bidi-font-family: 'Times New Roman'; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA">.<wbr>  In the quarter, ZYTIGA 
(abiraterone) achieved sales growth of over 70% generating sales of $344m 
annualising in excess of $1.<wbr>37bn.<wbr> U.<wbr>S.<wbr> sales grew 61%  to $161m, 
whilst international sales grew 83% to $183m</SPAN> </div><div style="margin-bottom: 10px;"><SPAN lang="EN-US" style="FONT-FAMILY: 'Arial','sans-serif'; FONT-SIZE: 10pt; mso-bidi-font-size: 12.0pt; mso-fareast-font-family: 'Times New Roman'; mso-bidi-font-family: 'Times New Roman'; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA">The US market is exhibiting strong growth of over 20% and Zytiga 
is continuing to increase its  market share in combined metastatic castrate 
prostate cancer market (28%  currently up 1.<wbr>5% sequentially).<wbr>  </SPAN> </div><div style="margin-bottom: 10px;"><SPAN lang="EN-US" style="FONT-FAMILY: 'Arial','sans-serif'; FONT-SIZE: 10pt; mso-bidi-font-size: 12.0pt; mso-fareast-font-family: 'Times New Roman'; mso-bidi-font-family: 'Times New Roman'; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA">Operational sales 
growth outside of the U.<wbr>S was even stronger 83.<wbr>4% versus first quarter 2012 
and on sequential basis up over 20%.<wbr>  
ZYTIGA is improved in more than 75 countries.<wbr></SPAN> </div><div style="margin-bottom: 10px;"><SPAN lang="EN-US" style="FONT-FAMILY: 'Arial','sans-serif'; FONT-SIZE: 10pt; mso-bidi-font-size: 12.0pt; mso-fareast-font-family: 'Times New Roman'; mso-bidi-font-family: 'Times New Roman'; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA"><SPAN lang="EN-US" style="FONT-FAMILY: 'Arial','sans-serif'; FONT-SIZE: 10pt; mso-bidi-font-size: 12.0pt; mso-fareast-font-family: 'Times New Roman'; mso-bidi-font-family: 'Times New Roman'; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA">Management noted that two factors pre-chemo and additional country 
approval were the major drivers of the uptick in ZYTIGA sales.<wbr> No 
breakdown was disclosed about the respective growth in the pre-chemo and 
post-chemo settings.<wbr> Zytiga is now approved in more than 75 
countries.<wbr></SPAN></SPAN> </div><div style="margin-bottom: 10px;"><SPAN lang="EN-US" style="FONT-FAMILY: 'Arial','sans-serif'; FONT-SIZE: 10pt; mso-bidi-font-size: 12.0pt; mso-fareast-font-family: 'Times New Roman'; mso-bidi-font-family: 'Times New Roman'; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA"><SPAN lang="EN-US" style="FONT-FAMILY: 'Arial','sans-serif'; FONT-SIZE: 10pt; mso-bidi-font-size: 12.0pt; mso-fareast-font-family: 'Times New Roman'; mso-bidi-font-family: 'Times New Roman'; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA">With regard to its upcoming patent expiry, management noted that it 
was working on this but refused to expand on its strategy.<wbr></SPAN></SPAN> </div><div><SPAN lang="EN-US" style="FONT-FAMILY: 'Arial','sans-serif'; FONT-SIZE: 10pt; mso-bidi-font-size: 12.0pt; mso-fareast-font-family: 'Times New Roman'; mso-bidi-font-family: 'Times New Roman'; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA"><SPAN lang="EN-US" style="FONT-FAMILY: 'Arial','sans-serif'; FONT-SIZE: 10pt; mso-bidi-font-size: 12.0pt; mso-fareast-font-family: 'Times New Roman'; mso-bidi-font-family: 'Times New Roman'; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA">Source: <a href="http://www.jnj.com" class="defaultlink" title="www.jnj.com">jnj.com</a></SPAN></SPAN> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20130431&edate=20130101&rec=8898">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-04-16T18:28:19+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-04-16T18:28:19+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Approval Of Allergan's New Migraine Medication Likely To Be Deferred Until Q413</title>
	<pubDate>2013-04-16T16:25:10+02:00</pubDate>
	<wp:post_id>3984</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Allergan has received a complete response letter from the FDA 
regarding Levadex (dihydroergotamine) inhalation aeosol for the acute treatment 
of migraine which implies that FDA will require a re-inspection of Exemplaf 
Pharma's facility prior to approval.<wbr> Based on timelines for this to occur 
Allergan now estimates that approval should be forthcoming by end Q42013.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Key Content Of The CRL</STRONG> </div><div style="margin-bottom: 10px;">The main issues cited in the CRL were already identified by the FDA in prior 
discussions with Allergan, hence the company has already taken action to address 
those concerns.<wbr> </div><div style="margin-bottom: 10px;">The cannister filling at Exemplar Pharma was one key concern which Allergan 
has tried to address through securing the supply chain.<wbr> Allergan completed the 
purchase of Exemplar on April 12th 2013 for less than $20m.<wbr> Allergan has 
appointed senior members of its Technical Operations team to oversee 
improvements but as stated above believes a re-inspection will be required prior 
to approval.<wbr> It has already taken action regarding the manufacturing process for 
the final filled process but this was not reviewed by the FDA in terms of the 
current PDUFA timeline.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Labelling Progressing According To Plan</STRONG> </div><div style="margin-bottom: 10px;">Despite these concerns Allergan appeears to be pleased that it has already 
received draft labelling from the FDA, which is expected to 
recieve minimal revision.<wbr> </div><div style="margin-bottom: 10px;">Source: <A href="http://www.allergan.com">www.<wbr>allergan.<wbr>com</A>
 </div><div><PRE style="TEXT-ALIGN: left; PADDING-BOTTOM: 0px; TEXT-TRANSFORM: none; FONT-VARIANT: normal; FONT-STYLE: normal; TEXT-INDENT: 0px; MARGIN: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; FONT-FAMILY: monospace; LETTER-SPACING: normal; COLOR: rgb(0,0,0); FONT-SIZE: 1.2em; FONT-WEIGHT: normal; WORD-SPACING: 0px; PADDING-TOP: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px">    
 
</PRE> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20130431&edate=20130101&rec=6973">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-04-16T16:25:10+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-04-16T16:25:10+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Acorda Achieves POC In Post-Stroke & Cerebral Palsy Study</title>
	<pubDate>2013-04-16T11:28:56+02:00</pubDate>
	<wp:post_id>3985</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Acorda Therapeutica has found that a POC study with dalfampridine, an extended release formulation of the marketed drug Ampyra, improved walking in patients with post-stroke deficits.<wbr> The results are sufficiently robust that Acorda plans to proceed with a clinical development programme for this indication.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Study Design</STRONG> </div><div style="margin-bottom: 10px;">The study included 83 participatns who had experienced an ischemic stroke at least six month prior to enrollment and residual chronic motor deficits.<wbr> </div><div style="margin-bottom: 10px;">As part of its crossover design, patients received dalfampridine-ER 10mg and placebo for 14 days twice daily, with a wash-out period in between during which the participants received placebo.<wbr> The primary goal of the study was to assess safety and tolerability as well as various efficacy measures.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Key Findings</STRONG> </div><div style="margin-bottom: 10px;">A clear signal of efficacy was seen with the active treatment.<wbr> Dalfampridine-ER treatment was associated with a positive change vs.<wbr> placebo on a scale of functional independence.<wbr> </div><div style="margin-bottom: 10px;">Improvement was demonstrated a in walking test measured by the Timed 25-Foot Walk (T25FW) and in a functional independence measurement scale.<wbr> </div><div style="margin-bottom: 10px;">The safety findings were consistent with previous clinical trials and post-marketing experience with Ampyra in multiple sclerosis.<wbr> The most common AEs reporeted in the study were dizziness (10.<wbr>4% active 2.<wbr>5% placebo), nausea (3.<wbr>9% active, 6.<wbr>2% placebo), fatigue (5.<wbr>2% active, 3.<wbr>7% placebo), insomnia (5.<wbr>2% active, 2.<wbr>5% placebo) and arthralgia (2.<wbr>6% active, 3.<wbr>7% placebo).<wbr> </div><div style="margin-bottom: 10px;">Three patients experienced a seizure during the study.<wbr> One in a patient on placebo (with no prior exposure to dalfampridine-ER), one whilst taking dalfampridine-ER and one in a patient who took an intentional overdose of dalfampridine-ER.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Cerebral Palsy Data</STRONG> </div><div style="margin-bottom: 10px;">A seperate POC study including 24 adult patients with cerebral palsy.<wbr>is reported to have demonstrated potential treatment acitvity on measures of walking and hand strength, however, these dara are still being analysed to determine if the results are sufficiently robust to warrent further clinical studies.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Next Steps</STRONG> </div><div style="margin-bottom: 10px;">The company plans to analyse both studies in more detail with a view to discussing the data from the post-stroke deficit study with the FDA and presenting both sets of results at an appropriate medical forum.<wbr> </div><div>Source: <A href="http://www.acorda.com">www.<wbr>acorda.<wbr>com</A> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20130431&edate=20130101&rec=6971">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-04-16T11:28:56+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-04-16T11:28:56+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>New Parkinson's Disease Drug Moves Into PhII Development</title>
	<pubDate>2013-04-16T11:16:00+02:00</pubDate>
	<wp:post_id>3986</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Neuroderm has announced the enrollment in its phIIa tiral of ND0612, 
a new subcutaneous liquid formualtion of levodopa/<wbr>carbidopa administered via a 
patch pump, is now ongoing.<wbr> </div><div style="margin-bottom: 10px;">In a previous phI study, ND0612 was shown to be safe and tolerable.<wbr> Moreover, 
steady state levodopa concentrations were maintained in a practical manner 
during both night and day.<wbr> </div><div style="margin-bottom: 10px;">The ongoing phIIa study will further assess safety and tolerability as well 
as PK parameters.<wbr> </div><div style="margin-bottom: 10px;">ND0612 is based on a proprietary subcutaneous drug formulation that bypasses 
the digestive tract.<wbr> improving bioavailability and steady state concentrations 
of the drug.<wbr> </div><div style="margin-bottom: 10px;">The overall objective of treatment is to improve the management of motor 
fluctuations in patients on current standard of care with oral levodopa 
therapy.<wbr> </div><div>Source:www.<wbr>neuroderm.<wbr>com </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20130431&edate=20130101&rec=6970">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-04-16T11:16:00+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-04-16T11:16:00+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Otsuka Filing For Polycystic Kidney Disease Accepted By The FDA</title>
	<pubDate>2013-04-16T11:03:32+02:00</pubDate>
	<wp:post_id>3987</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Otsuka pharmaceuticals has announced that the FDA has accepted for priority review the company's NDA submission for the potential use of tolvaptan to treat autosomal dominant polycystic kidney disease.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>What is Tolvaptin</STRONG> </div><div style="margin-bottom: 10px;">Tolvaptin is a selective V2 vasopressin receptor antagonist that appears to reduce the development and growth of kidney cysts that are associated with the pain, hypertension, decreased kidney function and ultimately kidney failuer associated with this disease.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Basis For Filing</STRONG> </div><div style="margin-bottom: 10px;">Otsuka has filed for approval based on results of a pivotal phIII study the results of which have been published in the New England Journal of Medicine (December 20th 2012).<wbr> </div><div style="margin-bottom: 10px;">In this phase 3, multicenter, double-blind, placebo-controlled, 3-year trial, 1445 patients, 18 to 50 years of age, who had ADPKD with a total kidney volume of 750 ml or more and an estimated creatinine clearance of 60 ml per minute or more, were assigned in a 2:1 ratio to receive tolvaptan, a V<SUB>2</SUB>-receptor antagonist, at the highest of three twice-daily dose regimens that the patient found tolerable, or placebo.<wbr> The primary outcome was the annual rate of change in the total kidney volume.<wbr> </div><div style="margin-bottom: 10px;"><STRONG> Key Study Findings</STRONG> </div><div style="margin-bottom: 10px;">Over a 3-year period, the increase in total kidney volume in the tolvaptan group was 2.<wbr>8% per year (95% confidence interval [CI], 2.<wbr>5 to 3.<wbr>1), versus 5.<wbr>5% per year in the placebo group (95% CI, 5.<wbr>1 to 6.<wbr>0; P&lt;0.<wbr>001).<wbr> </div><div style="margin-bottom: 10px;">The composite end point favored tolvaptan over placebo (44 vs.<wbr> 50 events per 100 follow-up-years, P=0.<wbr>01), with lower rates of worsening kidney function (2 vs.<wbr> 5 events per 100 person-years of follow-up, P&lt;0.<wbr>001) and kidney pain (5 vs.<wbr> 7 events per 100 person-years of follow-up, P=0.<wbr>007).<wbr> </div><div style="margin-bottom: 10px;">Tolvaptan was associated with a slower decline in kidney function (reciprocal of the serum creatinine level, &minus;2.<wbr>61 [mg per milliliter]<SUP>&minus;1</SUP> per year vs.<wbr> &minus;3.<wbr>81 [mg per milliliter]<SUP>&minus;1</SUP> per year; P&lt;0.<wbr>001).<wbr> </div><div style="margin-bottom: 10px;">There were fewer ADPKD-related adverse events in the tolvaptan group but more events related to aquaresis (excretion of electrolyte-free water) and hepatic adverse events unrelated to ADPKD, contributing to a higher discontinuation rate (23%, vs.<wbr> 14% in the placebo group).<wbr> </div><div style="margin-bottom: 10px;">If approved by the FDA tolvaptan will become the first pharmaceutical therapy to be approved in the US for patients suffering from ADPKD.<wbr> The FDA PDUFA date for this NDA is September 1st 2013.<wbr> </div><div>Source: <A href="http://www.otsuka.com">www.<wbr>otsuka.<wbr>com</A> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20130431&edate=20130101&rec=7323">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-04-16T11:03:32+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-04-16T11:03:32+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category endocrinology > <![CDATA[Endocrinology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Additional Insights on SPARC's Octreotide Depot</title>
	<pubDate>2013-04-15T16:33:16+02:00</pubDate>
	<wp:post_id>3988</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: In addition to the strategic intelligence provided on April 10th in Traction CI, please find below management's remark re the threat of oral Octreotide or lanreotide, position re Pasireotide LAR, and intent route for filing Octreotide1M.<wbr> Of note, the company does not plan to develop the drug for cancer diagnostic purposes by combining with the radio-labeled indium, and outlined the development of goserelin acetate being a 'wrong information'.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">When questionned on the rational for going 505(b)(2), Management answered that " .<wbr>.<wbr>.<wbr> we cannot file the ANDA because it is a different polymer .<wbr>.<wbr>.<wbr>".<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><U>To quote D.<wbr> Shanghvi</U> (Chairman and Managing Director) " .<wbr>.<wbr>.<wbr> we do not have a detailed analysis on preference of physicians.<wbr> However, many indications if you see in specially the CNS area, the once a month product coming after once-a-day oral products have done quite well.<wbr> So I think there would be a room for both, oral as well as once-amonth or once-a-three month injectable product.<wbr> If it is a choice between once-a-day oral product and once-a-day injectable product then clearly once a day oral product will get a very large market share.<wbr> But once-a-month I think there is a trade-off between compliance and convenience".<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Management indicated that if Novartis manages to get Pasreotide LAR approved, he will " .<wbr>.<wbr>.<wbr> see a role for continued use of Octreotide".<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div>Please see <a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20130431&edate=20130101&rec=6954" class="defaultlink">Neurology6954: Sun Pharma Advanced Research R&D Presentation</a>.<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20130431&edate=20130101&rec=7320">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-04-15T16:33:16+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-04-15T16:33:16+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category endocrinology > <![CDATA[Endocrinology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>re: Comparison of Efficacy and Safety of Degarelix 1M Vs Goserelin in China</title>
	<pubDate>2013-04-15T10:47:49+02:00</pubDate>
	<wp:post_id>3989</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="border-left: 2px solid #8B1010; padding: 0px 0px 5px 12px; margin-bottom: 3px;"><span style="font-weight: bold; font-size: 14px;">Comparison of Efficacy and Safety of Degarelix 1M Vs Goserelin in China</span>&nbsp;<br><span style="font-size: 12px;">Comment: Clinicaltrials.<wbr>gov is listing a new Ferring-sponsored PhIII study which will evaluate degarelix 1M/<wbr>goserelin in nearly 280 Chinese patients with prostate cancer requiring androgen ablation therapy.<wbr> The PE will assess cumulative probability of testosterone at castrate level (≤0.<wbr>5 ng/<wbr>mL).<wbr></span>&nbsp;&nbsp;<a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20130431&edate=20130101&rec=8660">...</a><br></div><div>Feedback from Siew Kwan Chang has indicated that <SPAN style="text-transform: none; background-color: #ffffff; text-indent: 0px; display: inline !important; font: 13px arial, sans-serif; white-space: normal; float: none; letter-spacing: normal; color: #222222; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;">Med.<wbr> Rep's in GuangZhou Hospital have reported that Ferring intend to have 15 cases from this hospital.<wbr></SPAN> </div><!-- Comment details --><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20130431&edate=20130101&rec=8897">Add a Comment on this Article</a><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology8660">View thread  Oncology8660: Comparison of Efficacy and Safety of Degarelix 1M Vs Goserelin in China</a>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-04-15T10:47:49+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-04-15T10:47:49+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Ph2 Combining Bcl-2 Inhibitor+abiraterone for CRPC</title>
	<pubDate>2013-04-11T18:51:47+02:00</pubDate>
	<wp:post_id>3990</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Sponsored by the U.<wbr> of Medicine and Dentistry New Jersey and in collaboration with AbbVie, the POC randomized study will assess the effect of combining abiraterone with medicines that may block some of the ways that cells become resistant to abiraterone.<wbr> PE will evaluate biochemical response.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG><A href="http://clinicaltrials.gov/ct2/show/NCT01828476?recr=Open&amp;no_unk=Y&amp;phase=012&amp;fund=2&amp;rcv_s=03%2F11%2F2013&amp;rank=194"><STRONG></STRONG></A> </div><div style="margin-bottom: 10px;">Start date: April 2013 - Completion dates: April 2015 /<wbr> April 2016 </div><div style="margin-bottom: 10px;">Recruitment: approx 53 </div><div style="margin-bottom: 10px;">PI: Robert Dipaola, MD </div><div>Source: clinicaltrials.<wbr>gov </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20130431&edate=20130101&rec=8896">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-04-11T18:51:47+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-04-11T18:51:47+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Revalesio’s RNS60 to Enter POC Comparison Study Vs Avonex for RRMS</title>
	<pubDate>2013-04-11T17:22:21+02:00</pubDate>
	<wp:post_id>3991</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: In a study recently published in the journal PLOS ONE, RNS60 halted disease progression, prevented inflammation in the brain and spinal column while also protecting against demyelination.<wbr> The research demonstrated that administration of RNS60 – either at early disease onset or late at the relapsing phase – halted disease progression.<wbr> PE of this study will assess change in number of GAD-enhancing lesions from baseline.<wbr> </div><div style="margin-bottom: 10px;"><U>Reference</U>: PLOS ONE (Protection of Tregs, Suppression of Th1 and Th17 Cells, and Amelioration of Experimental Allergic Encephalomyelitis by a Physically-Modified Saline – December 20, 2012).<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG><A href="http://clinicaltrials.gov/ct2/show/NCT01714089?recr=Open&amp;no_unk=Y&amp;cond=%22multiple+sclerosis%22&amp;phase=012&amp;fund=2&amp;rank=13"><STRONG></STRONG></A> </div><div style="margin-bottom: 10px;">Start date: June 2013 - Completion: June 2015 </div><div style="margin-bottom: 10px;">Recruitment: approx 270 </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Focused on the development of a new class of novel therapeutics for the treatment of inflammatory diseases using proprietary charge-stabilized nano-structure (CSN) technology (<A href="http://revalesio.com/about-our-technology/">http:/<wbr>/<wbr>revalesio.<wbr>com/<wbr>about-our-technology/<wbr></A>).<wbr> </div><div><EM>Source: Revalesio; clinicaltrials.<wbr>gov</EM> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20130431&edate=20130101&rec=6968">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-04-11T17:22:21+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-04-11T17:22:21+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Acadia Shares Jump 47% as FDA Gives The Nod To File For Parkinson's Disease Psychosis</title>
	<pubDate>2013-04-11T16:42:15+02:00</pubDate>
	<wp:post_id>3992</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: In a suprise develompent.<wbr> Acadia as been told by the FDA that the 
company can file for approval of pimvanserin and that it does not need a 
confirmatory trial as previously planned.<wbr> </div><div style="margin-bottom: 10px;">Data from a trial, which was re-designed in mid-2012 after a previous trial 
had failed has shown that pimavanserin is significantly better than placebo at 
reducing psychotic effects of Parkinson's disease psychosis.<wbr> the drug failed to 
meet the goals of a previous phIII study in 2009 due to an unusually high 
placebo effect.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Why is there high unmet need?</STRONG> </div><div style="margin-bottom: 10px;">Most current antipsychotic drugs cannot be used in Parkinson's disease 
patients as they block dopamine in the brain, as this is the primary target of 
drug therapy for PD.<wbr> Pimvanserin works by a different mecahnism by blocking 
serotonin receptors.<wbr> </div><div style="margin-bottom: 10px;">Parkinson's disease psychosis is very troublesome and develops in up to 60% 
of patients as their disease progresses.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Other areas of application</STRONG> </div><div style="margin-bottom: 10px;">In addition to PD psychosis, pimvanserin is also being tested in 
schizophrenia and Alzheimer disease psychosis.<wbr> </div><div>Source: <A href="http://www.acadia.com">www.<wbr>acadia.<wbr>com</A> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20130431&edate=20130101&rec=6963">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-04-11T16:42:15+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-04-11T16:42:15+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Duchenne's Area Hots Up As GSK Data Edorses POC for Exon Skipping</title>
	<pubDate>2013-04-11T16:29:38+02:00</pubDate>
	<wp:post_id>3993</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Efficacy data on GSK/<wbr>Prosensa's drisapersen to be presented later 
this week at the Oligonucleotide Conference in Cold Spring Harbor reinforces 
Sarepta's Duchenne Muscular Dystrophy platform supporting the exon skipping 
hypothesis and derisking the clinical profile of Sarepta's DMD efforts.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>What does the data show?</STRONG> </div><div style="margin-bottom: 10px;">Top-line data released in absract form shows a fairly clear benefit over 
placebo in terms of 6MWT with the continuous treatment arm demonstrating a 39 
meter difference at 24 weeks and a 35-metere difference at 48 weeks.<wbr> </div><div style="margin-bottom: 10px;">Drispersen (GSK) and eteplirsen (Sarepta) are mechanistically similar, using 
base pairing to resent the translation of the dystrophin gene by skipping over 
exon 51.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Key To Product Differentiation</STRONG> </div><div style="margin-bottom: 10px;">The safety profile of the products may differ with early indications that the 
Sarpeta drug may have the better safety profile.<wbr> It is suggested that 
drisapersen usage is associated with proteninuria and has an effect on 
platelets.<wbr> The PMO backbone of eteplirsen is believed to have created a safer 
profile.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Sales Potential</STRONG> </div><div style="margin-bottom: 10px;">With a projected annual treatment cost of $400,000 Cannaccord Genuity 
analysts are now predicting that eteplirsen willl garner sales of over $800m by 
2020 with a launch now expected in 2015.<wbr> Sarepta's share price has risen 
strongly since its phIIb data was reported and now stands at $1.<wbr>26bn.<wbr> </div><div>Source: Analysts reports &amp; Oligonucleotide Conference 
Abstract </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20130431&edate=20130101&rec=6962">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-04-11T16:29:38+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-04-11T16:29:38+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>New Observational Study Highlights Allergan's Interest in the Masseter Hypertrophy Indication</title>
	<pubDate>2013-04-11T15:44:43+02:00</pubDate>
	<wp:post_id>3994</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: To quote A-G Benoit (GMD Aesthetic), masseter hypertrophy is a very common use of botulinum toxin in Asia, and the interest for it is raising in other regions.<wbr> There is a very little data available on the topic.<wbr> This study could be a first step for a full clinical study on the efficacy and safety of the toxin in masseter hypertrophy treatment.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG><A href="http://clinicaltrials.gov/ct2/show/NCT01821534?recr=Open&amp;no_unk=Y&amp;fund=2&amp;rcv_s=03%2F10%2F2013&amp;rank=66"><STRONG></STRONG></A> </div><div style="margin-bottom: 10px;">Title: Reliability of a Masseter Muscle Prominence Scale and Lower Facial Shape Classification </div><div style="margin-bottom: 10px;">Start date: March 2013 - Est Completion Date: Aug 2013 </div><div style="margin-bottom: 10px;">Recruitment: approx.<wbr> 204 (men and women; 18 years+) </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">The masseter<EM> </EM>runs from the temporal bone (that forms part of the sides and base of the skull) to the lower jaw (the mandible).<wbr> It lifts the lower jaw, to close the mouth.<wbr> The masseter is the strongest muscle in your body.<wbr> </div><div style="margin-bottom: 10px;">Please click here to see the animation: <A href="http://upload.wikimedia.org/wikipedia/commons/1/13/Masseter_muscle_animation_small.gif">Masseter muscle</A> </div><div><EM>Source: clinicaltrials.<wbr>gov</EM> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20130431&edate=20130101&rec=6959">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-04-11T15:44:43+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-04-11T15:44:43+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Highlights from Analyst Call with Investigator of Revance's Topical Toxin and Botox/Xeomin Trials</title>
	<pubDate>2013-04-11T13:09:49+02:00</pubDate>
	<wp:post_id>3995</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Analyst at Deutsche Bank hosted a call with the co-director of SkinCare Physicians, a private practice in the Boston area with 60k patients in 2012, about the cosmetic dermatology market.<wbr> Selected messages are provided below.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Dr Dover is an associate clinical professor of dermatology at Yale U.<wbr> School of Medicine and an author of &gt;400 scientific publications.<wbr> He also co-authored/<wbr>edited &gt;40 dermatology focused textbooks.<wbr> </div><div style="margin-bottom: 10px;">SkinCare Physicians is the highest volume procurer of neurotoxins and dermal filler in New England.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Dr.<wbr> Dover indicated that there have been some price movements in the dermal filler market recently, with Valeant raising the price on Restylane/<wbr>Perlane by 10% for smaller practices and ~3% for high volume practices similar to his own.<wbr> He noted that Allergan followed immediately, increasing prices on the Juvederm line of products.<wbr> </div><div style="margin-bottom: 10px;">With respect to neurotoxins, Dr.<wbr> Dover commented that “he’s not seen price increases yet” – hinting that he would expect some going forward.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Dr.<wbr> Dover indicated that he and other high volume colleagues are receiving significant attention from Allergan in its promotion of Botox Cosmetic.<wbr> Conversely, he has witnessed a recent drop off in the historically high service levels from Medicis representatives now that the company is part of Valeant.<wbr> </div><div style="margin-bottom: 10px;">Dr.<wbr> Dover indicated that for the first time since its launch, his practice is considering the possibility of shifting some level of Dysport use (50%+ of his neurotoxin business) to Botox.<wbr> He noted that with Dysport being priced ~$100/<wbr>vial less than Botox historically, this pricing differential brings in an extra $100k/<wbr>year to the bottom line of his practice.<wbr> Hence, if Allergan is willing to offer some additional economic inducements (i.<wbr>e.<wbr>, match the difference in pricing), he would consider switching.<wbr> That said, Dr.<wbr> Dover continues to believe that Dysport offers some performance advantages over Botox – particularly as he believes it creates a more “natural look.<wbr>” </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">He noted that his clinic will soon participate in the upcoming Phase 3 trial in treating wrinkles.<wbr> </div><div style="margin-bottom: 10px;">He indicated that patients seem very interested in a topical option – even those who’ve historically received injections.<wbr> He is very optimistic about the product, particularly in hyperhidrosis, where he believes RT001 (if approved) will eventually become the treatment of choice.<wbr> </div><div style="margin-bottom: 10px;">That said, while RT001 offers the benefit of no injections, patients will be subject to waiting 30 minutes or more at doctor offices post treatment as the cream takes effect under medical supervision – which could prove somewhat cumbersome in his view.<wbr> </div><div style="margin-bottom: 10px;"><EM><U>Source</U>: A replay of this conference call will be available until April 17, 2013.<wbr> For callers in the US, please call +1 855-859-2056.<wbr> For international callers, please call +1 404-537-3406.<wbr> The access code for both dial-in numbers is 30911972.<wbr></EM> </div><div><STRONG></STRONG> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20130431&edate=20130101&rec=6957">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-04-11T13:09:49+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-04-11T13:09:49+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Roche Reports Q1:13 Results</title>
	<pubDate>2013-04-11T12:49:41+02:00</pubDate>
	<wp:post_id>3996</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Growth was seen in the Pharma division (+6%), all geo areas, with US and Emerging Markets (+11% overall; +20% in China) being the major drivers.<wbr> Of note, Octreolin/<wbr>RG3806 for acromegaly was mentionned in the Ph3 development pipeline as new NME following in-licensing.<wbr> Submission is planned to occur in 2014 (EU+US).<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10382_6_ScreenCapture6.jpg"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10382_2_ScreenCapture2.jpg"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10382_5_ScreenCapture5.jpg"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10382_3_ScreenCapture3.jpg"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10382_4_ScreenCapture4.jpg"> </div><div><STRONG></STRONG> </div><!-- Comment details --><a name="pharmaworld10382attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10382_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(33,2 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10382_2_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(34,3 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10382_3_ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(13,8 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10382_4_ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(33,9 KB)<br>&nbsp;&nbsp;5.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10382_5_ScreenCapture5.jpg">ScreenCapture5.jpg</a>&nbsp;&nbsp;(34,4 KB)<br>&nbsp;&nbsp;6.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10382_6_ScreenCapture6.jpg">ScreenCapture6.jpg</a>&nbsp;&nbsp;(55,8 KB)<br>&nbsp;&nbsp;7.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10382_7_ScreenCapture7.jpg">ScreenCapture7.jpg</a>&nbsp;&nbsp;(38,4 KB)<br>&nbsp;&nbsp;8.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10382_8_ScreenCapture8.jpg">ScreenCapture8.jpg</a>&nbsp;&nbsp;(13,3 KB)<br>&nbsp;&nbsp;9.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10382_9_ScreenCapture9.jpg">ScreenCapture9.jpg</a>&nbsp;&nbsp;(26,4 KB)<br>&nbsp;&nbsp;10.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10382_10_Roche%255firp1q13e.pdf">Roche_irp1q13e.pdf</a>&nbsp;&nbsp;(1,8 MB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20130431&edate=20130101&rec=10382">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-04-11T12:49:41+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-04-11T12:49:41+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category pharma-news > <![CDATA[Pharma News]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>GSK Bets on "Electroceuticals"</title>
	<pubDate>2013-04-11T11:55:30+02:00</pubDate>
	<wp:post_id>3997</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: GSK believes it is ahead of rivals in this emerging area.<wbr> The company plans $1M prize to jump-start "electroceuticals" with the objectives to treat diseases by targeting electrical signals, and to have "the first medicine that speaks the electrical language of the body ready for approval by the end of this decade".<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Please see <a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20130431&edate=20130101&rec=6956" class="defaultlink">Neurology6956: St Jude's Medical Receives CE Mark Approval of New DBS System For Both Primary & Secondary Dystonia</a>.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">The new field of "electroceuticals" has grabbed the attention of a number of academic research groups, which are already mapping neural circuits in animals and humans, and working on potential interventions for testing in clinical trials.<wbr> </div><div style="margin-bottom: 10px;">The idea is to use the electrical impulses that form the language" of the body's nervous system to address a range of diseases, from high blood pressure to breathing problems and, eventually, brain disorders.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Given the early-satge nature of thework, the aim of GSK will be: </div><div style="margin-bottom: 10px;"><UL><LI>to play a coordinating role in bioelectronics</LI>
<LI>to brin researchers together</LI>
</UL> </div><div style="margin-bottom: 10px;">GSK will host a global forum in December to bring research leaders together and collectively identify one key hurdle in the field.<wbr> The $1 million prize will go to the research group able to overcome that hurdle.<wbr><BR> </div><div><EM>Source: Thomson One</EM> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20130431&edate=20130101&rec=10381">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-04-11T11:55:30+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-04-11T11:55:30+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category pharma-news > <![CDATA[Pharma News]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>St Jude's Medical Receives CE Mark Approval of New DBS System For Both Primary & Secondary Dystonia</title>
	<pubDate>2013-04-11T11:41:38+02:00</pubDate>
	<wp:post_id>3998</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Yesterday St Jude Medical became the first company to  receive 
European approval for its  its Brio<SUP>™</SUP>, Libra<SUP>™</SUP> and 
Libra<I>XP</I><SUP>™ </SUP>deep brain stimulation (DBS) systems for managing the 
symptoms of intractable primary and secondary dystonia.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>The treatment is designed for patients who do not respond to 
medication.<wbr></STRONG> </div><div style="margin-bottom: 10px;">DBS therapy for dystonia involves the delivery of mild electrical pulses to a 
specific target in the brain.<wbr> Stimulation is delivered to one of two regions, 
the subthalamic nucleus (STN) or the globus pallidus interna (GPi), areas of the 
brain involved with controlling movement.<wbr> Irregular nerve signals responsible 
for some of the disabling symptoms are stimulated by DBS therapy, ultimately 
helping the patient improve movement </div><div style="margin-bottom: 10px;"><STRONG>Features Of New Device</STRONG> </div><div style="margin-bottom: 10px;">St.<wbr> Jude Medical’s Brio neurostimulator is the world’s smallest DBS device.<wbr> 
Slightly larger than the face of a typical man’s watch, the Brio neurostimulator 
has a thin 10 mm profile and features the greatest recommended implant depth of 
any rechargeable DBS device.<wbr> The thin profile and greater implant depth 
potentially makes the neurostimulator less noticeable and well suited for 
patients with a small body type.<wbr> The Brio rechargeable neurostimulator is also 
the longest-lasting rechargeable DBS device on the market and has a 10-year 
battery life.<wbr> Additionally, the Libra and Libra<I>XP</I> non-rechargeable DBS 
devices have forty-percent more battery capacity than any neurostimulators in 
their class to maximize time between device replacement procedures.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>DBS Indication Status</STRONG> </div><div style="margin-bottom: 10px;">St.<wbr> Jude Medical DBS therapy is also approved in <LOCATION value="LR/eur">Europe</LOCATION> and <LOCATION value="LC/au;LB/anz">Australia</LOCATION> for the treatment of the disabling 
symptoms of Parkinson's disease.<wbr> Additionally, the company is evaluating DBS 
therapy in clinical studies for depression and essential tremor.<wbr> St.<wbr> Jude 
Medical DBS systems are not approved for use in the U.<wbr>S.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6956_1_ScreenCapture1.jpg"> </div><div style="margin-bottom: 10px;"><BR>Medtronic's DBS device is approved by the FDA in the US as a 
Humanitarian device for treating primary dystonia resistant to 
medication.<wbr> </div><div>Source: <a href="http://www.sjm.com" class="defaultlink" title="www.sjm.com">sjm.com</a> </div><!-- Comment details --><a name="neurology6956attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6956_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(177,3 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20130431&edate=20130101&rec=6956">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-04-11T11:41:38+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-04-11T11:41:38+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Sun Pharma Advanced Research R&D Presentation</title>
	<pubDate>2013-04-10T15:32:49+02:00</pubDate>
	<wp:post_id>3999</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: A recent presentation by Sun Pharma's research facility highlighted 
the breadth of its novel drug delivery programme and the change in priority 
amongst some of the programmes, most notably its oral baclofen for spasticity 
and depot octreotide for acromegaly.<wbr> The former is making strong progress 
forward, whilst an IND filing for the depot octreotide has slipped back in 
time.<wbr> </div><div style="margin-bottom: 10px;">The tables below illustrate the breadth and status of Sun's various drug 
delivery &amp; NCE programmes.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6954_1_ScreenCapture1.jpg"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6954_2_ScreenCapture2.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6954_3_ScreenCapture3.jpg"> </div><div style="margin-bottom: 10px;"><STRONG>Status of the Baclfen programme</STRONG> </div><div style="margin-bottom: 10px;">SPARC is developing an extended reslease formulation of baclofen using its 
proprietary Gastro Retentive Innovative Device (GRID TM) technology.<wbr> The product 
will be a once daily formulation that can be taken after food for optimal 
bioavailability and minimal sedation.<wbr> It will be available in 6 strenghts i.<wbr>e.<wbr> 
10/<wbr>20/<wbr>30/<wbr>40/<wbr>50/<wbr>60mg for individualised dosing and greater dose flexibility.<wbr> </div><div style="margin-bottom: 10px;">The formulation is covered by patens covering the formulation, once daily 
dosing and indication patents with the last patent expiring in 2027 </div><div style="margin-bottom: 10px;">Regulatory approval will be sought using the 505B (2) route, the same as 
proposed by Xenoport for its arbaclofen formulation.<wbr> Development is ongoing with 
a 300 patient phIII randomised placebo controllled tril ongoing under an SPA 
with the FDA.<wbr> 20 sites are actively recruiting patients.<wbr> Simulataneously, an 
open label safety study in 200 patients is ongoing as is a 135 patient 
pharmacodynamic study to prove once-a-day dosing.<wbr> </div><div style="margin-bottom: 10px;">Meanwhile, in India the product is registered and marketed and a clinical 
study in 180 patients evaluating the use of Baclofen GRS to treat Alochol 
dependence has completed with the results expected in Q1FY14.<wbr> A phase 2 dose 
finding study is planned in the EU for Q2FY14.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Status of the Octreotide depot programme</STRONG> </div><div style="margin-bottom: 10px;">Little was mentioned regarding this programme other than that there is a plan 
to file a US IND in FY15.<wbr> This is defintely later than was suggested by primary 
intelligence work undertaken in October last year, suggesting either delays with 
the programme or re-prioritisation within the development pipeline.<wbr> This 
point will be further investigated in further upcoming primary intelligence 
screening to be undertaken this quarter.<wbr> </div><div>Source: <A href="http://www.sparc.com">www.<wbr>sparc.<wbr>com</A> </div><!-- Comment details --><a name="neurology6954attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6954_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(631 B)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6954_2_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(125 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6954_3_ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(109,4 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20130431&edate=20130101&rec=6954">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-04-10T15:32:49+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-04-10T15:32:49+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Astellas' Myrbetriq (OAB) Available in Pharmacies Across Canada</title>
	<pubDate>2013-04-10T15:32:38+02:00</pubDate>
	<wp:post_id>4000</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Myrbetriq™ (mirabegron, extended-release tablets) is indicated for the treatment of OAB with symptoms of urge urinary incontinence, urgency and urinary frequency.<wbr> The product is an important growth driver for Astellas and is part of the company's strategy to establish a leadership position in UroOncology.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">- Helps to increase bladder capacity by relaxing the detrusor smooth muscle during the storage phase of the urinary bladder fill-void cycle.<wbr> </div><div style="margin-bottom: 10px;">- Reduces the activity of an overactive bladder as well as treats the related symptoms.<wbr> </div><div><EM>Source: Astellas</EM> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20130431&edate=20130101&rec=8891">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-04-10T15:32:38+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-04-10T15:32:38+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Aileron Therapeutics' Stapled Peptides and Prostate Cancer Model</title>
	<pubDate>2013-04-10T15:18:18+02:00</pubDate>
	<wp:post_id>4001</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: New preclinical data demonstrating that ATSP-9172, Aileron' Stapled Peptide inhibitor of HIF-1α<B>-</B>dependent transcription, exhibits on-target binding activity, favorable pharmacokinetic properties and potent <I>in vivo</I> efficacy in a human prostate cancer model.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Late-breaking poster presentation: “ATSP-9172, a novel Stapled Peptide inhibitor of HIF-dependent transcriptional activity with <I>in vivo </I>antitumor efficacy in a preclinical model of prostate cancer”abstract number LB-304 </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8889_1_ScreenCapture1.jpg"> </div><div style="margin-bottom: 10px;">ATSP-9172 is a Stapled Peptide drug candidate designed to mimic the structure and function of the CITED2 protein, a known negative regulator of HIF-1α.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">In this study, Aileron researchers showed that ATSP-9172 directly disrupts the HIF-1α /<wbr>p300 interaction in cancer cells and specifically down-regulates the transcription of HIF-1α target genes without affecting off-target gene expression.<wbr> </div><div style="margin-bottom: 10px;">The study further demonstrated favorable solubility and pharmacokinetic properties of high systemic exposure, low plasma clearance and long elimination half-life.<wbr> </div><div style="margin-bottom: 10px;">Finally, dose-dependent inhibition of tumor growth in a human prostate cancer xenograft model was seen following intravenous administration of ATSP-9172 on an every other day schedule.<wbr> </div><div><EM>Source: Aileron Therapeutics</EM> </div><!-- Comment details --><a name="oncology8889attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8889_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(52,4 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20130431&edate=20130101&rec=8889">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-04-10T15:18:18+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-04-10T15:18:18+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Antisense Therapeutics Initiates Ph2 Acromegaly Trial</title>
	<pubDate>2013-04-10T13:32:13+02:00</pubDate>
	<wp:post_id>4002</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Antisense Therapeutics has dosed its first patient in its ph2 trials 
of its new antisense acromegaly therapeutic ATL1103.<wbr> </div><div style="margin-bottom: 10px;">Five sites in the UK and two in Spain have now been intiated and are ready to 
recruit patients and the first patient has been dosed in one of the Spanish 
trial sites.<wbr> Regulatory approval is also being sought in France with the 
expectation that French sites will be initiated during April/<wbr>May 2013.<wbr> </div><div style="margin-bottom: 10px;">As a recap the primary endpoint of the trial are to evaluate the safety and 
tolerability of ALT1103 and to evaluate both single and multiple doses and the 
drug's PK profile.<wbr> A secondary endpoint that will be evaluated will be the 
reduction in IGF-1.<wbr> </div><div style="margin-bottom: 10px;">Antisense is expecting a steady rate of enrollment </div><div>Source: <a href="http://www.antisense-therapeutics.com" class="defaultlink" title="www.antisense-therapeutics.com">antisense-therape&hellip;</a> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20130431&edate=20130101&rec=7319">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-04-10T13:32:13+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-04-10T13:32:13+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category endocrinology > <![CDATA[Endocrinology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>New Immunotherapeutic Cancer Therapy Attracts Attention at AACR Meeting</title>
	<pubDate>2013-04-10T13:04:21+02:00</pubDate>
	<wp:post_id>4003</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Roche presented phI data at the AACR meeting on a novel 
class of immunotherapeutic drugs that targets a protein called PD-L1.<wbr> The phase 
I study with MPDL320A was designed as a dose escalation study but the drug 
demonstrated clear anti-tumour activity in a broad range of cancers.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>What do PD-LI inhibitors do?</STRONG> </div><div style="margin-bottom: 10px;">MPDL320A is an engineered antibody that targetd PD-L1.<wbr> It enables T cells of 
the immune system to more effectively attack cancer cells.<wbr> PD-L1 is found on the 
surface of many cancer cells and impairs the immune system's ability to fight 
the disease.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Key Findings</STRONG> </div><div style="margin-bottom: 10px;">The drug was administered intravenously every three weeks and no dose 
limiting toxicities were observed.<wbr> Moreover, responses have been durable with 
some advanced patients still alive after more than one year.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Roche's Differentiated Approach</STRONG> </div><div style="margin-bottom: 10px;">According to a report on Reuters, researchers at Genentch believe the PD-L1 
approach may be more selective and safer than similar PD-1 inhibitors being 
developed by other companies as the latter not only impact the target on cancer 
cells but potentially another receptor PD-L2 on health cells causing lung 
inflammation.<wbr> </div><div style="margin-bottom: 10px;">Roche is apparently working on a diagnositc aimed at helping to better 
identify the patients most likely to respond to PD-L1 therapy.<wbr> </div><div style="margin-bottom: 10px;">The lead investigator in the PD-L1 phase I study was Dr Micahel Gordon 
Research Director at the Pinnacle Oncology Hematology Unit in Scottsdale 
Arizona.<wbr> </div><div>Source: <A href="http://www.aacr.com">www.<wbr>aacr.<wbr>com</A> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20130431&edate=20130101&rec=8888">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-04-10T13:04:21+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-04-10T13:04:21+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>EMA Report on Patient Recruitment & Geographical Location Of Clinical Trials</title>
	<pubDate>2013-04-10T12:23:18+02:00</pubDate>
	<wp:post_id>4004</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: The EMA has publishe a report which reviews the geographical 
location of patients included in pivotal trials submitted in marketing 
applications to the European Medicine Agency between Jan 2005 and December 2011.<wbr> 
During this period 62% of patients were recruited outside of the European 
Economic Area.<wbr> </div><div style="margin-bottom: 10px;">More than 34% of patients were enrolled in North America, while almost 28% 
were recruited in Africa, the Middle East, Asia, the Pacific, Australia, New 
Zealand, Central or South America, the Commonwealth of Independent States (CIS) 
or non-European Union (EU) Eastern Europe.<wbr> Of note, 9.<wbr>4% of patients were 
recruited in the Middle East, Asia or the Pacific and another 9.<wbr>4% in Central or 
South America.<wbr> </div><div style="margin-bottom: 10px;">The information on the geographical location of clinical trials allows the 
European medicines network to allocate resources for inspections where they are 
most needed, and to promote cooperation with local regulators and 
capacity-building activities to support and strengthen local supervision in 
countries where clinical trials are being conducted today.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Major trends </STRONG> </div><div style="margin-bottom: 10px;">During the observation period the major trends in the number of patients 
submitted in MAAs to the European Medicines Agency are as shown below: </div><div style="margin-bottom: 10px;"><UL><LI>Middle East /<wbr> Asia /<wbr> Pacific: an increase from 2.<wbr>0% in 2005 to 12.<wbr>8% in 
  2011;</LI>
<LI class="last">CIS: an increase from 0.<wbr>8% in 2005 to 7.<wbr>5% in 2011.<wbr></LI>
<LI class="last">In the EU /<wbr> EEA /<wbr> European Free Trade Association (EFTA), there 
  was a decrease from 37.<wbr>0% in 2005 to 31.<wbr>2% in 2011.<wbr> Within this region, the 
  contribution of the 15 countries that were members of the EU before May 2004 
  plus Norway, Iceland and Liechtenstein fell from 32.<wbr>1% to 19.<wbr>4% over the 
  observation period.<wbr> The contribution of the countries that became Member 
  States of the EU in 2004 and 2007 increased from 4.<wbr>7% in 2005 to 11.<wbr>7% in 
  2011.<wbr></LI>
<LI class="last">In North America, there was a decrease from 42.<wbr>8% in 2005 to 
  31.<wbr>5% in 2011.<wbr></LI>
</UL> </div><div style="margin-bottom: 10px;"><STRONG>Evolution in GCP inspections</STRONG> </div><div style="margin-bottom: 10px;">The number of GCP inspections in third countries carried out by the 
inspectors of the national competent authorities of the EU /<wbr> EEA Member States 
on behalf of the EU has increased by more than four times between 2006 and 2011.<wbr> 
Both routine and triggered inspections have increased over the years.<wbr> </div><div style="margin-bottom: 10px;">A total of 357 sites were inspected at the request of the Agency's CHMP between 1997 and 2011, with most 
inspections taking place since 2007.<wbr> The pivotal trials submitted between 2005 
and 2011 involved 70,291 investigator sites.<wbr> </div><div style="margin-bottom: 10px;">The country outside of the EU /<wbr> EEA /<wbr> EFTA area with the highest number of 
requested inspections was the United States (21.<wbr>6%), followed by India (4.<wbr>5%), 
Canada (4.<wbr>5%), Russia (3.<wbr>1%), Argentina (2.<wbr>2%) and China (1.<wbr>7%).<wbr> </div><div style="margin-bottom: 10px;">The top three countries where bioequivalence trials 
for generic applications were inspected were India, Italy and Canada.<wbr> </div><div>A copy of the full report is attached for your review </div><!-- Comment details --><a name="pharmaworld10380attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10380_1_EMA%20Report%20On%20Clinical%20Trial%20Locations%20April%202013.pdf">EMA Report On Clinical Trial Locations April 2013.pdf</a>&nbsp;&nbsp;(655,5 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20130431&edate=20130101&rec=10380">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-04-10T12:23:18+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-04-10T12:23:18+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category pharma-news > <![CDATA[Pharma News]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>SMC Did Not Recommend BOTOX (Migraine) for Reimbursement</title>
	<pubDate>2013-04-09T17:50:02+02:00</pubDate>
	<wp:post_id>4005</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: In April, the Scottish Medicines Consortium (SMC) did not recommend the drug for the prophylaxis of headaches in adults with chronic migraine.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">The supporting evidence came from two Phase III studies: <STRONG>PREEMPT 1 and 2</STRONG>.<wbr> </div><div style="margin-bottom: 10px;">The SMC considered that pooled analysis of the two pivotal studies showed that Botox significantly reduced the frequency of headache days in comparison to placebo.<wbr> </div><div style="margin-bottom: 10px;">The cost-utility analysis submitted by the company estimated the base-case incremental cost per QALY to be GBP12,176, based on an incremental cost of GBP1,012 and a QALY gain of 0.<wbr>08.<wbr> </div><div style="margin-bottom: 10px;">However, the sensitivity analyses showed that the results were sensitive to the assumed transitional probabilities, changes in utility values, the time horizon, the stopping criteria and cost of Botox, and its administration.<wbr> </div><div style="margin-bottom: 10px;">Given the uncertainties, the economic case was not considered to be demonstrated.<wbr> </div><div><EM>Source: Global Insight</EM> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20130431&edate=20130101&rec=6952">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-04-09T17:50:02+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-04-09T17:50:02+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Highlights from Anti-aging Medicine World Congress (AMWC) – Focus on Competitors</title>
	<pubDate>2013-04-09T13:59:02+02:00</pubDate>
	<wp:post_id>4006</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Allergan had a strong presence with an all day Master Class Sympo, a Come Meet the Experts area on its booth, and an Expert Meeting in Cannes.<wbr> Merz presented its new free online platform, celebrated the 10 years of Radiesse(R), and dedicated its two-hour sympo to “Real world meets ideal world”.<wbr> Medy-Tox celebrated with champagne the completion of its second plant (for the EU market), and Hugel promoted Dermalax™, its new CE certified HA filler.<wbr> More details are provided below.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Launched in Paris in 2003 and taking place annually in Monaco since 2005, the Anti-aging Medicine World Congress (AMWC) has over the last 10 years become the largest world congress in this area.<wbr> Over 7500 participants from &gt;120 countries WW were expected.<wbr> </div><div style="margin-bottom: 10px;">This year, the congress has honored Russian Federation.<wbr> The 1st AMWC EEU will take place in Moscow (June 14-15, 2013).<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><U>Booth</U> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6948_1_ScreenCapture1.jpg"> </div><div style="margin-bottom: 10px;"><U>Sympo</U> </div><div style="margin-bottom: 10px;">- The satellite symposium entitled “The Power of V4 in facial rejuvenation: a new “whole face” approach” was relayed live on Allegan’s booth.<wbr> It was centered on anatomy of the face and linked with techniques of injection for toxin and fillers, and organized in 3 sessions: </div><div style="margin-bottom: 10px;">The “perioral area”, the “midface area” and the “periorbital” sessions were organized in the same way: first part dedicated to an Allergan product, the second to anatomy, physiology and the effect of aging, and the third to a live demonstration.<wbr> </div><div style="margin-bottom: 10px;">- At the end of the congress Allergan sponsored its first Expert Meeting of 2013 in Cannes.<wbr> The objectives of this meeting were to provide with knowledge on how to educate and train others on the strategies used to treat the perioral, midface and periorbital areas, first individually and then as part of the whole face approach, and guidance on how to deliver high-quality and engaging presentations.<wbr> </div><div style="margin-bottom: 10px;"><U>Poster</U> </div><div style="margin-bottom: 10px;">Key posters which show studies conducted by very well-known KOLs from US and Canada: </div><div style="margin-bottom: 10px;"><B>A Multi-center Randomized, Placebo-controlled Study to Evaluate the Efficacy and Safety of repeat  with onabotulinumtoxinA</B> <U>Jean Carruthers</U> The conclusions indicate that repeated onabotulinumtoxinA of CFL alone or concurrently with GL are associated with significantly reduced CFL severity as well as significantly higher subject satisfaction and additional patient-reported outcomes.<wbr> The safety profile was consistent with the approved GL indication.<wbr> </div><div style="margin-bottom: 10px;">() </div><div style="margin-bottom: 10px;"><STRONG>Safety and Efficacy Study of Botulinum Toxin Type A for the  </STRONG><U>Dr Nowell Solish</U> </div><div style="margin-bottom: 10px;">Study design:<STRONG> </STRONG><A href="http:///“,”http://clinicaltrials.gov/ct2/show/NCT01391299?term=NCT01391299&amp;rank=1“,”">http:/<wbr>/<wbr>clinicaltrials.<wbr>gov/<wbr>ct2/<wbr>show/<wbr>NCT01391299?term=NCT01391299&amp;rank=1</A> </div><div style="margin-bottom: 10px;">() </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><UL><LI></LI>
<LI></LI>
</UL> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><U>On the Booth</U> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6948_5_ScreenCapture3.jpg"> </div><div style="margin-bottom: 10px;"><U>Sympo</U> </div><div style="margin-bottom: 10px;">The fully attended symposium titled “Real world meets ideal world — from single syringe to multiple injectables” was chaired by Prof N.<wbr> Zerbani (Italy) and co-chaired by Dr T.<wbr> Pavicic (Germany).<wbr> </div><div style="margin-bottom: 10px;">The objectives were to provide insights into how best to inject Radiesse, and the considerations to take into account when shaping the face with Bocouture, Glytone and Radiesse.<wbr> </div><div style="margin-bottom: 10px;">Dr K.<wbr> Goldie (UK), Dr M.<wbr> Imhof (Germany), and Dr M.<wbr> Landau (Israel) shared their best injection practice of Radiesse.<wbr> Dr J.<wbr> van Loghem (Netherlands) demonstrated how to combine the 3 products for a full face approach.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6948_6_ScreenCapture4.jpg"> </div><div style="margin-bottom: 10px;">The free online platform (<A href="http:///“,”http://www.merzaesthetics.eu/expertsarea“,”">www.<wbr>merzaesthetics.<wbr>eu/<wbr>expertsarea</A>) presented in the Expert’s area of the booth, is an interactive tool (such as treatment test, a personalized library) and contains videos and pictures for physicians.<wbr> A Doc Check account is necessary to access it.<wbr> </div><div style="margin-bottom: 10px;"><B>Hugel Pharma Presence</B> </div><div style="margin-bottom: 10px;"><U>Booth</U> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6948_7_ScreenCapture5.jpg"> </div><div style="margin-bottom: 10px;"><STRONG>Dermalax Technology</STRONG> </div><div style="margin-bottom: 10px;"><UL><LI>Crosslinked HA soft tissue filler</LI>
<LI>Duration: &gt;12 months</LI>
<LI>The company indicated that 'Dermalax Deep' already is CE ceritifed, and that others will be around Q3:13.<wbr></LI>
</UL> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6948_8_ScreenCapture6.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6948_9_ScreenCapture7.jpg"> </div><div><STRONG>With many thanks to the Aesthetic Franchise for their reading and additional comments and feedback.<wbr></STRONG> </div><!-- Comment details --><a name="neurology6948attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6948_2_Allergan%255fA%20Multi%2dcenter%20Randomized,%20Placebo%2dcontrolled%20Study%20to%20Evaluate%20the%20Efficacy%20and%20Safety%20of%20repeat%20Treatments%20of%20Crows%e2%80%99s%20Feet%20lines%20and%20Glabellar%20Lines%20with%20onabotulinumtoxinA.jpg">Allergan_A Multi-center Randomized, Placebo-controlled Study to Evaluate the Efficacy and Safety of repeat Treatments of Crows’s Feet lines and Glabellar Lines with onabotulinumtoxinA.jpg</a>&nbsp;&nbsp;(3,3 MB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6948_3_Allergan%255fSafety%20and%20Efficacy%20Study%20of%20Botulinum%20Toxin%20Type%20A%20for%20the%20Treatment%20of%20Forehead%20and%20Frown%20Lines.jpg">Allergan_Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Forehead and Frown Lines.jpg</a>&nbsp;&nbsp;(3,4 MB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6948_4_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(119,9 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20130431&edate=20130101&rec=6948">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-04-09T13:59:02+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-04-09T13:59:02+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Roche & ISIS Enter Huntington's Disease Drug Development Deal Valued At > $390m</title>
	<pubDate>2013-04-09T11:26:27+02:00</pubDate>
	<wp:post_id>4007</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Roche &amp; ISIS Pharmaceuticals announced a deal late yesterday to develop a treatment for Huntington's disease combining ISIS's antisense technology with Roche's brain shuttle programme.<wbr> The latter facilitates the penetration of drugs into the brain.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Deal Terms</STRONG> </div><div style="margin-bottom: 10px;">Roche has agreed to make a $30m upfront payment securing the option to license the developed drugs through the completion of the first phase I trial.<wbr> Isis will be eligible to receive up to $362m in milestone payments as well as tiered royalties on sales.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Initial Focus Of The Collaboration</STRONG> </div><div style="margin-bottom: 10px;">Isis's drug candidates ISIS-388241, ISIS-387898 and ISIS-408737 that block all forms of the huntingtin protein will form part of the initial focus of the collaboration.<wbr> If Roche exercises its option, it will assume responsibiliity for all global development regulatory and commercialisation activitities.<wbr> Meanwhile, ISIS will be responsible for the discovery and development of candidates prior to Roche exercising its option.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Preclinical Data On The ISIS Drugs</STRONG> </div><div style="margin-bottom: 10px;">In October 2012, preclinical data were presented at the 42nd Annual SFN Meeting in New Orleans, LA.<wbr> In primary paired cortical neurons from YAC18 and BACHD mice, the lead ASO showed mutant huntingtin protein (HTT) knockdown from 39 to 68% and negligible wild-type HTT knockdown.<wbr> In the humanized cell line, Hu97/<wbr>18, without induction of CNS toxicity, intracerebroventricular injection of the lead ASOs exhibited 70 to 85% mutant HTT knockdown and 0 to 24% wild-type HTT knockdown.<wbr> </div><div style="margin-bottom: 10px;">Commenting on its preclinical data Frank Bennett Senior VP of Research noted:- </div><div style="margin-bottom: 10px;">"Over the past several years, we've been working closely with Dr.<wbr> Don Cleveland at the Ludwig Institute at UCSD and the CHDI Foundation to develop antisense drugs that have demonstrated activity in animal models of the disease.<wbr> In these studies, we've been able to demonstrate that inhibiting production of both forms of the huntingtin protein reverses Huntington's disease-like signs in these models.<wbr>" </div><div style="margin-bottom: 10px;"><P class="pwrapper">"This work, which was published in Neuron last year, is encouraging and suggests that simultaneously inhibiting or reducing both the normal and the abnormal huntingtin protein could halt disease progression without any deleterious effects.<wbr> We believe that this approach could be therapeutically beneficial for all patients with Huntington's disease.<wbr>"</P> </div><div style="margin-bottom: 10px;"><P class="pwrapper">"In parallel, in conjunction with Dr.<wbr> David Corey of the University of Texas Southwest (sic) [Southwestern] (09:46) Medical School and other collaborators, we have developed antisense drugs that selectively inhibit the production of only the abnormal huntingtin protein, leaving the normal form of the protein alone.<wbr> This personalized approach would target subsets of Huntington's patients based upon the sequence of their huntingtin gene and could be used to develop a suite of antisense drugs each unique to particular huntingtin gene sequence.<wbr>"</P> </div><div style="margin-bottom: 10px;"><P class="pwrapper">"While this approach would require us to develop and test several drugs, it offers the best opportunity to selectively reduce abnormal huntingtin protein in the patient without affecting levels of the normal huntingtin protein.<wbr>"</P> </div><div style="margin-bottom: 10px;"><STRONG>Other Companies With An Antisense/<wbr>siRNA Therapeutic Approach</STRONG> </div><div style="margin-bottom: 10px;">Amongst the raft of other companies focused on the development of drug's for Huntington's Disease those targeting suprrsion of the Huntington protein with either an antisense or siRNA therapeutic approaches include Alnylam.<wbr>.<wbr> Benitiec, Sangamo, and Lundbeck.<wbr> All candidates are currently in preclinical development.<wbr> </div><div style="margin-bottom: 10px;">Commenting on the differences between the two approaches Stanley Cooke Chairman &amp; CEO of ISIS stated </div><div style="margin-bottom: 10px;">"Of course, the mechanisms are similar in that you're using oligonucleotides to target an RNA and cause its degradation.<wbr> Beyond that, though, there are very meaningful differences.<wbr> siRNA – traditional siRNA, other than the single-strand siRNA that we created, uses double-stranded RNA molecules.<wbr> And as a consequence of the physical chemical properties of those molecules, the challenges of delivery of siRNA are still substantial and require either lipid formulations o r for the liver at least, GalNAc.<wbr>".<wbr> </div><div style="margin-bottom: 10px;"><P class="pwrapper">"Looking in the brain, the distribution of single-strand antisense drugs that we're using in this program is much broader.<wbr> And as a consequence, we see much greater efficacy and breadth of utility in the central nervous system than I think has been seen with siRNA.<wbr>"</P> </div><div style="margin-bottom: 10px;"><P class="pwrapper"><STRONG>Current Status Of The Progamme</STRONG></P> </div><div style="margin-bottom: 10px;"><P class="pwrapper">The program is apparently still in the discovery phase – late-discovery phase.<wbr> So, the next step is to select the first development candidate and then moving into toxicology.<wbr> When the lead candidate does enter phI which is still some time away it is likely to be tested in patients not in human volunteers because of the intrathecal nature of the administration.<wbr></P> </div><div style="margin-bottom: 10px;"><P class="pwrapper">Clinical development will begin, as is typical, in patients with significant disease.<wbr> As more is known about whether the drug is bringing benefit and what the side effects are, ISIS is confident that over time the drugs will be used earlier and earlier in the disease.<wbr> </P> </div><div>Source: <A href="http://www.isis.com/">www.<wbr>isis.<wbr>com</A> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20130431&edate=20130101&rec=6944">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-04-09T11:26:27+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-04-09T11:26:27+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>re: Recent published results about two innovative pharmaceutical forms of leuprorelin</title>
	<pubDate>2013-04-09T09:16:37+02:00</pubDate>
	<wp:post_id>4008</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="border-left: 2px solid #8B1010; padding: 0px 0px 5px 12px; margin-bottom: 3px;"><span style="font-size: 12px;">Very interesting paper which shows that a 5mg dose of leuprorelin could be sufficient to cover a 3 month release in achievieng testosterone suppression .<wbr> For the ones which were part of the "microimplant" IPSEN  project of Barcelona some years ago , similar results were obtained in phase 1.<wbr> In a nutsheel , if the SR formulation is able to limit /<wbr> suppress the initial release of LHRH analog (called "burst") , then it looks possible to reduce the amount of API in the formulation .<wbr>.<wbr>.<wbr>.<wbr></span>&nbsp;<br></div><div style="margin-bottom: 10px;">Interesting data to support the difference in API concentration between the implant and microsphere leuprolide formulations.<wbr> </div><div style="margin-bottom: 10px;"><SPAN style="line-height: 1.5em;">In Greece the leuprolide implant product is under the brand name Prostaplant and is marketed by  local company Lavipharm.<wbr> it was launched Dec 2011 and end of 2012 </SPAN> </div><div><SPAN style="line-height: 1.5em;">reached a 3.<wbr>2% MS in volumes.<wbr> </SPAN> </div><!-- Comment details --><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20130431&edate=20130101&rec=10378">Add a Comment on this Article</a><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10375">View thread  PharmaWorld10375: Recent published results about two innovative pharmaceutical forms of leuprorelin</a>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-04-09T09:16:37+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-04-09T09:16:37+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category pharma-news > <![CDATA[Pharma News]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Paper Clarifies Biological Activity of Daewoong's BoNT-A</title>
	<pubDate>2013-04-08T18:16:07+02:00</pubDate>
	<wp:post_id>4009</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: The paper shows that the characteristics of Botox(R) and DWP450 are almost the same.<wbr> The effectiveness was evaluated in terms of the compound muscle action potential (CMAP) and conduction velocity after injection.<wbr> Authors conclude that DWP450 used in this electrophysiological study had similar effect compared with Botox(R), and propose that a split-body electrophysiological protocol will be useful in establishing the comparative effectiveness of new BTX products.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6933_1_ScreenCapture1.jpg"> </div><div style="margin-bottom: 10px;">Of note, the research received no specific grant from any funding.<wbr> </div><div><A href="http://ipsen-london.beaufour-ipsen.com/priv/Kim2013HET.pdf">http:/<wbr>/<wbr>ipsen-london.<wbr>beaufour-ipsen.<wbr>com/<wbr>priv/<wbr>Kim2013HET.<wbr>pdf</A> </div><!-- Comment details --><a name="neurology6933attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6933_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(75,2 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20130431&edate=20130101&rec=6933">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-04-08T18:16:07+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-04-08T18:16:07+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Highlights from Anti-aging Medicine World Congress (AMWC) – Focus on Botulinum Toxin</title>
	<pubDate>2013-04-08T17:48:47+02:00</pubDate>
	<wp:post_id>4010</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: This report provides key messages from the four-hour session on botulinum toxin, such as the results from a small pilot study using the micro droplet technique for crow’s feet using (incobotulinumtoxinA), the outcomes of a Swiss study on the QoL before and after treatment of focal hyperhidrosis, and the safety of toxin and HA in the same syringe presented by A Pickett.<wbr> In order to get the best of muscular balance, many speakers did emphasize the importance of a good knowledge in anatomy and physiology as well as injection technique.<wbr> Of note the Myoscience’s Focused Cold Therapy, once again presented as an alternative treatment to neurotoxin, expected to reach the EU market this year.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Launched in Paris in 2003 and taking place annually in Monaco since 2005, the Anti-aging Medicine World Congress (AMWC) has over the last 10 years become the largest world congress in this area.<wbr> Over 7500 participants from &gt;120 countries WW were expected.<wbr> </div><div style="margin-bottom: 10px;">This year, the congress has honored Russian Federation.<wbr> The 1<SUP>st</SUP> AMWC EEU will take place in Moscow (June 14-15, 2013).<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Comment: Micro droplet technique with BoNT-A is a common treatment option in skin rejuvenation.<wbr> Nevertheless scientific data are rare.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> presented selected results from a small pilot study titled “Micro droplet Technique with incobotulinumtoxinA for the treatment of crow’s feet” (<I>submitted</I>).<wbr> Study design: </div><div style="margin-bottom: 10px;"><UL><LI>Recruitment: 4 women aged 18-85 years with moderate to severe LCL (CF) at maximum expression (Merz’ scale severity score 3 to 4) and in a stable medical condition.<wbr></LI>
<LI>Objective: to investigate the efficacy and safety of the addition of the micro droplet technique to conventional injections for the treatment of CF with botulinum toxin type A, free from complexing proteins (<STRONG>incobotulinumtoxinA</STRONG>).<wbr></LI>
<LI>Time of investigation: Day 0 (visit 1); week 4 (visit 2); week 12 (visit 3).<wbr></LI>
<LI>Subject assessment and investigator assessment (see below) were evaluated.<wbr></LI>
</UL> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6931_1_ScreenCapture1.jpg"> </div><div style="margin-bottom: 10px;">His conclusion is that the addition of the micro droplet technique to standard practice for injecting incobotulinumtoxinA is a promising procedure for the treatment of CF in women with moderate to severe wrinkles, and that the technique is well tolerated and safe.<wbr> </div><div style="margin-bottom: 10px;">He added that although this is a limited set of data, it provides insights into the potential for this technique and should serve as a stimulus for larger studies to evaluate the benefits of the microdroplet technique for CF as well as rhytides in other facial areas.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> concluded her presentation outlining that botulinum toxin probably works for very fine lines, whereas for severe peri-oral wrinkles combination therapy is required.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6931_2_ScreenCapture2.jpg"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> presented the challenge of BoNT in the lower face such as the difficulty to identify the specific muscles (more subcutaneous tissue in the lower face, thicker dermis, proximity between antagonistic muscles) that can lead to injection in the wrong muscle.<wbr> </div><div style="margin-bottom: 10px;">He highlighted considerable risk of side effects.<wbr> He also warned on the importance of the patient selection and suggested a combination of filler, surgery and BoNT-A for the best clinical results.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"> presented selected results from a Swiss cross selectional longitudinal study on the life quality before and after treatment of focal hyperhidrosis.<wbr> Key slides are presented below: </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6931_3_ScreenCapture3.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6931_4_ScreenCapture4.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6931_5_ScreenCapture5.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6931_6_ScreenCapture6.jpg"> </div><div style="margin-bottom: 10px;"><U>Dilution</U>: Because injection of the toxin is painful, he suggested the reconstitution of the toxin with preserved saline (“Pain difference associated with injection of abobotulinumtoxinA reconstituted with preserved saline and preservative-free saline: a prospective, randomized, side-by-side, double-blind study”.<wbr> Allen SB; Goldberg NA — Dermatol Surg 2012).<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG>  presented: </div><div style="margin-bottom: 10px;">- the results of a small pilot study in 5 patients, treated for CG +/<wbr>- glabella with Perlane and Dysport in the same syringe.<wbr> After 8 weeks of observation, subjects reported they were all pleased with their results.<wbr> (Hyaluronic Acide Filler and Botulinum Neurotoxin Delivered Simultaneously in the Same Syringe for Effective and Convenient Combination Aesthetic Rejuvenation Therapy - J Drugs Dermatol.<wbr> 2010 Sep;9(9):1135-8.).<wbr> </div><div style="margin-bottom: 10px;">- the “pretty good” results obtained for “scratched faces” in 25 patients treated with 3 different BoNT, 3 different HA and different injection techniques, with a follow-up from 3 to 18 months (B.<wbr> Môle - Treatment of Dynamic Facial Wrinkles Through the Simultaneous Combined Use of Botulinum Toxin A and Hyaluronic Acid - Ann Chir Plast Esthet.<wbr> 2012 Jun;57(3):194-201. doi: 10.<wbr>1016/<wbr>j.<wbr>anplas.<wbr>2012.<wbr>02.<wbr>001.<wbr> Epub 2012 Mar 7.<wbr>).<wbr> </div><div style="margin-bottom: 10px;">When it comes to the safety, A.<wbr> Pickett concluded that those are preliminary studies only, and that great care is needed in BoNT dosage.<wbr> Also, HA properties are highly specific and adjusted to use, and that dilution may not give desired results.<wbr> In conclusion, he highlighted that more work is needed in controlled trials.<wbr> </div><div><STRONG>With many thanks to the Aesthetic Franchise for their reading and additional comments and feedback.<wbr></STRONG> </div><!-- Comment details --><a name="neurology6931attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6931_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(98,2 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6931_2_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(77,9 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6931_3_ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(81,3 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6931_4_ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(76,4 KB)<br>&nbsp;&nbsp;5.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6931_5_ScreenCapture5.jpg">ScreenCapture5.jpg</a>&nbsp;&nbsp;(81,4 KB)<br>&nbsp;&nbsp;6.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6931_6_ScreenCapture6.jpg">ScreenCapture6.jpg</a>&nbsp;&nbsp;(73,4 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20130431&edate=20130101&rec=6931">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-04-08T17:48:47+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-04-08T17:48:47+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Bavarian Nordic Takes Steps to Try & Shorten The Development Time Of Prostvac</title>
	<pubDate>2013-04-08T15:28:19+02:00</pubDate>
	<wp:post_id>4011</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Bavarian Nordic has reported on an agreed and updated 
statistical analysis plan with the FDA for its on-going PROSPECT PhIII trial of 
Prostvac in CRPC patients with metastatic disease, The trial now includes a 
pre-specified interim analysis of the data to evaluate whether the trial should 
be stopped early for efficacy reasons.<wbr> In the event of the latter a BLA could be 
filed earlier than anticipated.<wbr> </div><div style="margin-bottom: 10px;">There have been some issues with enrollment into the PROSPECT trial which is 
currently ongoing at almost 100 sites in 10 countries.<wbr> The new President of 
Bavarian Nordics Immunotherapeutics has recently taken steps to try and enhance 
recruitment.<wbr> Specifially efforst are now being directed towards high performing 
centres.<wbr> These new measures are aimed at completing enrolment within the next 
year.<wbr> </div><div>Source: <A href="http://www.bavarian.nordic.com">www.<wbr>bavarian.<wbr>nordic.<wbr>com</A> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20130431&edate=20130101&rec=8887">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-04-08T15:28:19+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-04-08T15:28:19+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Astellas and Ambrx Have Signed Oncology Deal Worth >$300M</title>
	<pubDate>2013-04-08T15:04:58+02:00</pubDate>
	<wp:post_id>4012</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: The deal covers the discovery and development of novel antibody drug conjugates (ADCs), which allow for the targeted delivery of drugs to the target tissue.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">In 2012, Ambrx had similar agreement with BMS and Merck KGaA<SPAN style="TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(49,102,50); TEXT-INDENT: 0px; DISPLAY: inline !important; FONT: 14px/22px Helvetica, Arial, sans-serif; WHITE-SPACE: normal; FLOAT: none; LETTER-SPACING: normal; COLOR: rgb(26,26,26); WORD-SPACING: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"></SPAN> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><U>Upfront payment</U>: Ambrx will receive $15M as well as &gt;$285M in potential near and long term research, development, regulatory and sales based milestones for an undisclosed number of targets for ADCs in oncology.<wbr> </div><div style="margin-bottom: 10px;"><U>Territory</U>: Astellas will receive worldwide rights to develop and commercialize ADCs for oncology.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Please see @: <A href="http://www.ambrx.com/technology/antibody-conjugates.aspx">http:/<wbr>/<wbr>www.<wbr>ambrx.<wbr>com/<wbr>technology/<wbr>antibody-conjugates.<wbr>aspx</A> </div><div><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8884_1_ScreenCapture1.jpg"> </div><!-- Comment details --><a name="oncology8884attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8884_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(60,9 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20130431&edate=20130101&rec=8884">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-04-08T15:04:58+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-04-08T15:04:58+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>re: Recent published results about two innovative pharmaceutical forms of leuprorelin</title>
	<pubDate>2013-04-08T09:43:52+02:00</pubDate>
	<wp:post_id>4013</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="border-left: 2px solid #8B1010; padding: 0px 0px 5px 12px; margin-bottom: 3px;"><span style="font-weight: bold; font-size: 14px;">Recent published results about two innovative pharmaceutical forms of leuprorelin</span>&nbsp;<br><span style="font-size: 12px;"><STRONG>Comment :</STRONG> <SPAN style="line-height: 1.5em;">Two innovative pharmaceutical forms of leuprorelin acetate have been developed as 1-month and 3-month implants for the treatment of advanced hormone-dependent prostate cancer.<wbr> </SPAN><SPAN style="line-height: 1.5em;">Results of clinical studies</SPAN><SPAN style="line-height: 1.5em;"> have been described in two recent publications.<wbr></SPAN></span>&nbsp;&nbsp;<a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20130431&edate=20130101&rec=10375">...</a><br></div><div>Very interesting paper which shows that a 5mg dose of leuprorelin could be sufficient to cover a 3 month release in achievieng testosterone suppression .<wbr> For the ones which were part of the "microimplant" IPSEN  project of Barcelona some years ago , similar results were obtained in phase 1.<wbr> In a nutsheel , if the SR formulation is able to limit /<wbr> suppress the initial release of LHRH analog (called "burst") , then it looks possible to reduce the amount of API in the formulation .<wbr>.<wbr>.<wbr>.<wbr> <a name="PharmaWorld10378c"></a><br><div style="border: 1px solid #AAA; background-color: #FFF; margin-left: 10px; padding: 5px;"><div style="margin-bottom: 10px;">Interesting data to support the difference in API concentration between the implant and microsphere leuprolide formulations.<wbr> </div><div style="margin-bottom: 10px;"><SPAN style="line-height: 1.5em;">In Greece the leuprolide implant product is under the brand name Prostaplant and is marketed by  local company Lavipharm.<wbr> it was launched Dec 2011 and end of 2012 </SPAN> </div><div><SPAN style="line-height: 1.5em;">reached a 3.<wbr>2% MS in volumes.<wbr> </SPAN> </div></div></div><!-- Comment details --><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20130431&edate=20130101&rec=10377">Add a Comment on this Article</a><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10375">View thread  PharmaWorld10375: Recent published results about two innovative pharmaceutical forms of leuprorelin</a>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-04-08T09:43:52+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-04-08T09:43:52+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category pharma-news > <![CDATA[Pharma News]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Recent published results about two innovative pharmaceutical forms of leuprorelin</title>
	<pubDate>2013-04-05T18:22:47+02:00</pubDate>
	<wp:post_id>4014</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;"><STRONG>Comment :</STRONG> <SPAN style="line-height: 1.5em;">Two innovative pharmaceutical forms of leuprorelin acetate have been developed as 1-month and 3-month implants for the treatment of advanced hormone-dependent prostate cancer.<wbr> </SPAN><SPAN style="line-height: 1.5em;">Results of clinical studies</SPAN><SPAN style="line-height: 1.5em;"> have been described in two recent publications.<wbr></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="line-height: 1.5em;">Implants have been probably formulated by Hexal company.<wbr> Hexal is a part of the Sandoz division of Novartis.<wbr> It is specialized in biosimilar products and in subcutaneous formulation.<wbr> In 2007 Hexal brought on the German market the first Leuprorelin depot for the treatment of advanced hormone-dependant prostate cancer.<wbr></SPAN> </div><div style="margin-bottom: 10px;">The first paper is a large post marketing surveillance study.<wbr> <SPAN style="line-height: 1.5em;">It assessed 818 patients with </SPAN><SPAN style="line-height: 1.5em;">advanced hormone-dependent prostate cancer </SPAN><SPAN style="line-height: 1.5em;">who were treated with three injections of either </SPAN><SPAN style="line-height: 1.5em;">the 1-month or 3-month implant.<wbr></SPAN> </div><div style="margin-bottom: 10px;">Compared with baseline, a significant decrease in both testosterone and PSA levels were measured after the first and second injections of leuprorelin implant.<wbr> These results were confirmed for both the 1-month and 3-month implants in separate analyses.<wbr> Switching, without treatment interruption, from Trenantone&reg; (Takeda Pharma GmBH, Aachen, Germany) to the leuprorelin implant resulted in a significant decrease in the mean serum testosterone concentrations (P &lt; 0.<wbr>05) and a nonsignificant increase in the proportion of patients reaching castrate testosterone levels, while the number of patients with PSA values &le;4 ng/<wbr>mL significantly increased (P = 0.<wbr>045).<wbr> </div><div style="margin-bottom: 10px;">In the second paper, t<SPAN style="line-height: 1.5em;">wo therapeutic studies of the 1-month implant were performed: a randomized, </SPAN><SPAN style="line-height: 1.5em;">controlled study comparing the leuprorelin implant with leuprorelin prolonged-release </SPAN><SPAN style="line-height: 1.5em;">microspheres (Enantone) as the active control; and a single-arm study of the leuprorelin </SPAN><SPAN style="line-height: 1.5em;">implant.<wbr> For the 3-month implant, four therapeutic studies were performed: a randomized, </SPAN><SPAN style="line-height: 1.5em;">controlled study comparing the leuprorelin implant with leuprorelin prolonged-release </SPAN><SPAN style="line-height: 1.5em;">microspheres (Trenantone) as the active control; a single-arm study of the leuprorelin </SPAN><SPAN style="line-height: 1.5em;">implant; and two long-term studies with the 3-month implant administered twice, either 12 </SPAN><SPAN style="line-height: 1.5em;">or 16 weeks apart.<wbr></SPAN> </div><div style="margin-bottom: 10px;">In the comparator-controlled studies, both implants were as effective as the microspheres for achieving successful testosterone suppression and normalization of prostate-specific antigen (PSA) levels.<wbr> </div><div style="margin-bottom: 10px;">Leuprorelin from the 3-month implant has an approximately fourfold higher bioavailability than in the prolonged-release microspheres; this explains why the 3-month implant formulation is at least as effective in achieving successful testosterone suppression despite containing less than half the amount of active substance.<wbr> </div><div style="margin-bottom: 10px;">Studies were funded by Sandoz International GmbH.<wbr> </div><div style="margin-bottom: 10px;">Second paper coauthors are employees of Hexal AG.<wbr> </div><div style="margin-bottom: 10px;">Source : <A href="http://link.springer.com/article/10.1007%2Fs12325-013-0010-y">http:/<wbr>/<wbr>link.<wbr>springer.<wbr>com/<wbr>article/<wbr>10.<wbr>1007%2Fs12325-013-0010-y</A> </div><div>and <A href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3547534/pdf/10.1177_1756287212471096.pdf">http:/<wbr>/<wbr>www.<wbr>ncbi.<wbr>nlm.<wbr>nih.<wbr>gov/<wbr>pmc/<wbr>articles/<wbr>PMC3547534/<wbr>pdf/<wbr>10.<wbr>1177_1756287212471096.<wbr>pdf</A> </div><!-- Comment details --><span style="font-weight: bold; font-style: italic;"><br>Comments</span><a name="PharmaWorld10377c"></a><br><div style="border: 1px solid #AAA; background-color: #FFF; margin-left: 10px; padding: 5px;"><div>Very interesting paper which shows that a 5mg dose of leuprorelin could be sufficient to cover a 3 month release in achievieng testosterone suppression .<wbr> For the ones which were part of the "microimplant" IPSEN  project of Barcelona some years ago , similar results were obtained in phase 1.<wbr> In a nutsheel , if the SR formulation is able to limit /<wbr> suppress the initial release of LHRH analog (called "burst") , then it looks possible to reduce the amount of API in the formulation .<wbr>.<wbr>.<wbr>.<wbr> <a name="PharmaWorld10378c"></a><br><div style="border: 1px solid #AAA; background-color: #FFF; margin-left: 10px; padding: 5px;"><div style="margin-bottom: 10px;">Interesting data to support the difference in API concentration between the implant and microsphere leuprolide formulations.<wbr> </div><div style="margin-bottom: 10px;"><SPAN style="line-height: 1.5em;">In Greece the leuprolide implant product is under the brand name Prostaplant and is marketed by  local company Lavipharm.<wbr> it was launched Dec 2011 and end of 2012 </SPAN> </div><div><SPAN style="line-height: 1.5em;">reached a 3.<wbr>2% MS in volumes.<wbr> </SPAN> </div></div></div></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20130431&edate=20130101&rec=10375">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-04-05T18:22:47+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-04-05T18:22:47+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category pharma-news > <![CDATA[Pharma News]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Has NanoMedicine Reached An Inflection Point?</title>
	<pubDate>2013-04-05T17:50:59+02:00</pubDate>
	<wp:post_id>4015</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment This is the question raised by two major collaborations struck within 
the first 14 weeks of the year, one with Amgen and the other with Pfizer.<wbr> Both 
deals signed with a private company Bind Therapeutics cover the development 
of so called "Accurins".<wbr> small molecule extended release formulations.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Deal Terms</STRONG> </div><div style="margin-bottom: 10px;">The Amgen partnership covering an undisclosed proprietary kinase inhibitor 
involved a $46.<wbr>5m upfront payment and development milestones of $134m </div><div style="margin-bottom: 10px;">The Pfizer partnership, by contrast, covering multiple undisclosed molecules 
was secured with a $50m upfront and milestones of $160m </div><div style="margin-bottom: 10px;"><STRONG>The Technology Platform</STRONG> </div><div style="margin-bottom: 10px;">Bind's technology is based around surrounding active ingredients with a 
capsule that contains targeting ligands and a resorbably shell that can 
disintegrate on a site-or disease -specific basis.<wbr> A surface layer of 
polyethylene glycol attracts water and makes the drug appear to immune cells as 
a water droplet and thus evades the body's resistance mechanisms.<wbr> </div><div style="margin-bottom: 10px;">The Accurins can incorporate a broad range of therapeutic payloads including 
small moleucules, peptides, proteins and nucleic acids such as siRNA and 
mRNA.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10374_2_ScreenCapture2.jpg"> </div><div style="margin-bottom: 10px;">Bind's own drug candidate BIND-014 is an Accurin that delivers docetaxel 
through targeting prostate-specific membrane antigen (PSMA).<wbr> BIND is presenting 
phI data with this product at the AACR meeting next week and has just started 
phII development.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Company Background</STRONG> </div><div style="margin-bottom: 10px;">Bind Therapeutics, based in Cambridge Masachusetts and a MIT 
spin-out, has raised more than $70m through venture financing since it was 
founded in 2007 including a $35m series D financing in 2011.<wbr> Backers include 
Polaris Venture Partners and ARCH Venture Partners.<wbr> </div><div><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10374_1_ScreenCapture1.jpg"> </div><!-- Comment details --><a name="pharmaworld10374attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10374_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(60,9 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10374_2_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(86,9 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20130431&edate=20130101&rec=10374">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-04-05T17:50:59+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-04-05T17:50:59+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category pharma-news > <![CDATA[Pharma News]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>The Rebirth Of Peptide Technology</title>
	<pubDate>2013-04-05T15:46:20+02:00</pubDate>
	<wp:post_id>4016</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Subscribers to Biocentury have been invited to download a 
complimentary copy of the inaugural issue of the The SciBx Collection access to 
which is provided through the link below.<wbr> The first issue focus on the 
increasingly important field of macrocycles and constrained peptides and 
highlights the rebirth in drug discovery that has happened over the last 5 years 
in which at least 12 biotech companies are now participating.<wbr> Almost half 
of these were founded in the last five years.<wbr> </div><div style="margin-bottom: 10px;">Link to publication and key companies highlighted are shown below.<wbr> </div><div style="margin-bottom: 10px;"><A href="http://www.biocentury.com/Data/StaticContent/ContentFiles/scibx%20collections%20april_web.pdf">http:/<wbr>/<wbr>www.<wbr>biocentury.<wbr>com/<wbr>Data/<wbr>StaticContent/<wbr>ContentFiles/<wbr>scibx%20collections%20april_web.<wbr>pdf</A> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10373_1_ScreenCapture1.jpg"> </div><div><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10373_2_ScreenCapture2.jpg"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10373_3_ScreenCapture3.jpg"> </div><!-- Comment details --><a name="pharmaworld10373attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10373_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(209,5 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10373_2_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(139,8 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10373_3_ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(185 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20130431&edate=20130101&rec=10373">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-04-05T15:46:20+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-04-05T15:46:20+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category pharma-news > <![CDATA[Pharma News]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Mutlinationals Turn Their Focus To Acquiring In Brazil</title>
	<pubDate>2013-04-05T13:07:40+02:00</pubDate>
	<wp:post_id>4017</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Three large multinationals are reportedly in a race to acquired the 
Brazilian company Ache Laboratories in a deal that could be worth over $5bn.<wbr> All 
three companies are eager to growh their business in Latin America particularly 
in Brazil.<wbr> </div><div style="margin-bottom: 10px;">Ache which was established in 1966 posesses over 260 brands marketed in appox 
605 dosage forms and covering 120 therapeutic classes.<wbr> Prescription products 
constitute over 80% of Ache's sales making it the leading supplier of 
prescription medicines in the country.<wbr> the group has over 3,300 employees 
including a sales force of over 1,800 professionals  and a presence in 
various other Latin Amercian countries outside Brazil including Mexico, Colombia 
&amp; Venezuela.<wbr> </div><div>Source: Pharma-E-Track </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20130431&edate=20130101&rec=10372">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-04-05T13:07:40+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-04-05T13:07:40+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category pharma-news > <![CDATA[Pharma News]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>New Medullary Thyroid Cancer Agent Moves Into PhII Development</title>
	<pubDate>2013-04-04T18:32:39+02:00</pubDate>
	<wp:post_id>4018</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: GlobeImmune has initiated a phII trial to evaluate its immunotherapy 
GI-6207 in patients with medullary thyroid cancer.<wbr> The drug is being developed 
as part of a collaborative R&amp;D agreement between the NCI and 
GlobeImmune.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Study Design</STRONG> </div><div style="margin-bottom: 10px;">The phII cross-over trial will enroll a total of 34 patients.<wbr> 
Patients will be treated with either GI-6207 for one year or be observed for six 
months and then treated with CI-6207 for one year.<wbr> The primary endpoint for the 
study will be the effect of FI-6207 on changes in calcitonin leves after 6 
months of treatment versus observation.<wbr> Calcitonin is a tumour marker that 
correlates with tumour size in MTC.<wbr> </div><div style="margin-bottom: 10px;">Observation is the current standard of care for minimally symptomatic MTC 
with low tumour burden.<wbr> However, in this setting GlobeImmune believes it will be 
able to evaluted GI-6207 induced immune responses and potentially correlate them 
with calcitonin levels in a short time-frame.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>What Is GI-6207</STRONG> </div><div>The product consists of whole, heat-killed recombinant S.<wbr>cerevisiae yeast 
genetically engineered to express a modified version of the human 
carcinoembryonic antigen (CEA) protein as the target cancer antigen.<wbr> CEA is 
over-expressed in multiple human epithelial cancers including MTC, where CEA is 
almost universally expressed and is a diagnostic marker of disease.<wbr> Preclinical 
studies have shown that GI-6207 can induce an immune respnose to CEA as well as 
therapeutic anti-tumour responses.<wbr> A previous phI study of monotherapy GI-6207 
demonstrated preliminary safety and tolerability, enhanced immune responses and 
stable disease in 20% (5/<wbr>25) of subjects beyond three months.<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20130431&edate=20130101&rec=7318">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-04-04T18:32:39+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-04-04T18:32:39+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category endocrinology > <![CDATA[Endocrinology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Zytiga's Authorisation & Reimbursement In Italy</title>
	<pubDate>2013-04-04T17:43:42+02:00</pubDate>
	<wp:post_id>4019</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Thanks to Davide Pugliese (Product Manager Italy), we have learnt 
that on the <SPAN lang="EN-US" style="FONT-FAMILY: Arial, sans-serif; COLOR: rgb(34,34,34); FONT-SIZE: 10pt">22nd March, Zytiga's authorisation and price agreement was 
published in the Official Gazette for the post-docetaxel setting.<wbr> 
</SPAN><SPAN lang="EN-US" style="FONT-FAMILY: Arial, sans-serif; COLOR: rgb(34,34,34); FONT-SIZE: 10pt">The ex-factory price negotiation is <B>€ 3850</B> (not including law discounts 5% +5%) 
for 1 month of therapy (120 tablet of 250 mg/<wbr>tablet).<wbr></SPAN> </div><div style="margin-bottom: 10px;"><SPAN lang="EN-US" style="FONT-FAMILY: Arial, sans-serif; COLOR: rgb(34,34,34); FONT-SIZE: 10pt">In addition there was a negotiation on additional discounts (not 
public).<wbr> It 'also provided a system of <B>payment by result and 
i</B></SPAN><SPAN style="FONT-FAMILY: Arial, sans-serif; COLOR: rgb(34,34,34); FONT-SIZE: 10pt">t 
was set an expenditure ceiling of € 33 million (for 12 months of sales), 
renewable on the same terms.<wbr> </SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="FONT-FAMILY: Arial, sans-serif; COLOR: rgb(34,34,34); FONT-SIZE: 10pt">If 
the company wants to renegotiate the ceiling (33 Mio), the price will need 
to be renegotiated accordingly.<wbr></SPAN> </div><div><SPAN lang="EN-US" style="FONT-FAMILY: Arial, sans-serif; COLOR: rgb(34,34,34); FONT-SIZE: 10pt">Note: the drug was considered a potential pharmacological innovation, 
but despite this, it’s under mandatory law discounts of 5% +5% (usually 
innovative medicines are excluded from these 
discounts).<wbr></SPAN> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20130431&edate=20130101&rec=8883">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-04-04T17:43:42+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-04-04T17:43:42+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Auxilium To Advance The Development Of Xiaflex For Frozen Shoulder Syndrome</title>
	<pubDate>2013-04-04T14:18:37+02:00</pubDate>
	<wp:post_id>4020</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Auxillium recently announced positive top-line data from a Xiaflex 
Frozen Shoulder Syndrome PhIIa study noting a statistical significant 
improvement in range of motion compared to exercise only.<wbr> The drug will now 
progress into a placebo controlled study in the 2H2013.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>What Is Frozen Shoulder Syndrome</STRONG> </div><div style="margin-bottom: 10px;">FSS is a common, prolonged, painful condition of the shoulder in which 
increased capsular collagen thickening and subsequent capsular contraction in 
the shoulder joint is thought to cause a loss of range of motion in the 
shoulder.<wbr>  The condition is believed to affect approximately two to five 
percent of the general adult population and the full duration of the disease can 
last from approximately 1 year to up to 3.<wbr>5 years.<wbr><SUP>1 
</SUP>  The majority of cases are currently managed conservatively 
with prolonged physical therapy and occasionally with steroid injections.<wbr><SUP>   </SUP>It is estimated that approximately 300,000 
cases of FSS are diagnosed annually and approximately 10% are treated with an 
invasive intervention (surgery or manipulation under anesthesia) on an annual 
basis.<wbr><SUP>2</SUP> </div><div style="margin-bottom: 10px;"><STRONG>Study Design</STRONG> </div><div style="margin-bottom: 10px;">The phase IIa study was an open-label, controlled 
dose-ranging study designed to assess the safety and efficacy of CCH for the 
treatment of Stage 2 unilateral idiopathic FSS in comparison to an exercise-only 
control group.<wbr> The study involved 50 adult men and women at 11 sites throughout 
the U.<wbr>S.<wbr>  Four cohorts of 10 patients each received up to three 
ultrasound-guided extraarticular injections of varying doses of CCH (ranging 
from 0.<wbr>29 mg to 0.<wbr>58 mg in three different volumes; 0.<wbr>5, 1.<wbr>0, or 2.<wbr>0 mL), 
separated by a minimum of 21 days.<wbr>  All patients were instructed to perform 
home shoulder exercises.<wbr> The fifth cohort of ten patients received no CCH 
injections and only performed home shoulder exercises.<wbr> The study's primary 
endpoint was the change (in degrees) from baseline to the day 92 follow-up in 
active forward flexion in the affected shoulder compared to the exercise-only 
cohort.<wbr>  Safety assessments were made during all study visits and 
immunogenicity testing was performed at screening and day 92.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Key Study Findings</STRONG> </div><div style="margin-bottom: 10px;">Both the 0.<wbr>58mg(1mL) and 0.<wbr>58mg(2mL) dosing arms showed 
positive, statistically significant improvement from baseline in forward flexion 
vs.<wbr> the exercise-only group.<wbr>  The 0.<wbr>58mg(1mL) dosing arm also showed 
statistically significant improvement from baseline in shoulder abduction vs.<wbr> 
the exercise-only group.<wbr>  Positive trends with improvement in degrees were 
also seen in other active range of motion ("AROM") assessments vs.<wbr> the 
exercise-only group.<wbr>  Twenty-nine study patients (72.<wbr>5%) received three CCH 
injections with 5 subjects receiving two injections and 6 subjects receiving one 
injection only.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Commenting on the results Dr James Tursi Auxilium's CMO 
stated</STRONG> </div><div style="margin-bottom: 10px;">"We are very pleased with study results demonstrating a dose response with 
CCH, significant improvement in multiple range of motion measurements and a 
well-tolerated safety profile in this phase IIa study.<wbr> We look forward to 
advancing the clinical development of CCH in Frozen Shoulder syndrome and are 
currently assessing options to determine the safest and optimal path forward in 
development.<wbr>" </div><div>Source: <a href="http://www.auxillium.com" class="defaultlink" title="www.auxillium.com">auxillium.com</a> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20130431&edate=20130101&rec=6930">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-04-04T14:18:37+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-04-04T14:18:37+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Registration Trial of Bayer's Visanne(R) Has Started in China</title>
	<pubDate>2013-04-03T18:30:13+02:00</pubDate>
	<wp:post_id>4021</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: The Ph3 study, started this month, will evaluate efficacy and safety of dienogest 2 mg oral tablets in the treatment of endometriosis.<wbr> PE will assess change of endometriosis associated pelvic pain (EAPP) measured by visual analog scale (VAS) from baseline to 24 weeks.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG><A href="http://clinicaltrials.gov/ct2/show/NCT01822080?recr=Open&amp;no_unk=Y&amp;phase=012&amp;fund=2&amp;rcv_s=03%2F03%2F2013&amp;rank=124"><STRONG></STRONG></A> </div><div style="margin-bottom: 10px;">2 study phases: a double-blind, randomized, placebo-controlled, parallel-group phase over 24 weeks, and an open-label extension phase with 2 mg DNG daily p.<wbr>o.<wbr> over 28 weeks for all subjects who completed the double-blind phase, irrespective of their treatment assignment in the first study phase.<wbr> </div><div style="margin-bottom: 10px;">Recruitment: 250 women </div><div style="margin-bottom: 10px;"><UL><LI>between 18 and 45 years of age, inclusive</LI>
<LI class="color-bullet" style="MARGIN-TOP: 0.7ex">with endometriosis confirmed by laparoscopy or laparotomy within five years but no later than 2 weeks before the Screening Visit</LI>
<LI class="color-bullet" style="MARGIN-TOP: 0.7ex">A score of at least 30 on a 100 mm visual analog scale (VAS) for endometriosis-associated pelvic pain at Screening Visit and Baseline Visit</LI>
<LI class="color-bullet" style="MARGIN-TOP: 0.7ex">Good general health (except for findings related to endometriosis, with or without infertility), as evidenced by medical history and complete physical and gynecological examination</LI>
<LI class="color-bullet" style="MARGIN-TOP: 0.7ex">Willingness to use a barrier method of contraception is required</LI>
</UL> </div><div style="margin-bottom: 10px;">Completion date: July 2014 - Feb 2015 </div><div>Location: China (20 sites) </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20130431&edate=20130101&rec=8879">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-04-03T18:30:13+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-04-03T18:30:13+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Cytokinetics Advances 2nd Neuromuscular Dysfunction Drug Into Clinic</title>
	<pubDate>2013-04-03T17:41:35+02:00</pubDate>
	<wp:post_id>4022</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Cytokinetics has announced the initiation of a first-in-humans, 
Phase I clinical trial of CK-2127107 in healthy male volunteers.<wbr> The drug 
is a novel small molecule activator of the fast skeletal muscle troponin 
complex, for the potential improvement of skeletal muscle function in 
diseases associated with neuromuscular dysfunction, muscular weakness, 
and/<wbr>or muscle fatigue e.<wbr>g.<wbr> ALS.<wbr> </div><div style="margin-bottom: 10px;">Like <I><STRONG>tirasemtiv</STRONG></I>, the lead drug candidate from the 
company’s skeletal muscle activator program, CK-2127107 slows the rate of 
calcium release from the regulatory troponin complex of fast skeletal muscle 
fibers, which sensitizes the sarcomere to calcium.<wbr> </div><div style="margin-bottom: 10px;">CK-2127107 was 
discovered in connection with Cytokinetics’ optimization of a different chemical 
series than that which produced <I>tirasemtiv</I>, which is currently being 
evaluated in BENEFIT-ALS (<B>B</B>linded <B>E</B>valuation of 
<B>N</B>euromuscular <B>E</B>ffects and <B>F</B>unctional <B>I</B>mprovement 
with <I><B>T</B>irasemtiv</I> in <B>ALS</B>).<wbr> BENEFIT-ALS is an international, 
double-blind, randomized, placebo-controlled, Phase IIb clinical trial designed 
to evaluate the safety, tolerability and potential efficacy of <I>tirasemtiv</I> 
in patients with amyotrophic lateral sclerosis (ALS).<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6929_1_ScreenCapture1.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6929_2_ScreenCapture2.jpg"> </div><div style="margin-bottom: 10px;">Advancing CK-2127107 to Phase I evaluation in healthy subjects is consistent 
with Cytokinetics’ corporate strategy to characterize a potential back-up 
compound to <I>tirasemtiv</I> in humans and to enable the evaluation of fast 
skeletal muscle troponin activation in a potentially broader set of clinical 
indications.<wbr> </div><div style="margin-bottom: 10px;"><B>About Cytokinetics </B> </div><div style="margin-bottom: 10px;">Cytokinetics is a 
clinical-stage biopharmaceutical company focused on the discovery and 
development of novel small molecule therapeutics that modulate muscle function 
for  Cytokinetics' lead drug candidate from its cardiac muscle 
contractility program, <I>omecamtiv mecarbil</I>, is in Phase II clinical 
development for the potential treatment of heart failure.<wbr> Amgen Inc.<wbr> holds an 
exclusive worldwide license (excluding Japan) to develop and 
commercialize <I>omecamtiv mecarbil</I> and related compounds.<wbr> Cytokinetics is 
independently developing <I>tirasemtiv</I> and CK-2127107.<wbr> <I>Tirasemtiv</I> is 
currently the subject of a Phase II clinical trials program and has been granted 
orphan drug designation and fast track status by the U.<wbr>S.<wbr> Food and Drug 
Administration and orphan medicinal product designation by the European 
Medicines Agency for the potential treatment of ALS.<wbr> </div><div><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6929_3_ScreenCapture3.jpg"> </div><!-- Comment details --><a name="neurology6929attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6929_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(95,7 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6929_2_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(87,6 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6929_3_ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(73,2 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20130431&edate=20130101&rec=6929">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-04-03T17:41:35+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-04-03T17:41:35+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Results of the Phase II Subcutaneous Pasireotide Extension Study in Acromegaly</title>
	<pubDate>2013-04-03T17:34:56+02:00</pubDate>
	<wp:post_id>4023</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: The full biochemichal control* at 6 months was met in 6 of the 26 evaluable patients (23%) .<wbr>The authors concluded that the response rate observed in this extension study is similar to that seen in the core study after 3 months of pasireotide (27%) and is consistent with the results of earlier studies of somatostatin analogues.<wbr> </div><div style="margin-bottom: 10px;">The 30 patients were selected for their response to pasireotide (biochemichal or clinical) at any of the 3 doses tested (200, 400 or 600 microg bid ) in the core study.<wbr> Dose adjustments were permitted up to 900 microg bid </div><div style="margin-bottom: 10px;">The proportions of patients with control of GH alone or IGF1 alone were also recorded at 6 months : 13/<wbr>26 (50%) achieved normal IGF1 and 12/<wbr>26 GH&lt;=2.<wbr>5 microg/<wbr>l.<wbr> </div><div style="margin-bottom: 10px;">*GH&lt;=2.<wbr>5 microg/<wbr>l and IGF1 within age and sex matched limits.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Long-term efficacy and safety of subcutaneous pasireotide in acromegaly: results from an open-ended, multicenter, Phase II extension study.<wbr> (NCT00171730)</STRONG> </div><div style="margin-bottom: 10px;">Authors Petersenn S ET AL.<wbr> Pituitary, 2013;():.<wbr>Electronic publication <A href="http://dx.doi.org/10.1007/s11102-013-0478-0" target="_blank">http:/<wbr>/<wbr>dx.<wbr>doi.<wbr>org/<wbr>10.<wbr>1007/<wbr>s11102-013-0478-0</A> </div><div style="margin-bottom: 10px;"><SPAN style="font-size: xx-small;"><EM>Pasireotide has a broader somatostatin receptor binding profile than other somatostatin analogues.<wbr> A 16-week, Phase II trial showed that pasireotide may be an effective treatment for acromegaly.<wbr> An extension to this trial assessed the long-term efficacy and safety of pasireotide.<wbr> This study was an open-label, single-arm, open-ended extension study (primary efficacy and safety evaluated at month 6).<wbr> Patients could enter the extension if they achieved biochemical control (GH &lt;= 2.<wbr>5 microg/<wbr>L and normal IGF-1) or showed clinically relevant improvements during the core study.<wbr> Thirty of the 60 patients who received pasireotide (200-900 microg bid) in the core study entered the extension.<wbr> At extension month 6, of the 26 evaluable patients, six were biochemically controlled, of whom five had achieved control during the core study.<wbr> Normal IGF-1 was achieved by 13/<wbr>26 patients and GH &lt;= 2.<wbr>5 microg/<wbr>L by 12/<wbr>26 at month 6.<wbr> Nine patients received pasireotide for &gt;=24 months in the extension; three who were biochemically controlled at month 24 had achieved control during the core study.<wbr> Of 29 patients with MRI data, nine had significant (&gt;=20 %) tumor volume reduction during the core study; an additional eight had significant reduction during the extension.<wbr> The most common adverse events were transient gastrointestinal disturbances; hyperglycemia-related events occurred in 14 patients.<wbr> Twenty patients had fasting plasma glucose shifted to a higher category during the extension.<wbr> However, last available glucose measurements were normal for 17 patients.<wbr> Pasireotide has the potential to be an effective, long-term medical treatment for acromegaly, providing sustained biochemical control and significant reductions in tumor volume</EM></SPAN> </div><div style="margin-bottom: 10px;"><STRONG>Pasireotide (SOM230) demonstrates efficacy and safety in patients with acromegaly: a randomized, multicenter, phase II trial.<wbr> (NCT00088582</STRONG> </div><div>Petersenn S; Schopohl J; ET AL  J Clin Endocrinol Metab, Jun 2010: vol.<wbr> 95: no.<wbr> 6: p.<wbr> 2781-9) <A href="http://jcem.endojournals.org/content/95/6/2781.full.pdf">http:/<wbr>/<wbr>jcem.<wbr>endojournals.<wbr>org/<wbr>content/<wbr>95/<wbr>6/<wbr>2781.<wbr>full.<wbr>pdf</A> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20130431&edate=20130101&rec=7314">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-04-03T17:34:56+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-04-03T17:34:56+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category endocrinology > <![CDATA[Endocrinology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>PROVENGE DTC Ads Are Stimulating Patient Interest</title>
	<pubDate>2013-04-03T17:21:49+02:00</pubDate>
	<wp:post_id>4024</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Leerink &amp; Swann published an investment note yesterday 
highlighting the positive impact Dendreon's DTC advertising is having on Google 
search on the drug with numbers at a two year high and surpassing the search 
record for Zytiga and Xtandi.<wbr> </div><div style="margin-bottom: 10px;">The analysts examined this data as an early indicator of the effectivenss of 
the campaign.<wbr> Although the early trends are encouragin and suggest DTC is having 
the intended impact, it remains to be seen if this increased search volume will 
yield more patients requensting and ultiately receiving the drug, particularly 
as such a campaign is untested in the oncology market.<wbr> </div><div style="margin-bottom: 10px;">Dendreon has stated that its expected television budget is $5m per 
quarter.<wbr> </div><div><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8877_1_ScreenCapture1.jpg"> </div><!-- Comment details --><a name="oncology8877attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8877_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(83,5 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20130431&edate=20130101&rec=8877">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-04-03T17:21:49+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-04-03T17:21:49+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>The Endometriosis Therapy Area Landscape</title>
	<pubDate>2013-04-03T16:06:09+02:00</pubDate>
	<wp:post_id>4025</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Competition currently evolves around follow-on products roll-out (such as hybrids of leuprorelin and triptorelin), local competitors (specifically in IC countries), and Bayer's VISANNE(R), an endometriosis focused product already marketed in some countries, and which recently entered Ph3 in Chinese patients.<wbr> You will find attached an overview of the competitive market in the endometriosis field, the strategy of the key players as well as a detailed profile of their product candidates.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8876_7_ScreenCapture6.jpg"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8876_6_ScreenCapture5.jpg"> </div><div><STRONG></STRONG> </div><!-- Comment details --><a name="oncology8876attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8876_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(38,7 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8876_2_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(104,4 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8876_4_ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(105,4 KB)<br>&nbsp;&nbsp;5.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8876_5_ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(106,2 KB)<br>&nbsp;&nbsp;6.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8876_6_ScreenCapture5.jpg">ScreenCapture5.jpg</a>&nbsp;&nbsp;(107,6 KB)<br>&nbsp;&nbsp;7.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8876_7_ScreenCapture6.jpg">ScreenCapture6.jpg</a>&nbsp;&nbsp;(46,2 KB)<br>&nbsp;&nbsp;9.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8876_9_TAL%255fEndometriosis%255fApril2013%20for%20Traction%255ffinalV1.pptx">TAL_Endometriosis_April2013 for Traction_finalV1.pptx</a>&nbsp;&nbsp;(779,2 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20130431&edate=20130101&rec=8876">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-04-03T16:06:09+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-04-03T16:06:09+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Valeant Tops its Offer for the Acquisition of Obagi</title>
	<pubDate>2013-04-03T14:33:57+02:00</pubDate>
	<wp:post_id>4026</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Valeant and Obagi have executed an amendment to their Agreement and Plan of Merger, dated March 29th as Valeant has come back with a higher bid.<wbr> The new offer now is $24.<wbr>00 per share in cash (vs $19.<wbr>75, and $22.<wbr>00 for Merz).<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">According to analysts, </div><div style="margin-bottom: 10px;">- With its network of over 6,500 physicians, Obagi is valuable to any serious aesthetic company that is trying to establish a U.<wbr>S.<wbr> presence.<wbr> From a Merz perspective, this physician network could strengthen the company's attempts to establish newly launched Xeomin as well as its dermal filler portfolio.<wbr> </div><div style="margin-bottom: 10px;">- To Valeant, Obagi's physician network may be a way to defend its recently acquired Medicis relationships.<wbr> </div><div><EM>Source: Cantor; Valeant</EM> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20130431&edate=20130101&rec=6926">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-04-03T14:33:57+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-04-03T14:33:57+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Aspireo Reports Results of Ph2a Study in Acromegaly Patients</title>
	<pubDate>2013-04-03T10:51:20+02:00</pubDate>
	<wp:post_id>4027</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Analysis of the results shows that Somatoprim demonstrated a dose-dependent effect on lowering excess hGH on treatment-naïve patients with acromegaly.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><U>NOTE</U></STRONG> </div><div style="margin-bottom: 10px;"><UL><LI>
Screening of the publication did not provide any additional information on the results.<wbr> </LI>
<LI>
Aspireo's PR seems to be the unique source of information.<wbr> </LI>
<LI>
Data may be presented at the next ECE congress (end of April 2013 in Copenhagen).<wbr></LI>
</UL> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">- to assess safety, tolerability and efficacy of single ascending doses of Somatoprim in up to 20 treatment-naïve acromegaly patients.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">No SAEs were reported, and the reported AEs were mild to moderate and of transient nature.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div>Please see <a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20130431&edate=20130101&rec=7158" class="defaultlink">Endocrinology7158: Aspireo Starts Ph2a Study with Somatoprim for Acromegaly</a>.<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20130431&edate=20130101&rec=7311">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-04-03T10:51:20+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-04-03T10:51:20+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category endocrinology > <![CDATA[Endocrinology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Revance Therapeutics Secures Financing For PhIII BoNT-A Trials</title>
	<pubDate>2013-04-02T18:18:39+02:00</pubDate>
	<wp:post_id>4028</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Revance has announced today that it has raised $33 million in a Series E financing and the conversion of $71 million in convertible debt into the Series E preferred stock.<wbr> The financing included significant investment from new and old investors.<wbr> </div><div style="margin-bottom: 10px;">The proceeds of the financing will be used to support the recently announced Phase 3 trials for the topical delivery of the botulinum toxin type A RT-001 to reduce the severity of crow&rsquo;s feet wrinkles (see <a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20130431&edate=20130101&rec=6894" class="defaultlink">Neurology6894: Revance Progress with its Topical Toxin for Moderate to Severe Crow's Feet Lines</a>).<wbr> Additionaly, it will be used to support the development of the injectable toxin RT002.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Venture Financing Scources</STRONG> </div><div style="margin-bottom: 10px;">Revance&rsquo;s investors include Essex Woodlands, NovaQuest Pharma Opportunities Fund, Delphi Ventures, Vivo Ventures, Technology Partners, Shepherd Ventures, Bio*One Capital and Pac-Link Ventures, Palo Alto Fund and other leading institutional investors.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Status of Other Development Programmes</STRONG> </div><div style="margin-bottom: 10px;">RT001 is also currently in Phase 2 trials for the topical treatment of hyperhidrosis and chronic migraine headache.<wbr> </div><div style="margin-bottom: 10px;">RT002 is currently in Phase 1/<wbr>2 trials.<wbr> </div><div>Source: <A href="http://www.revance.com">www.<wbr>revance.<wbr>com</A> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20130431&edate=20130101&rec=6922">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-04-02T18:18:39+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-04-02T18:18:39+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Merck Co Inc Signs 200 Million Peptide Deal With Ra Pharma</title>
	<pubDate>2013-04-02T18:08:07+02:00</pubDate>
	<wp:post_id>4029</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment Ra Pharmaceuticals today has entered into a collaboration with 
Merck,  focused on the development of Cyclomimetics™, a new class of 
peptide-like compounds that have the diversity and specificity of antibodies 
whilst retaining many of the charactersitics of small molecules.<wbr> </div><div style="margin-bottom: 10px;">Under the agreement, Ra Pharmaceuticals will use its proprietary Extreme 
Diversity™ platform to develop Cyclomimetic candidates for protein targets in 
multiple therapeutic areas.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Deal Terms</STRONG> </div><div style="margin-bottom: 10px;">Under the terms of the agreement, Ra Pharmaceuticals is eligible to receive 
up to $200 million in payments, including up-front and research funding, as well 
as upon the achievement of discovery, development, regulatory and 
commercialization milestones for multiple targets.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>About Cyclomimetics™ </STRONG> </div><div style="margin-bottom: 10px;">Cyclomimetics™ are peptide-like molecules characterized by their cyclic 
structure and backbone and side-chain modifications that provide unique, 
beneficial properties not found in natural peptides.<wbr> The result is a highly 
specific and stable molecule with improved cell permeability and the potential 
for greatly increased bioavailability.<wbr> </div><div style="margin-bottom: 10px;">Cyclomimetics are generated using the Company’s proprietary Extreme 
Diversity™ platform.<wbr> The platform is unique in that it combines in vitro display 
technology, a completely defined translation system and a wide variety of 
non-natural amino acids.<wbr> Unlike certain other display technologies, in vitro 
display does not require the use of a bacterial or yeast host, and it can 
produce libraries of 10 to 100 trillion members.<wbr> Further, the technology has the 
potential to address protein-protein interactions and other previously 
undruggable targets.<wbr> </div><div style="margin-bottom: 10px;">About Ra Pharmaceuticals </div><div style="margin-bottom: 10px;">Ra Pharma was incorporated in 2008 and secured a $27M Series A in February of 
2010 led by New Enterprise Associates with Morgenthaler Ventures, Novartis 
Venture Funds and Amgen Ventures participating.<wbr> </div><div>Source: <A href="http://www.merck.com">www.<wbr>merck.<wbr>com</A> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20130431&edate=20130101&rec=10368">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-04-02T18:08:07+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-04-02T18:08:07+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category pharma-news > <![CDATA[Pharma News]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Merz Overbids Valeant's Offer with a "Superior Proposal" for the Acquisition of Obagi</title>
	<pubDate>2013-04-02T17:14:46+02:00</pubDate>
	<wp:post_id>4030</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Merz Pharma today outlined a proposal to acquire all of the outstanding common stock of Obagi for $22 per share in cash (end of March, Valeant offered $19.<wbr>75$ per share in cash).<wbr>This proposal represents a 58% premium to Obagi’s closing share price on Thursday, March 14, 2013.<wbr> In a letter sent to the Board of Directors of Obagi, Merz CEO highlighted that 'the company has the necessary cash on hand to fund the transaction', with 'absolutely no financing risk'.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">- Given Merz’s portfolio of injectables, Obagi is a natural fit for Merz.<wbr> </div><div style="margin-bottom: 10px;">- This acquisition would also expand Merz U.<wbr>S.<wbr> market presence, and strengthen and diversify its dermatology portfolio through additional quality skin care options.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">In the Merz PR, it is reported that : On March 20, 2013, Obagi announced that it entered into a definitive merger agreement with Valeant Pharmaceuticals International, Inc.<wbr> At that time, Merz was engaged in ongoing discussions with Obagi regarding a potential combination, and was not made aware that Obagi was contemplating signing a deal with another party on an accelerated timeframe.<wbr> Merz has delivered its proposal to Obagi’s Board and believes it constitutes a “Superior Proposal” under the terms of the Obagi/<wbr>Valeant merger agreement.<wbr> Importantly, the Merz proposal also represents a significant premium to the offer from Valeant".<wbr> </div><div style="margin-bottom: 10px;">Reference in Traction CI, please See <a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20130431&edate=20130101&rec=6866" class="defaultlink">Neurology6866: Valeant to Acquire Obagi Medical for $344M</a>.<wbr> </div><div><EM>Source: <A href="http://www.merz.com/press/pressreleases/company_2/detail_1216.jsp?source=pmov&amp;tabId=1">Merz</A></EM> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20130431&edate=20130101&rec=6915">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-04-02T17:14:46+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-04-02T17:14:46+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Medivation/Astellas Provide Update on PREVAIL</title>
	<pubDate>2013-04-02T13:31:43+02:00</pubDate>
	<wp:post_id>4031</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: On a PR issued April 1st, Astellas announced that the companies have established an updated interim analysis plan expected to occur in 2013.<wbr>  </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">- <STRONG>PREVAIL Design</STRONG>: <A href="http://clinicaltrials.gov/ct2/show/NCT01212991?term=prevail&amp;rank=6">http:/<wbr>/<wbr>clinicaltrials.<wbr>gov/<wbr>ct2/<wbr>show/<wbr>NCT01212991?term=prevail&amp;rank=6</A>.<wbr> </div><div style="margin-bottom: 10px;">- <STRONG>Final Recruitment</STRONG>: 1,717  </div><div style="margin-bottom: 10px;">- <STRONG>Sites</STRONG> :  </div><div><EM>Source: Astellas</EM> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20130431&edate=20130101&rec=8870">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-04-02T13:31:43+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-04-02T13:31:43+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Industry's Largest Growth Drivers Through to 2017</title>
	<pubDate>2013-04-02T12:00:05+02:00</pubDate>
	<wp:post_id>4032</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Among the 10 products listed by <EM>First Word</EM>, one can note the Biogen Idec's Tecfidera (oral MS therapy), and Medivation/<wbr>Astellas' Xtandi.<wbr> The biggest growth driver is yet to launch (initial roll-out is expected in 2014).<wbr> Additionnal information as well as highlights on key points about Tecfidera, which is expected to become the first choice of treatment for MS, are provided below.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">- Gilead's Sofosbuvir (for hepatitis C) - sales growth 2012-2017 +4.<wbr>3 billion) </div><div style="margin-bottom: 10px;">- Roche's Perjeta (for HER2-positive breast cancer) </div><div style="margin-bottom: 10px;">- Merck's Januvia (for type 2 diabetes) </div><div style="margin-bottom: 10px;"><STRONG>- Biogen Idec's Tecfidera for MS</STRONG> - sales expected to reach approx.<wbr> $3.<wbr>3 billion by 2017 </div><div style="margin-bottom: 10px;">Approved last month, consensus among analysts, KOLs and physicians indicates the drug will emerge as the 1st-line treatment of choice for the condition over the next few years, despite being the third-to-market oral treatment (behind Novartis' Gilenya and Sanofi's Aubagio).<wbr> </div><div style="margin-bottom: 10px;"><UL><LI><U>DRUG POSITION</U>- Of 300 neurologists polled by FirstWord in 2012, 44% indicated that Tecfidera would likely be the oral MS therapy they would be prescribing the most in 2 years time.<wbr></LI>
<LI><U>DRUG EFFICAY/<wbr>SAFETY</U>- Consensus suggests that efficacy is comparable to Gilenya, but with superior safety.<wbr></LI>
<LI><U>DRUG INDICATION</U>- Tecfidera and Gilenya expected to vie for 1st-line status.<wbr> The drug will primarily assume market share from older injectable therapies (Avonex, Betaseron, Copaxone and Rebif collectively known as the ABCRs).<wbr> A recent poll of US-based neurologists demonstrated that 66% of respondents expect to first use Tecfidera at the expense of ABCR therapies.<wbr></LI>
<LI><U>COST OF TREATMENT</U>- The drug will be priced @ $54 900 per patient per year (lower that the $60 000 annual cost for Novartis' Gilenya, higher than Sanofi's Aubagio which costs $ 45 000 annually).<wbr></LI>
</UL> </div><div style="margin-bottom: 10px;">- AbbVie's Humira (for RA) </div><div style="margin-bottom: 10px;">- BMS' Eliquis for VT </div><div style="margin-bottom: 10px;">- Regeneron/<wbr>Bayer's Eylea for AMD </div><div style="margin-bottom: 10px;">- Celgene's Revlimid for MM </div><div style="margin-bottom: 10px;">- Gilead's Stribild for HIV </div><div style="margin-bottom: 10px;"><STRONG>- Medivation/<wbr>Astellas' Xtandi</STRONG> for prostate cancer - Second-to-market behind Zytiga </div><div><EM>Source: FirstWord</EM> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20130431&edate=20130101&rec=10363">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-04-02T12:00:05+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-04-02T12:00:05+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category pharma-news > <![CDATA[Pharma News]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Sanofi Reports Strategy to Grow Double-digit Sales in China</title>
	<pubDate>2013-04-02T11:21:43+02:00</pubDate>
	<wp:post_id>4033</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Sanofi CEO reported the company expects that its sales in China will grow by more than 10% over the next 5 years thanks to the expansion of the animal health and vaccines business in the country.<wbr> Globally, the group's ambitions is to reach double digit growth in emerging markets, rare diseases and multiple sclerosis (with the new Genszyme).<wbr> Additional steps are provided below.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">- Opening of 4 new manufacturing plants in 2013 to increase th eproduction of vaccines, drug, consumer HC and animal health products.<wbr> </div><div style="margin-bottom: 10px;">- Increasing the presence in China's smaller cities, as the government builds new hospitals and clinics.<wbr> </div><div style="margin-bottom: 10px;">- Discussion around the creation of a system with Chinese officials that would allow higher prices for medicines with longer development times, and larger investments.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Emerging markets, including China, accounted for 31.<wbr>9% of the company's revenue.<wbr> </div><div style="margin-bottom: 10px;">Sales in China recorded &gt; $1.<wbr>28 billion.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Growth ambition by Growth Platform (March 25th presentation): </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10362_1_ScreenCapture1.jpg"> </div><div><EM>Source: Sanofi; Wall Street Journal</EM> </div><!-- Comment details --><a name="pharmaworld10362attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10362_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(90,1 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20130431&edate=20130101&rec=10362">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-04-02T11:21:43+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-04-02T11:21:43+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category pharma-news > <![CDATA[Pharma News]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>EAU Highlights - Allergan Overview</title>
	<pubDate>2013-03-28T17:44:41+01:00</pubDate>
	<wp:post_id>4034</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Allergan will be launching their new MS screening tool next month and introduced the delegates to the BoNee Needle to aid injecting into the bladder.<wbr> </div><div style="margin-bottom: 10px;"><B>Intelligence uncovered regarding TheraCoat’s TC-3 Gel</B> — a novel Internal Cavity Drug Retention (ICDR) system via reverse thermal gelation technology (which is being mixed with mitomycin for NMIBC) is also being looked at in the US as a potential needle-free alternative to Botox for use in NDO or IOAB pts.<wbr> This study is investigator sponsored and at this time  no results are available.<wbr>  Allergan has not been in discussion with the company.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6908_1_ScreenCapture1.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6908_2_ScreenCapture2.jpg"> </div><div style="margin-bottom: 10px;">*Full company/<wbr>product slide deck available upon request* </div><div style="margin-bottom: 10px;">Allergan’s symposia was dedicated to discussing the DIGNITY data, injection tips and a patient video of injecting BOTOX with the BoNee needle.<wbr> The CI team was unable to attend but did speak to a representative on the stand who discussed the new MS Urinary Function Screening Tool which will be launched next month.<wbr> </div><div style="margin-bottom: 10px;">The stand had LCD screens showing DIGNITY data as well as a light panel highlighting the countries in the EU where Botox has been approved for NDO and iOAB.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6908_3_ScreenCapture3.jpg"> </div><div style="margin-bottom: 10px;"><STRONG>BoNee Needle</STRONG> </div><div style="margin-bottom: 10px;">The BoNee Needle was designed with Urologists to facilitate bladder wall injection.<wbr> It is not clear at this stage what the agreement or collaboration with Porges (a division of Coloplast) and Allergan is.<wbr> Both parties funded the symposia.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6908_4_ScreenCapture4.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6908_5_ScreenCapture5.jpg"> </div><div style="margin-bottom: 10px;"><STRONG>MS Screening Tool</STRONG> </div><div style="margin-bottom: 10px;">The screening tool is self-administered to help identify MS patients who could benefit from urologic evaluation.<wbr> </div><div style="margin-bottom: 10px;">Any checked box in the 3<SUP>rd</SUP> or 4<SUP>th</SUP> right hand column would incur a point.<wbr> A score of ≥3 would indicate that the patient may need further evaluation of their bladder health.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6908_6_ScreenCapture6.jpg"> </div><div><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6908_7_ScreenCapture7.jpg"> </div><!-- Comment details --><a name="neurology6908attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6908_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(82,3 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6908_2_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(96,5 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6908_3_ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(88,5 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6908_4_ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(7,4 KB)<br>&nbsp;&nbsp;5.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6908_5_ScreenCapture5.jpg">ScreenCapture5.jpg</a>&nbsp;&nbsp;(34,1 KB)<br>&nbsp;&nbsp;6.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6908_6_ScreenCapture6.jpg">ScreenCapture6.jpg</a>&nbsp;&nbsp;(77,8 KB)<br>&nbsp;&nbsp;7.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6908_7_ScreenCapture7.jpg">ScreenCapture7.jpg</a>&nbsp;&nbsp;(95,2 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20130431&edate=20130101&rec=6908">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-03-28T17:44:41+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-03-28T17:44:41+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Rituximab to be Investigated as Neoadjuvant Therapy for Prostate Cancer</title>
	<pubDate>2013-03-28T17:34:42+01:00</pubDate>
	<wp:post_id>4035</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: The small pilot study in 18 patients will determine whether depletion of B cells by rituximab will result in a decrease in the extent of B cell infiltration of the prostatic cancer.<wbr> PE will measure hsitologic RR after one cycle of the drug.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">There is now substantial evidence that B cells are recruited into prostate cancers by CXCL13 released by the tumor cells.<wbr> B cells release lymphotoxin which drives malignant cell proliferation through the NFkB pathway.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG><A href="http://clinicaltrials.gov/ct2/show/NCT01804712?recr=Open&amp;no_unk=Y&amp;fund=2&amp;rcv_s=02%2F28%2F2013&amp;rank=237"><STRONG></STRONG></A> </div><div style="margin-bottom: 10px;">Sponsor: St Howell, M.<wbr>D (U of California, San Diego) </div><div style="margin-bottom: 10px;">Collaborator: Genentech </div><div style="margin-bottom: 10px;">Start date: March 2013 </div><div style="margin-bottom: 10px;">Completion date: March 2016 /<wbr> March 2017 </div><div style="margin-bottom: 10px;">Location: USA </div><div><EM>Source: clinicaltrials.<wbr>gov</EM> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20130431&edate=20130101&rec=8869">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-03-28T17:34:42+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-03-28T17:34:42+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Eisai's NerBloc® Launched in Japan for Cervical Dystonia</title>
	<pubDate>2013-03-28T16:51:52+01:00</pubDate>
	<wp:post_id>4036</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Eisai launched NerBloc® Intramuscular Injection 2500 Units (botulinum toxin type B) on March 27 as a treatment for cervical dystonia.<wbr> The drug's efficacy was proved in the double-blind Study 131 trial against placebo, with the most common adverse events including difficulty in swallowing, dry mouth, and thirst.<wbr><BR> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">28,902 yen ($306.<wbr>54) per vial containing 2500U.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6903_1_ScreenCapture1.jpg"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Eisai acquired the exclusive rights to develop and market NerBloc in Japan from Elan in September 2000 and was approved as the marketing authorization holder following product development.<wbr> </div><div style="margin-bottom: 10px;">NerBloc was then listed on the National Health Insurance (NHI) drug price list on February 22, 2013.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><UL><LI><U>Study Design</U>: Multicenter, randomized, double-blind, placebo-controlled, parallel, dose-response trial</LI>
<LI>
<DIV><TR><TD scope="row"><U>Eligibility</U>:</TD>
</TR>

<TD>&nbsp;</TD>

 130 <TD>Patients with cervical dystonia (between 20 and 74 years old, inclusive)</TD>

 </DIV></LI>
</UL> </div><div style="margin-bottom: 10px;">
<UL><LI>
<DIV><U>Primary Objective</U>: <TD>&nbsp;</TD>

 <TD>Evaluation of safety and efficacy of botulinum toxin type B</TD>

 </DIV></LI>
</UL> </div><div style="margin-bottom: 10px;">
<UL><LI>
<DIV><U>Study Arms</U>: <TD>&nbsp;</TD>

 <TD>Botulinum toxin type B 2500, 5000 and 10000 units, placebo</TD>

 </DIV></LI>
</UL> </div><div style="margin-bottom: 10px;">
<UL><LI>
<DIV><U>Duration</U>: <TD>&nbsp;</TD>

 <TD>Single-dose administration</TD>

 </DIV></LI>
</UL> </div><div style="margin-bottom: 10px;">In a double-blind, placebo-controlled trial (Study 131) conducted by Eisai in Japan in patients with CD, NerBloc showed statistically significant improvement in TWSTRS (Toronto Western Spasmodic Torticollis Rating Scale) total score from baseline to week four versus placebo.<wbr> </div><div style="margin-bottom: 10px;">No serious side effects were reported, with the most common adverse events being difficulty in swallowing, dry mouth and thirst.<wbr> </div><div><EM>Source: Eisai</EM> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20130431&edate=20130101&rec=6903">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-03-28T16:51:52+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-03-28T16:51:52+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>EAU Highlights - Enzalutamide and TAK700 Data</title>
	<pubDate>2013-03-28T16:10:45+01:00</pubDate>
	<wp:post_id>4037</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Both Takeda with TAK700 and Astellas with Enzalutamide (XTANDI) highlighted their desire to move into additional earlier disease treatment settings, TAK700 into nmCPRC and enzalutamide into the hormone naive segement.<wbr>, The unmet need in the growing nmCRPC was highlighted by Axel Heindenreich, GTx's poster on Capesaris also garnered much attention due to the low rate of flushing observed compared to Lupron therapy.<wbr> </div><div style="margin-bottom: 10px;">Enzalutamide had little presence at this meeting with one phase II poster in hormone na&iuml;ve pts .<wbr> During the Astellas symposia, the link was made between enzalutamide's profile and the unmet needs in the pre-chemo CRPC setting with the slide below highlighted followed by a slide depicting the study schema for the PREVAIL trial.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8864_2_ScreenCapture2.jpg"> </div><div style="margin-bottom: 10px;">Intelligence uncovered by a PI with the PREVAIL study (pre-chemo) noted that the trial had completed enrollment in September 2012 and should read out after the summer.<wbr> This is slightly earlier than Medivation's recent guidance which pointed to a possible December timeframe (see <a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20130431&edate=20130101&rec=8831" class="defaultlink">Oncology8831: Medivation Guidance on PREVAIL & New Registrational Trials In Earlier Treatment Settings</a>).<wbr> </div><div style="margin-bottom: 10px;">The TERRAIN study (schema below) has reached 85% enrollment and should be fully enrolled in the next 3-4 months and hopefully read out at the beginning of 2014.<wbr> Druing Cora Steinberg&rsquo;s presentation, she mentioned that enzalutamide was 8x more potent that bicalutamide.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8864_3_ScreenCapture3.jpg"> </div><div style="margin-bottom: 10px;"><U>Poster 674 Enzalutamide Monotherapy: Results from a P2 study in hormone na&iuml;ve PCa pts</U> </div><div style="margin-bottom: 10px;">&sect; Primary objectives &mdash; effect of ENZ on PSA.<wbr> Secondary objectives included evaluation of effects on endocrine hormone levels and BMD, lean and fat body mass and safety/<wbr>tolerability.<wbr> </div><div style="margin-bottom: 10px;">&sect; 25 wk open label single arm study conducted across 12 sites in Austria, Belgium, Denmark, Czech Republic and Germany </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8864_4_ScreenCapture4.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8864_5_ScreenCapture5.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8864_6_ScreenCapture6.jpg"> </div><div style="margin-bottom: 10px;">Finally, during Axel wrap up session, he presented &lsquo;what is new with enzalutamide&rsquo; </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8864_7_ScreenCapture7.jpg"> </div><div style="margin-bottom: 10px;">TAK700 also had little on display with a phase 2 poster in nmCRPC pts.<wbr> However, during Axel Heidenreich&rsquo;s talk, which provided a round up of activities in the CRPC space the unmet need in this area was mentioned.<wbr> Attached is a recent poster from ESMO which highlights the growing prevalence in the European markets.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8864_8_ScreenCapture8.jpg"> </div><div style="margin-bottom: 10px;"><U>Poster 100: A phase II study of TAK700 in nmCRPC and rising PSA pts.<wbr> Data are presented as of 25<SUP>th</SUP> Jan 2013 and the study is currently ongoing</U> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8864_9_ScreenCapture9.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8864_10_ScreenCapture10.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8864_11_ScreenCapture11.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8864_12_ScreenCapture12.jpg"> </div><div style="margin-bottom: 10px;">An interesting phase II poster presented with GTx-758 (Capesaris&reg;) a selective estrogen receptor (ER) alpha agonist.<wbr> This poster was selected as one of the best posters at the EAU and was garnering much attention from the delegates.<wbr> </div><div style="margin-bottom: 10px;">A new phase 2 study will start in the autumn looking at lower doses as they have seen the same effect with 125mg-500mg as with the 1000mg.<wbr> The author stated <EM>the PSA change is nothing to write home about yet, it&rsquo;s really the side effect profile, "hot flashes in particular we are excited about.<wbr>"</EM> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8864_13_ScreenCapture13.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8864_14_ScreenCapture14.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8864_15_ScreenCapture15.jpg"> </div><div><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8864_16_ScreenCapture16.jpg"> </div><!-- Comment details --><a name="oncology8864attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8864_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(62 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8864_2_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(62,9 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8864_3_ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(49 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8864_4_ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(96,4 KB)<br>&nbsp;&nbsp;5.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8864_5_ScreenCapture5.jpg">ScreenCapture5.jpg</a>&nbsp;&nbsp;(51,6 KB)<br>&nbsp;&nbsp;6.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8864_6_ScreenCapture6.jpg">ScreenCapture6.jpg</a>&nbsp;&nbsp;(121,9 KB)<br>&nbsp;&nbsp;7.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8864_7_ScreenCapture7.jpg">ScreenCapture7.jpg</a>&nbsp;&nbsp;(62 KB)<br>&nbsp;&nbsp;8.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8864_8_ScreenCapture8.jpg">ScreenCapture8.jpg</a>&nbsp;&nbsp;(58,1 KB)<br>&nbsp;&nbsp;9.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8864_9_ScreenCapture9.jpg">ScreenCapture9.jpg</a>&nbsp;&nbsp;(71,7 KB)<br>&nbsp;&nbsp;10.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8864_10_ScreenCapture10.jpg">ScreenCapture10.jpg</a>&nbsp;&nbsp;(102,4 KB)<br>&nbsp;&nbsp;11.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8864_11_ScreenCapture11.jpg">ScreenCapture11.jpg</a>&nbsp;&nbsp;(90,6 KB)<br>&nbsp;&nbsp;12.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8864_12_ScreenCapture12.jpg">ScreenCapture12.jpg</a>&nbsp;&nbsp;(72 KB)<br>&nbsp;&nbsp;13.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8864_13_ScreenCapture13.jpg">ScreenCapture13.jpg</a>&nbsp;&nbsp;(128,5 KB)<br>&nbsp;&nbsp;14.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8864_14_ScreenCapture14.jpg">ScreenCapture14.jpg</a>&nbsp;&nbsp;(66,3 KB)<br>&nbsp;&nbsp;15.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8864_15_ScreenCapture15.jpg">ScreenCapture15.jpg</a>&nbsp;&nbsp;(108,7 KB)<br>&nbsp;&nbsp;16.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8864_16_ScreenCapture16.jpg">ScreenCapture16.jpg</a>&nbsp;&nbsp;(63,2 KB)<br>&nbsp;&nbsp;17.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8864_17_Prevalence%20of%20nmCRPC%20in%20Europe.pdf">Prevalence of nmCRPC in Europe.pdf</a>&nbsp;&nbsp;(502,9 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20130431&edate=20130101&rec=8864">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-03-28T16:10:45+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-03-28T16:10:45+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Record Gene Haul Points To Better Screening In Breast, Prostate & Ovarian Cancer</title>
	<pubDate>2013-03-28T15:58:21+01:00</pubDate>
	<wp:post_id>4038</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: New research published yesterday has nearly doubled the number of 
genetic variations implicated in a number of key cancers offering fresh avenues 
for screening at-risk patients.<wbr> The largest every study which has analysed the 
DNA of 200,000 people (50% with cancer) has identified 74 gene changes 
associated with three hormone-related cancers.<wbr> </div><div style="margin-bottom: 10px;">Ros Eeles of the UK Institute of Cancer Research is quoted as saying that the 
new findings represent the biggest lead forward yet in our understanding of the 
genetic basis of prostate cancer.<wbr> The study found 23 new genetic variations 
(SNPs0 linked to prostate cancer 16 of which were linked to the more aggressive 
form of the disease.<wbr> </div><div style="margin-bottom: 10px;">Doug Easton from the University of Cambridge, the lead researcher on the 
project believes that new cancer screening programmes will arise from this 
research and that within 10 years this might be commonly used paving the 
way for identification of men at very high risk of developing prostate cancer 
during their lifetime.<wbr> </div><div style="margin-bottom: 10px;">The new research has been published in a series of papers in Nature 
Genetics, Nature Communications, PLOS Genetics and the American Journal of Human 
Genetics and Human Molecular Genetics </div><div>Source: <a href="http://www.reuters.com" class="defaultlink" title="www.reuters.com">reuters.com</a> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20130431&edate=20130101&rec=8863">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-03-28T15:58:21+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-03-28T15:58:21+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Clinical Progress with Omeros' PDE10 for Huntington Disease</title>
	<pubDate>2013-03-28T15:50:53+01:00</pubDate>
	<wp:post_id>4039</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: OMS824’s emerging profile in Phase 1 suggests oral, once-daily dosing, which predictably reaches therapeutic levels in the brain and could be potent.<wbr> Analyst at Wedbush believe the clean Ph1 results create a strong foundation for testing efficacy in Ph2 trials for HD followed by schizophrenia.<wbr> Trial could begin in H2 2013 and provide results in H1 2014.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Omeros' PDE10 program is supported by funds from The Stanley Medical Research Institute, a non-profit corporation that supports research on the causes and treatment of schizophrenia and bipolar disorder.<wbr> </div><div style="margin-bottom: 10px;">- to obtain orphan Drug designation in the US (which could result in a premium pricing).<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">PDE10 is an enzyme that is expressed in areas of the brain strongly linked to schizophrenia and other psychotic disorders.<wbr> PDE10 inhibitors have been shown to be as effective <I>in vivo</I> as current anti-psychotic drugs.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">As of February 15, 2012, Omeros owned one issued patent and four pending patent applications in the US and nine pending patent application in foreign markets that claim proprietary PDE10 inhibitors.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Pfizer recently announced the start of a Ph2 with its drug candidate - PF-02545920 is an oral, twice-daily phosphodiesterase 10A (PDE10A) inhibitor.<wbr> Biochemical and behavioral data indicate that PDE10A inhibition activates cAMP/<wbr>PKA signalling in the basal ganglia, leading to the potentiation of dopamine D₁ receptor signalling, and concomitant inhibition of dopamine D₂receptor signalling - (see <a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20130431&edate=20130101&rec=6860" class="defaultlink">Neurology6860: Pfizer's PDE10 Inhibitor to Enter Ph2 for Early Huntington's Disease</a>).<wbr> </div><div><EM>Source: Omeros; Thomson One</EM> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20130431&edate=20130101&rec=6898">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-03-28T15:50:53+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-03-28T15:50:53+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>EAU Highlights - J&J Symposia</title>
	<pubDate>2013-03-28T14:13:56+01:00</pubDate>
	<wp:post_id>4040</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"><UL type="disc"><LI></LI>
<LI></LI>
<LI></LI>
<LI></LI>
<LI></LI>
</UL> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div> </div><!-- Comment details --><a name="oncology8860attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8860_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(50,5 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8860_2_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(52 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8860_3_ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(53,2 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8860_4_ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(50,3 KB)<br>&nbsp;&nbsp;5.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8860_5_ScreenCapture5.jpg">ScreenCapture5.jpg</a>&nbsp;&nbsp;(29,4 KB)<br>&nbsp;&nbsp;6.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8860_6_ScreenCapture6.jpg">ScreenCapture6.jpg</a>&nbsp;&nbsp;(58,3 KB)<br>&nbsp;&nbsp;7.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8860_7_ScreenCapture7.jpg">ScreenCapture7.jpg</a>&nbsp;&nbsp;(76,1 KB)<br>&nbsp;&nbsp;8.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8860_8_ScreenCapture8.jpg">ScreenCapture8.jpg</a>&nbsp;&nbsp;(53,2 KB)<br>&nbsp;&nbsp;9.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8860_9_ScreenCapture9.jpg">ScreenCapture9.jpg</a>&nbsp;&nbsp;(48,9 KB)<br>&nbsp;&nbsp;10.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8860_10_ScreenCapture10.jpg">ScreenCapture10.jpg</a>&nbsp;&nbsp;(50,2 KB)<br>&nbsp;&nbsp;11.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8860_11_ScreenCapture11.jpg">ScreenCapture11.jpg</a>&nbsp;&nbsp;(51,3 KB)<br>&nbsp;&nbsp;12.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8860_12_ScreenCapture12.jpg">ScreenCapture12.jpg</a>&nbsp;&nbsp;(73,5 KB)<br>&nbsp;&nbsp;13.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8860_13_ScreenCapture13.jpg">ScreenCapture13.jpg</a>&nbsp;&nbsp;(76,1 KB)<br>&nbsp;&nbsp;14.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8860_14_ScreenCapture14.jpg">ScreenCapture14.jpg</a>&nbsp;&nbsp;(62,6 KB)<br>&nbsp;&nbsp;15.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8860_15_ScreenCapture15.jpg">ScreenCapture15.jpg</a>&nbsp;&nbsp;(78 KB)<br>&nbsp;&nbsp;16.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8860_16_ScreenCapture16.jpg">ScreenCapture16.jpg</a>&nbsp;&nbsp;(43,1 KB)<br>&nbsp;&nbsp;17.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8860_17_ScreenCapture17.jpg">ScreenCapture17.jpg</a>&nbsp;&nbsp;(42,2 KB)<br>&nbsp;&nbsp;18.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8860_18_ScreenCapture18.jpg">ScreenCapture18.jpg</a>&nbsp;&nbsp;(105,6 KB)<br>&nbsp;&nbsp;19.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8860_19_ScreenCapture19.jpg">ScreenCapture19.jpg</a>&nbsp;&nbsp;(52,1 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20130431&edate=20130101&rec=8860">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-03-28T14:13:56+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-03-28T14:13:56+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>PROLOR Reinforces its Patent Portfolio for its Long-Acting hGH</title>
	<pubDate>2013-03-28T10:34:25+01:00</pubDate>
	<wp:post_id>4041</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: PROLOR has received a notice of allowance from the USPTO for a new patent application covering the company's hGH-CTP for decreasing body fat.<wbr> Treatment with human growth hormone may help decrease the excessive body fat that can characterize growth hormone deficiency in adults.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">- the fifth for hGH-CTP since 2009 </div><div style="margin-bottom: 10px;">- expected to issue in the next few months </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">- March 2012 Initiation of a Phase II trial in children with growth hormone deficiency.<wbr> This trial is currently expected to conclude in 2013.<wbr> </div><div style="margin-bottom: 10px;">- May 2012 - top-line results from the four–month treatment extension of Phase II Clinical Trial, which demonstrated that a single weekly injection of hGH-CTP has the potential to replace seven consecutive daily injections of currently marketed hGH.<wbr> These results further validate the dosing regimen for Phase III trial.<wbr> </div><div><EM>Source: PROLOR Biotech</EM> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20130431&edate=20130101&rec=7308">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-03-28T10:34:25+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-03-28T10:34:25+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category endocrinology > <![CDATA[Endocrinology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>CureVac's Vaccine to Enter Ph2b for mCRPC</title>
	<pubDate>2013-03-27T18:06:51+01:00</pubDate>
	<wp:post_id>4042</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: The trial aims at validating the safety and investigating the efficacy of the mRNA-based cancer vaccine in patients with mCRPC.<wbr> PE will assess OS.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG><A href="http://www.clinicaltrials.gov/ct2/show/NCT01817738?term=curevac&amp;rank=2"><STRONG></STRONG></A> </div><div style="margin-bottom: 10px;">Recruitment: approx.<wbr> 200 </div><div style="margin-bottom: 10px;">Locations: EU (8 sites) </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8859_1_ScreenCapture1.jpg"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8859_2_ScreenCapture2.jpg"> </div><!-- Comment details --><a name="oncology8859attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8859_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(37 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8859_2_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(32,1 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20130431&edate=20130101&rec=8859">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-03-27T18:06:51+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-03-27T18:06:51+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Revance Progress with its Topical Toxin for Moderate to Severe Crow's Feet Lines</title>
	<pubDate>2013-03-27T17:43:33+01:00</pubDate>
	<wp:post_id>4043</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: This is the second Ph3 trial in line with the company registration process.<wbr> Approx.<wbr> 2200 participants will be recruited in the US.<wbr> The objective is to evaluate the long-term safety of the drug after repeat application.<wbr> PE will assess incidences of AEs and serious AEs.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG><A href="http://clinicaltrials.gov/ct2/show/NCT01818076?recr=Open&amp;no_unk=Y&amp;fund=2&amp;rcv_s=02%2F27%2F2013&amp;rank=179"><STRONG></STRONG></A> </div><div style="margin-bottom: 10px;">Start date: Feb 2013 </div><div style="margin-bottom: 10px;">Completion dates: April 2015 /<wbr> December 2015.<wbr> </div><div style="margin-bottom: 10px;"><EM>Source: clinicaltrials.<wbr>gov</EM> </div><div style="margin-bottom: 10px;"><STRONG>Background in Traction CI</STRONG> </div><div>See <a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20130431&edate=20130101&rec=6784" class="defaultlink">Neurology6784: Ph3 Trial of Revance's RT001 Topical Toxin for Crow's Feet Lines (CFL)</a>.<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20130431&edate=20130101&rec=6894">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-03-27T17:43:33+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-03-27T17:43:33+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Evotec Reports Strong Progress in All Units of its "Action Plan 2016"</title>
	<pubDate>2013-03-27T14:18:24+01:00</pubDate>
	<wp:post_id>4044</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Evotec achieved continued profitable growth in 2012 with revenues up 9% to EUR 87.<wbr>3 m (2011: EUR 80.<wbr>1 m).<wbr> Management reported that the three business units of the 'Action Plan 2016', Evotec 1-Execute/<wbr>2-Integrate/<wbr>3-Innovate, achieved strong progress during 2012.<wbr> Key slides highlighting the group's activities in Huntington's disease and endometriosis are provided below.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> aims to deliver cost efficient and industrialised services for drug discovery on a fee-for-service basis.<wbr> </div><div style="margin-bottom: 10px;">Evotec looks for continued 2-digit revenue growth and gross margin expansion in this lower value, fee for service business in 2013.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10358_3_ScreenCapture3.jpg"> </div><div style="margin-bottom: 10px;"><STRONG>Examples for Strategic Collaborations</STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10358_4_ScreenCapture4.jpg"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> is the systematic approach to progress targets through the pre-clinic, on a research payments, milestones and royalties success basis.<wbr> </div><div style="margin-bottom: 10px;">Evotec anticipates further new partnerships (including expanded customer reach to biotech/<wbr>small-midsized pharma) and more milestones in ongoing alliances as to underpin the shift to higher value, integrated drug discovery alliances.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10358_2_ScreenCapture2.jpg"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> involves accelerating promising drug discovery ideas and assets to partnerships with upfront payments, premium research fees, milestones.<wbr> </div><div style="margin-bottom: 10px;">Evotec expects the start of several clinical trials within existing drug discovery alliances (e.<wbr>g.<wbr> MedImmune, Boehringer Ingelheim, J&amp;J), while also targeting one ‘rollover/<wbr> commercialization’.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10358_1_ScreenCapture1.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10358_5_ScreenCapture5.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10358_6_ScreenCapture6.jpg"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10358_7_ScreenCapture7.jpg"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10358_8_ScreenCapture8.jpg"> </div><div><EM>Source: Evotec</EM> </div><!-- Comment details --><a name="pharmaworld10358attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10358_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(27,2 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10358_2_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(29,6 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10358_3_ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(34,6 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10358_4_ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(49,4 KB)<br>&nbsp;&nbsp;5.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10358_5_ScreenCapture5.jpg">ScreenCapture5.jpg</a>&nbsp;&nbsp;(97,6 KB)<br>&nbsp;&nbsp;6.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10358_6_ScreenCapture6.jpg">ScreenCapture6.jpg</a>&nbsp;&nbsp;(87,8 KB)<br>&nbsp;&nbsp;7.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10358_7_ScreenCapture7.jpg">ScreenCapture7.jpg</a>&nbsp;&nbsp;(60,3 KB)<br>&nbsp;&nbsp;8.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10358_8_ScreenCapture8.jpg">ScreenCapture8.jpg</a>&nbsp;&nbsp;(67 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20130431&edate=20130101&rec=10358">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-03-27T14:18:24+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-03-27T14:18:24+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category pharma-news > <![CDATA[Pharma News]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>EAU Highlights - Ferring's Degarelix Symposia</title>
	<pubDate>2013-03-27T13:32:17+01:00</pubDate>
	<wp:post_id>4045</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;">This message was supported by a treatment algorithm presented during the wrap-up section of the symposia.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8854_22_ScreenCapture22.jpg"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"><UL><LI> </LI>
<LI> </LI>
<LI> </LI>
<LI> </LI>
</UL> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div> </div><!-- Comment details --><a name="oncology8854attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;21.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8854_21_ScreenCapture21.jpg">ScreenCapture21.jpg</a>&nbsp;&nbsp;(33,4 KB)<br>&nbsp;&nbsp;22.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8854_22_ScreenCapture22.jpg">ScreenCapture22.jpg</a>&nbsp;&nbsp;(33 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20130431&edate=20130101&rec=8854">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-03-27T13:32:17+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-03-27T13:32:17+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>First FFA2 Inhibitor to be Evaluated Clinically</title>
	<pubDate>2013-03-27T10:23:32+01:00</pubDate>
	<wp:post_id>4046</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Galapagos reported that the positive outcome of the phase 1 study with GLPG0974 supports progression to a POC trial next month for ulcerative colitis (UC).<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">GLPG0974 is an orally available small molecule that reduces migration of neutrophils by potent inhibition of FFA2 (free fatty acid receptor 2, formerly known as GPR43).<wbr> </div><div style="margin-bottom: 10px;">Overactivity of neutrophils is a cause of tissue damage in illnesses such as inflammatory bowel disease (IBD).<wbr> </div><div style="margin-bottom: 10px;">A reduction of neutrophil activation and migration by inhibition of FFA2 may provide for a novel anti-inflammatory treatment approach.<wbr> </div><div style="margin-bottom: 10px;">By inhibiting FFA2, GLPG0974 prevents free fatty acid-induced activation and migration of neutrophils towards an inflammatory site, such as in the gut of patients with inflammatory bowel disease.<wbr> </div><div><EM>Source: Galapagos</EM> </div><!-- Comment details --><span style="font-weight: bold; font-style: italic;"><br>Comments</span><a name="GastroEnterology1918c"></a><br><div style="border: 1px solid #AAA; background-color: #FFF; margin-left: 10px; padding: 5px;"><div style="margin-bottom: 10px;">The drug has entered into the first Ph2 trial for testing safety and efficacy, with top-line results expected Q1:14.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Trial Details</STRONG> </div><div style="margin-bottom: 10px;"><UL><LI>Design: Four-week study with approx.<wbr> 45 patients with mild to moderate UC </LI>
<LI>Objective: to assess efficacy, effects on selected biomarkers, afety and tolerability and PK.<wbr> </LI>
<LI>Regimen: patients will receive either 200 mg of the drug twice-daily or placebo for a period of 4 weeks.<wbr> </LI>
<LI>Location: Belgium; Latvia; Czech Rep.<wbr> and Slovakia.<wbr></LI>
</UL> </div><div><EM>Source: Galapagos</EM> </div></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20130431&edate=20130101&rec=1881">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-03-27T10:23:32+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-03-27T10:23:32+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category gastroenterology > <![CDATA[gastroenterology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Otsuka Cements The Largest Deal This Year With Lundbeck</title>
	<pubDate>2013-03-26T18:06:19+01:00</pubDate>
	<wp:post_id>4047</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Otsuka has signed a deal worth $825m with Lundbeck covering a 
CNS-based alliance centred around Lundbeck's Alzheimer's and schizophrenia 
candidate LuAE58054 a selective 5HT-6 receptor antagonist.<wbr> The total 
upfront fee was $150m.<wbr> </div><div style="margin-bottom: 10px;">The long-term collaborators have seen some success with their neurological 
efforts, most recently with the US approval of the long-acting schizophrenia 
product Abilify.<wbr> </div><div style="margin-bottom: 10px;">However, sceptics suggest that Alzheimer's is a tougher prospect and with the 
drug yet to start phIII $825m looks a little racy.<wbr> The plan is to commence 
a phIII programme in more than 2500 patients during the course of 2013.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Deal Terms</STRONG> </div><div style="margin-bottom: 10px;">Under the terms of the agreement, Lundbeck will grant Otsuka co-development 
and co-commercialisation rights to LiAE58054 in the US, Canada, East Asia 
including Japan, major European countries and Nordic countries.<wbr> </div><div style="margin-bottom: 10px;">Both companies will share the sales, development and commercialisation costs, 
whilst Lundbeck is entitled to up to $675m in regulatory and sales milestones.<wbr> 
Additional specific financial terms of the agreement remain undisclosed.<wbr> </div><div>Source: <A href="http://www.lundbeck.com">www.<wbr>lundbeck.<wbr>com</A> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20130431&edate=20130101&rec=10357">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-03-26T18:06:19+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-03-26T18:06:19+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category pharma-news > <![CDATA[Pharma News]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>AbbVie's Elagolix to Enter Ph2b for Uterine Fibroids (UF)</title>
	<pubDate>2013-03-25T17:38:43+01:00</pubDate>
	<wp:post_id>4048</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: The 4-arm trial will assess safety and efficacy of elagolix alone and in combination with add-back therapy vs.<wbr> placebo on heavy menstrual bleeding in premenopausal women with UF.<wbr> Primary endpoint will determine change in menstrual blood loss.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG><A href="http://clinicaltrials.gov/ct2/show/NCT01817530?recr=Open&amp;no_unk=Y&amp;fund=2&amp;rcv_s=02%2F25%2F2013&amp;rank=86"><STRONG></STRONG></A> </div><div style="margin-bottom: 10px;">Recruitment: approx.<wbr> 280 (18 to 49 years at screening) </div><div style="margin-bottom: 10px;">Start date: March 2013 </div><div style="margin-bottom: 10px;">Completion dates: July 2014 /<wbr> January 2015 </div><div style="margin-bottom: 10px;">Location: USA </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8853_1_ScreenCapture1.jpg"> </div><!-- Comment details --><a name="oncology8853attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8853_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(165,7 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20130431&edate=20130101&rec=8853">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-03-25T17:38:43+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-03-25T17:38:43+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Revance Appoints New CFO</title>
	<pubDate>2013-03-25T15:13:59+01:00</pubDate>
	<wp:post_id>4049</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Lauren Silvernail (53) will oversee Revance's finance and accounting, corporate development and investors and public relations.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6890_3_ScreenCapture3.jpg"> </div><div style="margin-bottom: 10px;">- Previously CFO and VP Corporate Development at ISTA.<wbr> </div><div style="margin-bottom: 10px;">- Prior to ISTA she served in various operating and corproate development positions for <U>Allergan</U>, most recently as VP Business Development.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><STRONG>RT001</STRONG> - Gel </div><div style="margin-bottom: 10px;"><UL><LI>phase 3 trials for LCL (see <a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20130431&edate=20130101&rec=6784" class="defaultlink">Neurology6784: Ph3 Trial of Revance's RT001 Topical Toxin for Crow's Feet Lines (CFL)</a>).<wbr></LI>
<LI>phase 2 trials for hyperhidrosis, and headache prophylaxis in patients with chronic migraine</LI>
</UL> </div><div style="margin-bottom: 10px;"><STRONG>RT002</STRONG> - Injectable </div><div style="margin-bottom: 10px;"><UL><LI>
phase 1/<wbr>phase 2 for spasmodic torticollis; headache prophylaxis in patients with chronic migraine; hyperhidrosis</LI>
</UL> </div><div><EM>Source: FirstWord</EM> </div><!-- Comment details --><a name="neurology6890attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6890_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(94,6 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6890_2_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(86,8 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6890_3_ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(4,1 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20130431&edate=20130101&rec=6890">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-03-25T15:13:59+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-03-25T15:13:59+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Key Messages from Aeterna Zentaris Earning Conference Call</title>
	<pubDate>2013-03-25T11:11:27+01:00</pubDate>
	<wp:post_id>4050</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Alongside its financial results, management highlighted that 2012 was a challenging year for the company as it had to face disappointing Ph3 results for perifosine (in colorectal cancer).<wbr> It highlighted near-term value drivers are AEZS-108 (specifically targets LHRH receptors which are present in endometrial, breast, bladder,  and ovarian cancer), and AEZS-130 (first oral diagnostic for adult growth hormone deficiency ; preparation of the marketing and launch strategy).<wbr> Of note, the progression of AEZS-120 (oral tumour vaccine candidate for prostate cancer).<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8851_1_ScreenCapture1.jpg"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">- pre-clinical data presented at the Congress of the Societe Internationale d'Urologie in Japan.<wbr> The presentation underlines the feasibility of an oral therapeutic vaccination approach against prostate cancer.<wbr> The production, pharmacology, safety, and toxicology program was conducted and successfully finalized in agreement with the regulatory authorities.<wbr> This program was partially sponsored by a grant from the German government.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8851_5_ScreenCapture5.jpg"> </div><div style="margin-bottom: 10px;">Status/<wbr>Indication: EMA classification as advanced therapeutic medicinal product (ATMP); EMA Scientific Advice received with no principle objectives with respect to start Ph1; CTA/<wbr>IND filing in preparation.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8851_3_ScreenCapture3.jpg"> </div><div style="margin-bottom: 10px;">Status/<wbr>Indication: Ph1/<wbr>ph2 in castration-and taxane resistant prostate cancer internalization in circulating tumor cells (CTCs).<wbr> The Ph1 portion of the NIH funded Ph1/<wbr>ph2 has been completed and recruitment for the Ph2 portion.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8851_2_ScreenCapture2.jpg"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8851_4_ScreenCapture4.jpg"> </div><div>Status/<wbr>Indication: Ph3 - Diagnostic test for AGHD </div><!-- Comment details --><a name="oncology8851attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8851_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(122 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8851_2_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(46 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8851_3_ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(29,2 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8851_4_ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(17,7 KB)<br>&nbsp;&nbsp;5.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8851_5_ScreenCapture5.jpg">ScreenCapture5.jpg</a>&nbsp;&nbsp;(76,2 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20130431&edate=20130101&rec=8851">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-03-25T11:11:27+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-03-25T11:11:27+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Nomura Highlights Medy-Tox As One Of Its Top Buys Due To Export Growth & Emerging Potential Of Next Generation Toxin</title>
	<pubDate>2013-03-25T11:01:48+01:00</pubDate>
	<wp:post_id>4051</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: After a recent company visit, Nomura's bullish investment report on Medy-Tox highlights some key points about market entry of the group's next generation freeze-dried toxin formulation, expected in Korea Q413 and launches elsewhere of Neuronox.<wbr> It believes any licensing deal covering EU &amp; US market entry (expected mid-2013) will prove to be a share price catalyst.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Neuronox Launch Sequence</STRONG> </div><div style="margin-bottom: 10px;">Medytox expects to get product registration for Neuronox in Russia in Q213, Mexico in 1H13 and Columbia 2H13.<wbr> It views approval in Russia as a promising event for the company since Russia has a KRW60bn aesthetic market with predicted CAGR of 14% over the next few year.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6888_1_ScreenCapture1.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6888_2_ScreenCapture2.jpg"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6888_3_ScreenCapture3.jpg"> </div><div style="margin-bottom: 10px;"><STRONG>Market Entry Of Daewoong's Product</STRONG> </div><div style="margin-bottom: 10px;">Commenting on the market entry of Daewoong's botulinum toxin which is expected in September this year, Nomura believes the real impact of the product will not be felt until FY14 when Medytox's domestic contribution from sales of Neuronox is likely to be 38%.<wbr> DWP's target is to garner 18% market share in FY14.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Launch Of Next Generation Medy-Tox Toxin</STRONG> </div><div style="margin-bottom: 10px;">However to counter this impact, Medy-Tox expects to launch its next generation product in Korea in Q413.<wbr> The company has apparently already submitted an application to the KDFA w/<wbr>c 4th March (seemingly based on a phII trial which completed in November 2012) and is expecting approval later this year.<wbr> This next generation product is a freeze dried product which is HSA free.<wbr> It is not a liquid formulation as development of the latter is running about 1.<wbr>5-2 years behind the freeze dried preparation.<wbr> The new formulation is expected to be marketed at higher price than the company's current product.<wbr> </div><div>Source: Nomura Report 11.<wbr>03.<wbr>13 </div><!-- Comment details --><a name="neurology6888attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6888_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(70,3 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6888_2_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(96,1 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6888_3_ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(109,6 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20130431&edate=20130101&rec=6888">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-03-25T11:01:48+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-03-25T11:01:48+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>NPS Enters Into Global Commercialisation Deal With Takeda</title>
	<pubDate>2013-03-22T18:00:24+01:00</pubDate>
	<wp:post_id>4052</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: NPS has entered into a deal with Takeda to regain ex-US rights to tedlutide for short bowel syndrome and Preotact for osteoporosis.<wbr> This will strengthen its footprint as a global commercial rare disease company.<wbr> The company's 2013 priorities remain the successful US launch of Gattex for short bowel syndrome and the submission of the US marketing application for its parathyroid hormone (PTH 1-84) for hyperparathyroidism.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Deal Terms</STRONG> </div><div style="margin-bottom: 10px;">NSP has reqacquired the rights for $50m upfront in the form of common stock of NPSP.<wbr> Additionally its is to receive milestone payment of $30m in the first calendar year that combined sales exceed $750m.<wbr> </div><div style="margin-bottom: 10px;">Commenting on the divestment Frank Morich, CCO of Takeda said: "Orphan drugs like teduglutide , serve high unmet needs.<wbr> We are confident that as an orphan and specialty company NPS is best suited to maximise the value of teduglutide and PTH 1-84.<wbr> The structure of this transaction allows us to particiapte in NPS's future success with these products.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Current Regulatory Status of The Two Products</STRONG> </div><div style="margin-bottom: 10px;">Teduglutide, marketed in the U.<wbr>S.<wbr> under the trade name Gattex<SUP></SUP>, is approved in Europe under the trade name Revestive Teduglutide was approved in the European Union and the U.<wbr>S.<wbr> in August and December 2012, respectively.<wbr> PTH 1-84 is approved for post-menopausal osteoporosis in the European Union since April 2006, where it is known under the trade name Preotact&reg;.<wbr> NPS is developing PTH 1-84 under the brand name Natpara<SUP></SUP> in the U.<wbr>S.<wbr> for the treatment of hypoparathyroidism </div><div style="margin-bottom: 10px;"><STRONG>Next Steps</STRONG> </div><div style="margin-bottom: 10px;">Having completed this transformational event, NPS has retained the consulting services of Sandy Smith, who  served as Executive Vice President and President of Genzyme's International Group.<wbr> Under Sandy's leadership, Genzyme's International revenue grew to 65% of Genzyme's nearly $5 billion in revenues.<wbr> He was also responsible for Genzyme's successful global launch of 12 new products.<wbr> </div><div style="margin-bottom: 10px;"><P class="pwrapper">Sandy will work to lay the foundation of NPS international expansion and position PTH and teduglutide for global commercial success.<wbr> Over the next few months, it is planned that he will focus on the following three priorities.<wbr></P> </div><div style="margin-bottom: 10px;"><UL><LI>
designing and implementomg NPS global corporate structure;.<wbr> 

</LI>
<LI>
defining the group's global business model iendtifying key leaders of the international organization; and 

</LI>
<LI>
thirdly develop global product strategies that maximize the commercial value of teduglutide and PTH.<wbr>

</LI>
</UL> </div><div>Source: <A href="http://www.npsp.com">www.<wbr>npsp.<wbr>com</A> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20130431&edate=20130101&rec=7305">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-03-22T18:00:24+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-03-22T18:00:24+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category endocrinology > <![CDATA[Endocrinology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>New MOA To Target All Forms Of DMD</title>
	<pubDate>2013-03-22T17:35:40+01:00</pubDate>
	<wp:post_id>4053</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Summit Corporation, a UK based drug discovery and development 
company has outlined its plans for the continued development of utrophin 
modulators for the treatment of Duchenne Muscular Dystrophy.<wbr> It believes these 
modulators, in contrast, to more late stage development candidats have the 
ability to treat all genetic forms of the disease.<wbr> </div><div style="margin-bottom: 10px;">Summit's lead candidate SMT C1100 is expected to eneter clinical development 
in the 2H2013.<wbr> There are also earlier-stage next generation molecules that are 
being developed to add further value to the programme.<wbr> </div><div style="margin-bottom: 10px;">Teh clinnical programme hopes to quickly establish POC through the use of 
novel biomarkers developed specifically to measure aspects of muscle health.<wbr> </div><div style="margin-bottom: 10px;">Summit intends to present its utrophin modulation programme and biomarker 
development at the upcoming Muscular Dystrophy Association Confernece in April 
in Wahsington (April 21st to 24th).<wbr> </div><div>Source: <A href="http://www.summit.com">www.<wbr>summit.<wbr>com</A> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20130431&edate=20130101&rec=6886">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-03-22T17:35:40+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-03-22T17:35:40+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>AZ Signs New Technology Deal</title>
	<pubDate>2013-03-22T14:12:52+01:00</pubDate>
	<wp:post_id>4054</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;"><P style="BORDER-BOTTOM: 0px; BORDER-LEFT: 0px; PADDING-BOTTOM: 0px; TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; MARGIN: 0px 0px 18px; OUTLINE-STYLE: none; OUTLINE-COLOR: invert; PADDING-LEFT: 0px; OUTLINE-WIDTH: 0px; PADDING-RIGHT: 0px; FONT: 12px/1.6em Arial, Helvetica, sans-serif; WHITE-SPACE: normal; LETTER-SPACING: normal; COLOR: rgb(0,0,0); VERTICAL-ALIGN: baseline; BORDER-TOP: 0px; BORDER-RIGHT: 0px; WORD-SPACING: 0px; PADDING-TOP: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px">Comment: 
AstraZeneca has announced an exclusive agreement with Moderna Therapeutics 
to discover, develop and commercialise pioneering messenger RNA therapeutics™ 
for the treatment of serious cardiovascular, metabolic and renal diseases as 
well as cancer.<wbr> Through this agreement AZ will have the option to select up to 
40 drug products for clinical development.<wbr></P> </div><div style="margin-bottom: 10px;"><P style="BORDER-BOTTOM: 0px; BORDER-LEFT: 0px; PADDING-BOTTOM: 0px; TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; MARGIN: 0px 0px 18px; OUTLINE-STYLE: none; OUTLINE-COLOR: invert; PADDING-LEFT: 0px; OUTLINE-WIDTH: 0px; PADDING-RIGHT: 0px; FONT: 12px/1.6em Arial, Helvetica, sans-serif; WHITE-SPACE: normal; LETTER-SPACING: normal; COLOR: rgb(0,0,0); VERTICAL-ALIGN: baseline; BORDER-TOP: 0px; BORDER-RIGHT: 0px; WORD-SPACING: 0px; PADDING-TOP: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"><STRONG>Deal 
Terms</STRONG></P> </div><div style="margin-bottom: 10px;"><P style="BORDER-BOTTOM: 0px; BORDER-LEFT: 0px; PADDING-BOTTOM: 0px; TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; MARGIN: 0px 0px 18px; OUTLINE-STYLE: none; OUTLINE-COLOR: invert; PADDING-LEFT: 0px; OUTLINE-WIDTH: 0px; PADDING-RIGHT: 0px; FONT: 12px/1.6em Arial, Helvetica, sans-serif; WHITE-SPACE: normal; LETTER-SPACING: normal; COLOR: rgb(0,0,0); VERTICAL-ALIGN: baseline; BORDER-TOP: 0px; BORDER-RIGHT: 0px; WORD-SPACING: 0px; PADDING-TOP: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px">Under 
the terms of the agreement, AstraZeneca will make a large upfront payment 
of $240 million.<wbr> AstraZeneca will have exclusive access to select any target of 
its choice in cardiometabolic diseases, as well as selected targets in oncology, 
over a period of up to five years for subsequent development of messenger 
RNA.<wbr></P> </div><div style="margin-bottom: 10px;"><P style="BORDER-BOTTOM: 0px; BORDER-LEFT: 0px; PADDING-BOTTOM: 0px; TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; MARGIN: 0px 0px 18px; OUTLINE-STYLE: none; OUTLINE-COLOR: invert; PADDING-LEFT: 0px; OUTLINE-WIDTH: 0px; PADDING-RIGHT: 0px; FONT: 12px/1.6em Arial, Helvetica, sans-serif; WHITE-SPACE: normal; LETTER-SPACING: normal; COLOR: rgb(0,0,0); VERTICAL-ALIGN: baseline; BORDER-TOP: 0px; BORDER-RIGHT: 0px; WORD-SPACING: 0px; PADDING-TOP: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px">Additionally, 
Moderna is entitled to an additional $180 million for the achievement of three 
technical milestones.<wbr> Moderna will also be entitled to development and 
commercial milestone payments as well as royalties on drug sales ranging from 
high single digits to low double digits for each product.<wbr> </P> </div><div style="margin-bottom: 10px;"><P style="BORDER-BOTTOM: 0px; BORDER-LEFT: 0px; PADDING-BOTTOM: 0px; TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; MARGIN: 0px 0px 18px; OUTLINE-STYLE: none; OUTLINE-COLOR: invert; PADDING-LEFT: 0px; OUTLINE-WIDTH: 0px; PADDING-RIGHT: 0px; FONT: 12px/1.6em Arial, Helvetica, sans-serif; WHITE-SPACE: normal; LETTER-SPACING: normal; COLOR: rgb(0,0,0); VERTICAL-ALIGN: baseline; BORDER-TOP: 0px; BORDER-RIGHT: 0px; WORD-SPACING: 0px; PADDING-TOP: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px">AstraZeneca 
will lead the preclinical, clinical development and commercialisation of 
therapeutics resulting from the agreement and Moderna will be responsible for 
designing and manufacturing the messenger RNA against selected targets.<wbr></P> </div><div style="margin-bottom: 10px;"><P style="BORDER-BOTTOM: 0px; BORDER-LEFT: 0px; PADDING-BOTTOM: 0px; TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; MARGIN: 0px 0px 18px; OUTLINE-STYLE: none; OUTLINE-COLOR: invert; PADDING-LEFT: 0px; OUTLINE-WIDTH: 0px; PADDING-RIGHT: 0px; FONT: 12px/1.6em Arial, Helvetica, sans-serif; WHITE-SPACE: normal; LETTER-SPACING: normal; COLOR: rgb(0,0,0); VERTICAL-ALIGN: baseline; BORDER-TOP: 0px; BORDER-RIGHT: 0px; WORD-SPACING: 0px; PADDING-TOP: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"><STRONG>Nature 
of Moderna' s Technology</STRONG></P> </div><div style="margin-bottom: 10px;"><P style="BORDER-BOTTOM: 0px; BORDER-LEFT: 0px; PADDING-BOTTOM: 0px; TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; MARGIN: 0px 0px 18px; OUTLINE-STYLE: none; OUTLINE-COLOR: invert; PADDING-LEFT: 0px; OUTLINE-WIDTH: 0px; PADDING-RIGHT: 0px; FONT: 12px/1.6em Arial, Helvetica, sans-serif; WHITE-SPACE: normal; LETTER-SPACING: normal; COLOR: rgb(0,0,0); VERTICAL-ALIGN: baseline; BORDER-TOP: 0px; BORDER-RIGHT: 0px; WORD-SPACING: 0px; PADDING-TOP: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px">Moderna’s 
uses proprietary messenger RNA containing naturally occurring nucleotide 
analogues, which are designed to stimulate the body’s natural ability to produce 
intracellular and secreted therapeutic proteins without triggering an innate 
immune response.<wbr> </P> </div><div style="margin-bottom: 10px;"><P style="BORDER-BOTTOM: 0px; BORDER-LEFT: 0px; PADDING-BOTTOM: 0px; TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; MARGIN: 0px 0px 18px; OUTLINE-STYLE: none; OUTLINE-COLOR: invert; PADDING-LEFT: 0px; OUTLINE-WIDTH: 0px; PADDING-RIGHT: 0px; FONT: 12px/1.6em Arial, Helvetica, sans-serif; WHITE-SPACE: normal; LETTER-SPACING: normal; COLOR: rgb(0,0,0); VERTICAL-ALIGN: baseline; BORDER-TOP: 0px; BORDER-RIGHT: 0px; WORD-SPACING: 0px; PADDING-TOP: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px">The 
secreted proteins will be released into the bloodstream to potentially restore 
function elsewhere in the body.<wbr> Using messenger RNA also has the potential 
advantage of dramatically reducing the time and expense associated with creating 
therapeutic proteins using current recombinant technologies.<wbr></P> </div><div style="margin-bottom: 10px;"><P style="BORDER-BOTTOM: 0px; BORDER-LEFT: 0px; PADDING-BOTTOM: 0px; TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; MARGIN: 0px 0px 18px; OUTLINE-STYLE: none; OUTLINE-COLOR: invert; PADDING-LEFT: 0px; OUTLINE-WIDTH: 0px; PADDING-RIGHT: 0px; FONT: 12px/1.6em Arial, Helvetica, sans-serif; WHITE-SPACE: normal; LETTER-SPACING: normal; COLOR: rgb(0,0,0); VERTICAL-ALIGN: baseline; BORDER-TOP: 0px; BORDER-RIGHT: 0px; WORD-SPACING: 0px; PADDING-TOP: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"><STRONG>Commenting 
on the deal Pascal Soriot, Chief Executive Officer of AstraZeneca, 
said</STRONG>: </P> </div><div style="margin-bottom: 10px;"><P style="BORDER-BOTTOM: 0px; BORDER-LEFT: 0px; PADDING-BOTTOM: 0px; TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; MARGIN: 0px 0px 18px; OUTLINE-STYLE: none; OUTLINE-COLOR: invert; PADDING-LEFT: 0px; OUTLINE-WIDTH: 0px; PADDING-RIGHT: 0px; FONT: 12px/1.6em Arial, Helvetica, sans-serif; WHITE-SPACE: normal; LETTER-SPACING: normal; COLOR: rgb(0,0,0); VERTICAL-ALIGN: baseline; BORDER-TOP: 0px; BORDER-RIGHT: 0px; WORD-SPACING: 0px; PADDING-TOP: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px">“Today’s 
agreement signals an exciting move for AstraZeneca and our focus on innovation.<wbr> 
Together with Moderna, we are pushing the boundaries of science in the 
pioneering field of messenger RNA therapeutics™.<wbr> Where current drug discovery 
technologies can target only a fraction of the disease-relevant proteins in the 
human genome, we have the potential to create completely new medicines to treat 
patients with serious cardiometabolic diseases and cancer.<wbr>”</P> </div><div><P style="BORDER-BOTTOM: 0px; BORDER-LEFT: 0px; PADDING-BOTTOM: 0px; TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; MARGIN: 0px 0px 18px; OUTLINE-STYLE: none; OUTLINE-COLOR: invert; PADDING-LEFT: 0px; OUTLINE-WIDTH: 0px; PADDING-RIGHT: 0px; FONT: 12px/1.6em Arial, Helvetica, sans-serif; WHITE-SPACE: normal; LETTER-SPACING: normal; COLOR: rgb(0,0,0); VERTICAL-ALIGN: baseline; BORDER-TOP: 0px; BORDER-RIGHT: 0px; WORD-SPACING: 0px; PADDING-TOP: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px">Source: 
<A href="http://www.astrazeneca.com">www.<wbr>astrazeneca.<wbr>com</A></P> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20130431&edate=20130101&rec=10355">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-03-22T14:12:52+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-03-22T14:12:52+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category pharma-news > <![CDATA[Pharma News]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>J&J Expects to Seek U.S. Approval of its Botulinum Toxin in 2014</title>
	<pubDate>2013-03-22T13:05:57+01:00</pubDate>
	<wp:post_id>4055</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: The J&amp;J "product" will target medical aesthetic first and could be available in the US in 2015, overseas a few years later, the company said.<wbr> The data from completed late-stage trials has not yet been unveiled, but David Wilson, president of J&amp;J's Mentor division, told Reuters he was pleased with the results.<wbr> Valeant and Merz did not comment on the potential J&amp;J threat.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Wilson reported that: </div><div style="margin-bottom: 10px;">- "J&amp;J aims to leapfrog Dsyport and Xeomin and become a solid No.<wbr> 2 in the market".<wbr> </div><div style="margin-bottom: 10px;">- “What we hope to offer is a product of certainly comparable quality to Botox.<wbr>.<wbr>.<wbr>to basically be on par with them” in terms of effectiveness and safety".<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">The fiercest competition between the products will likely occur in emerging markets such as China and South America, where Botox is not firmly entrenched.<wbr> (Morningstar's Waterhouse).<wbr> </div><div style="margin-bottom: 10px;">Analysts and dermatologists said J&amp;J's product would need to work faster, last longer or be significantly cheaper than Botox in order to wrest market share from the original injectable wrinkle fighter.<wbr> </div><div style="margin-bottom: 10px;">Patients aren't quick to switch from something with which they are familiar (Dermatologist in West Palm Beach, Florida).<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><EM>Source: TAL_Traction</EM> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Q113 earnings conference call (April 16).<wbr> </div><div><EM>Source: Thomson One</EM> </div><!-- Comment details --><a name="neurology6877attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6877_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(63,8 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20130431&edate=20130101&rec=6877">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-03-22T13:05:57+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-03-22T13:05:57+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Merck's China Trials Offshoring Saves 30%</title>
	<pubDate>2013-03-22T09:06:50+01:00</pubDate>
	<wp:post_id>4056</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Dr.<wbr> Peter Aurup, Head of Global Clinical Trial Operations (GCTO) at Merck Research Laboratories has revealed that the company realized a 25-30% cost saving after establishing a data management center in China, as part of Merck's expanded global reach through both outsourcing and offshoring.<wbr> Notably, the center features 5% foreign professionals who assist in training local staff.<wbr> </div><div style="margin-bottom: 10px;">Nevertheless, Aurup remarked that the 20% turnover rate presents a specific challenge, as do expectations placed on local employees tasked with project responsibilities.<wbr> </div><div style="margin-bottom: 10px;">Merck has increased the number of outsourced clinical trials to 50% from 10% in 2008 and 2009, including trials for biosimilar, respiratory, diabetes and hypertension drug development programs.<wbr> </div><div><EM>Source: GBI</EM> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20130431&edate=20130101&rec=10351">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-03-22T09:06:50+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-03-22T09:06:50+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category pharma-news > <![CDATA[Pharma News]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>BMS to Launch at Least 4 New Diabetes Drugs in China by 2015</title>
	<pubDate>2013-03-22T09:03:18+01:00</pubDate>
	<wp:post_id>4057</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: BMS China President Jean-Christophe Pointeau underscored that diabetes is one of BMS China's most significant business areas, in line with Chinese government policies designed to boost chronic disease prevention and treatment and medical insurance coverage expansion.<wbr> </div><div style="margin-bottom: 10px;">The China National Plan for Chronic Disease Prevention and Treatment (2012-2015) lists diabetes as a top priority, and according to a National People's Congress report, China will increase its healthcare expenditure by 27.<wbr>1% YOY in 2013.<wbr> The Chinese diabetic population has been projected to rise from 92.<wbr>4 million to 130 million by 2030.<wbr> </div><div style="margin-bottom: 10px;">Competition is expected from Sanofi (NYSE: SNY) and Novo Nordisk (NYSE: NVO), which are both increasing emerging market diabetes R&amp;D investment.<wbr> </div><div><EM>Source: GBI</EM> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20130431&edate=20130101&rec=7304">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-03-22T09:03:18+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-03-22T09:03:18+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category endocrinology > <![CDATA[Endocrinology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Key Messages from Bayer Meet Management Conference</title>
	<pubDate>2013-03-21T16:10:40+01:00</pubDate>
	<wp:post_id>4058</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: The healthcare sessions were presided over by the interim divisional head, Wolfgang Plischke.<wbr> The sessions focused on the roll out of the key late-stage assets, with Xarelto leading the way.<wbr> Emerging markets continue to be very important contributors for growth (37% of 2012 sales).<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10350_1_ScreenCapture1.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10350_2_ScreenCapture2.jpg"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10350_4_ScreenCapture4.jpg"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10350_6_ScreenCapture6.jpg"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10350_5_ScreenCapture5.jpg"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10350_3_ScreenCapture3.jpg"> </div><!-- Comment details --><a name="pharmaworld10350attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10350_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(49,1 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10350_2_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(54,8 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10350_3_ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(58,3 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10350_4_ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(54,2 KB)<br>&nbsp;&nbsp;5.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10350_5_ScreenCapture5.jpg">ScreenCapture5.jpg</a>&nbsp;&nbsp;(67,4 KB)<br>&nbsp;&nbsp;6.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10350_6_ScreenCapture6.jpg">ScreenCapture6.jpg</a>&nbsp;&nbsp;(75,6 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20130431&edate=20130101&rec=10350">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-03-21T16:10:40+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-03-21T16:10:40+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category pharma-news > <![CDATA[Pharma News]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Key Messages from AstraZeneca Investor Day</title>
	<pubDate>2013-03-21T14:48:00+01:00</pubDate>
	<wp:post_id>4059</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Management highlighted 3 ambitions for the group (Focus, Accelerate and Transform), its focus in 3 therapy areas (cardio-metabolism; oncology and respiratory/<wbr>inflammation), driven by infection and vaccines and neuroscience, the increase proximity to bioscience clusters around 3 strategic sites (Gaithersburg; Cambridge, Mölndal), and its focus on 5 growth platforms (Cardiovascular; Diabetes; Emerging Markets; Respiratory; Japan).<wbr> Business development activity, which will be lead by newly appointed Marc Dunoyer (ex GSK), was cited as being a key priority.<wbr> Restructuring strategy as well as key slides are provided below.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">In addition to R&amp;D reshaping program ($1.<wbr>4bn cost, 1,600 positions, $190m benefits from 2016), SG&amp;A headcount will be reduced by 2,300 (EU field force, back office).<wbr> Combined with the balance of the Ph III program, headcount will reduce by 5,050 through 2016, at a cost of $2.<wbr>3bn ($1.<wbr>7bn cash).<wbr> Astra expects benefits of $800m per annum from 2016 (c5% of current cost base).<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10346_11_ScreenCapture10.jpg"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10346_2_ScreenCapture2.jpg"> </div><div style="margin-bottom: 10px;"><U><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10346_12_ScreenCapture11.jpg">Marc Dunoyer</U> (newly created role of Executive VP, Global Portfolio &amp; Product Strategy) will be responsible for driving business strategy, including business development, mergers and acquisitions, portfolio and product strategies.<wbr> </div><div style="margin-bottom: 10px;">His most critical priorities will be to bolster the core growth platforms and therapy areas through well executed business development initiatives and leadership of internal efforts.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10346_1_ScreenCapture1.jpg"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">- Upcoming Major Events to 2017 from 2013 </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10346_3_ScreenCapture3.jpg"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10346_4_ScreenCapture4.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10346_5_ScreenCapture5.jpg"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">A key growth platform for AZ.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10346_6_ScreenCapture6.jpg"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10346_8_ScreenCapture8.jpg"> </div><div style="margin-bottom: 10px;">Basically, 2 drugs being developed for prostate cancer: </div><div style="margin-bottom: 10px;"><STRONG>Olaparib</STRONG> </div><div style="margin-bottom: 10px;"><UL><LI>Five Phase III in ovarian, gastric and breast</LI>
<LI>Three Phase II in lung</LI>
<LI>Two Phase IB in prostate</LI>
</UL> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10346_9_ScreenCapture9.jpg"> </div><div style="margin-bottom: 10px;"><STRONG>AZD5363 (AKT inhibitor)</STRONG> </div><div style="margin-bottom: 10px;"><UL><LI>Personalized strategy (See <a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20130431&edate=20130101&rec=8491" class="defaultlink">Oncology8491: AstraZeneca AKT Inhibitor to Enter Ph1 for mCRPC</a>).<wbr></LI>
</UL> </div><div><STRONG></STRONG> </div><!-- Comment details --><a name="pharmaworld10346attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;7.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10346_7_ScreenCapture7.jpg">ScreenCapture7.jpg</a>&nbsp;&nbsp;(91,4 KB)<br>&nbsp;&nbsp;10.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10346_10_AZ%20Investor%20Day%255fMarch%2021%202013.pdf">AZ Investor Day_March 21 2013.pdf</a>&nbsp;&nbsp;(2,5 MB)<br>&nbsp;&nbsp;12.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10346_12_ScreenCapture11.jpg">ScreenCapture11.jpg</a>&nbsp;&nbsp;(4,4 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20130431&edate=20130101&rec=10346">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-03-21T14:48:00+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-03-21T14:48:00+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category pharma-news > <![CDATA[Pharma News]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Nice Rejects Novartis' Afinitor for Breast Cancer</title>
	<pubDate>2013-03-21T09:15:41+01:00</pubDate>
	<wp:post_id>4060</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: The drug has been rejected due to uncertainty over its survival benefits in the condition.<wbr> During its FY12 financial results, management reported that Afinitor has the potential to exceed sales of USD 2 bn in breast cancer alone by 2017.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Afinitor (everolimus) is the 1st mTOR inhibitor to be approved for post-menopausal women with advanced-receptor positive, HER2-negative breast cancer.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">- approved in July 2012 in the US abd EU for HR+/<wbr>HER2-advanced breast cancer.<wbr> </div><div style="margin-bottom: 10px;">- Launched in the US, Germany, Austria, Argentina, UK and Canada.<wbr> </div><div style="margin-bottom: 10px;">- Afinitor 2012 sales grew 85% vs previous year and reached $797M.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8848_1_ScreenCapture1.jpg"> </div><div><EM>Source: Biocentury; Novartis</EM> </div><!-- Comment details --><a name="oncology8848attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8848_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(31,2 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20130431&edate=20130101&rec=8848">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-03-21T09:15:41+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-03-21T09:15:41+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Retrospective Review of BOTOX® and Xeomin® for Blepharospasm and Cervical Dystonia</title>
	<pubDate>2013-03-20T17:57:17+01:00</pubDate>
	<wp:post_id>4061</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Allergan is sponsoring a retrospective chart review to evaluate the doses of the different toxins used for the treatment of cervical dystonia and blepharospasm in clinica practice.<wbr> PE will assess dose of botulinum toxin used to treat the conditions.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG><A href="http://clinicaltrials.gov/ct2/show/NCT01814774?recr=Open&amp;no_unk=Y&amp;fund=2&amp;rcv_s=02%2F20%2F2013&amp;rank=187"><STRONG></STRONG></A> </div><div style="margin-bottom: 10px;">Recruitment: approx 90 men/<wbr>women (18 years and older) </div><div style="margin-bottom: 10px;"><UL style="MARGIN-TOP: 1ex; MARGIN-BOTTOM: 1ex"><LI class="color-bullet" style="MARGIN-TOP: 0.7ex">confirmed primary diagnosis of idiopathic cervical dystonia or blepharospasm for at least 2 years</LI>
<LI class="color-bullet" style="MARGIN-TOP: 0.7ex">treatment with Xeomin® and BOTOX® for at least 1 year each</LI>
</UL> </div><div style="margin-bottom: 10px;">
Start date: Jan.<wbr> 2013 - Completion date: June 2013 </div><div><EM>Source: clinicaltrials.<wbr>gov</EM> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20130431&edate=20130101&rec=6872">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-03-20T17:57:17+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-03-20T17:57:17+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>BOTOX® After Laser Resurfacing in Chinese Men/Women with Glabellar Lines</title>
	<pubDate>2013-03-20T17:44:24+01:00</pubDate>
	<wp:post_id>4062</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: A new Ph4 trial has started in Beijing to evaluate safety and efficacy of the treatment.<wbr> PE will measure investigator's assessment of the severity of frown lines at maximum contraction using the 4-point facial wrinkle scale.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG><A href="http://clinicaltrials.gov/ct2/show/NCT01814670?recr=Open&amp;no_unk=Y&amp;fund=2&amp;rcv_s=02%2F20%2F2013&amp;rank=176"><STRONG></STRONG></A> </div><div style="margin-bottom: 10px;">ecruitment: approx.<wbr> 200 men/<wbr>women (18 years to 60 years).<wbr> </div><div style="margin-bottom: 10px;">Completion dates: Feb.<wbr> 2014 /<wbr> May 2014.<wbr> </div><div style="margin-bottom: 10px;">Inclusion criteria: moderate to severe frown lines - facial laser treatment between 4 to 8 weeks prior to Day 1.<wbr> </div><div><EM>Source: clinicaltrials.<wbr>gov</EM> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20130431&edate=20130101&rec=6871">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-03-20T17:44:24+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-03-20T17:44:24+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>PhII Localised Prostate Cancer Treatment Trial Continues To Progress Well</title>
	<pubDate>2013-03-20T16:58:14+01:00</pubDate>
	<wp:post_id>4063</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Nymox Corporation has announced that the IDMC for the Company's 
Phase 2 study of NX-1207 for low risk localized prostate cancer (NX03-0040) has 
reported a third positive analysis of safety data from the clinical trial.<wbr> The 
150 patient trial is due to complete in terms of its efficacy endpoint in April 
2013.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Study Design</STRONG> </div><div style="margin-bottom: 10px;">The NX03-0040 study tests both low and high doses of NX-1207 for their effect 
on low grade localized prostate cancer.<wbr> In the study, the NX-1207 dose is 
administered directly into the area of the prostate where the cancer was 
detected.<wbr> </div><div style="margin-bottom: 10px;">The procedure is performed by a urologist in an office setting, does not 
require anaesthesia, sedation, or catheterization, takes only a few minutes and 
involves minimal discomfort to the patient.<wbr> </div><div style="margin-bottom: 10px;">Patients in the study are randomly allocated to either low or high dose 
NX-1207 or to active surveillance (no treatment).<wbr> Patients undergoing active 
surveillance in the trial also have the opportunity to receive NX-1207 after 
their trial active surveillance participation is completed.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Localised Cancer Statistics</STRONG> </div><div style="margin-bottom: 10px;">The American Cancer Society estimates that in 2012 more than 240,000 men in 
the United States will be newly diagnosed with prostate cancer and more than 
28,000 men will die from the disease.<wbr> Most cases are detected via 
prostate-specific antigen (PSA) screening and usually found to have localized 
tumors.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Other Developments With NX-1207</STRONG> </div><div>NX-1207 is also in late stage Phase 3 development in the U.<wbr>S.<wbr> for the 
treatment of benign prostatic hyperplasia.<wbr> Phase 3 trial activities of NX-1207 
for BPH have recently begun in Europe sponsored by Recordati S.<wbr>p.<wbr>A.<wbr>, the 
company's European licensing partner for the BPH indication.<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20130431&edate=20130101&rec=8847">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-03-20T16:58:14+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-03-20T16:58:14+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Valeant to Acquire Obagi Medical for $344M</title>
	<pubDate>2013-03-20T14:22:07+01:00</pubDate>
	<wp:post_id>4064</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Valeant has a long story of acquisitions.<wbr> It recently purchased Medicis which provides the company with a good branded US dermatology platform.<wbr> With Obagi, it will have access to proprietary topical aesthetic and therapeutic prescription-strength skin care systems in the physician-dispensed market.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Valeant will acquire all of the outstanding common stock of Obagi for <MONEY>$19.<wbr>75</MONEY> per share in cash, which represents a 42% premium to Obagi’s closing share price on <CHRON>Thursday, March 14, 2013</CHRON>, the last trading day prior to the disclosure of its fourth quarter and full year 2012 earnings, and a 40% premium to the thirty day prior stock price.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Using its <EM>Penetrating Therapeutics™ technologies</EM>, Obagi Medical's products are designed to improve penetration of agents across the skin barrier for common and visible skin conditions in adult skin including premature aging, photodamage, hyperpigmentation, acne, sun damage, rosacea, and soft tissue deficits, such as fine lines and wrinkles.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">- Product lines: please see @ <A href="http://www.obagi.com/patients/product-line">http:/<wbr>/<wbr>www.<wbr>obagi.<wbr>com/<wbr>patients/<wbr>product-line</A> </div><div style="margin-bottom: 10px;"><UL><LI>cosmetic, over-the-counter and prescription products, including 4% hydroquinone.<wbr></LI>
</UL> </div><div style="margin-bottom: 10px;">Products are sold and promoted only through physician offices and requires education by a physician on proper use.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6866_2_ScreenCapture2.jpg"> </div><div>Reference on Valeant in Traction CI please see <a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20130431&edate=20130101&rec=6837" class="defaultlink">Neurology6837: Key Takeaways from Valeant Q4 and FY12 Results</a>.<wbr> </div><!-- Comment details --><a name="neurology6866attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6866_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(118,1 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6866_2_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(195,6 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20130431&edate=20130101&rec=6866">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-03-20T14:22:07+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-03-20T14:22:07+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Almirall May Discontinue Selling Sativex for Spasticity in Germany</title>
	<pubDate>2013-03-20T10:53:28+01:00</pubDate>
	<wp:post_id>4065</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: The drug was launched in July 2011 after obtaining approval in May.<wbr> Since June 2012 Almirall has been in price negotiations and unable to a agree satisfactory price with the German National Association of Statutory Health Insurance Funds.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">GW Pharm.<wbr>'s management reported that " .<wbr>.<wbr>.<wbr> the decision in Germany is in distinct contrast to the price agreed in every other EU country to date".<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Almirall plans to take all necessary steps to challenge the decision, which may include suspension or withdrawal of supply.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Noting that Sativex is already approved in 20 countries, with marketing already having started in 8 of them, Almirall presents the decision by the GKV as a contrast from the way the drug has been received in other European countries.<wbr> </div><div>This may reflect the efforts being made by the company to protect its price in the European countries that use Germany as a reference market; with no exact information on the price offered by the GKV, it is hard to assess how much of a gap there is between the German price offer and the prices the drug has secured in other countries.<wbr> However, this situation is certainly indicative of a harshening regulatory situation in Germany.<wbr>The product has not bee approved in the US, where it is currently in Ph3 for advanced cancer pain.<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20130431&edate=20130101&rec=6865">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-03-20T10:53:28+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-03-20T10:53:28+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Bayer's Radium-223 Dichloride to be Tested for mCRPC with Bone Metastasis in Asia</title>
	<pubDate>2013-03-19T17:30:57+01:00</pubDate>
	<wp:post_id>4066</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: The Ph3 study is expected to last 4 years, and recruit patients in China, South Korea, Taiwan and Singapore.<wbr> Primary endpoint will assess OS, and safety variables will be summarized in a descriptive manner based on AEs collection, laboratory changes, changes in vital signs and ECG.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG><A href="http://clinicaltrials.gov/ct2/show/NCT01810770?recr=Open&amp;no_unk=Y&amp;fund=2&amp;rcv_s=02%2F19%2F2013&amp;rank=167"><STRONG></STRONG></A> </div><div style="margin-bottom: 10px;">Recruitment: approx.<wbr> 150 </div><div style="margin-bottom: 10px;">Start date: March 2013 </div><div style="margin-bottom: 10px;">Completion dates: April 2017 </div><div style="margin-bottom: 10px;">Protocol: Radium-223 dichloride, 50 kBq/<wbr>kg body weight, will be administered as a slow bolus IV injection at 4 week intervals for up to 6 doses.<wbr> </div><div><EM>Source: clinicaltrials.<wbr>gov</EM> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20130431&edate=20130101&rec=8845">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-03-19T17:30:57+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-03-19T17:30:57+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Significant Milestone for BMS and Merck Serono in China</title>
	<pubDate>2013-03-19T12:18:52+01:00</pubDate>
	<wp:post_id>4067</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Merck Serono and BMS have signed a collaboration agreement for the promotion of the different formulations of Glucophage® (type 2 diabetes).<wbr> The product has been marketed by Bristol- Myers Squibb-SASS in China since 1999.<wbr> The two companies will utilize their existing resources and complementary strengths, with Bristol-Myers Squibb-SASS continuing to manufacture Glucophage’s IR® (immediate release) formulation.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">- to expand the geographic distribution of Glucophage®.<wbr> </div><div style="margin-bottom: 10px;">- to provide diabetes-related health and medical information including education for health professionals.<wbr> </div><div style="margin-bottom: 10px;">- to increase outreach to hospitals.<wbr> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;">Glucophage® (metformin hydrochloride) is a prescription-only medicine indicated for the treatment of type 2 diabetes mellitus particularly in overweight patients when diet and exercise alone have failed.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">- China now has the most people with diabetes of any country in the world.<wbr> It has become a major public health problem in China with &gt;90 million people suffering from the disease (<EM>International Diabetes Federation.<wbr> press-statement-china-study</EM>).<wbr> </div><div style="margin-bottom: 10px;">- Current estimates are that &gt;60% of patients with type 2 diabetes are undiagnosed (<EM>Yang W, et al.<wbr> N Engl J Med.<wbr> 2010; 362(12): 1090-101</EM>), possibly due to a combination of poor public awareness and limited opportunities for diagnosis.<wbr> </div><div><EM>Source: Merck Serono PR</EM> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20130431&edate=20130101&rec=7301">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-03-19T12:18:52+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-03-19T12:18:52+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category endocrinology > <![CDATA[Endocrinology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Positive Results of Biocancell's Targeted Therapy for Bladder Cancer</title>
	<pubDate>2013-03-19T11:55:49+01:00</pubDate>
	<wp:post_id>4068</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: The Israeli company reported positive results from the Ph2b of BC-819 in the treatment of patients with itermediate-risk superficial bladder cancer who did not respond to chemotherapy or BCG.<wbr> Management indicated it was in discussion with several large drugmakers for further development and commercialisation of the therapy.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">- Design: Please see <A href="http://clinicaltrials.gov/ct2/show/NCT00595088?term=BC-819&amp;rank=3">NCT00595088</A> </div><div style="margin-bottom: 10px;">- Results: </div><div style="margin-bottom: 10px;"><UL><LI>24 of 31 patients who completed 12-month of BC-819 treatment and 12 of 25 who completed 24-months of BC-819 treament did not develop new tumours.<wbr> </LI>
<LI>&gt;80% of patients in the BC-819 arm displayed no functional impairment acc to the Karnofsky Performance Scale during the study period.<wbr></LI>
</UL> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"><UL><LI></LI>
<LI></LI>
</UL> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><A href="http://www.biocancell.com/about-us">BioCancell</A>'s patented, personalized cancer therapy approach is based on the identification of target oncogenes, such as <A href="http://www.biocancell.com/h19">H19</A>.<wbr> </div><div style="margin-bottom: 10px;">H19 is significantly expressed in over thirty-three different forms of cancer, including superficial bladder carcinoma and pancreatic, ovarian and metastatic liver cancer, while laying dormant and non-expressed in non-cancerous cells.<wbr> </div><div><EM>Source: Clinicaltrials.<wbr>gov; company website; ThomsonOne.<wbr></EM> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20130431&edate=20130101&rec=8844">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-03-19T11:55:49+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-03-19T11:55:49+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>BIND Biosciences' Accurins Lead Drug to Enter POC for mCRPC</title>
	<pubDate>2013-03-18T17:47:32+01:00</pubDate>
	<wp:post_id>4069</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Phase 2 has been designed to determine the safety and efficacy of BIND-014 (docetaxel nanoparticles for injectable suspension), administered to approx.<wbr> 40 men with mCRPC.<wbr> PE will determine the eficacy of the drug by rPFS.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG><A href="http://clinicaltrials.gov/ct2/show/NCT01812746?recr=Open&amp;no_unk=Y&amp;fund=2&amp;rcv_s=02%2F18%2F2013&amp;rank=116"><STRONG></STRONG></A> </div><div style="margin-bottom: 10px;">Start date: April 2013 - Completion dates: Aug.<wbr> 2014 /<wbr> Dec.<wbr> 2015.<wbr> </div><div style="margin-bottom: 10px;">PI: Howard Scher, MD (Memorial Sloan-Kettering Cancer Center).<wbr> </div><div style="margin-bottom: 10px;">Location: USA (1 site).<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><A href="http://www.bindbio.com/content/pages/company/aboutrussia.jsp">Accurins Platform</A> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8841_1_ScreenCapture1.jpg"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div>See <a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20130431&edate=20130101&rec=8714" class="defaultlink">Oncology8714: Amgen and BIND Biosciences Sign $180M Nanomedicine Deal</a>.<wbr> </div><!-- Comment details --><a name="oncology8841attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8841_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(49,8 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20130431&edate=20130101&rec=8841">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-03-18T17:47:32+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-03-18T17:47:32+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Progenics Increases Its Focus On Prostate Cancer - Both Imaging & Therapy</title>
	<pubDate>2013-03-18T15:05:54+01:00</pubDate>
	<wp:post_id>4070</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Progenics elaborated on its recent purchase of Molecular Insight 
during its fourth quarter earnings call last week, suggesting that it supports 
the group's progress towards becoming a preeminent oncology-focused company with 
prostate cancer developments providing a core orientation.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Prostate Cancer Imaging</STRONG> </div><div style="margin-bottom: 10px;">Earlier this 
month, Progenics reported positive clinical data from a study of imaging agents that were part of the Molecular Insight acquisition.<wbr> The paper summarizing these data were selected as the cover feature for the March issue of the Journal of Nuclear Medicine.<wbr> </div><div style="margin-bottom: 10px;"><P class="pwrapper">Progenics noted that Imaging 
options that currently exist are limited in their ability to diagnose and stage prostate cancer.<wbr> Data from studies of the compounds discussed in that journal paper and from MIP-1404, all of which we acquired from Molecular Insight indicate that PSMA is a robust target for prostate cancer molecular imaging.<wbr> </P> </div><div style="margin-bottom: 10px;"><P class="pwrapper">Progenics believes that a radiolabeled small molecule, which binds PSMA with high affinity has the potential to detect prostate cancer throughout the body offering an improved way to visualize prostate cancer with a high degree of specificity and sensitivity.<wbr> </P> </div><div style="margin-bottom: 10px;"><P class="pwrapper"><STRONG>CRPC Therapy</STRONG></P> </div><div style="margin-bottom: 10px;"><P class="pwrapper">Elsewhere in its pipeline, 
the PSMA ADC Phase II study of up to 75 patients with metastatic castration-resistant prostate cancer is ongoing.<wbr> This is an open label trial to assess any tumor activity as measured by responses in PSA, circulating tumor cells, pain and change in tumor size as measured under RECIST criteria.<wbr> Tolerability 
and safety are also being assessed.<wbr> There are currently 
25 sites open and which expect to complete enrollment by the end of this year.<wbr></P> </div><div style="margin-bottom: 10px;"><P class="pwrapper">Phase I data on this product was presented at ASCO GU 
this year, the poster presentation for which is attached</P> </div><div style="margin-bottom: 10px;"><P class="pwrapper"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8839_1_ScreenCapture1.jpg"></P> </div><div style="margin-bottom: 10px;"><P class="pwrapper"><STRONG>Commenting on the company's first 30 day 
impression/<wbr>decisions regarding Molecular Insight Mark Baker CEO 
noted:-</STRONG></P> </div><div style="margin-bottom: 10px;"><P class="pwrapper firstP">"The bottom line of that is that we will be closing the Cambridge facility of Molecular Insight, just a few people from Molecular Insight will be joining us and I don't see any overall increase in our head count as a result of that acquisition.<wbr> And, I think we're following the path that we said that we would, when we announced the acquisition we're moving forward with the Phase II trial of the MIP-1404 imaging agent.<wbr> As I've come to deepen my knowledge around the potential for an imaging agent In prostate cancer, I have to 
say, my excitement about that program has been building.<wbr> And the Azedra program, the Ultra-Orphan program for this rare adrenal gland tumor continues to be of great interest and our first effort there is to meet with the Agency, as I've said and get a path forward, given that there is an SPA in place and there is data that satisfies that SPA, although the trial was stopped prematurely because of Molecular Insight's financial troubles.<wbr>"</P> </div><div style="margin-bottom: 10px;"><P class="pwrapper">There are early-stage programs there focusing on small molecule, targeting the PSMA, and we're continuing to evaluate those.<wbr> But the priority are the Phase II program for the imaging agent and the Azedra program.<wbr> And when you add that to our PSMA program, we have now with this acquisition moved into a position of having three late-stage oncology programs whereas previously we had one.<wbr></P> </div><div><P class="pwrapper">Source: <A href="http://www.progenics.com">www.<wbr>progenics.<wbr>com</A></P> </div><!-- Comment details --><a name="oncology8839attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8839_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(36,6 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8839_2_PSMA%20ADC%20ASCO%255fGU%255f2013%255fWEBSITE%255f021413%5b2%5d.pdf">PSMA ADC ASCO_GU_2013_WEBSITE_021413[2].pdf</a>&nbsp;&nbsp;(291,1 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20130431&edate=20130101&rec=8839">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-03-18T15:05:54+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-03-18T15:05:54+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>The Growth Imperative for AstraZeneca</title>
	<pubDate>2013-03-18T11:35:30+01:00</pubDate>
	<wp:post_id>4071</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: In comments made public at recent events, new CEO Pascal Soriot stressed future strategy being 1/<wbr>short-term priority: optimise growth drivers; 2/<wbr>medium-term: return AZ to growth overall; 3/<wbr> long-term: to rebuild R&amp;D by exploiting leading science better, and remain focussed on innovation.<wbr> Of note this CEO's comment: ".<wbr>.<wbr>.<wbr> we are going to be rebuilding oncology.<wbr> .<wbr>.<wbr>.<wbr> oncology is also close to my heart".<wbr> On March 18, management announced plans to invest in strategic R&amp;D in the UK, the US and Sweden to improve pipeline productivity.<wbr> Over the 2013-2016 period, the proposed investment and associated changes will lead to the relocation of nearly 2,500 roles and an overall estimated reduction in headcount in the region of 1,600 roles.<wbr> Key points are highlighted below.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Under the plans, AstraZeneca’s small molecule and biologics R&amp;D activities will be concentrated in 3 strategic centres: </div><div style="margin-bottom: 10px;"><UL><LI>Cambridge, UK; </LI>
<LI>Gaithersburg, US; and </LI>
<LI>Mölndal, Sweden.<wbr> </LI>
</UL> </div><div style="margin-bottom: 10px;">The proposals are expected to be fully implemented by 2016.<wbr> The main changes are as follows: </div><div style="margin-bottom: 10px;"><UL><LI><U>Alderley Park, Cheshire, UK</U>: Under the proposals, research and development work will no longer be carried out at Alderley Park.<wbr> Approximately 1,600 roles will relocate from Alderley Park, with the significant majority going to the new centre in Cambridge and the remainder to the company’s nearby Macclesfield manufacturing facility or other AstraZeneca sites overseas.<wbr> At least 700 non-R&amp;D roles are expected to remain at Alderley Park.<wbr> AstraZeneca is committed to exploring all options to ensure that Alderley Park has a successful future.<wbr></LI>
<LI><U>Wilmington, Delaware, US</U>: With the exit of the Global Medicines Development group and the relocation of global marketing and US specialty care commercial roles, about 1,200 roles will leave Wilmington.<wbr> There will be a net increase of approximately 300 roles in Gaithersburg.<wbr> The changes announced today will lead to an estimated overall reduction of about 650 positions in the US; while around 170 will relocate to other AstraZeneca sites in the US or overseas.<wbr> Wilmington will remain the North America commercial headquarters, with a population of about 2,000 at the AstraZeneca site.<wbr></LI>
<LI><U>London, UK</U>: The majority of corporate and global commercial roles based in London are expected to move to the new centre in Cambridge with some going to other AstraZeneca sites.<wbr> Following the transfer of the company’s headquarters to Cambridge, AstraZeneca’s Paddington office will close by 2016.<wbr> Currently, around 350 roles are based in London.<wbr></LI>
</UL> </div><div style="margin-bottom: 10px;">The programme is expected to incur $1.<wbr>4 billion in one-time restructuring charges, of which $800 million are likely to be cash costs.<wbr> In addition, the company will invest approximately $500 million in establishing the new centre in Cambridge.<wbr> Annualised benefits of approximately $190 million are expected by 2016 for the programme.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><STRONG>Rationale</STRONG> </div><div style="margin-bottom: 10px;">AstraZeneca faces $6 bln revenue falls as generics bite.<wbr> </div><div style="margin-bottom: 10px;"><U>Loss of Exclusivity by Brand</U> </div><div style="margin-bottom: 10px;">Sustainable revenues from: </div><div style="margin-bottom: 10px;"><UL><LI>Casodex: fast decline in US/<wbr>WE, but stable in emerging markets</LI>
<LI>Zoladex: device technology and difficult to manufacture</LI>
</UL> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8835_5_ScreenCapture5.jpg"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><UL><LI>cardiovascular drug Brilinta</LI>
<LI>the diabetes franchise</LI>
</UL> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8835_6_ScreenCapture6.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8835_2_ScreenCapture2.jpg"> </div><div style="margin-bottom: 10px;"><UL><LI>emerging markets, notably China.<wbr></LI>
<LI>the respiratory franchise (currently largely based around Symbicort).<wbr></LI>
<LI>the relatively young pharma business in Japan.<wbr></LI>
</UL> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">More news to come on March 21 at Analysts/<wbr>Investors Day will outline the ambitions for the company.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div>See <a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20130431&edate=20130101&rec=10020" class="defaultlink">PharmaWorld10020: AstraZeneca Appoints New CEO</a>.<wbr> </div><!-- Comment details --><a name="oncology8835attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8835_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(74 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8835_3_ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(4 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8835_4_ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(7,4 KB)<br>&nbsp;&nbsp;7.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8835_7_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(30 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20130431&edate=20130101&rec=8835">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-03-18T11:35:30+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-03-18T11:35:30+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Interest In The DMD Market Gathers Pace</title>
	<pubDate>2013-03-18T09:54:33+01:00</pubDate>
	<wp:post_id>4072</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment PTC Therapeutics concluded a very successful private fund 
raising last week raising $60m to fund phase III development of its Duchenne 
Muscular Dystrophy Drug ataluren.<wbr> The latter demonstrated a statistically 
significant improvement in walking distance in a phIIb trial.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Regulatory Status &amp; Requirements</STRONG> </div><div style="margin-bottom: 10px;">A phase III DMD study is set to begin this half and should complete by 
2H2015.<wbr> the EAM is already reviewing an MAA seeking conditional approval of 
ataluren though approval appears to be viewed as a long shot.<wbr> The FDA 
has recommende that an additional study beyond the group's PhIIb 
trial be undertaken before seeking approval in the US </div><div style="margin-bottom: 10px;"><STRONG>Details of New Financing</STRONG> </div><div style="margin-bottom: 10px;">The financing was led by new investor Brookside Capital the public equity 
afficiliate of Bain Capital.<wbr> Additional new invesotrs included Adage 
Capital, Jennison Assocaites, Longwood Fund and its existing set of 7 venture 
capital groups.<wbr> Two new borad seats were allocated to Brookside and the Longwood 
fund.<wbr> </div><div style="margin-bottom: 10px;">Meanwhile, Sarepta Therapeutics has seen its market cap spike by 910% since 
reporting its phIIb data last July giving it a current market cap of  
$1.<wbr>03bn.<wbr> </div><div style="margin-bottom: 10px;">PTC has raised at least $271.<wbr>6 million since it was founded in 1998 and 
currently has no immenent plans to IPO.<wbr> </div><div>Source: <A href="http://www.ptctherapeutics.com">www.<wbr>ptctherapeutics.<wbr>com</A> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20130431&edate=20130101&rec=6863">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-03-18T09:54:33+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-03-18T09:54:33+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>re: Daewoong's European Ambition</title>
	<pubDate>2013-03-18T09:25:15+01:00</pubDate>
	<wp:post_id>4073</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="border-left: 2px solid #8B1010; padding: 0px 0px 5px 12px; margin-bottom: 3px;"><span style="font-weight: bold; font-size: 14px;">Daewoong's European Ambition</span>&nbsp;<br><span style="font-size: 12px;">Comment: Korean Daewoong Pharmaceuticals is gaining a foothold in 
the European market through a distrubtion partnership with Turkey's leading 
pharmaceutical company Abdi Ibrahim for its biosimilar Epogen.<wbr> Although, we 
are not aware of Daewoong's specific intent to enter Europe with its new toxin 
DWP450, this is the first indication of the company's ambition to 
enter the European markets with its products</span>&nbsp;&nbsp;<a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20130431&edate=20130101&rec=6859">...</a><br></div><div>Abdi Ibrahim is the former distributor of Allergan in Turkey before they decide to go direct in the country.<wbr> </div><!-- Comment details --><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20130431&edate=20130101&rec=6862">Add a Comment on this Article</a><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology6859">View thread  Neurology6859: Daewoong's European Ambition</a>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-03-18T09:25:15+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-03-18T09:25:15+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Pfizer's PDE10 Inhibitor to Enter Ph2 for Early Huntington's Disease</title>
	<pubDate>2013-03-15T18:08:25+01:00</pubDate>
	<wp:post_id>4074</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Administration of PDE10 inhibitors has been shown to provide symptomatic and neuropathological improvements in mouse models as well as extending lifespan.<wbr> The trial will evaluate the safety, tolerability and brain function of 2 doses of PF-0254920 in subjects with early Huntington's Disease.<wbr> PE will assess change from baseline to D28 of unified HD rating scale.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG><A href="http://clinicaltrials.gov/ct2/show/NCT01806896?recr=Open&amp;no_unk=Y&amp;fund=2&amp;rcv_s=02%2F15%2F2013&amp;rank=217"><STRONG></STRONG></A> </div><div style="margin-bottom: 10px;">Start date: April 2013 /<wbr> Completion date: March 2015 </div><div style="margin-bottom: 10px;">Recruitment: approx.<wbr> 65 </div><div>Site: US </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20130431&edate=20130101&rec=6860">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-03-15T18:08:25+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-03-15T18:08:25+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Daewoong's European Ambition</title>
	<pubDate>2013-03-15T17:50:23+01:00</pubDate>
	<wp:post_id>4075</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Korean Daewoong Pharmaceuticals is gaining a foothold in 
the European market through a distrubtion partnership with Turkey's leading 
pharmaceutical company Abdi Ibrahim for its biosimilar Epogen.<wbr> Although, we 
are not aware of Daewoong's specific intent to enter Europe with its new toxin 
DWP450, this is the first indication of the company's ambition to 
enter the European markets with its products </div><div style="margin-bottom: 10px;">Daewoong regards this development as an important milestone for the 
company because of the requirement for "high quality products conforming to 
rigorous EU guidelines" </div><div style="margin-bottom: 10px;">Having signed a contract with Turkey-based Abdi Ibrahim, the 
latter will have the right to distribute EPOSIS a pre-filled liquid syringe 
verson of erythropoietin and Easyef dermal solution in Turkey.<wbr> Both products are 
expected to complete the approval process by 2015.<wbr> Expectations are that these 
products will generate more than $13m and $25m in sales five years post 
launch.<wbr> </div><div>Source: <A href="http://www.daewoong.co.kr">www.<wbr>daewoong.<wbr>co.<wbr>kr</A> </div><!-- Comment details --><span style="font-weight: bold; font-style: italic;"><br>Comments</span><a name="Neurology6862c"></a><br><div style="border: 1px solid #AAA; background-color: #FFF; margin-left: 10px; padding: 5px;"><div>Abdi Ibrahim is the former distributor of Allergan in Turkey before they decide to go direct in the country.<wbr> </div></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20130431&edate=20130101&rec=6859">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-03-15T17:50:23+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-03-15T17:50:23+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>ENETS Intelligence - NVS Symposia Highlights</title>
	<pubDate>2013-03-15T13:19:32+01:00</pubDate>
	<wp:post_id>4076</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"><UL><LI></LI>
<LI></LI>
<LI></LI>
<LI></LI>
</UL> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"><UL><LI></LI>
<LI></LI>
<LI></LI>
<LI></LI>
</UL> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"><UL><LI></LI>
<LI></LI>
<LI></LI>
</UL> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"><SPAN lang="EN-US" style="FONT-FAMILY: 'Arial','sans-serif'; FONT-SIZE: 12pt; mso-fareast-font-family: 'MS Mincho'; mso-fareast-theme-font: minor-fareast; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA"></SPAN> </div><div style="margin-bottom: 10px;"><SPAN lang="EN-US" style="FONT-FAMILY: 'Arial','sans-serif'; FONT-SIZE: 12pt; mso-fareast-font-family: 'MS Mincho'; mso-fareast-theme-font: minor-fareast; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA"></SPAN> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div> </div><!-- Comment details --><a name="endocrinology7297attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7297_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(24,6 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7297_2_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(24,2 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7297_3_ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(57,2 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7297_4_ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(48,9 KB)<br>&nbsp;&nbsp;5.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7297_5_ScreenCapture5.jpg">ScreenCapture5.jpg</a>&nbsp;&nbsp;(43,2 KB)<br>&nbsp;&nbsp;6.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7297_6_ScreenCapture6.jpg">ScreenCapture6.jpg</a>&nbsp;&nbsp;(28,2 KB)<br>&nbsp;&nbsp;7.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7297_7_ScreenCapture7.jpg">ScreenCapture7.jpg</a>&nbsp;&nbsp;(45,4 KB)<br>&nbsp;&nbsp;8.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7297_8_ScreenCapture8.jpg">ScreenCapture8.jpg</a>&nbsp;&nbsp;(41 KB)<br>&nbsp;&nbsp;9.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7297_9_ScreenCapture9.jpg">ScreenCapture9.jpg</a>&nbsp;&nbsp;(51 KB)<br>&nbsp;&nbsp;10.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7297_10_ScreenCapture10.jpg">ScreenCapture10.jpg</a>&nbsp;&nbsp;(47,9 KB)<br>&nbsp;&nbsp;11.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7297_11_ScreenCapture11.jpg">ScreenCapture11.jpg</a>&nbsp;&nbsp;(49,2 KB)<br>&nbsp;&nbsp;12.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7297_12_ScreenCapture12.jpg">ScreenCapture12.jpg</a>&nbsp;&nbsp;(40,1 KB)<br>&nbsp;&nbsp;13.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7297_13_ScreenCapture13.jpg">ScreenCapture13.jpg</a>&nbsp;&nbsp;(54,4 KB)<br>&nbsp;&nbsp;14.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7297_14_ScreenCapture14.jpg">ScreenCapture14.jpg</a>&nbsp;&nbsp;(46,8 KB)<br>&nbsp;&nbsp;15.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7297_15_ScreenCapture15.jpg">ScreenCapture15.jpg</a>&nbsp;&nbsp;(46,5 KB)<br>&nbsp;&nbsp;16.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7297_16_ScreenCapture16.jpg">ScreenCapture16.jpg</a>&nbsp;&nbsp;(63,3 KB)<br>&nbsp;&nbsp;17.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7297_17_ScreenCapture17.jpg">ScreenCapture17.jpg</a>&nbsp;&nbsp;(65 KB)<br>&nbsp;&nbsp;18.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7297_18_ScreenCapture18.jpg">ScreenCapture18.jpg</a>&nbsp;&nbsp;(53,4 KB)<br>&nbsp;&nbsp;19.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7297_19_ScreenCapture19.jpg">ScreenCapture19.jpg</a>&nbsp;&nbsp;(45,7 KB)<br>&nbsp;&nbsp;20.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7297_20_ScreenCapture20.jpg">ScreenCapture20.jpg</a>&nbsp;&nbsp;(48,4 KB)<br>&nbsp;&nbsp;21.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7297_21_ScreenCapture21.jpg">ScreenCapture21.jpg</a>&nbsp;&nbsp;(46,9 KB)<br>&nbsp;&nbsp;22.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7297_22_ScreenCapture22.jpg">ScreenCapture22.jpg</a>&nbsp;&nbsp;(61,5 KB)<br>&nbsp;&nbsp;23.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7297_23_ScreenCapture23.jpg">ScreenCapture23.jpg</a>&nbsp;&nbsp;(52,2 KB)<br>&nbsp;&nbsp;24.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7297_24_ScreenCapture24.jpg">ScreenCapture24.jpg</a>&nbsp;&nbsp;(50,6 KB)<br>&nbsp;&nbsp;25.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7297_25_ScreenCapture25.jpg">ScreenCapture25.jpg</a>&nbsp;&nbsp;(46,7 KB)<br>&nbsp;&nbsp;26.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7297_26_ScreenCapture26.jpg">ScreenCapture26.jpg</a>&nbsp;&nbsp;(46,5 KB)<br>&nbsp;&nbsp;27.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7297_27_ScreenCapture27.jpg">ScreenCapture27.jpg</a>&nbsp;&nbsp;(51,9 KB)<br>&nbsp;&nbsp;28.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7297_28_ScreenCapture28.jpg">ScreenCapture28.jpg</a>&nbsp;&nbsp;(59,9 KB)<br>&nbsp;&nbsp;29.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7297_29_ScreenCapture29.jpg">ScreenCapture29.jpg</a>&nbsp;&nbsp;(55,5 KB)<br>&nbsp;&nbsp;30.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7297_30_ScreenCapture30.jpg">ScreenCapture30.jpg</a>&nbsp;&nbsp;(42,9 KB)<br>&nbsp;&nbsp;31.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7297_31_ScreenCapture31.jpg">ScreenCapture31.jpg</a>&nbsp;&nbsp;(45,5 KB)<br>&nbsp;&nbsp;32.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7297_32_ScreenCapture32.jpg">ScreenCapture32.jpg</a>&nbsp;&nbsp;(58,7 KB)<br>&nbsp;&nbsp;33.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7297_33_ScreenCapture33.jpg">ScreenCapture33.jpg</a>&nbsp;&nbsp;(50,8 KB)<br>&nbsp;&nbsp;34.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7297_34_ScreenCapture34.jpg">ScreenCapture34.jpg</a>&nbsp;&nbsp;(41,1 KB)<br>&nbsp;&nbsp;35.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7297_35_ScreenCapture35.jpg">ScreenCapture35.jpg</a>&nbsp;&nbsp;(46,6 KB)<br>&nbsp;&nbsp;36.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7297_36_ScreenCapture36.jpg">ScreenCapture36.jpg</a>&nbsp;&nbsp;(43,5 KB)<br>&nbsp;&nbsp;37.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7297_37_ScreenCapture37.jpg">ScreenCapture37.jpg</a>&nbsp;&nbsp;(59,9 KB)<br>&nbsp;&nbsp;38.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7297_38_ScreenCapture38.jpg">ScreenCapture38.jpg</a>&nbsp;&nbsp;(59,6 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20130431&edate=20130101&rec=7297">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-03-15T13:19:32+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-03-15T13:19:32+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category endocrinology > <![CDATA[Endocrinology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Weekly Teva's rGH to Enter Ph2 in Adults With Growth Hormone Deficiency</title>
	<pubDate>2013-03-14T17:45:51+01:00</pubDate>
	<wp:post_id>4077</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: The objective of the Ph2 study is to assess the clinical effect of TV-1106.<wbr> PE will measure IGF-I concentration change from baseline.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG><A href="http://clinicaltrials.gov/ct2/show/NCT01811576?recr=Open&amp;no_unk=Y&amp;fund=2&amp;rcv_s=02%2F14%2F2013&amp;rank=185"><STRONG></STRONG></A> </div><div style="margin-bottom: 10px;">Recruitment: approx.<wbr> 50 </div><div style="margin-bottom: 10px;">Start date: March 2013 Completion date: March /<wbr> April 2015.<wbr> </div><div>Location: US; EU.<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20130431&edate=20130101&rec=7296">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-03-14T17:45:51+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-03-14T17:45:51+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category endocrinology > <![CDATA[Endocrinology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>ENETS Intelligence - Part One</title>
	<pubDate>2013-03-14T15:17:52+01:00</pubDate>
	<wp:post_id>4078</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"><UL><LI>
</LI>
<LI>
</LI>
<LI>
</LI>
<LI>
</LI>
</UL> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"><SPAN lang="EN-US" style="font-size: 11pt; font-family: 'Arial','sans-serif'; mso-fareast-font-family: 'MS Mincho'; mso-fareast-theme-font: minor-fareast; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA;"></SPAN> </div><div style="margin-bottom: 10px;"><SPAN lang="EN-US" style="font-size: 11pt; font-family: 'Arial','sans-serif'; mso-fareast-font-family: 'MS Mincho'; mso-fareast-theme-font: minor-fareast; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA;"></SPAN> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"><SPAN lang="EN-US" style="font-size: 11pt; font-family: 'Arial','sans-serif'; mso-fareast-font-family: 'MS Mincho'; mso-fareast-theme-font: minor-fareast; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA;"></SPAN> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"><SPAN lang="EN-US" style="font-size: 11pt; font-family: 'Arial','sans-serif'; mso-fareast-font-family: 'MS Mincho'; mso-fareast-theme-font: minor-fareast; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA;"></SPAN> </div><div style="margin-bottom: 10px;"><SPAN lang="EN-US" style="font-size: 11pt; font-family: 'Arial','sans-serif'; mso-fareast-font-family: 'MS Mincho'; mso-fareast-theme-font: minor-fareast; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA;"></SPAN> </div><div style="margin-bottom: 10px;"><SPAN lang="EN-US" style="font-size: 11pt; font-family: 'Arial','sans-serif'; mso-fareast-font-family: 'MS Mincho'; mso-fareast-theme-font: minor-fareast; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA;"><SPAN lang="EN-US" style="font-size: 11pt; font-family: 'Arial','sans-serif'; mso-fareast-font-family: 'MS Mincho'; mso-fareast-theme-font: minor-fareast; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA;"></SPAN></SPAN> </div><div style="margin-bottom: 10px;"><SPAN lang="EN-US" style="font-size: 11pt; font-family: 'Arial','sans-serif'; mso-fareast-font-family: 'MS Mincho'; mso-fareast-theme-font: minor-fareast; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA;"><SPAN lang="EN-US" style="font-size: 11pt; font-family: 'Arial','sans-serif'; mso-fareast-font-family: 'MS Mincho'; mso-fareast-theme-font: minor-fareast; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA;"></SPAN></SPAN> </div><div style="margin-bottom: 10px;"><SPAN lang="EN-US" style="font-size: 11pt; font-family: 'Arial','sans-serif'; mso-fareast-font-family: 'MS Mincho'; mso-fareast-theme-font: minor-fareast; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA;"><SPAN lang="EN-US" style="font-size: 11pt; font-family: 'Arial','sans-serif'; mso-fareast-font-family: 'MS Mincho'; mso-fareast-theme-font: minor-fareast; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA;"><SPAN lang="EN-US" style="font-size: 11pt; font-family: 'Arial','sans-serif'; mso-fareast-font-family: 'MS Mincho'; mso-fareast-theme-font: minor-fareast; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA;"></SPAN></SPAN></SPAN> </div><div style="margin-bottom: 10px;"><SPAN lang="EN-US" style="font-size: 11pt; font-family: 'Arial','sans-serif'; mso-fareast-font-family: 'MS Mincho'; mso-fareast-theme-font: minor-fareast; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA;"><SPAN lang="EN-US" style="font-size: 11pt; font-family: 'Arial','sans-serif'; mso-fareast-font-family: 'MS Mincho'; mso-fareast-theme-font: minor-fareast; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA;"><SPAN lang="EN-US" style="font-size: 11pt; font-family: 'Arial','sans-serif'; mso-fareast-font-family: 'MS Mincho'; mso-fareast-theme-font: minor-fareast; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA;"></SPAN></SPAN></SPAN> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div> </div><!-- Comment details --><a name="endocrinology7291attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7291_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(45,3 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7291_2_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(44,8 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7291_3_ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(69,3 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7291_4_ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(50,7 KB)<br>&nbsp;&nbsp;5.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7291_5_ScreenCapture5.jpg">ScreenCapture5.jpg</a>&nbsp;&nbsp;(48,7 KB)<br>&nbsp;&nbsp;6.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7291_6_ScreenCapture6.jpg">ScreenCapture6.jpg</a>&nbsp;&nbsp;(50,3 KB)<br>&nbsp;&nbsp;7.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7291_7_ScreenCapture7.jpg">ScreenCapture7.jpg</a>&nbsp;&nbsp;(52,4 KB)<br>&nbsp;&nbsp;8.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7291_8_ScreenCapture8.jpg">ScreenCapture8.jpg</a>&nbsp;&nbsp;(58,6 KB)<br>&nbsp;&nbsp;9.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7291_9_ScreenCapture9.jpg">ScreenCapture9.jpg</a>&nbsp;&nbsp;(63,7 KB)<br>&nbsp;&nbsp;10.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7291_10_ScreenCapture10.jpg">ScreenCapture10.jpg</a>&nbsp;&nbsp;(60,6 KB)<br>&nbsp;&nbsp;11.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7291_11_ScreenCapture11.jpg">ScreenCapture11.jpg</a>&nbsp;&nbsp;(34,2 KB)<br>&nbsp;&nbsp;12.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7291_12_ScreenCapture12.jpg">ScreenCapture12.jpg</a>&nbsp;&nbsp;(49,6 KB)<br>&nbsp;&nbsp;13.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7291_13_ScreenCapture13.jpg">ScreenCapture13.jpg</a>&nbsp;&nbsp;(53,9 KB)<br>&nbsp;&nbsp;14.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7291_14_ScreenCapture14.jpg">ScreenCapture14.jpg</a>&nbsp;&nbsp;(54 KB)<br>&nbsp;&nbsp;15.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7291_15_ScreenCapture15.jpg">ScreenCapture15.jpg</a>&nbsp;&nbsp;(83,3 KB)<br>&nbsp;&nbsp;16.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7291_16_ScreenCapture16.jpg">ScreenCapture16.jpg</a>&nbsp;&nbsp;(82,9 KB)<br>&nbsp;&nbsp;17.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7291_17_ScreenCapture17.jpg">ScreenCapture17.jpg</a>&nbsp;&nbsp;(56,5 KB)<br>&nbsp;&nbsp;18.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7291_18_ScreenCapture18.jpg">ScreenCapture18.jpg</a>&nbsp;&nbsp;(49,7 KB)<br>&nbsp;&nbsp;19.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7291_19_ScreenCapture19.jpg">ScreenCapture19.jpg</a>&nbsp;&nbsp;(54,8 KB)<br>&nbsp;&nbsp;20.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7291_20_ScreenCapture20.jpg">ScreenCapture20.jpg</a>&nbsp;&nbsp;(48,1 KB)<br>&nbsp;&nbsp;21.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7291_21_ScreenCapture21.jpg">ScreenCapture21.jpg</a>&nbsp;&nbsp;(68,7 KB)<br>&nbsp;&nbsp;22.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7291_22_ScreenCapture22.jpg">ScreenCapture22.jpg</a>&nbsp;&nbsp;(25,1 KB)<br>&nbsp;&nbsp;23.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7291_23_ScreenCapture23.jpg">ScreenCapture23.jpg</a>&nbsp;&nbsp;(74,5 KB)<br>&nbsp;&nbsp;24.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7291_24_ScreenCapture24.jpg">ScreenCapture24.jpg</a>&nbsp;&nbsp;(54,7 KB)<br>&nbsp;&nbsp;25.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7291_25_ScreenCapture25.jpg">ScreenCapture25.jpg</a>&nbsp;&nbsp;(50,1 KB)<br>&nbsp;&nbsp;26.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7291_26_ScreenCapture26.jpg">ScreenCapture26.jpg</a>&nbsp;&nbsp;(65,3 KB)<br>&nbsp;&nbsp;27.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7291_27_ScreenCapture27.jpg">ScreenCapture27.jpg</a>&nbsp;&nbsp;(64,4 KB)<br>&nbsp;&nbsp;28.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7291_28_ScreenCapture28.jpg">ScreenCapture28.jpg</a>&nbsp;&nbsp;(56,9 KB)<br>&nbsp;&nbsp;29.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7291_29_ScreenCapture29.jpg">ScreenCapture29.jpg</a>&nbsp;&nbsp;(56,6 KB)<br>&nbsp;&nbsp;30.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7291_30_ScreenCapture30.jpg">ScreenCapture30.jpg</a>&nbsp;&nbsp;(61,7 KB)<br>&nbsp;&nbsp;31.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7291_31_ScreenCapture31.jpg">ScreenCapture31.jpg</a>&nbsp;&nbsp;(66,1 KB)<br>&nbsp;&nbsp;32.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7291_32_ScreenCapture32.jpg">ScreenCapture32.jpg</a>&nbsp;&nbsp;(54,8 KB)<br>&nbsp;&nbsp;33.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7291_33_ScreenCapture33.jpg">ScreenCapture33.jpg</a>&nbsp;&nbsp;(94,2 KB)<br>&nbsp;&nbsp;34.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7291_34_ScreenCapture34.jpg">ScreenCapture34.jpg</a>&nbsp;&nbsp;(77,3 KB)<br>&nbsp;&nbsp;35.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7291_35_ScreenCapture35.jpg">ScreenCapture35.jpg</a>&nbsp;&nbsp;(36,4 KB)<br>&nbsp;&nbsp;36.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7291_36_ScreenCapture36.jpg">ScreenCapture36.jpg</a>&nbsp;&nbsp;(95,6 KB)<br>&nbsp;&nbsp;37.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7291_37_ScreenCapture37.jpg">ScreenCapture37.jpg</a>&nbsp;&nbsp;(35,3 KB)<br>&nbsp;&nbsp;38.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7291_38_ScreenCapture38.jpg">ScreenCapture38.jpg</a>&nbsp;&nbsp;(70,9 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20130431&edate=20130101&rec=7291">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-03-14T15:17:52+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-03-14T15:17:52+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category endocrinology > <![CDATA[Endocrinology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>re: The Toxin Therapeutic Therapy Area Landscape</title>
	<pubDate>2013-03-14T09:30:09+01:00</pubDate>
	<wp:post_id>4079</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="border-left: 2px solid #8B1010; padding: 0px 0px 5px 12px; margin-bottom: 3px;"><span style="font-weight: bold; font-size: 14px;">The Toxin Therapeutic Therapy Area Landscape</span>&nbsp;<br><span style="font-size: 12px;">Comment: As part of our ongoing commitment to the recently launched CI/<wbr>SIS 
Therapy Area Landscape Service, you will find attached an overview of the 
competitive landscape in the botulinum toxin therapeutic area.<wbr></span>&nbsp;&nbsp;<a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20130431&edate=20130101&rec=6836">...</a><br></div><div style="margin-bottom: 10px;">Dear Jackie, there is one company I recently came across of relevance to this - Theracoat (<a href="http://www.theracoat.com/" class="defaultlink" title="http://www.theracoat.com/">theracoat.com/<wbr></a>).<wbr> I briefly met their VP Business Development at the Drug Delivery Partnerships conference.<wbr> They have a novel hydrogel polymer that gels when it reaches body temperature.<wbr> They are using it to increase retention time and control release of drugs in cavities - focussing on the bladder.<wbr> </div><div style="margin-bottom: 10px;">The polymer is not absorbed and eventually passes out in the urine.<wbr> I can't comment on the strengths and weaknesses of their technology is as only had a brief chat with him.<wbr> They are about to enter Phase 2 for overactive bladder using botulinum toxin (apparently the "protocol is currently being finalised").<wbr> The hope is that the delivery system will enhance efficacy, and provide longer duration of action.<wbr> The trial will be done under a grant received by the University of Ostrava Medical Center, Czech Republic, and plan to buy Allergan's Botox from pharmacies prior to formulating it in their system (which as you will appreciated doesn't sound ideal from a CMC perspective).<wbr> They do not currently have a relationship with Allergan (so could use Dysport instead), although you should note that Allergan had a heavy presence at the conference (CEO, VP Pharm Dev, and bus.<wbr> dev.<wbr> were present), so I expect they made contact with them.<wbr> </div><div>Best regards,<BR>Andy </div><!-- Comment details --><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20130431&edate=20130101&rec=6855">Add a Comment on this Article</a><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology6836">View thread  Neurology6836: The Toxin Therapeutic Therapy Area Landscape</a>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-03-14T09:30:09+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-03-14T09:30:09+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>ADT+TAK-700 vs. ADT+Bicalutamide for Metastatic Prostate Cancer</title>
	<pubDate>2013-03-13T19:10:00+01:00</pubDate>
	<wp:post_id>4080</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: The Southwest Oncology Group in collaboration with Millennium have started a Ph3 to compare OS in newly dagnosed metastatic hormone sensitive prostate cancer randomly assigned to ADT + TAK700 (Orteronel) vs ADT + bicalutamide (Casodex).<wbr> PE will assess OS.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG><A href="http://clinicaltrials.gov/ct2/show/NCT01809691?recr=Open&amp;no_unk=Y&amp;fund=2&amp;rcv_s=02%2F13%2F2013&amp;rank=284"><STRONG></STRONG></A> </div><div style="margin-bottom: 10px;">Recruitment: approx.<wbr> 1486 </div><div style="margin-bottom: 10px;">Start date: March 2013 - Completion date: July 2020 </div><div style="margin-bottom: 10px;">Location: USA </div><div style="margin-bottom: 10px;"><U>Protocol</U> </div><div><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8832_1_ScreenCapture1.jpg"> </div><!-- Comment details --><a name="oncology8832attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8832_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(104,3 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20130431&edate=20130101&rec=8832">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-03-13T19:10:00+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-03-13T19:10:00+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>New Trial with Anterios' ANT-1401</title>
	<pubDate>2013-03-13T18:55:11+01:00</pubDate>
	<wp:post_id>4081</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: A Phase 2 started this month in approx.<wbr> 100 participants (men and women) with moderate-to-severe Crow's Feet.<wbr> PE will assess Investigator's Global Assessment Scale.<wbr> </div><div style="margin-bottom: 10px;">Interestingly, this drug is not listed in the company's pipeline.<wbr> The protocol of the trial does not allow the identificationthe drug, which is different from the one in development for hyperhidrosis and canthal lines.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG><A href="http://clinicaltrials.gov/ct2/show/NCT01809964?recr=Open&amp;no_unk=Y&amp;fund=2&amp;rcv_s=02%2F13%2F2013&amp;rank=153"><STRONG></STRONG></A> </div><div style="margin-bottom: 10px;">Completion dates: Aug.<wbr> 2013 /<wbr> Nov.<wbr> 2013.<wbr> </div><div>Location: US (7 sites).<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20130431&edate=20130101&rec=6854">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-03-13T18:55:11+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-03-13T18:55:11+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>re: Shire Buys Swedish Neonatal Specialist Premacure To Access IGF-1 For ROP</title>
	<pubDate>2013-03-13T17:55:38+01:00</pubDate>
	<wp:post_id>4082</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="border-left: 2px solid #8B1010; padding: 0px 0px 5px 12px; margin-bottom: 3px;"><span style="font-weight: bold; font-size: 14px;">Shire Buys Swedish Neonatal Specialist Premacure To Access IGF-1 For ROP</span>&nbsp;<br><span style="font-size: 12px;">Comment: Shire has purchased Swedish biotech company Premacure for an indisclosed sum with the intention of continuing to develop its insulin-like growth factor to treat retinopathy or prematurity currently in phII development.<wbr></span>&nbsp;&nbsp;<a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20130431&edate=20130101&rec=7288">...</a><br></div><div><SPAN style="text-transform: none; background-color: #ffffff; text-indent: 0px; display: inline !important; font: 12px arial, sans-serif; white-space: normal; float: none; letter-spacing: normal; color: #222222; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;">In response to yesterday's article Sandra Blethen (US Medical Affairs) has noted that Tercica supported studies by Dr Lois Smith (of Harvard) for this indication.<wbr> the data were promising, but there were some issues.<wbr> The perception that IGF-1 was part of the process that led to diabetic retinopathy including the worsening of preexisting retinopathy in subjects with retinopathy enrolled in Genetech's studies of IGF-1 in diabetes.<wbr> Interpretation of these data was complicated by the fact that retinopathy can worsen when a person with poorly controlled diabetes gets into good control.<wbr> All of this leads to some questions: Did Premacure licence this indication from Dr Smith? How far along was their clinical development plan? Where do they plan to get the IGF-1? </SPAN> </div><!-- Comment details --><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20130431&edate=20130101&rec=7290">Add a Comment on this Article</a><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7288">View thread  Endocrinology7288: Shire Buys Swedish Neonatal Specialist Premacure To Access IGF-1 For ROP</a>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-03-13T17:55:38+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-03-13T17:55:38+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category endocrinology > <![CDATA[Endocrinology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Medivation Guidance on PREVAIL & New Registrational Trials In Earlier Treatment Settings</title>
	<pubDate>2013-03-13T17:41:42+01:00</pubDate>
	<wp:post_id>4083</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: During the Barclay's Capital investor conference yesterday, Medivation gave a little more guidance on its expectations regarding the unblinding of the PREVAIL pre-chemotherapy trial with XTANDI (enzalutamide) and emphatically stated its support for registration trials in the MO and hormone naive treatment settings.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>In response to a question on PREVAIL Clarence Machado Chief Busines Officer made the following comments:-</STRONG> </div><div style="margin-bottom: 10px;">"I think it's obviously a hugely important strategic decision when to conduct your interim analysis and you want to be able to do so on the basis of the most wholesome set of data that you have.<wbr> So our approach with respect to PREVAIL is really the same as it was with respect to AFFIRM.<wbr> We were able to see all of the data from Zytiga's post chemo study and use that in order to calculate the timing of our own interim analysis and show quite signficiant results.<wbr>" </div><div style="margin-bottom: 10px;">"We plan to do the same thing for PREVAIL.<wbr> We've seen the results of the 302 study.<wbr> We've seen aspects in their data which were a little bit different than what one might have expected for example that the surivavl curves did not change until about 18 months into the study.<wbr> This was a little bit odd and different to what was seen in in 301.<wbr> So we've taken those factors on board and we;ve made our best guess as to the appropriate metrics to use.<wbr>" </div><div style="margin-bottom: 10px;">"That being said, while we're not commenting on the likely timing, I think the kind of triangulation strategy that you are following is probably a helpful way to look at things.<wbr> As you pointed out the Zytiga 302 study finished accuring patients in May 2010.<wbr> They conducted their interim in December 2011, so 19,19 months after last paitent in.<wbr>" </div><div style="margin-bottom: 10px;">"They had about 1,100 patients in the study versus 1700 in ours.<wbr> So they had quite a bit less power, which would all else equal suggeste that we could look sooner than they did and still achieve comparable results.<wbr> Remember we completed accrual in May 2012 so 18, 19 months for us would be December of this year.<wbr>" </div><div style="margin-bottom: 10px;">"On the other hand, we would also expect to see longer survival in the treatment arm in our study than was the case with Zytiga 302, exactly as seen in AFFIRM versus the 301 study.<wbr>" </div><div style="margin-bottom: 10px;">"How much longer? Obviously that's a question we'd all like to know the answer to.<wbr> We won't until we get the results from the study.<wbr> But all else equal that would push than 18-month timing a little bit further out.<wbr> So it's a bit of a balacing act as you correctly pointed out.<wbr>" </div><div style="margin-bottom: 10px;"><STRONG>With regard to strategy regarding earlier patient segments Machado also made some interesting comments:-</STRONG> </div><div style="margin-bottom: 10px;">"Yes so obviously these are two huge growth drivers for the business moving forward.<wbr> If you divide prostate into four large buckets , we've covered two of those with registrational studies (AFFIRM and PREVAIL).<wbr> The two that we have not covered are the two that you mentioned, the non-metastatic CRPC and hormone-naive.<wbr> We consider both of those to be very large, very significant commercial opportunities because there really is a multiplier effect.<wbr>" </div><div style="margin-bottom: 10px;">"As you go earlier into the treatment algorithm, not only do the number of patients increase, but the time you would expect each patient to remain on treatment also increases.<wbr>.<wbr>.<wbr> So M0 would be the next earliest and hormone naive would be the earliest of all.<wbr> As we discussed in our earnings call a couple of weeks ago, <STRONG>we have approved a collaboration budget with Astellas in 2013 which includes funding for upstream development including registrational development.<wbr></STRONG> <STRONG>We consider it to be an absolutely vital corporate objective to extend the use of XTANDI as early in the treatment algorithm as we possibly can and with patents expiring in 2027 in the US and 2026 in Europe and Japan, it makes this a pretty compelling investment from a business perspective.<wbr>"</STRONG> </div><div style="margin-bottom: 10px;">"The strategy about how to do this, I think is one that's going to be complex.<wbr> As we mentioned, <STRONG>these are long, expensive studies, five to seven years duration about &pound;150-$200m each.<wbr></STRONG> So they're decisions that have to be made carefully.<wbr>" </div><div>Source: <A href="http://www.medivation.com">www.<wbr>medivation.<wbr>com</A> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20130431&edate=20130101&rec=8831">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-03-13T17:41:42+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-03-13T17:41:42+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Next Step of Galderma's Growth in the Aesthetic Area</title>
	<pubDate>2013-03-13T14:22:38+01:00</pubDate>
	<wp:post_id>4084</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Nuvo Research Inc has announced the US launch of Pliagllis, an analgesic peelable cream, partnered with Galderma.<wbr> The product's efficacy, safety, rapid onset of action and ease of use promise to greatly improve the experience of patients by providing analgesia while they are undergoing superficial dermatologic and cosmetic procedures.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><U>Indication</U>: local analgesia for superficial aesthetic procedures including dermal filler injection, pulsed dye laser therapy, facial laser resurfacing and laser-assisted tattoo removal.<wbr> </div><div style="margin-bottom: 10px;"><U>MOA</U>: Pliaglis uses Nuvo’s proprietary phase-changing technology to form a pliable peel on the skin when exposed to air.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6851_3_ScreenCapture3.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6851_1_ScreenCapture1.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6851_2_ScreenCapture2.jpg"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6851_4_ScreenCapture4.jpg"> </div><!-- Comment details --><a name="neurology6851attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6851_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(11,7 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6851_2_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(29 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6851_3_ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(61,4 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6851_4_ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(118,5 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20130431&edate=20130101&rec=6851">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-03-13T14:22:38+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-03-13T14:22:38+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>External Reports</title>
	<pubDate>2013-03-13T11:16:34+01:00</pubDate>
	<wp:post_id>4085</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;"><DIV class="ii" id="ici665.01ii">External reports from different suppliers can be found by clicking on the corresponding links in the following table.<wbr></DIV> </div><div style="margin-bottom: 10px;"><DIV class="i" id="ici665.015i">
<DIV class="ii" id="ici665.015ii">
<TABLE align="left" border="1" cellpadding="3" cellspacing="0" class="normaltable" style="background-color: #f5f5f5; width: 600px; border: #ffffff 1px solid;"><TBODY><TR><TD align="left" style="height: 50px; border: #ffffff 3px solid;"><SPAN style="font-size: medium;"><STRONG><A class="defaultlink" href="traction#/cat&amp;proj=Pharmaworld&amp;edate=All&amp;cat=%3a%3a*%3areport&amp;rec=665&amp;rsin=/link%20%3a%3a*%3areport%20all%20%27DataMonitor%27%20c(%22Datamonitor%22%20)&amp;find=(c%20%22Datamonitor%22)&amp;title=DataMonitor&amp;wassearch=true">DataMonitor</A></STRONG></SPAN></TD>
<TD align="left" style="height: 50px; border: #ffffff 3px solid;"><SPAN style="font-size: medium;"><STRONG><A class="defaultlink" href="traction#/cat&amp;proj=Pharmaworld&amp;edate=All&amp;cat=%3a%3a*%3areport&amp;rec=665&amp;rsin=/link%20%3a%3a*%3areport%20all%20%27Business%20Insights%27%20(c(%22business%20insight%22)%20OR%20(c(%22business%20insights%22)%20OR%20c(%22Reuters%22%20)))&amp;find=(OR%20(c%20%22business%20insight%22)%20(OR%20(c%20%22business%20insights%22)%20(c%20%22Reuters%22)))&amp;title=Business%20Insights&amp;wassearch=true">Business Insights</A><STRONG></STRONG></STRONG></SPAN></TD>
</TR>
</TBODY>
</TABLE>
</DIV>
</DIV> </div><div><DIV class="i hovered" id="ici665.017i">
<DIV class="ii">See complete list of external report <A class="defaultlink" href="traction#/cat&amp;proj=Pharmaworld&amp;edate=All&amp;cat=%3a%3a*%3areport&amp;rec=665&amp;rsin=/link%20%3a%3a*%3areport%20all%20%27here.%27%20()&amp;title=here.">here.<wbr></A></DIV>
</DIV> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20130431&edate=20130101&rec=10336">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-03-13T11:16:34+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-03-13T11:16:34+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category pharma-news > <![CDATA[Pharma News]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>re: The Toxin Therapeutic Therapy Area Landscape</title>
	<pubDate>2013-03-13T07:34:39+01:00</pubDate>
	<wp:post_id>4086</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="border-left: 2px solid #8B1010; padding: 0px 0px 5px 12px; margin-bottom: 3px;"><span style="font-weight: bold; font-size: 14px;">The Toxin Therapeutic Therapy Area Landscape</span>&nbsp;<br><span style="font-size: 12px;">Comment: As part of our ongoing commitment to the recently launched CI/<wbr>SIS 
Therapy Area Landscape Service, you will find attached an overview of the 
competitive landscape in the botulinum toxin therapeutic area.<wbr></span>&nbsp;&nbsp;<a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20130431&edate=20130101&rec=6836">...</a><br></div><div style="margin-bottom: 10px;">Dear Jackie, </div><div>Thanks for this.<wbr>  I will examine closer and add comments if possible.<wbr> At first glance It is very useful.<wbr>  Gavin Assauw </div><!-- Comment details --><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20130431&edate=20130101&rec=6849">Add a Comment on this Article</a><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology6836">View thread  Neurology6836: The Toxin Therapeutic Therapy Area Landscape</a>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-03-13T07:34:39+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-03-13T07:34:39+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Bavarian Nordic FY12 Results</title>
	<pubDate>2013-03-12T19:03:06+01:00</pubDate>
	<wp:post_id>4087</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Management has confirmed its short-term objectives regarding PROSTVAC: 1/<wbr>to report data from NCI-sponsored clinical trials, 2/<wbr>to prepare the Kvistgaard facility for commercial manufacturing, and 3/<wbr>to transfer production of clinical trial material from Berlin facility to Kvistgaard facility.<wbr> It is the Company’s mid to long-term strategy to license and commercialize PROSTVAC® globally through partnerships.<wbr> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"><UL><LI>PROSPECT study: 10 countries now active, remaining countries to open within the next 3 months</LI>
<LI>Additional CRO resources engaged; intensified dialogue with sites</LI>
</UL> </div><div style="margin-bottom: 10px;">Also See <a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20130431&edate=20130101&rec=8602" class="defaultlink">Oncology8602: PhIII PROSPECT Trial In CRPC Aims To Complete Enrollment in 2013</a>.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8823_1_ScreenCapture1.jpg"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8823_2_ScreenCapture2.jpg"> </div><!-- Comment details --><a name="oncology8823attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8823_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(20,6 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8823_2_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(32,3 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20130431&edate=20130101&rec=8823">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-03-12T19:03:06+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-03-12T19:03:06+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Shire Buys Swedish Neonatal Specialist Premacure To Access IGF-1 For ROP</title>
	<pubDate>2013-03-12T17:56:20+01:00</pubDate>
	<wp:post_id>4088</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Shire has purchased Swedish biotech company Premacure for an indisclosed sum with the intention of continuing to develop its insulin-like growth factor to treat retinopathy or prematurity currently in phII development.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Deal Terms </STRONG> </div><div style="margin-bottom: 10px;">Although undisclosed terms are known to include an upfront followed by milestones contingent on clinical development and commercialisation.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Acquisition rational</STRONG> </div><div style="margin-bottom: 10px;">The purchase of Premacure fits Shire's strategy of purchasing products for the treatment of rare diseases where it can potentially charge a high price.<wbr> </div><div style="margin-bottom: 10px;">Premacure owns exclusive worldwide rights to develop and commercialize Insulin-Like Growth Factor 1 (IGF-I) together with or without its natural binding protein, IGFBP-3, as a product for the “prevention of complications of preterm birth”.<wbr> </div><div>Source: <A href="http://www.premacure.com/">www.<wbr>premacure.<wbr>com</A> - <A href="http://www.shire.com/">www.<wbr>shire.<wbr>com</A> </div><!-- Comment details --><span style="font-weight: bold; font-style: italic;"><br>Comments</span><a name="Endocrinology7290c"></a><br><div style="border: 1px solid #AAA; background-color: #FFF; margin-left: 10px; padding: 5px;"><div><SPAN style="text-transform: none; background-color: #ffffff; text-indent: 0px; display: inline !important; font: 12px arial, sans-serif; white-space: normal; float: none; letter-spacing: normal; color: #222222; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;">In response to yesterday's article Sandra Blethen (US Medical Affairs) has noted that Tercica supported studies by Dr Lois Smith (of Harvard) for this indication.<wbr> the data were promising, but there were some issues.<wbr> The perception that IGF-1 was part of the process that led to diabetic retinopathy including the worsening of preexisting retinopathy in subjects with retinopathy enrolled in Genetech's studies of IGF-1 in diabetes.<wbr> Interpretation of these data was complicated by the fact that retinopathy can worsen when a person with poorly controlled diabetes gets into good control.<wbr> All of this leads to some questions: Did Premacure licence this indication from Dr Smith? How far along was their clinical development plan? Where do they plan to get the IGF-1? </SPAN> </div></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20130431&edate=20130101&rec=7288">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-03-12T17:56:20+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-03-12T17:56:20+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category endocrinology > <![CDATA[Endocrinology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Eisai's New Strategic Plans for R&D and Marketing In and Outside Japan</title>
	<pubDate>2013-03-12T15:27:23+01:00</pubDate>
	<wp:post_id>4089</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Eisai has announced a number of strategic organisational changes as it struggles to cope with loss of patent protection against its two top earners Aricept (donepezil) and Pariet/<wbr>Aciphex (rabeprazole).<wbr> A press conference on 7 March led by company president Haruo Naito was accompanied by a release on the firm's website, with a number of changes outlined.<wbr> Eisai is targeting at least JPY100 billion in revenues growth from emerging markets within the next five years, with China set to be the biggest contributor with JPY65 billion.<wbr> Key slides are provided below.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;">In terms of its domestic operations in Japan, the firm is to be divided into two units, an Integrated Community Unit focused on marketing Aricept, while the Oncology HHC unit will focus on developing Eisai's breast cancer drug Halaven (eribulin mesylate).<wbr> </div><div style="margin-bottom: 10px;">Intensive strategy, with 220 new medical representatives to be recruited across the Oncology and Integrated Community units.<wbr> </div><div style="margin-bottom: 10px;">The stated goal is to transform into a low-margin, high-volume model through a "new pricing policy, regional best partnership, and category mix model".<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8821_1_ScreenCapture1.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8821_2_ScreenCapture2.jpg"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">The plan is to use tiered pricing to maximise access to drugs in emerging markets.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"> </div><div> </div><!-- Comment details --><a name="oncology8821attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8821_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(112,6 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8821_2_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(103,4 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8821_3_ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(94,8 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8821_4_ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(93,1 KB)<br>&nbsp;&nbsp;5.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8821_5_ScreenCapture5.jpg">ScreenCapture5.jpg</a>&nbsp;&nbsp;(157,6 KB)<br>&nbsp;&nbsp;6.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8821_6_ScreenCapture6.jpg">ScreenCapture6.jpg</a>&nbsp;&nbsp;(151 KB)<br>&nbsp;&nbsp;7.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8821_7_ScreenCapture7.jpg">ScreenCapture7.jpg</a>&nbsp;&nbsp;(131,2 KB)<br>&nbsp;&nbsp;8.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8821_8_EISAI%255fe4523%255f130308.pdf">EISAI_e4523_130308.pdf</a>&nbsp;&nbsp;(5,5 MB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20130431&edate=20130101&rec=8821">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-03-12T15:27:23+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-03-12T15:27:23+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Mini Review Involving the PI3K/Akt/mTOR Pathway in the Treatment of pNETs</title>
	<pubDate>2013-03-12T12:25:55+01:00</pubDate>
	<wp:post_id>4090</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Financial support for medical edtorial assistance was provided by Novartis.<wbr> The conclusion shows that recent studies support the rationale for combination treatment and dual/<wbr>multi-targeted agents with the aim of targeting different components of the PI3K/<wbr>Akt/<wbr>mTOR pathway.<wbr> The use of biomarkers for predicting disease outcome or defining patient subgroups that may benefit from new treatment options will facilitate improved disease management in patients with pNETs.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7286_3_ScreenCapture3.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7286_2_ScreenCapture2.jpg"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Link: <A href="http://www.sciencedirect.com/science/article/pii/S0304383513001286">http:/<wbr>/<wbr>www.<wbr>sciencedirect.<wbr>com/<wbr>science/<wbr>article/<wbr>pii/<wbr>S0304383513001286</A> </div><div style="margin-bottom: 10px;"><H1 class="svTitle" style="BORDER-BOTTOM: 0px; BORDER-LEFT: 0px; PADDING-BOTTOM: 0px; TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; MARGIN: 0px 0px 6px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; FONT: 700 1.4em/1.5em 'Arial Unicode MS', 'Arial Unicode', Arial, 'URW Gothic L', Helvetica, Tahoma, sans-serif; WHITE-SPACE: normal; LETTER-SPACING: normal; COLOR: rgb(92,92,92); CLEAR: both; VERTICAL-ALIGN: baseline; BORDER-TOP: 0px; BORDER-RIGHT: 0px; WORD-SPACING: 0px; PADDING-TOP: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"> TPI3K/<wbr>Akt/<wbr>mTOR pathway inhibitors in the therapy of pancreatic neuroendocrine tumors</H1> </div><div style="margin-bottom: 10px;"><UL class="authorGroup noCollab" style="BORDER-BOTTOM: 0px; BORDER-LEFT: 0px; PADDING-BOTTOM: 0px; TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(255,255,255); LIST-STYLE-TYPE: none; TEXT-INDENT: 0px; MARGIN: 0px 0px 6px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; FONT: 100 13px/20px 'Arial Unicode MS', 'Arial Unicode', Arial, 'URW Gothic L', Helvetica, Tahoma, sans-serif; WHITE-SPACE: normal; LETTER-SPACING: normal; COLOR: rgb(46,46,46); VERTICAL-ALIGN: baseline; BORDER-TOP: 0px; BORDER-RIGHT: 0px; WORD-SPACING: 0px; PADDING-TOP: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"><LI style="BORDER-BOTTOM: 0px; BORDER-LEFT: 0px; PADDING-BOTTOM: 0px; MARGIN: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; DISPLAY: inline; FONT-SIZE: 13px; VERTICAL-ALIGN: baseline; BORDER-TOP: 0px; FONT-WEIGHT: 100; BORDER-RIGHT: 0px; PADDING-TOP: 0px"><A class="authorName" href="http://www.sciencedirect.com/science/article/pii/S0304383513001286#" id="authname_N34b46bd8N2550fa78" style="BORDER-BOTTOM: 0px; BORDER-LEFT: 0px; PADDING-BOTTOM: 0px; MARGIN: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; COLOR: rgb(49,108,157); FONT-SIZE: 13px; VERTICAL-ALIGN: baseline; BORDER-TOP: 0px; FONT-WEIGHT: 100; BORDER-RIGHT: 0px; TEXT-DECORATION: none; PADDING-TOP: 0px">Edward M.<wbr> Wolin</A></LI>
</UL> </div><div><UL class="affiliation" style="BORDER-BOTTOM: 0px; BORDER-LEFT: 0px; PADDING-BOTTOM: 0px; TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(255,255,255); LIST-STYLE-TYPE: none; TEXT-INDENT: 0px; MARGIN: 0px 0px 6px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; FONT: 100 0.8em/20px 'Arial Unicode MS', 'Arial Unicode', Arial, 'URW Gothic L', Helvetica, Tahoma, sans-serif; WHITE-SPACE: normal; LETTER-SPACING: normal; COLOR: rgb(92,92,92); VERTICAL-ALIGN: baseline; BORDER-TOP: 0px; BORDER-RIGHT: 0px; WORD-SPACING: 0px; PADDING-TOP: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"><LI style="BORDER-BOTTOM: 0px; BORDER-LEFT: 0px; PADDING-BOTTOM: 0px; MARGIN: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; DISPLAY: block; FONT-SIZE: 11px; VERTICAL-ALIGN: baseline; BORDER-TOP: 0px; FONT-WEIGHT: 100; BORDER-RIGHT: 0px; PADDING-TOP: 0px"><SPAN style="BORDER-BOTTOM: 0px; BORDER-LEFT: 0px; PADDING-BOTTOM: 0px; MARGIN: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; FONT-SIZE: 11px; VERTICAL-ALIGN: baseline; BORDER-TOP: 0px; BORDER-RIGHT: 0px; PADDING-TOP: 0px">Division of Hematology/<wbr>Oncology, Samuel Oschin Cancer Center, Cedars-Sinai Medical Center, 8700 Beverly Blvd.<wbr>, Los Angeles, CA 90048, USA</SPAN></LI>
</UL> </div><!-- Comment details --><a name="endocrinology7286attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7286_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(69,8 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7286_2_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(77,5 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7286_3_ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(86,7 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20130431&edate=20130101&rec=7286">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-03-12T12:25:55+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-03-12T12:25:55+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category endocrinology > <![CDATA[Endocrinology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>New Pasireotide Trial</title>
	<pubDate>2013-03-12T12:13:26+01:00</pubDate>
	<wp:post_id>4091</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: ClinicalTrials.<wbr>gov is listing a new 100 patient Novartis study which will allow access to pasireotide for patients benefiting from treatment in other Novartis sponsored trials.<wbr> Patients will be followed-up for a period of 10 years and recruitment will start in May.<wbr> </div><div style="margin-bottom: 10px;">Interestingly, many of the eligible indication are not licensed at the current time apart from Cushing's Disease but are being evaluted in terms of pasireotide use e.<wbr>g.<wbr> neuroendocrine tumours, Dumping syndrome.<wbr> Ectopic ACTH tumours, prostate cancer, melanoma negative for bRAF and melanoma negative for nRAS.<wbr> Hence the study will enable those completing these trial to continue with the study drug if they have benefited from treatment and enable the collection of long-term safety data.<wbr> </div><div style="margin-bottom: 10px;">Secondly for the approved or potentially soon to be approved indication it may provide access to drug where reimbursement is an issue and finally there is probab ly an element of patient capture behind the studies strategic intent.<wbr> </div><div style="margin-bottom: 10px;"><DIV class="info-title" style="TEXT-ALIGN: left; TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(255,255,255); MARGIN-TOP: 0px; TEXT-INDENT: 0px; FONT: bold 13px/1.4em arial, 'Nimbus Sans L', sans-serif; WHITE-SPACE: normal; LETTER-SPACING: normal; COLOR: rgb(0,0,0); WORD-SPACING: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px">ClinicalTrials.<wbr>gov Identifier:</DIV> </div><div><DIV class="identifier" style="TEXT-ALIGN: left; TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; FONT: 16px/1.4em arial, 'Nimbus Sans L', sans-serif; WHITE-SPACE: normal; MARGIN-BOTTOM: 9px; LETTER-SPACING: normal; COLOR: rgb(0,0,0); WORD-SPACING: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"><A href="http://clinicaltrials.gov/ct2/results?term=NCT01794793&amp;Search=Search">NCT01794793</A></DIV> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20130431&edate=20130101&rec=7285">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-03-12T12:13:26+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-03-12T12:13:26+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category endocrinology > <![CDATA[Endocrinology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Takeda Seeks Regulatory Approval For New Ulcerative Colitis Therapy</title>
	<pubDate>2013-03-12T11:58:34+01:00</pubDate>
	<wp:post_id>4092</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Takeda has submitted an MAA to the EMA for vedolizumab to treat 
moderately to severely active ulcerative colitis and Crohn's disease.<wbr> </div><div style="margin-bottom: 10px;">Takeda is currently planning to submit a BLA to the FDA for the compound for 
both indications this year.<wbr> </div><div style="margin-bottom: 10px;">Vedolizumab is a humanized mAb against integrin alpha (4) beta (7).<wbr> </div><div>Source: <a href="http://www.takeda.com" class="defaultlink" title="www.takeda.com">takeda.com</a> </div><!-- Comment details --><span style="font-weight: bold; font-style: italic;"><br>Comments</span><a name="GastroEnterology1910c"></a><br><div style="border: 1px solid #AAA; background-color: #FFF; margin-left: 10px; padding: 5px;"><div style="margin-bottom: 10px;"><SPAN style="text-transform: none; background-color: #ffffff; text-indent: 0px; display: inline !important; font: 13px arial, sans-serif; white-space: normal; float: none; letter-spacing: normal; color: #222222; word-spacing: 0px; -webkit-text-stroke-width: 0px;">FDA has accepted and granted Priority Review to a BLA from </SPAN>Takeda <SPAN style="text-transform: none; background-color: #ffffff; text-indent: 0px; display: inline !important; font: 13px arial, sans-serif; white-space: normal; float: none; letter-spacing: normal; color: #222222; word-spacing: 0px; -webkit-text-stroke-width: 0px;">for vedolizumab to treat moderately to severely active ulcerative colitis (UC).<wbr> The pharma expects a decision in 1Q14.<wbr> </SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="text-transform: none; background-color: #ffffff; text-indent: 0px; display: inline !important; font: 13px arial, sans-serif; white-space: normal; float: none; letter-spacing: normal; color: #222222; word-spacing: 0px; -webkit-text-stroke-width: 0px;">The agency also is reviewing vedolizumab to treat Crohn's disease under a standard review time frame.<wbr> Takeda, which submitted a single BLA to FDA in June, said the agency chose to review the indications under different timelines.<wbr></SPAN> </div><div><EM><SPAN style="line-height: normal; text-transform: none; background-color: #ffffff; font-variant: normal; text-indent: 0px; display: inline !important; font-family: arial, sans-serif; white-space: normal; float: none; letter-spacing: normal; color: #222222; font-size: 13px; font-weight: normal; word-spacing: 0px; -webkit-text-stroke-width: 0px;">Source: Biocentury</SPAN></EM> </div></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20130431&edate=20130101&rec=1879">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-03-12T11:58:34+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-03-12T11:58:34+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category gastroenterology > <![CDATA[gastroenterology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Impax/GSK's Rytary Approval Still On Hold As FDA Continues To Scrutinise cGMP Violations</title>
	<pubDate>2013-03-12T11:53:56+01:00</pubDate>
	<wp:post_id>4093</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: The FDA has completed its re-inspection of Impax's Hayward 
manufacturing facility and still apprears to have some issues concerning cGMP 
violations.<wbr> Impax is now stating that it plans for a 2014 launch of its extended 
release carbidopa/<wbr>levadopa formulation Rytary.<wbr> </div><div style="margin-bottom: 10px;">At the end of its recent review the FDA issued a Form 483 with 12 
observations, 3 of which were repear observation included in a 2011 warning 
letter about cGMP violations.<wbr> </div><div style="margin-bottom: 10px;">In January the FDA issued a complete response letter for an NDA for Rytary to 
treat idiopathic PD.<wbr> According ot the company the agency is requiring a 
"satisfactory re-inspection" of the Hayward Facility something that may 
still be in question.<wbr> </div><div style="margin-bottom: 10px;">Impax has said it will respond to the FDA's recent observations within 15 
days of the Form 482 receipt and has " has every intention of meeting the very 
high standards set by the FDA" </div><div>Source: <a href="http://www.impax.com" class="defaultlink" title="www.impax.com">impax.com</a> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20130431&edate=20130101&rec=6848">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-03-12T11:53:56+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-03-12T11:53:56+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>One Step Forward Another Step Back</title>
	<pubDate>2013-03-12T11:29:53+01:00</pubDate>
	<wp:post_id>4094</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Dendreon's pathway forward is far from clear as on Friday its CEO 
indicated that Q1 consensus sales estimates were too high.<wbr> The company had 
previously indicated that 1Q sales would be sequentially below Q4 sales but now 
the indication is that the decline is more significant.<wbr> </div><div style="margin-bottom: 10px;">Whilst the company is remaining positive about a return to growth after Q1 as 
a DTC campaign gets underway, the investment community appears to remain more 
sceptical with competitive forces from the new oral therapies Zytiga 
and Xtandi believed to be hampering growth.<wbr> </div><div style="margin-bottom: 10px;">FirstWord is indicating in its new report on the prostate cancer market that 
KOL sentiment to the drug is not positive and that many European KOLs are 
sceptical about whether European marketing authorisation will be forthcoming and 
if is whether the drug will actually be prescribed or reimbursed.<wbr> </div><div><A href="http://www.firstwordplus.com/therapy_trends_kol_insights_prostate_cancer_more_info_form.do;jsessionid=B3F6DF30F599CE523F2B113AF0E68B58">http:/<wbr>/<wbr>www.<wbr>firstwordplus.<wbr>com/<wbr>therapy_trends_kol_insights_prostate_cancer_more_info_form.<wbr>do;jsessionid=B3F6DF30F599CE523F2B113AF0E68B58</A> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20130431&edate=20130101&rec=8820">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-03-12T11:29:53+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-03-12T11:29:53+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Telormedix' TMX-101 to Enter in the Clinic for CIS in the Bladder</title>
	<pubDate>2013-03-11T18:07:02+01:00</pubDate>
	<wp:post_id>4095</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: The company has recruited the 1st patient in a Ph2 of TMX-101, a TLR-7 agonist.<wbr> Full details of the trial design is provided below.<wbr> </div><div style="margin-bottom: 10px;">According to Neal D.<wbr> Shore, M.<wbr>D.<wbr>, the Medical Director of the Carolina Urologic Research Center and principal investigator in this trial .<wbr>.<wbr>.<wbr> “TMX-101 has already demonstrated a strong disease-modifying cytokine response in a clinical trial involving patients with non-muscle invasive bladder cancer (NMIBC).<wbr> CIS is obviously a more aggressive cancer, but we do know that it responds well to immunotherapeutic interventions.<wbr> We are therefore extremely hopeful that targeting TLR-7 with TMX-101 will prove to be a successful and efficacious treatment option in these patients.<wbr>” </div><div style="margin-bottom: 10px;"><STRONG></STRONG><A href="http://clinicaltrials.gov/ct2/show/NCT01731652?term=NCT01731652&amp;rank=1"><STRONG></STRONG></A> </div><div style="margin-bottom: 10px;">- Drug Description: TMX-101 is a new formulation of Imiquimod optimized for intravesical delivery.<wbr> </div><div style="margin-bottom: 10px;">- Indication: TMX-101 is being developed as a potential treatment for patients with non-invasive bladder cancer, including patients with CIS bladder cancer.<wbr> </div><div style="margin-bottom: 10px;">- Recruitment: 6 CIS patients recruited from private urology clinics in the USA to examine the efficacy of the drug over six doses.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20130431&edate=20130101&rec=8710" class="defaultlink">Oncology8710: Telormedix granted IND for Phase II Bladder Cancer Study</a>.<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20130431&edate=20130101&rec=8819">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-03-11T18:07:02+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-03-11T18:07:02+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Celgene Reported on ABRAXANE Franchise at Cowen Conference</title>
	<pubDate>2013-03-11T11:35:22+01:00</pubDate>
	<wp:post_id>4096</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Management has planned that pancreatic indication for ABRAXANE will enhance annual growth +2 percentage points, and REVLIMID reach approx.<wbr> 50% of total 2017 sales.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8817_1_ScreenCapture1.jpg"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8817_2_ScreenCapture2.jpg"> </div><!-- Comment details --><a name="oncology8817attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8817_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(75,7 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8817_2_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(97 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20130431&edate=20130101&rec=8817">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-03-11T11:35:22+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-03-11T11:35:22+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>More Companies Interested in Algeta's Thorium-227</title>
	<pubDate>2013-03-08T20:22:59+01:00</pubDate>
	<wp:post_id>4097</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Algeta's CEO reported to Bloomber that it is working wih Sanofi, Ablynx, Affibody and Immunomedics in studying their MAbs linked with Thorium-27.<wbr> The company believes it may be possible to develop a pipeline of targeted alpha-pharmaceuticals, termed Targeted Thorium Conjugates (TTCs).<wbr> </div><div style="margin-bottom: 10px;">TTC Strategy </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8816_1_ScreenCapture1.jpg"> </div><div style="margin-bottom: 10px;">During 2013, Algeta will identify and progress lead preclinical candidates.<wbr> </div><div><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8816_2_ScreenCapture2.jpg"> </div><!-- Comment details --><a name="oncology8816attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8816_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(69,4 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8816_2_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(48,3 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20130431&edate=20130101&rec=8816">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-03-08T20:22:59+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-03-08T20:22:59+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Cancer Drugs to be Included on China's Revised EDL</title>
	<pubDate>2013-03-08T19:53:43+01:00</pubDate>
	<wp:post_id>4098</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: While no specific date was given for the release of the EDL, China's minister of health, Chen Zhu confirmed that the list will be expanded to around 500 drugs, and contain oncology drugs, drugs for severe cardiovascular disease, nervous system conditions, psychotropic drugs, as well as blood plasma.<wbr> </div><div style="margin-bottom: 10px;">The Ministry of health has promised that the expanded EDL will be accompanied by reforms to the provincial tendering system that will place greater emphasis on quality of drugs rather than price alone, but it remains to be seen exactly how this will be effected.<wbr> </div><div style="margin-bottom: 10px;">Health officials have stated that the expanded EDL will play a more prominent role in China's grassroots healthcare institutions in the future, and they estimate that up to 40–50% of hospitals' total prescriptions will be for EDL drugs.<wbr> This has led to further concerns particularly for local pharma firms that there could be an imbalance created in the market due to the growing importance of the EDL.<wbr> On the positive side, local media speculate that the addition of oncology and other therapeutic areas to the EDL will probably be a catalyst for greater investment in research by Chinese firms hoping to develop drugs suitable for listing.<wbr> </div><div>Source: Global Insight </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20130431&edate=20130101&rec=10331">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-03-08T19:53:43+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-03-08T19:53:43+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category pharma-news > <![CDATA[Pharma News]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Key Messages from Merck Serono FY12 Results</title>
	<pubDate>2013-03-07T17:49:56+01:00</pubDate>
	<wp:post_id>4099</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: During 2012, the Group realized around €115 million in net savings as a result of the restructuring initiative “Fit for 2018.<wbr>” The majority of savings (~€ 100 million) were achieved in Merck Serono.<wbr> The company reported first results of efficiency program now clearly visible in P&amp;L.<wbr> </div><div style="margin-bottom: 10px;"><DIV class="headerNC"><STRONG></STRONG></DIV> </div><div style="margin-bottom: 10px;"><DIV class="headerNC"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7282_7_copiedImage%5b0%5d.png"></DIV> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7282_3_ScreenCapture3.jpg"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Sales generated outside of Europe climbed to 58% in 2012 (2011: 54%), driven by the strong performance in North America, which reported an organic sales increase of 17% to € 1,335 million, and represented 22% of the division’s sales.<wbr> </div><div style="margin-bottom: 10px;">Sales in the Rest of World regions grew 12% organically to € 422 million while organic growth in the Emerging Markets grew by 6.<wbr>8% and represented € 1,737 million of total sales for the division.<wbr> </div><div style="margin-bottom: 10px;">Challenging business conditions in Europe, impacted by lower pricing as well as healthcare budget cuts, resulted in a 2.<wbr>1% organic decline in sales to € 2,502 million.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7282_2_ScreenCapture2.jpg"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7282_1_ScreenCapture1.jpg"> </div><!-- Comment details --><a name="endocrinology7282attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;4.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7282_4_ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(79 KB)<br>&nbsp;&nbsp;5.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7282_5_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(55,2 KB)<br>&nbsp;&nbsp;6.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7282_6_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(60,5 KB)<br>&nbsp;&nbsp;7.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7282_7_copiedImage%5b0%5d.png">copiedImage[0].png</a>&nbsp;&nbsp;(125,7 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20130431&edate=20130101&rec=7282">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-03-07T17:49:56+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-03-07T17:49:56+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category endocrinology > <![CDATA[Endocrinology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Key Messages from Acino's FY12 Results</title>
	<pubDate>2013-03-07T12:45:08+01:00</pubDate>
	<wp:post_id>4100</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Alongside the presentation of the financial results, J-D Bonny (Head of R&amp;D) reported further strengthening of the "implant platform".<wbr> He highlighted a US-FDA agreement regarding harmonized clinical study design for US and EU.<wbr> Of note, the progression to Ph1 of Goserelin implant in Japan (prostate and mamma carcinoma), and the estimated approval dates of of Leuprorelin 1M/<wbr>3M in the US (Q4 16 and Q1 17 respectively).<wbr> While Gosacin(R) (Goserelin) has been listed in Acino's BTC (direct marketing under the own brand "Acino Switzerland"), Leuprorelin is intended to be out-licensed.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_dkphybrids_220_6_ScreenCapture6.jpg"> </div><div style="margin-bottom: 10px;"><UL><LI></LI>
<LI></LI>
<LI></LI>
<LI></LI>
</UL> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;">Number of Acino's own projects increased to28 from 20 (in 2011).<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_dkphybrids_220_4_ScreenCapture4.jpg"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_dkphybrids_220_1_ScreenCapture1.jpg"> </div><div style="margin-bottom: 10px;">Group revenue increased by 91% to €257.<wbr>1M (vs €134.<wbr>9M in 2011).<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_dkphybrids_220_3_ScreenCapture3.jpg"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;">CEO strongly focused on Acino providing high quality products, hence more expensive "to merit the Swiss made brand/<wbr>label".<wbr> </div><div style="margin-bottom: 10px;">Acino intends to grow its BtC business (products for international markets) through additional product launches (from own development and in-licensing) and by expanding the geographic reach.<wbr> </div><div style="margin-bottom: 10px;"><BLOCKQUOTE dir="ltr" style="MARGIN-RIGHT: 0px">
<P>In numerous markets in the MENA region and in Asia, local registration of new Acino products and preparations for market entry are progressing.<wbr> The geographic expansion went one step further with the new cooperation between Acino and Medial D&amp;P Ltd.<wbr> (<a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=DKPHybrids&sdate=20130431&edate=20130101&rec=203" class="defaultlink">DKPHybrids203: Acino Expands its Business in the CIS Region</a>).<wbr></P>
<P>In the attempt to fuel future growth and to escape price pressure in the European markets, the out-licensing activities have been stepped up to cover all regions worldwide.<wbr> </P>
<P>A cooperation agreement with a Japanese company and licensing deals with partners in China and India are in negotiation.<wbr> </P>
<P>Further territorial expansion in 2013 is anticipated in Asia and Latin America (BtC).<wbr></P></BLOCKQUOTE> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Discussions ongoing in China, 'long, but promising outcomes by 2015".<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_dkphybrids_220_7_ScreenCapture7.jpg"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_dkphybrids_220_5_ScreenCapture5.jpg"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">CEO highlighted that Acino is "resistant" and "preemptive".<wbr> He confirmed the antibiotics business, "loss making business" is now out.<wbr> Pipeline for the BtB business is "very solid and promising".<wbr> </div><div><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_dkphybrids_220_8_ScreenCapture8.jpg"> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=DKPHybrids&sdate=20130431&edate=20130101&rec=220">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-03-07T12:45:08+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-03-07T12:45:08+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category dkphybrids > <![CDATA[dkphybrids]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Prana To Highlight Positive Impact of PBT434 On Key Protein Linked To Parkinson's Disease</title>
	<pubDate>2013-03-06T16:59:57+01:00</pubDate>
	<wp:post_id>4101</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Prana has announced that key data on PBT434 will be presented at an 
upcoming meeting showing that PBT434 reduces the aggregation and accumulation of 
alpha synuclein, a protein that aggregates in the substantia nigra in 
Parkinson's disease.<wbr> </div><div style="margin-bottom: 10px;">In three different Parkinson Disease animal models, Prana has demonstrated 
that PBT434 significantly prevents the death of substantia nigra cells.<wbr> 
Moreover, marked improvements in motor function and co-ordination were also 
seen.<wbr> </div><div style="margin-bottom: 10px;">The data is to be presented at the upcoming conference on Alzheimer's 
and Parkinson Disease in Florence 6th-10th March in a talk entitled " 
The role of nitrated TAU in PD" </div><div>Source: <A href="http://www.pranabiotech.com">www.<wbr>pranabiotech.<wbr>com</A> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20130431&edate=20130101&rec=6847">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-03-06T16:59:57+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-03-06T16:59:57+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>EC Backing For $187m Funding For Rare Diseases</title>
	<pubDate>2013-03-06T16:44:44+01:00</pubDate>
	<wp:post_id>4102</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div><DIV style="BORDER-BOTTOM: medium none; TEXT-ALIGN: left; BORDER-LEFT: medium none; BACKGROUND-COLOR: #ffffff; COLOR: #000000; OVERFLOW: hidden; BORDER-TOP: medium none; BORDER-RIGHT: medium none; TEXT-DECORATION: none">
<P>Comment: A few days ago the European Commission 
mapped out a plan to help spur development of 200 new treatments for rare 
diseases by the year 2020.<wbr> It plans to commit $187 million for 26 research 
projects.<wbr></P>
<P>The research initiative aims to bring together some 300 
investigators--academics, biotech and pharma investigators--from 29 countries to 
work on new treatments related to cardiovascular disease, acute liver failure, 
rare kidney disease and more.<wbr> And it adds to a series of initiatives that now 
account for 100 projects and about $650 million in EC financing.<wbr> </P>
<P>"Most rare diseases affect children and most of them are devastating genetic 
disorders resulting in greatly reduced quality of life and premature death," 
said Máire Geoghegan-Quinn, the EU Commissioner for Research, Innovation and 
Science, in a statement.<wbr> "We hope that these new research projects will bring 
patients, their families and health professionals closer to a cure and support 
them in their daily battle with disease.<wbr>"</P>
<P><BR>The new projects will bring the number of EU-funded collaborative 
research projects related to rare diseases to close to 100 over the last six 
years, representing a total investment of almost 500 million euros.<wbr><BR><BR>- In 
late January, the EU announced new funding of 38 million euros, under the 
IRDiRC, for research towards new treatments and the development of a central 
global rare-disease hub involving 70 institutions that will allow scientists to 
share data from their genomics research projects.<wbr><BR><BR>The four projects, 
which will receive the funding over the next six years, are for the following 
international collaborations:<BR>- EURenOMICS, led by Heidelberg University 
Medical Centre, Germany, to identify the genetic and epigenetic causes of rare 
kidney disorders;<BR>- Neuromics, led by the University of Tubingen, Germany, to 
address rare neurodegenerative and neuromuscular disorders using next-generation 
whole-exome sequencing;<BR>- RD-Connect, led by Newcastle University, UK, to 
develop a global infrastructure to share the research or rare disease projects; 
and<BR>- SUPPORT-IRDiRC, led by INSERM, France, to support international 
rare-disease collaboration through IRDiRC.<wbr></P>
<P>Source: <A href="http://europa.eu/rapid/press-release_MEMO-13-148_en.htm?locale=en">http:/<wbr>/<wbr>europa.<wbr>eu/<wbr>rapid/<wbr>press-release_MEMO-13-148_en.<wbr>htm?locale=en</A><BR></P></DIV> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20130431&edate=20130101&rec=10330">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-03-06T16:44:44+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-03-06T16:44:44+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category pharma-news > <![CDATA[Pharma News]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>PROLOR Reinforces hGH Patent Portfolio</title>
	<pubDate>2013-03-05T17:28:55+01:00</pubDate>
	<wp:post_id>4103</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: The company has received a notice of allowance from the U.<wbr>S.<wbr> Patent and Trademark Office for a new patent application covering the company's long-acting CTP-enhanced human growth hormone (hGH-CTP).<wbr> Upon issuance, the new patent will provide PROLOR with additional intellectual property protection that covers methods for decreasing body fat in humans through the use of hGH-CTP therapy.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Ph3 trials in AGHD is expected to debute later 2013.<wbr> </div><div>Ph2 trials in PGHD is currently ongoing.<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20130431&edate=20130101&rec=7281">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-03-05T17:28:55+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-03-05T17:28:55+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category endocrinology > <![CDATA[Endocrinology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Silence's ATU027 to be Tested in Pancreatic Cancer</title>
	<pubDate>2013-03-05T17:04:18+01:00</pubDate>
	<wp:post_id>4104</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Silence Therapeutics has received formal approval from the German authorities (BfArM) for its phase 1b/<wbr>2a combination trial into pancreatic cancer.<wbr> The trial will test Silence's Atu027 in combination with Gemcitabine.<wbr> ATU027 is now the most advanced RNAi Oncology program in the world.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">It is expected that the 1b element of the trial will last for 3 months and the 2a element scheduled to begin in July 2013 and ending approximately in July 2014.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">BfArM has also encouraged Silence, primarily due to the exceptional safety profile of ATU027 in phase 1, to apply for 1b/<wbr>2a trials using Atu-027 as a combination therapy across a wide range of cancers.<wbr> It indicated that these further trials could be run broadly in parallel with pancreatic cancer.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Silence Therapeutics is the only company worldwide who can effectively deliver siRNAs to multiple locations in the human body.<wbr> </div><div>Together with the strong patent position in its' synthetic siRNA, AtuRNAi, Silence Therapeutics is amongst a handful of companies who have the freedom to operate in this space </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20130431&edate=20130101&rec=8814">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-03-05T17:04:18+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-03-05T17:04:18+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Positive PhI Data With New Pump Patch Liquid PD Formulation</title>
	<pubDate>2013-03-05T10:51:23+01:00</pubDate>
	<wp:post_id>4105</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Neuroderm announced yesterday positive results from a phI PK trial 
with ND0612, a proprietary levodopa/<wbr>cabidopa liquid formulation administered 
subcutaneously through a patch pump.<wbr> </div><div style="margin-bottom: 10px;">In a double-blind placeob controlled dose-escalation trial in yound healthy 
volunteers ND-612 was shown to be safe and tolerable in all of the tested 
doses.<wbr> </div><div style="margin-bottom: 10px;">Importantly, clinically meaningful levodopa concentrations were reached and 
for the first time in man, steady state levodopa concentration were maintained 
both day and night (the elusive holy grail of PD levodopa therapy).<wbr> </div><div style="margin-bottom: 10px;">Traditionally levodopa and carbidopa are administered orally and suffer from 
an unfavourable PK profile due to low bioavailability.<wbr> </div><div>Source: <a href="http://www.neuromed.com" class="defaultlink" title="www.neuromed.com">neuromed.com</a> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20130431&edate=20130101&rec=6845">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-03-05T10:51:23+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-03-05T10:51:23+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Calypso Biotech to be the Sixth Spin-Off Company of Merck Serono</title>
	<pubDate>2013-03-04T16:06:18+01:00</pubDate>
	<wp:post_id>4106</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: The new formed Calypso Biotech will continue R&amp;D of preclinical antibody programs from Merck Serono in the field of gastrointestinal immunological disorders.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">- Merck Serono will invest €2.<wbr>5M as seed funding </div><div style="margin-bottom: 10px;">- Co-Founders: Drs.<wbr> Yolande Chvatchko and Alain Vicari, two seasoned immunologists with strong experience in team management and drug discovery expertise.<wbr> </div><div>- Employees: 3 </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20130431&edate=20130101&rec=1877">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-03-04T16:06:18+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-03-04T16:06:18+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category gastroenterology > <![CDATA[gastroenterology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Anterios Expands its BTXA Topical Gel Program</title>
	<pubDate>2013-03-01T19:29:38+01:00</pubDate>
	<wp:post_id>4107</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: A Phase 2 started this month in approx.<wbr> 52 participants (men and women) with primary axillary hyperhidrosis.<wbr> PE will assess HDSS.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG><A href="http://clinicaltrials.gov/ct2/show/NCT01799824?recr=Open&amp;no_unk=Y&amp;phase=012&amp;fund=2&amp;rcv_s=02%2F01%2F2013&amp;rank=44"><STRONG></STRONG></A> </div><div style="margin-bottom: 10px;">Inclusion Criteria </div><div style="margin-bottom: 10px;"><UL style="MARGIN-TOP: 1ex; MARGIN-BOTTOM: 1ex"><LI class="color-bullet" style="MARGIN-TOP: 0.7ex">ages 18 - 70 years of age</LI>
<LI class="color-bullet" style="MARGIN-TOP: 0.7ex">diagnosis of moderate to severe primary axillary hyperhidrosis</LI>
<LI class="color-bullet" style="MARGIN-TOP: 0.7ex">≥50 mg of sweat production/<wbr>axilla in 5 minutes as measured gravimetrically</LI>
<LI class="color-bullet" style="MARGIN-TOP: 0.7ex">HDSS score of ≥3</LI>
</UL> </div><div style="margin-bottom: 10px;">Completion date: Aug.<wbr> 2013 </div><div style="margin-bottom: 10px;">Location: USA </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6842_2_ScreenCapture2.jpg"> </div><!-- Comment details --><a name="neurology6842attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6842_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(53,2 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6842_2_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(91,2 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20130431&edate=20130101&rec=6842">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-03-01T19:29:38+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-03-01T19:29:38+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Hikma to Consider Possible Sale of its Injectable-Medicines Business</title>
	<pubDate>2013-03-01T19:14:03+01:00</pubDate>
	<wp:post_id>4108</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Analyst at Panmure Gordon &amp; Co sees the business could be sold for as much as $1.<wbr>5 billion, while Jefferies International said the unit could fetch as much as $2.<wbr>2 billion.<wbr> Separately, Hikma is considering options for its U.<wbr>S.<wbr> oral generic-drug business.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Please see <a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20130431&edate=20130101&rec=8810" class="defaultlink">Oncology8810: Mylan To Acquire Stride's Injectable Business Agila For $1.<wbr>6bn In Cash</a>.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Teva, Sandoz, Actavis.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8813_1_ScreenCapture1.jpg"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8813_2_ScreenCapture2.jpg"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8813_3_ScreenCapture3.jpg"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8813_4_ScreenCapture4.jpg"> </div><!-- Comment details --><a name="oncology8813attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8813_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(110,8 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8813_2_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(86,9 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8813_3_ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(77,3 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8813_4_ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(87,2 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20130431&edate=20130101&rec=8813">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-03-01T19:14:03+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-03-01T19:14:03+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Key Messages from Medivation Q4 and FY12 Results</title>
	<pubDate>2013-03-01T17:55:43+01:00</pubDate>
	<wp:post_id>4109</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Net sales of XTANDI reached approx.<wbr> $71M in the US for the FY 2012 thanks to the expanded access program (EAP), and the accelerated approval of the drug.<wbr> Management commentary suggested limited use of Xtandi in the pre-chemo setting as "the indication is in post chemo and that's what we're promoting".<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Medivation gave metrics on the launch for the first time, noting that 9,300 prescriptions were written by 1,600 individual prescribers from 300 accounts in 2012.<wbr> </div><div style="margin-bottom: 10px;">The 9,300 Rx in 17 weeks compares favorably to Zytiga's 10,200 prescriptions in its first 17 weeks on the market.<wbr> </div><div style="margin-bottom: 10px;">Oncologists wrote 98% of Xtandi scripts, with the remaining 2% written by urologists </div><div style="margin-bottom: 10px;">Management reported that " .<wbr>.<wbr>.<wbr> we currently have 60 sales representatives throughout the United States.<wbr> 150 total including the effort with Astellas and we are calling on urologists and oncologists.<wbr> We're currently right now targeting close to 9,000 physicians.<wbr> A majority of them, of course, are oncologists, and 2,000 of them are urologists".<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">(*<U>Reminder</U>: TERRAIN is enrolling metastatic patients and is being conducted primarily in Europe STRIVE will enroll both metastatic and non-metastatic patients and be conducted primarily in the United States.<wbr> Both TERRAIN and STRIVE are randomized, double-blind trials of enzalutamide head-to-head against bicalutamide, with a primary endpoint of progression-free survival).<wbr> </div><div style="margin-bottom: 10px;">Management oulined that " .<wbr>.<wbr>.<wbr>  Astellas is operationalizing the TERRAIN trial, and we'll be giving guidance on that.<wbr> Our trial, which is the STRIVE trial in the US, has only recently begun enrollment.<wbr> We haven't given guidance on either trial as about when the data will be available".<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Questionned on if data are expected this year, P Machado answered " .<wbr>.<wbr>.<wbr> We've not guided on PREVAIL.<wbr> I think we've consistently explained that at this point we're very focused on competition, and we want to keep those cards very close to our vest because we think those data are going to put us in a very strong position competitively.<wbr> And that it's best for the business to keep that to -- keep that to ourselves".<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div>It was indicated that the company is "continuing to enroll patients in our Phase 1 study evaluating the safety and tolerability of enzalutamide in breast cancer.<wbr> The study includes a dose escalation stage followed by an expansion where women with estrogen receptive positive breast cancer will be enrolled.<wbr> If the safety data are acceptable, our next step would be to advance into Phase 2 development".<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20130431&edate=20130101&rec=8811">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-03-01T17:55:43+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-03-01T17:55:43+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Key Messages from Bayer Investor Conference Call</title>
	<pubDate>2013-03-01T11:26:22+01:00</pubDate>
	<wp:post_id>4110</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Bayer increased sales organically by 5% to almost €40 billion for 2012.<wbr> Sales growth at pharma was driven by business expansion in North America and China(+23%).<wbr> Management expects its healthcare unit, with prescription, OTC and animal health drugs to see sales grow by 6% per year to €22 billion by 2015 (ex currency swings and portfolio changes).<wbr> Regarding Alpharadin new trials, management reported they will 'go into patients in earlier stages of disease, do combination trials, and look at additional tumours such as breast and osteosarcoma around year end".<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10326_7_ScreenCapture7.jpg"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10326_1_ScreenCapture1.jpg"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10326_2_ScreenCapture2.jpg"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">- Q4:12 </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10326_3_ScreenCapture3.jpg"> </div><div style="margin-bottom: 10px;">- FY2012 </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10326_6_ScreenCapture6.jpg"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10326_4_ScreenCapture4.jpg"> </div><div><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10326_5_ScreenCapture5.jpg"> </div><!-- Comment details --><a name="pharmaworld10326attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10326_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(61,2 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10326_2_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(37,2 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10326_3_ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(52 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10326_4_ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(69,3 KB)<br>&nbsp;&nbsp;5.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10326_5_ScreenCapture5.jpg">ScreenCapture5.jpg</a>&nbsp;&nbsp;(64,6 KB)<br>&nbsp;&nbsp;6.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10326_6_ScreenCapture6.jpg">ScreenCapture6.jpg</a>&nbsp;&nbsp;(56,4 KB)<br>&nbsp;&nbsp;7.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10326_7_ScreenCapture7.jpg">ScreenCapture7.jpg</a>&nbsp;&nbsp;(141,4 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20130431&edate=20130101&rec=10326">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-03-01T11:26:22+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-03-01T11:26:22+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category pharma-news > <![CDATA[Pharma News]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>re: Roche Acquires Rights To Octreolin in $595m Deal</title>
	<pubDate>2013-02-28T18:19:56+01:00</pubDate>
	<wp:post_id>4111</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="border-left: 2px solid #8B1010; padding: 0px 0px 5px 12px; margin-bottom: 3px;"><span style="font-weight: bold; font-size: 14px;">Roche Acquires Rights To Octreolin in $595m Deal</span>&nbsp;<br><span style="font-size: 12px;">Comment: Roche has entered into an agreement with Chiasma to develop and commercialise its proprietary oral octreotide formulation Octreolin for the treatment of acromegaly and NET.<wbr> The product is currently in phIII development for the treatment of acromegaly only.<wbr></span>&nbsp;&nbsp;<a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20130431&edate=20130101&rec=7265">...</a><br></div><div style="margin-bottom: 10px;">You will find the full list of participating centers (as well as their recruitment status and names of PI) of the phase III study, following the link: <A href="http://clinicaltrials.gov/ct2/show/study/NCT01412424?term=Chiasma&amp;rank=1&amp;show_locs=Y#locn">http:/<wbr>/<wbr>clinicaltrials.<wbr>gov/<wbr>ct2/<wbr>show/<wbr>study/<wbr>NCT01412424?term=Chiasma&amp;rank=1&amp;show_locs=Y#locn</A> </div><div style="margin-bottom: 10px;"><A href="http://clinicaltrials.gov/ct2/show/study/NCT01412424?term=Chiasma&amp;rank=1&amp;show_locs=Y#locn"></A><SPAN style="line-height: 1.5em;">You can see that out of the 14 countries involved, 12 are active (i.<wbr>e.<wbr> all except the US and Slovenia): Germany, Hungary, Israel, Italy, Lithuania, Mexico, Netherlands, Poland, Romania, Serbia, Slovakia, United Kingdom.<wbr></SPAN> </div><div style="margin-bottom: 10px;">The phase III trial <EM>&ldquo;Efficacy and Safety of Oral Octreolin in Patients With Acromegaly Who Are Currently Receiving Parenteral Somatostatin Analogs&rdquo;</EM> is enrolling 150 patients.<wbr> We can&rsquo;t have access to the split per country /<wbr> center.<wbr> </div><div style="margin-bottom: 10px;">Treatment duration is 7 months, and estimated completion date is October 2013.<wbr> </div><div style="margin-bottom: 10px;">Inclusion criteria are: Subjects with acromegaly defined as documented evidence of GH-secreting pituitary tumor that is abnormally responsive to glucose who is currently receiving a somatostatin analog.<wbr> </div><div style="margin-bottom: 10px;">Do not hesitate to post comments on Traction related to this trial, e.<wbr>g.<wbr> recruitment status, investigators&rsquo; or nurses&rsquo; feed-back, communication plan, &hellip; </div><div>Each and every information gathered will be very useful to feed the Octreolin war game planned this year.<wbr> </div><!-- Comment details --><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20130431&edate=20130101&rec=7280">Add a Comment on this Article</a><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7265">View thread  Endocrinology7265: Roche Acquires Rights To Octreolin in $595m Deal</a>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-02-28T18:19:56+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-02-28T18:19:56+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category endocrinology > <![CDATA[Endocrinology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Trophos's Pivotal SMA Study Gets Positive DMC Review</title>
	<pubDate>2013-02-28T18:13:37+01:00</pubDate>
	<wp:post_id>4112</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Trophos SA, a French clinical stage pharmaceutical company 
developing therapeutics for under-served medical needs in neurology, has 
announced the completion of the interim analysis of the pivotal efficacy study 
of olesoxime in Spinal Muscular Atrophy (SMA).<wbr> </div><div style="margin-bottom: 10px;"><STRONG>DMC Recommends Pivotal Study Should Continue <BR><BR></STRONG>The 
independent Data Monitoring Committee has reviewed the treatment effect at one 
year on the primary outcome measure of efficacy, change in motor function using 
the MFM scale, together with the latest safety report including 
electrocardiogram traces, periodic laboratory findings, haemostatic parameters 
and serious adverse events listings for all participants.<wbr> Based on the trial 
stopping criteria as defined in the protocol as well as no safety concerns 
related to olesoxime treatment, their recommendation is to continue the study as 
planned.<wbr> </div><div style="margin-bottom: 10px;">An interim analysis of efficacy, as included in the study 
protocol, has been conducted after all participants have been treated for one 
year.<wbr> Over 160 patients have been recruited into the trial between October 2010 
and September 2011.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Next Steps &amp; Timeline</STRONG> </div><div style="margin-bottom: 10px;">Following the recommendations of the DMC, the study will continue until 
all participants have been treated for two years with the last patient out 
scheduled for September 2013.<wbr> Top line results are expected by the end of 
2013.<wbr> </div><div style="margin-bottom: 10px;">The trial is substantially funded by Trophos' partnership with the 
Association Francaise contre les Myopathies (AFM-Telethon) The trial 
protocol has benefited from the EMA protocol advice procedure.<wbr> </div><div>Source: <A href="http://www.trophos.com">www.<wbr>trophos.<wbr>com</A> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20130431&edate=20130101&rec=6839">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-02-28T18:13:37+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-02-28T18:13:37+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Key Takeaways from Valeant Q4 and FY12 Results</title>
	<pubDate>2013-02-28T18:04:00+01:00</pubDate>
	<wp:post_id>4113</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: The company reported that it is continuing to see synergies emerging from the Medicis acquisition and that it is currently pursuing legal and R&amp;D cost synergies.<wbr> In terms of Dysport and what management is seeing with Merz having reentered the market, it was reported that 'Merz is obviously a very good company and is out marketing their product and our gang continues to be aggressive.<wbr> What's interesting, in terms of toxins, it competes more directly with Botox than our product.<wbr> Our product has some different attributes.<wbr> So it's more of a competition between Allergan and Merz in terms of the toxin'.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6837_1_ScreenCapture1.jpg"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">This year, Valeant is expecting two key product candidate approvals - efinaconazole in May 2013 and luliconazole in December 2013.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6837_2_ScreenCapture2.jpg"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Valeant indicated that it is now the fastest-growing pharmaceutical company in Poland, achieving 3% growth in 2012 while the overall Polish market shrank 6%.<wbr> </div><div style="margin-bottom: 10px;">In Asia, the firm delivered 20% growth as measured in local currencies.<wbr> </div><div style="margin-bottom: 10px;"><U>The neurology division</U> delivered positive growth in 4Q 2012, after six consecutive quarters of declines.<wbr> </div><div style="margin-bottom: 10px;">Valeant's Mexican division and the firm's main dermatology brands all achieved double-digit percentage growth in 2012.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6837_3_ScreenCapture3.jpg"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Valeant did not update 2013E guidance in the press release.<wbr> Management expects to do so on its Q1 2013 conference call (likely early March).<wbr> </div><div><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6837_4_ScreenCapture4.jpg"> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20130431&edate=20130101&rec=6837">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-02-28T18:04:00+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-02-28T18:04:00+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Mylan To Acquire Stride's Injectable Business Agila For $1.6bn In Cash</title>
	<pubDate>2013-02-28T15:11:15+01:00</pubDate>
	<wp:post_id>4114</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: After a tightly fought battle, Mylan has eclipsed Pfizer and others 
as the buyer of Agila an Indian Specialty Injectable business propelling Mylan 
to one of the top 3 players in the hospital injectable market and strenthening 
its capabilities in terms of injectable microspheres and gel forming 
implants.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Commenting on the acquisition Rajiv Malik President of Mylan 
noted:-</STRONG> </div><div style="margin-bottom: 10px;"><P class="pwrapper">"Leading up to this acquisition, Mylan has made significant progress building 
our injectables 
platform to various activities, 
including the 
acquisition of 
Merck KGaA's 
generics business, 
our Bioniche 
acquisition and 
our recent manufacturing expansion through 
the facility 
acquisition from 
SMS, in addition to our biologics and recently announced insulin 
analog collaborations, both 
with Biocon.<wbr>" 
</P> </div><div style="margin-bottom: 10px;"><P class="pwrapper">"We believe that the acquisition of Agila helps to fill significant gaps in our injectables business 
in terms of contracting capacity and technical capabilities.<wbr> With 
the injectables 
market expected 
to grow at a compound annual growth rate of 13% from 2011 to 2017, outpacing most other dosage forms, addressing 
these gaps was strategically 
important.<wbr>.<wbr>.<wbr>.<wbr> with this acquisition, we will meaningfully accelerate achievement 
of our target to create $1 billion institutional 
franchise.<wbr>" </P> </div><div style="margin-bottom: 10px;"><P class="pwrapper">"Agila has an impressive global portfolio and a track record of successfully developing, filing 
and receiving 
approval for 
injectable products, driven by their best-in-class R&amp;D 
platform.<wbr> In 
fact, Agila is 
far and away the 
market leader 
in terms of ANDA approval over the last five years and its approval times that FDA have run well ahead of injectables industry average.<wbr> 
Agila has a strong pipeline of 349 applications pending approval in addition to 307 global regulatory 
approvals already received.<wbr>" 
</P> </div><div style="margin-bottom: 10px;"><P class="pwrapper">"We expect to even further bolster this R&amp;D output as we integrate Agila.<wbr> Agila will bring us approximately an additional 350 scientists focused 
on injectables 
complementing the strong team we already have in place.<wbr> Together, we'll have comprehensive 
capabilities across vials, pre-filled syringes, 
ampoules, lyophilization, mini 
bags, cytotoxics 
and antibiotics.<wbr> 
<STRONG>This transaction also will make Mylan a significant 
player in advanced new technologies of the future, such as microspheres, liposome, nano-suspensions and 
gel-forming implants.<wbr> "</STRONG></P> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8810_1_ScreenCapture1.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8810_2_ScreenCapture2.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8810_3_ScreenCapture3.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8810_4_ScreenCapture4.jpg"> </div><div><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8810_5_ScreenCapture5.jpg"> </div><!-- Comment details --><a name="oncology8810attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8810_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(109 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8810_2_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(103,3 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8810_3_ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(111,7 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8810_4_ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(136,9 KB)<br>&nbsp;&nbsp;5.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8810_5_ScreenCapture5.jpg">ScreenCapture5.jpg</a>&nbsp;&nbsp;(154,2 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20130431&edate=20130101&rec=8810">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-02-28T15:11:15+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-02-28T15:11:15+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>The Toxin Therapeutic Therapy Area Landscape</title>
	<pubDate>2013-02-27T19:09:19+01:00</pubDate>
	<wp:post_id>4115</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: As part of our ongoing commitment to the recently launched CI/<wbr>SIS 
Therapy Area Landscape Service, you will find attached an overview of the 
competitive landscape in the botulinum toxin therapeutic area.<wbr> </div><div>This document has been created with collaborative input from the Franchise 
and we hope that you will find it a useful tool.<wbr> We encourage you to 
contribute to our internal knowledge of this therapy area by evaluating some of 
the Key Intelligence Topics included in the slide kit.<wbr> However, no matter 
what competitive information you have, please do keep us informed of any key 
developments in your countries.<wbr> In this manner we can look to build on our 
internal knowledge base and together leverage the utility of the tool for 
everybody's benefit.<wbr> </div><!-- Comment details --><span style="font-weight: bold; font-style: italic;"><br>Comments</span><a name="Neurology6849c"></a><br><div style="border: 1px solid #AAA; background-color: #FFF; margin-left: 10px; padding: 5px;"><div style="margin-bottom: 10px;">Dear Jackie, </div><div>Thanks for this.<wbr>  I will examine closer and add comments if possible.<wbr> At first glance It is very useful.<wbr>  Gavin Assauw </div></div><a name="Neurology6855c"></a><div style="border: 1px solid #AAA; background-color: #FFF; margin-left: 10px; padding: 5px;"><div style="margin-bottom: 10px;">Dear Jackie, there is one company I recently came across of relevance to this - Theracoat (<a href="http://www.theracoat.com/" class="defaultlink" title="http://www.theracoat.com/">theracoat.com/<wbr></a>).<wbr> I briefly met their VP Business Development at the Drug Delivery Partnerships conference.<wbr> They have a novel hydrogel polymer that gels when it reaches body temperature.<wbr> They are using it to increase retention time and control release of drugs in cavities - focussing on the bladder.<wbr> </div><div style="margin-bottom: 10px;">The polymer is not absorbed and eventually passes out in the urine.<wbr> I can't comment on the strengths and weaknesses of their technology is as only had a brief chat with him.<wbr> They are about to enter Phase 2 for overactive bladder using botulinum toxin (apparently the "protocol is currently being finalised").<wbr> The hope is that the delivery system will enhance efficacy, and provide longer duration of action.<wbr> The trial will be done under a grant received by the University of Ostrava Medical Center, Czech Republic, and plan to buy Allergan's Botox from pharmacies prior to formulating it in their system (which as you will appreciated doesn't sound ideal from a CMC perspective).<wbr> They do not currently have a relationship with Allergan (so could use Dysport instead), although you should note that Allergan had a heavy presence at the conference (CEO, VP Pharm Dev, and bus.<wbr> dev.<wbr> were present), so I expect they made contact with them.<wbr> </div><div>Best regards,<BR>Andy </div></div><a name="neurology6836attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6836_1_Final%20Toxins%20Landscape%2026th%20Feb%20%20(1).ppt">Final Toxins Landscape 26th Feb (1).ppt</a>&nbsp;&nbsp;(1,8 MB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20130431&edate=20130101&rec=6836">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-02-27T19:09:19+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-02-27T19:09:19+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Millennium/Takeda's Aurora Kinase A Inhibitor Entered New POC Trial</title>
	<pubDate>2013-02-27T17:50:44+01:00</pubDate>
	<wp:post_id>4116</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: This small multi-institutional single-arm, open-label Ph2 trial, sponsored by Weill Medical College of Cornell U.<wbr>, will assess MLN8237 (alisertib) in patients with histologically confirmed or clinically suspected metastatic neuroendocrine prostate cancer (NEPC).<wbr> PE will measure RR.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG><A href="http://clinicaltrials.gov/ct2/show/NCT01799278?phase=012&amp;fund=2&amp;rcv_s=01%2F27%2F2013&amp;rank=200"><STRONG></STRONG></A> </div><div style="margin-bottom: 10px;">Start date: Feb 2013 - Completion dates: Feb 2015/<wbr>Feb2016.<wbr> </div><div style="margin-bottom: 10px;">Recruitment: approx 10 male (&gt;18 years and older) </div><div style="margin-bottom: 10px;">Principal Investigator: Himisha Beltran, MD </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8808_2_ScreenCapture2.jpg"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8808_1_ScreenCapture1.jpg"> </div><!-- Comment details --><a name="oncology8808attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8808_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(16,4 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8808_2_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(153,1 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20130431&edate=20130101&rec=8808">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-02-27T17:50:44+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-02-27T17:50:44+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Auspex' ER Tablets of Tetrabenazine to Enter Ph3 for Chorea Associated with Huntington's Disease</title>
	<pubDate>2013-02-26T18:35:16+01:00</pubDate>
	<wp:post_id>4117</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Clinicaltrials.<wbr>gov is listing a new Ph3 trial designed to evaluate efficacy, safety and tolerability of Auspex' SD-809 ER in approx.<wbr> 90 participants.<wbr> PE will assess total maximal chorea score (TMC).<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG><A href="http://clinicaltrials.gov/ct2/show/NCT01795859?recr=Open&amp;no_unk=Y&amp;phase=012&amp;fund=2&amp;rcv_s=01%2F26%2F2013&amp;rank=89"><STRONG></STRONG></A> </div><div style="margin-bottom: 10px;">Start date: April 2013 - Completion dates: April 2014-April 2015 </div><div style="margin-bottom: 10px;"><U>Design</U> </div><div style="margin-bottom: 10px;">2-arm: Approximately 90 subjects will be randomized (1:1) into the study, with approximately 45 subjects receiving SD-809 ER and 45 subjects receiving placebo </div><div style="margin-bottom: 10px;">Location: approx.<wbr> 30 centers (US; Canada) </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Description: Clinical-stage, venture-financed company headquartered in San Diego, California.<wbr> </div><div style="margin-bottom: 10px;">Technology: Auspex Pharmaceuticals is utilizing the unique properties of deuterium to develop a pipeline drugs in several important disease areas.<wbr> </div><div><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6832_1_ScreenCapture1.jpg"> </div><!-- Comment details --><a name="neurology6832attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6832_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(35,1 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20130431&edate=20130101&rec=6832">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-02-26T18:35:16+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-02-26T18:35:16+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Hugel Stepping Up Marketing Efforts on Botulax</title>
	<pubDate>2013-02-26T18:10:05+01:00</pubDate>
	<wp:post_id>4118</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: At the recent IPRAS Congress, Hugel's satellite workshop was dedicated to a brief company overview, followed by a session on clinical study report, case sharing, and a live demo of Botulax in crow's feet, forehead line, glabellar lin and masseter reduction.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6831_2_ScreenCapture2.jpg"> </div><div><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6831_1_ScreenCapture1.jpg"> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20130431&edate=20130101&rec=6831">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-02-26T18:10:05+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-02-26T18:10:05+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>BETMIGA (mirabegron) Available in the UK for OAB</title>
	<pubDate>2013-02-26T12:03:25+01:00</pubDate>
	<wp:post_id>4119</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Mirabegron is now available via prescription in the UK.<wbr> It will become available throughout Europe as part of a phased launch plan.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Mirabegron is a once daily oral β3-adrenoceptor agonist discovered and developed by Astellas.<wbr> It is the first compound licensed in this new class of treatment for OAB, using a distinct mechanism of action compared to antimuscarinics.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20130431&edate=20130101&rec=8718" class="defaultlink">Oncology8718: Astellas Strengthens its UroOnco Position with EU Approval of Mirabegron for OAB</a> </div><div style="margin-bottom: 10px;"><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20130431&edate=20130101&rec=8362" class="defaultlink">Oncology8362: Astellas Boosts its Foothold in Urology</a>.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8803_1_ScreenCapture1.jpg"> ( ) </div><!-- Comment details --><a name="oncology8803attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8803_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(82,3 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20130431&edate=20130101&rec=8803">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-02-26T12:03:25+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-02-26T12:03:25+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Dendreon Q4 Figures Beat Street Estimates With Q4 PROVENGE Revenues of $85.5m</title>
	<pubDate>2013-02-26T10:58:53+01:00</pubDate>
	<wp:post_id>4120</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: The good news was accompanied by not such good news in that Dendreon 
is pointing to a decline in Q113 sales relative to Q412.<wbr> Drivers of this 
fall appear mutli-faceted and include a seasonal slowdown in enrollment, 
Superstorm Sandy, sales vacancies, new competition and traditional Q1 
seasonality for high-price infusion products.<wbr> </div><div style="margin-bottom: 10px;">Progress continues to be made on the expense side, with the expectation that 
COGS will be &lt;50% revenue by Q313 but breakeven increases to $105m due to 
planned incremental spend on DTC advertising, scheduled to begin in Q213.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Patient Flow</STRONG> </div><div style="margin-bottom: 10px;">Analysts are still wiating to see an inflection in the number of patients per 
account before recommending the shares.<wbr> 61 new accounts were added in Q412 which 
represents a sequential 8% increase.<wbr> However, the number of patients per account 
continues to decline (see chart below) albeit at a slower rate that in the 
previous two quarters.<wbr> </div><div style="margin-bottom: 10px;">Key Account Growth<img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8802_1_ScreenCapture1.jpg"> </div><div style="margin-bottom: 10px;">Management noted that the community setting oncology accounts now represent 
43% of the total buisiness whilst urology accounted for 28%.<wbr> Whilst adding new 
accounts is important it emphasised that the focus remains on penetrating 
existing accounts.<wbr> It claims that it has seen many accounts ramp up and, in 
fact, has one account that is now treating more than 30 patients per quarter for 
the last six months.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>New Sequencing Data</STRONG> </div><div style="margin-bottom: 10px;">Management also highlighted data at ASCO (Zytiga sequencing data) and claimed 
that feedback on the sequencing data was very positive as it begins to remove 
some concerns around how quickly patients can move to Zytiga post PROVENGE 
therapy.<wbr> The impact on Provenge sales has yet to be seen.<wbr> Xtandi sequencing 
(simiilar design to the Zytiga sequencing trial) and pre-metastatic 
screening  trials are in planning.<wbr> </div><div>Source: <A href="http://www.dendreon.com">www.<wbr>dendreon.<wbr>com</A> </div><!-- Comment details --><a name="oncology8802attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8802_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(83,3 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20130431&edate=20130101&rec=8802">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-02-26T10:58:53+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-02-26T10:58:53+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>re: Confirmatory Ph3 of Hugel's BoTXA for Essential Blepharospasm (EB) Has Completed in Korea</title>
	<pubDate>2013-02-26T10:52:39+01:00</pubDate>
	<wp:post_id>4121</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="border-left: 2px solid #8B1010; padding: 0px 0px 5px 12px; margin-bottom: 3px;"><span style="font-weight: bold; font-size: 14px;">re: Confirmatory Ph3 of Hugel's BoTXA for Essential Blepharospasm (EB) Has Completed in Korea</span>&nbsp;<br><span style="font-size: 12px;">Botulax seems to already have blepharospasm as the registered indication.<wbr> This Phase 3 would reinforce the dossier?</span>&nbsp;<br></div><div style="margin-bottom: 10px;">I found a study in clintrialtrials.<wbr>gov run in EB N<A href="http://clinicaltrials.gov/ct2/show/NCT01791881?term=01791881&amp;rank=1">CT01791881 </A>which is a confirmatory Phase 3.<wbr> Endpoints and duration of the trial would likely not support registration in the USA when compared to the recent approval of Xeomin in this country.<wbr> </div><div>Their strategy is maybe to gain registration in Latin America? </div><!-- Comment details --><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20130431&edate=20130101&rec=6830">Add a Comment on this Article</a><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology6810">View thread  Neurology6810: Confirmatory Ph3 of Hugel's BoTXA for Essential Blepharospasm (EB) Has Completed in Korea</a>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-02-26T10:52:39+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-02-26T10:52:39+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>New JV for Gedeon Richter in China</title>
	<pubDate>2013-02-25T18:39:01+01:00</pubDate>
	<wp:post_id>4122</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: The company has signed a series of agreements with the owners of its marketing partner, Rxmidas, targeting a reshaped and stronger direct presence in China.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><UL><LI>
<SPAN lang="EN-GB" style="FONT-FAMILY: 'verdana','sans-serif'; COLOR: #1f497d; FONT-SIZE: 10pt"></SPAN></LI>
<LI>Richter through the newly formed JV establishes its direct presence in China executing the promotion and lifecycle management of both Richter’s existing Rx products and licensed-in third party Rx products.<wbr></LI>
</UL> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><SPAN lang="EN-GB" style="FONT-FAMILY: 'verdana','sans-serif'; COLOR: #1f497d; FONT-SIZE: 10pt"></SPAN> </div><div style="margin-bottom: 10px;"><SPAN lang="EN-GB" style="FONT-FAMILY: 'verdana','sans-serif'; COLOR: #1f497d; FONT-SIZE: 10pt"></SPAN> </div><div style="margin-bottom: 10px;"><SPAN lang="EN-GB" style="FONT-FAMILY: 'verdana','sans-serif'; COLOR: #1f497d; FONT-SIZE: 10pt"></SPAN> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div>See <a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20130431&edate=20130101&rec=7953" class="defaultlink">Oncology7953: Richter Gains Marketing Rights for EsmyaTM (Uterine Myomas) in China, Russia and Other CIS Markets</a>.<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20130431&edate=20130101&rec=8801">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-02-25T18:39:01+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-02-25T18:39:01+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>re: Roche Acquires Rights To Octreolin in $595m Deal</title>
	<pubDate>2013-02-25T15:07:21+01:00</pubDate>
	<wp:post_id>4123</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="border-left: 2px solid #8B1010; padding: 0px 0px 5px 12px; margin-bottom: 3px;"><span style="font-weight: bold; font-size: 14px;">Roche Acquires Rights To Octreolin in $595m Deal</span>&nbsp;<br><span style="font-size: 12px;">Comment: Roche has entered into an agreement with Chiasma to develop and commercialise its proprietary oral octreotide formulation Octreolin for the treatment of acromegaly and NET.<wbr> The product is currently in phIII development for the treatment of acromegaly only.<wbr></span>&nbsp;&nbsp;<a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20130431&edate=20130101&rec=7265">...</a><br></div><div style="margin-bottom: 10px;">Very interesting info indeed.<wbr> </div><div>The Octreolin trial involves a lot of patients with Acromegaly condition, leading to a significant loss of patients in our market places.<wbr> Can we have the details of countries /<wbr> centers per country /<wbr> number of patients per country involved ? Can we estimate the duration for investigating these patients under octreoloin ? </div><!-- Comment details --><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20130431&edate=20130101&rec=7279">Add a Comment on this Article</a><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7265">View thread  Endocrinology7265: Roche Acquires Rights To Octreolin in $595m Deal</a>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-02-25T15:07:21+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-02-25T15:07:21+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category endocrinology > <![CDATA[Endocrinology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Allergan's Board Awards Pyott with Increased Compensation</title>
	<pubDate>2013-02-25T09:19:10+01:00</pubDate>
	<wp:post_id>4124</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Bloomberg reported that Pyott's compensation increased 51% in 2012 after Allergan awarded him almost $9.<wbr>4M in stock.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">An an SEC filing, Allergan said that the executive made $2.<wbr>1M, including the stock award, $1.<wbr>3M in salary, an almost $1.<wbr>7M cash bonus and $7M in options awards.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Allergan's Board noted that the award was part of a plan to keep Pyott with the company for at least 5 more years.<wbr> </div><div>Source: <A href="http://www.bloomberg.com/news/2013-02-22/allergan-ceo-s-pay-jumps-by-half-with-9-million-stock-award.html">Bloomberg</A> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20130431&edate=20130101&rec=6827">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-02-25T09:19:10+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-02-25T09:19:10+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Two Ph3 of Botox® Have Started in Japan for Aesthetic Indications</title>
	<pubDate>2013-02-22T17:05:13+01:00</pubDate>
	<wp:post_id>4125</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;"><P align="left" dir="ltr" style="MARGIN-RIGHT: 0px">Comment: Clinicaltrials.<wbr>gov is listing two new Ph3 trials assessing Botox® in aesthetic indications in Japan.<wbr> The trials will test the efficacy/<wbr>safety of different dosages (12U/<wbr>24U and 32U/<wbr>44U).<wbr> PE will assess the severity of CFLs at maximum smile using the facial wrinkle scale.<wbr> Both trials will recruit a total of approx.<wbr> 400 participants.<wbr> Additional details are provided below.<wbr></P> </div><div style="margin-bottom: 10px;"><P align="left" dir="ltr" style="MARGIN-RIGHT: 0px"><STRONG></STRONG><A href="http://clinicaltrials.gov/ct2/show/NCT01797081?recr=Open&amp;no_unk=Y&amp;phase=012&amp;fund=2&amp;rcv_s=01%2F22%2F2013&amp;rank=142"><STRONG></STRONG></A></P> </div><div style="margin-bottom: 10px;">The objective of the 4-arm randomized-controlled trial is to evaluate the safety and efficacy of Botox® (12U /<wbr> 24U) compared to placebo in approx 300 men and women with moderate to severe Crow's Feet Lines (CFLs).<wbr> </div><div style="margin-bottom: 10px;">Start date: Jan 2013 </div><div style="margin-bottom: 10px;">Completion dates: Feb 2014 - March 2015 </div><div style="margin-bottom: 10px;"><STRONG></STRONG><A href="http://clinicaltrials.gov/ct2/show/NCT01797094?recr=Open&amp;no_unk=Y&amp;phase=012&amp;fund=2&amp;rcv_s=01%2F22%2F2013&amp;rank=167"><STRONG></STRONG></A> </div><div style="margin-bottom: 10px;">The objective of the 2-arm randomized-controlled trial is to evaluate the safety and efficacy of Botox® (32U /<wbr> 44U) in approx 100 men and women with upper facial lines (Crow's Feet Lines and Frown Lines).<wbr> </div><div style="margin-bottom: 10px;">Start date: Feb 2013 </div><div>Completion dates: Feb 2014 - March 2015 </div><!-- Comment details --><a name="neurology6823attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6823_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(164,2 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20130431&edate=20130101&rec=6823">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-02-22T17:05:13+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-02-22T17:05:13+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>re: Roche Acquires Rights To Octreolin in $595m Deal</title>
	<pubDate>2013-02-22T15:53:16+01:00</pubDate>
	<wp:post_id>4126</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="border-left: 2px solid #8B1010; padding: 0px 0px 5px 12px; margin-bottom: 3px;"><span style="font-weight: bold; font-size: 14px;">Roche Acquires Rights To Octreolin in $595m Deal</span>&nbsp;<br><span style="font-size: 12px;">Comment: Roche has entered into an agreement with Chiasma to develop and commercialise its proprietary oral octreotide formulation Octreolin for the treatment of acromegaly and NET.<wbr> The product is currently in phIII development for the treatment of acromegaly only.<wbr></span>&nbsp;&nbsp;<a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20130431&edate=20130101&rec=7265">...</a><br></div><div style="margin-bottom: 10px;">Thanks to Kate Higgs (UK Medical Advisor) and a conversation she had with a UK endocrinologist participating in the Octreolin trial, we have learnt that Chiasma has been suggesting that the price of Octreolin should be higher than injectable therapy because of the "benefits" of oral administration.<wbr> This comment was not well received by the endocrinologist who perceived that such a price would cause funding and reimbursement issues.<wbr> </div><div style="margin-bottom: 10px;">The cost of goods associated with an oral therapy has always raised the possibility that the price of Octreolin would not be that low since the quantity of API required to achieve an acceptable level of bioavailability  is 200x the dose needed for injectable therapy.<wbr> </div><div>In addition to comments on price, the need for gastric acidity for the drug to be absorbed (i.<wbr>e.<wbr> it has to be taken on an empty stomach) and difficulties with co-administration with PPIs was also acknowledged but patients that have been treated with the drug have been positive about it.<wbr> </div><!-- Comment details --><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20130431&edate=20130101&rec=7276">Add a Comment on this Article</a><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7265">View thread  Endocrinology7265: Roche Acquires Rights To Octreolin in $595m Deal</a>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-02-22T15:53:16+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-02-22T15:53:16+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category endocrinology > <![CDATA[Endocrinology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Exelixis Expects Top-Line Post Chemt CRPC Data In 2014</title>
	<pubDate>2013-02-22T12:52:14+01:00</pubDate>
	<wp:post_id>4127</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Alongside yesterday's earnings figures, Exelixis announced that it has entered into a 3-year agreement with Swedish Orphan Biovitrum to commercialise Cabozantanib for medullary thyroid cancer in Europe.<wbr> </div><div style="margin-bottom: 10px;">No other indication is covered by the agreement, andExelixismaintains full commercial rights for COMETRIQ in MTC outside the covered territory and for all other indications on a global basis.<wbr> </div><div style="margin-bottom: 10px;">On November 29, 2012, Exelixisannounced that the EMA had accepted for review the MAA for COMETRIQ for the proposed indication of treatment of progressive, unresectable, locally advanced, or metastatic MTC.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Deal Terms</STRONG> </div><div style="margin-bottom: 10px;">Exelixis will continue to be responsible for regulatory approvals in the covered territory whilst Sobi will serve as the exclusive distributor of COMETRIQ in the covered territory </div><div style="margin-bottom: 10px;">Exelixis’ payments to Sobi include certain pre-determined fixed fees as well as potential performance based milestones related to the commercialization of the product in the covered territory.<wbr> </div><div style="margin-bottom: 10px;">Exelixis will book revenues based on product sold to Sobi.<wbr>Exelixishas the ability to terminate the agreement at will at any time upon payment of certain pre-determined fees.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Group Fourth Quarter &amp; F/<wbr>Y Financial Results</STRONG> </div><div style="margin-bottom: 10px;">Revenue for the quarter was $7.<wbr>8m and $47.<wbr>5m for the full year (lower than 2011 as a result of the wind-down of several collaborations).<wbr> Fourth quarter figures did not include any revenue for COMETRIQ as shipments only started in late January 2013.<wbr> </div><div style="margin-bottom: 10px;">R&amp;D expenses were $32.<wbr>5 million for the quarter and $128.<wbr>9m for the full year (down 18% for the full year reflecting the completion of the EXAM study in medullary thyroid).<wbr> </div><div style="margin-bottom: 10px;">The group ended the year with $634m in cash.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Progress With Clinical Development of Cabozantinib</STRONG> </div><div style="margin-bottom: 10px;">The two COMET trials in CRPC patients are progressing well with patient receruitment and enrollment in line with expectations.<wbr> Top-line data from both trials is expected in 2014.<wbr> COMET-1 end point is focused on overall survival whilst COMET-2 is on pain reduction.<wbr> </div><div style="margin-bottom: 10px;">Plans are also advanceing to evaluate cabozantinib in an earlier line of therapy of CRPC patients prior to chemotherapy.<wbr> It is working on the design of two phI/<wbr>II studies; one evaluating the combination of cabozantinib with enzalutamide and one evaluating the combination of cabozantinib with abiraterone.<wbr> These trials should start in 2H2013.<wbr> </div><div style="margin-bottom: 10px;">Beyond prostate the key priorities are the initiation of two planned phIII trials in RCC and HCC.<wbr> Both trials are expected to commence in Q32013.<wbr> </div><div style="margin-bottom: 10px;">The phIII RCC trial is being initiated based on the very promising data presented at ASCO in 2012 which demonstrated at PFS in heavily pretreated patients of 14.<wbr>7 months a figure which vastly exceeds that previously reported.<wbr> The study will compare cabozantinib against everolimus in patients who have received and progressed on one VEGFR tyrosine kinase inhibitor.<wbr> PE will be PFS.<wbr> </div><div style="margin-bottom: 10px;">The trial will include 664 patients has been powered based on the assumption of seeing a 5 month median PFS with everolimmus versus 7.<wbr>5 months with cabozantinib (i.<wbr>e.<wbr> a HR of 0.<wbr>67).<wbr> For the secondary endpoint of OS it is assumed that a 15 month OS will be seen with the everolimus arm and 20 months with cabozantinib.<wbr> </div><div style="margin-bottom: 10px;">The phIII HCC trial, by contrast, will be against placebo and conucted in 760 patients with advanced HCC across 200 sites.<wbr> Patients may have up to two prior systemic therapies and one of them must have been sorafenib.<wbr> The PE of the trial will be overall survival.<wbr> </div><div style="margin-bottom: 10px;">In addition to the above Exelixis has 20 ongoing or planned investigator sponsored studies and 13 studie under the IND associated with the CTEP programme.<wbr> </div><div>Source: <A href="http://www.exelixis.com/">www.<wbr>exelixis.<wbr>com</A> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20130431&edate=20130101&rec=8794">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-02-22T12:52:14+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-02-22T12:52:14+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Key Takeaways From Lexicon's Q4 and F12 Results</title>
	<pubDate>2013-02-22T08:58:05+01:00</pubDate>
	<wp:post_id>4128</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Lexicon has 5 clinical candidates in Ph2 and Ph3 development and all have shown initial human proofof- concept efficacy in Ph2.<wbr> Management started by reporting that 2012 was dominated by the positive results of its Ph2b trial of LX4211 (type 2 diabetes), and the initiation of the first Ph3 with LX1032 (telotristat etiprate) in carcinoid syndrome (data unlikely before H2:14 at the earliest).<wbr> Lexicon is exploring alternative indications for LX-2931 given the evolving RA competitive landscape, and is reformulating LX-7101 (glaucoma).<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Management reported it is on track 'to initiate Ph3 with a corporate partner in 2013.<wbr>' ' .<wbr>.<wbr>.<wbr> we are looking for a partnership where we think we can fund the program out of the partnership, and so that is something that we -- that is one of the objectives that we're seeking.<wbr> And we do want to have a significant level of involvement in the program as well, but those are some of the objectives that we have for that partnership process'.<wbr> </div><div style="margin-bottom: 10px;">- study ongoing in 20 patients with type 2 diabetes and moderate renal impairment with results planned for H1:13.<wbr> </div><div style="margin-bottom: 10px;">- combination with insulin for type 1 diabetes: 33 patients planned for recruitment.<wbr>  28-day study.<wbr> Results expected Q4:13.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><U>Ulcerative Colitis</U> </div><div style="margin-bottom: 10px;">Ongoing Ph2: recruitment of approx 60 patients with mild to moderate UC to be complete in Q2:13.<wbr> </div><div style="margin-bottom: 10px;"><U>Carcinoid Syndrome</U> </div><div style="margin-bottom: 10px;">Design of the Ph3: single pivotal study with 12 wks of placebo control and then after have patients in open label extension.<wbr> Dosage: placebo 250mg 3 times daily of telotristat, and 500mg 3 times daily of telotristat - Recruitment: approx 150 Sites: in process of getting sites (EU; US; Australia).<wbr> </div><div style="margin-bottom: 10px;">Management indicated they have planned to 'complete enrollment by Q2 of 2014, and if we're able to achieve that, then we should have results towards Q3 or Q4 of 2014.<wbr> That's an aggressive goal, we think we can do it.<wbr> That's why we're pushing hard on site initiations and enrollment.<wbr>" </div><div style="margin-bottom: 10px;"><STRONG>Analysts Views</STRONG> </div><div style="margin-bottom: 10px;">Morgan Stanley 'see the commercial opportunity as relatively limited given a small carcinoid syndrome population, relatively well treated with generic octreotide'.<wbr> </div><div style="margin-bottom: 10px;">Wedbush Securities 'estimate LX1032 for carcinoid syndrome may be launched in 2015 with gross sales reaching over $400 million in 2020'.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">A 360 patient Ph2 study - Fast-track status from the FDA.<wbr> Trial completion anticipated in Q3:13.<wbr> PE to assess stool consistency, and combined endpoint with abdominal pain.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;">The target of LX7101 is a kinase regulating IOP--LIM domain kinase 2 (LIMK2).<wbr> The goal for LX7101 is to become a once daily eye drop with a novel mechanism complementary to many marketed treatments for glaucoma.<wbr> The target of LX7101 is a kinase that is responsible for regulating intraocular pressure.<wbr> LX7101 is intended to lower IOP by enhancing the fluid outflow facility of the eye.<wbr> The goal of the LX7101 program is to develop a once-daily eye drop that lowers IOP by increasing the fluid outflow facility in the eye, a novel mechanism not currently addressed by approved products for glaucoma.<wbr> </div><div style="margin-bottom: 10px;">The company filed an IND in Q4:11 and shortly afterwards initiated a Phase 1/<wbr>2 proof-of-concept, first-in-man study to test safety, tolerability, and efficacy.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">In Q4/<wbr>FY:12, Lexicon reported $0.<wbr>2/<wbr>$1.<wbr>1 million in revenues and GAAP EPS (loss) of $(0.<wbr>05)/<wbr>$(0.<wbr>23), respectively.<wbr> </div><div>The company ended 2012 with about $223.<wbr>2 million in cash.<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20130431&edate=20130101&rec=7274">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-02-22T08:58:05+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-02-22T08:58:05+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category endocrinology > <![CDATA[Endocrinology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>re: Confirmatory Ph3 of Hugel's BoTXA for Essential Blepharospasm (EB) Has Completed in Korea</title>
	<pubDate>2013-02-22T03:34:25+01:00</pubDate>
	<wp:post_id>4129</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="border-left: 2px solid #8B1010; padding: 0px 0px 5px 12px; margin-bottom: 3px;"><span style="font-weight: bold; font-size: 14px;">re: Confirmatory Ph3 of Hugel's BoTXA for Essential Blepharospasm (EB) Has Completed in Korea</span>&nbsp;<br><span style="font-size: 12px;">Botulax seems to already have blepharospasm as the registered indication.<wbr> This Phase 3 would reinforce the dossier?</span>&nbsp;<br></div><div style="margin-bottom: 10px;">Anne-Gaelle is right.<wbr> As I check it out through KFDA, Hugel's botulinum Toxin A " Botulax " got BE approval as a registered indication from KFDA as of March 17, 2010.<wbr> </div><div style="margin-bottom: 10px;">There is no recent clinical study for EB completed these days.<wbr> </div><div>However, Hugel has been doing phase III study for CP in Korea to add new indication since mid of 2012 and will finish within 2013.<wbr> </div><!-- Comment details --><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20130431&edate=20130101&rec=6817">Add a Comment on this Article</a><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology6810">View thread  Neurology6810: Confirmatory Ph3 of Hugel's BoTXA for Essential Blepharospasm (EB) Has Completed in Korea</a>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-02-22T03:34:25+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-02-22T03:34:25+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Companion Biomarker Partnership to Advance Therapeutic Development for Huntington's Disease</title>
	<pubDate>2013-02-21T18:53:36+01:00</pubDate>
	<wp:post_id>4130</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: KineMed, Isis and CHDI will develop novel biomarkers for pre-clinical and clinical use in drug development and therapeutic monitoring.<wbr> I<SPAN style="WIDOWS: 2; TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; DISPLAY: inline !important; FONT: 13px arial, sans-serif; WHITE-SPACE: normal; ORPHANS: 2; FLOAT: none; LETTER-SPACING: normal; COLOR: rgb(34,34,34); WORD-SPACING: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"></SPAN><SPAN style="WIDOWS: 2; TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; DISPLAY: inline !important; FONT: 13px arial, sans-serif; WHITE-SPACE: normal; ORPHANS: 2; FLOAT: none; LETTER-SPACING: normal; COLOR: rgb(34,34,34); WORD-SPACING: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"></SPAN> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">The collaboration will use KineMed's translational biomarker platform with Isis' antisense therapeutic program for Huntington's disease (HD).<wbr> This collaboration, which builds on an earlier alliance between CHDI and KineMed to develop companion biomarkers of therapeutic response in HD, will provide Isis access to novel biomarkers for use in the development of an antisense drug to treat HD.<wbr> </div><div>KineMed's neurodegeneration biomarker of axonal transport deficit has been recently published in the Journal of Clinical Investigation and validated in patients with other neurological disorders: (<A href="http://www.jci.org/articles/view/64575">http:/<wbr>/<wbr>www.<wbr>jci.<wbr>org/<wbr>articles/<wbr>view/<wbr>64575</A>).<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20130431&edate=20130101&rec=6816">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-02-21T18:53:36+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-02-21T18:53:36+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Dana-Farber to Conduct Trial of Ziv-aflibercept + Octreotide LAR for Carcinoid Tumours</title>
	<pubDate>2013-02-21T18:23:50+01:00</pubDate>
	<wp:post_id>4131</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Ziv-aflibercept (a VEGF Trap) has recently been approved for patients with treatment-resistant colorectal cancer.<wbr> This Ph2 study will assess the combination to see if it slows the growth or spread of the disease.<wbr> PE will assess PFS.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG><A href="http://clinicaltrials.gov/ct2/show/NCT01782443?recr=Open&amp;no_unk=Y&amp;phase=012&amp;safe=Y&amp;rcv_s=01%2F21%2F2013&amp;rank=211"><STRONG></STRONG></A> </div><div style="margin-bottom: 10px;">Recruitment: approx 43 </div><div style="margin-bottom: 10px;"><P style="MARGIN-TOP: 0ex; MARGIN-BOTTOM: 1ex">Inclusion Criteria:</P> </div><div style="margin-bottom: 10px;"><UL style="MARGIN-TOP: 1ex; MARGIN-BOTTOM: 1ex"><LI class="color-bullet" style="MARGIN-TOP: 0.7ex">Histologically confirmed well differentiated or moderately differentiated neuroendocrine tumor from either a primary or metastatic site</LI>
<LI class="color-bullet" style="MARGIN-TOP: 0.7ex">Must have disease that is not amenable to curative resection</LI>
<LI class="color-bullet" style="MARGIN-TOP: 0.7ex">Must have evidence of disease progression within 12 months prior to study entry</LI>
<LI class="color-bullet" style="MARGIN-TOP: 0.7ex">Must have measurable disease (RECIST 1.<wbr>1)</LI>
<LI class="color-bullet" style="MARGIN-TOP: 0.7ex">Prior chemoembolization of local ablative therapies are allowed, provided there is measurable disease outside of the area treated, or documented evidence of progression at the site of prior treatment</LI>
<LI class="color-bullet" style="MARGIN-TOP: 0.7ex">No limit to number of prior treatments.<wbr> Prior bevacizumab allowed unless discontinued due to unacceptable toxicity.<wbr> Prior TKI targeting VEGF receptors allowed</LI>
<LI class="color-bullet" style="MARGIN-TOP: 0.7ex">Treatment with a somatostatin analog required for all subjects</LI>
<LI class="color-bullet" style="MARGIN-TOP: 0.7ex">Subjects with history of hypertension must be adequately controlled</LI>
<LI class="color-bullet" style="MARGIN-TOP: 0.7ex">Therapeutic anticoagulation is allowed.<wbr> Must be on a stable dose of anticoagulant medication</LI>
<LI class="color-bullet" style="MARGIN-TOP: 0.7ex">Must agree to use adequate contraception prior to study entry, for the duration of study participation and for 3 months after last administration of study drug.<wbr></LI>
</UL> </div><div style="margin-bottom: 10px;">
Start date: March 2013 - Completion date: March 2015 </div><div>Location: USA (3 sites) </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20130431&edate=20130101&rec=7273">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-02-21T18:23:50+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-02-21T18:23:50+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category endocrinology > <![CDATA[Endocrinology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Novel Peptide Based Therapeutic Vaccine Has Entered Ph1/Ph2a for Prostate Cancer</title>
	<pubDate>2013-02-21T18:05:10+01:00</pubDate>
	<wp:post_id>4132</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Ultimovacs' vaccine consists of a mix of peptides which are fragments of the enzyme telomerase expressed by cancer cells allowing them to divide endlessly.<wbr> In this study, &gt;21 patients with metastatic prostate cancer will receive UV1 at different dose levels.<wbr> PE will assess safety and tolerability.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG><A href="http://clinicaltrials.gov/ct2/show/NCT01784913?recr=Open&amp;no_unk=Y&amp;phase=012&amp;safe=Y&amp;rcv_s=01%2F21%2F2013&amp;rank=12"><STRONG></STRONG></A> </div><div style="margin-bottom: 10px;"><P style="MARGIN-TOP: 0ex; MARGIN-BOTTOM: 1ex">Inclusion Criteria:</P> </div><div style="margin-bottom: 10px;"><UL style="MARGIN-TOP: 1ex; MARGIN-BOTTOM: 1ex"><LI class="color-bullet" style="MARGIN-TOP: 0.7ex">Patients with advanced oligometastatic prostate cancer (PCa) without lung and/<wbr>or liver metastases who are eligible to CAB (GnRH-agonist combined with anti-androgen)</LI>
<LI class="color-bullet" style="MARGIN-TOP: 0.7ex">Patients already on GnRH-agonist must have a history sPSA &lt; 200 ng/<wbr>mL prior to start of GnRH-agonist treatment.<wbr> GnRH-agonist with or without bicalutamide can have been initiated up to 6 months prior inclusion.<wbr></LI>
<LI class="color-bullet" style="MARGIN-TOP: 0.7ex">Must be ambulatory with an ECOG performance status of 0 or 1 and not have contraindications for MRI (pacemaker, claustrophobia, metal splints).<wbr></LI>
<LI class="color-bullet" style="MARGIN-TOP: 0.7ex">Must be at least 18 years of age.<wbr></LI>
<LI class="color-bullet" style="MARGIN-TOP: 0.7ex">
Must have lab values as follows:
<UL style="MARGIN-TOP: 1ex; MARGIN-BOTTOM: 1ex"><LI class="color-bullet" style="MARGIN-TOP: 0.7ex">White Blood Cells ≥ 1.<wbr>5 x 109/<wbr>L</LI>
<LI class="color-bullet" style="MARGIN-TOP: 0.7ex">Platelets ≥ 100 x 109/<wbr>L</LI>
<LI class="color-bullet" style="MARGIN-TOP: 0.7ex">Hemoglobin ≥ 9g/<wbr>dL (≥ 5.<wbr>6 mmol/<wbr>L)</LI>
<LI class="color-bullet" style="MARGIN-TOP: 0.7ex">Creatinine ≤ 140 µmol/<wbr>L; if creatinine is borderline, the creatinine clearance ≥ 40 mL/<wbr>min;</LI>
<LI class="color-bullet" style="MARGIN-TOP: 0.7ex">Bilirubin &lt; 20% above the upper limit of normal</LI>
<LI class="color-bullet" style="MARGIN-TOP: 0.7ex">ASAT and ALAT ≤ 1.<wbr>5 the upper limit of normal</LI>
<LI class="color-bullet" style="MARGIN-TOP: 0.7ex">Albumin ≥ 2.<wbr>5 g/<wbr>L</LI>
<LI class="color-bullet" style="MARGIN-TOP: 0.7ex">Normal NSE</LI>
<LI class="color-bullet" style="MARGIN-TOP: 0.7ex">sPSA &lt; 200 ng/<wbr>mL.<wbr></LI>
</UL></LI>
</UL> </div><div style="margin-bottom: 10px;">
Start date Feb 2013 - Completion date: Jan 2015 </div><div style="margin-bottom: 10px;">Location: Oslo, Norway </div><div>PI: Wolfgang Lilleby, MD PhD Oslo U.<wbr> Hospital </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20130431&edate=20130101&rec=8792">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-02-21T18:05:10+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-02-21T18:05:10+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>New Indications Approved for Botox in Italy</title>
	<pubDate>2013-02-21T16:29:49+01:00</pubDate>
	<wp:post_id>4133</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Thanks to Patrizia Caglioni (PM), we have learnt that Botox has been approved for NDO and migraine.<wbr> Allergan may increase the FTEs to 12/<wbr>14 from 7 effective at the beginning of next month.<wbr> Of note, Merz is recruiting Italian center(s) to conduct an international pivotal study on CP.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Marketing authorization for the medicinal product for human use "Botox.<wbr>" (13A01015) (OJ n.<wbr> 35 of 11.<wbr>02.<wbr>2013 - Ordinary Suppl.<wbr> 10) </STRONG><STRONG>Retrieved determination no.<wbr> 68/<wbr>2013 of 23 January 2013</STRONG> </div><div style="margin-bottom: 10px;">Reimbursement scheme and price as a result of new therapeutic indications for BOTOX (Botulinum Toxin Type A).<wbr> </div><div style="margin-bottom: 10px;">- Urinary incontinence in adults with neurogenic detrusor overactivity resulting from neurogenic bladder due to stable sub cervical spinal injury or to multiple sclerosis.<wbr> </div><div style="margin-bottom: 10px;">- Symptoms relief in adults fulfilling the diagnostic criteria for chronic migraine (headaches on ≥ 15 days per month of which at least 8 days with migraine) in patients who have responded inadequately response or are intolerant to prophylactic migraine medications.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Classification for reimbursement</STRONG> </div><div style="margin-bottom: 10px;"><DIV dir="ltr" style="WIDOWS: 2; TEXT-TRANSFORM: none; BACKGROUND-COLOR: #ffffff; TEXT-INDENT: 0px; ZOOM: 1; FONT: 13px arial, sans-serif; WHITE-SPACE: normal; ORPHANS: 2; LETTER-SPACING: normal; COLOR: #222222; WORD-SPACING: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"></DIV> </div><div style="margin-bottom: 10px;"><DIV dir="ltr" style="WIDOWS: 2; TEXT-TRANSFORM: none; BACKGROUND-COLOR: #ffffff; TEXT-INDENT: 0px; ZOOM: 1; FONT: 13px arial, sans-serif; WHITE-SPACE: normal; ORPHANS: 2; LETTER-SPACING: normal; COLOR: #222222; WORD-SPACING: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"></DIV> </div><div style="margin-bottom: 10px;">Packaging: 100 units Allergan powder for solution injection »1 vial - M.<wbr>A.<wbr>H.<wbr> n.<wbr> 034883013 /<wbr> M (in base 10) 118KG5 (Under 32) - Class of eligibility H.<wbr> </div><div style="margin-bottom: 10px;">Ex-factory price (excluding VAT) € 142.<wbr>99.<wbr> </div><div>Retail price (including VAT) € 235.<wbr>99.<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20130431&edate=20130101&rec=6814">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-02-21T16:29:49+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-02-21T16:29:49+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>re: Confirmatory Ph3 of Hugel's BoTXA for Essential Blepharospasm (EB) Has Completed in Korea</title>
	<pubDate>2013-02-21T10:23:18+01:00</pubDate>
	<wp:post_id>4134</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="border-left: 2px solid #8B1010; padding: 0px 0px 5px 12px; margin-bottom: 3px;"><span style="font-weight: bold; font-size: 14px;">Confirmatory Ph3 of Hugel's BoTXA for Essential Blepharospasm (EB) Has Completed in Korea</span>&nbsp;<br><span style="font-size: 12px;">Comment: The objective of this trial was to compare the efficacy and safety of Hugel's botulinum toxin A against Botox in the treatment of EB, and to get a regulatory approval from KFDA.<wbr></span>&nbsp;&nbsp;<a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20130431&edate=20130101&rec=6810">...</a><br></div><div>Its a relatively small study - I would'nt have thought they'd be enough patients to statistically show non-inferiority, therefore not sure if it has a regulatory purpose.<wbr> A quick look at clintrial.<wbr>gov showed anther Korean toxin did a similar thing with an even smaller study (60 patients - NCT00682760 KbtxA, Pacific Pharmaceuticals, Korea) - will check to see if LRA are aware of any sort of local requirement ? </div><!-- Comment details --><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20130431&edate=20130101&rec=6813">Add a Comment on this Article</a><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology6810">View thread  Neurology6810: Confirmatory Ph3 of Hugel's BoTXA for Essential Blepharospasm (EB) Has Completed in Korea</a>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-02-21T10:23:18+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-02-21T10:23:18+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>re: Confirmatory Ph3 of Hugel's BoTXA for Essential Blepharospasm (EB) Has Completed in Korea</title>
	<pubDate>2013-02-20T14:44:00+01:00</pubDate>
	<wp:post_id>4135</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="border-left: 2px solid #8B1010; padding: 0px 0px 5px 12px; margin-bottom: 3px;"><span style="font-weight: bold; font-size: 14px;">Confirmatory Ph3 of Hugel's BoTXA for Essential Blepharospasm (EB) Has Completed in Korea</span>&nbsp;<br><span style="font-size: 12px;">Comment: The objective of this trial was to compare the efficacy and safety of Hugel's botulinum toxin A against Botox in the treatment of EB, and to get a regulatory approval from KFDA.<wbr></span>&nbsp;&nbsp;<a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20130431&edate=20130101&rec=6810">...</a><br></div><div>Botulax seems to already have blepharospasm as the registered indication.<wbr> This Phase 3 would reinforce the dossier? </div><!-- Comment details --><br><span style="font-weight: bold; font-style: italic;"><br>Comments</span><a name="Neurology6817c"></a><br><div style="border: 1px solid #AAA; background-color: #FFF; margin-left: 10px; padding: 5px;"><div style="margin-bottom: 10px;">Anne-Gaelle is right.<wbr> As I check it out through KFDA, Hugel's botulinum Toxin A " Botulax " got BE approval as a registered indication from KFDA as of March 17, 2010.<wbr> </div><div style="margin-bottom: 10px;">There is no recent clinical study for EB completed these days.<wbr> </div><div>However, Hugel has been doing phase III study for CP in Korea to add new indication since mid of 2012 and will finish within 2013.<wbr> </div></div><a name="Neurology6830c"></a><div style="border: 1px solid #AAA; background-color: #FFF; margin-left: 10px; padding: 5px;"><div style="margin-bottom: 10px;">I found a study in clintrialtrials.<wbr>gov run in EB N<A href="http://clinicaltrials.gov/ct2/show/NCT01791881?term=01791881&amp;rank=1">CT01791881 </A>which is a confirmatory Phase 3.<wbr> Endpoints and duration of the trial would likely not support registration in the USA when compared to the recent approval of Xeomin in this country.<wbr> </div><div>Their strategy is maybe to gain registration in Latin America? </div></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20130431&edate=20130101&rec=6812">Add a Comment on this Article</a><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology6810">View thread  Neurology6810: Confirmatory Ph3 of Hugel's BoTXA for Essential Blepharospasm (EB) Has Completed in Korea</a>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-02-20T14:44:00+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-02-20T14:44:00+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Confirmatory Ph3 of Hugel's BoTXA for Essential Blepharospasm (EB) Has Completed in Korea</title>
	<pubDate>2013-02-19T18:24:33+01:00</pubDate>
	<wp:post_id>4136</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: The objective of this trial was to compare the efficacy and safety of Hugel's botulinum toxin A against Botox in the treatment of EB, and to get a regulatory approval from KFDA.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG><A href="http://clinicaltrials.gov/ct2/show/NCT01791881?phase=012&amp;fund=2&amp;rcv_s=01%2F19%2F2013&amp;rank=147"><STRONG></STRONG></A> </div><div style="margin-bottom: 10px;">Recruitment: approx 172 </div><div><UL style="MARGIN-TOP: 1ex; MARGIN-BOTTOM: 1ex"><LI class="color-bullet" style="MARGIN-TOP: 0.7ex">Adult between ages 18 and 75 years</LI>
<LI class="color-bullet" style="MARGIN-TOP: 0.7ex">All patients, diagnosed of essential blepharospasm, with Grade 2~4 of Severity of Spmasm (by Scott's Method).<wbr></LI>
</UL> </div><!-- Comment details --><span style="font-weight: bold; font-style: italic;"><br>Comments</span><a name="Neurology6812c"></a><br><div style="border: 1px solid #AAA; background-color: #FFF; margin-left: 10px; padding: 5px;"><div>Botulax seems to already have blepharospasm as the registered indication.<wbr> This Phase 3 would reinforce the dossier? </div><span style="font-weight: bold; font-style: italic;"></span><a name="Neurology6817c"></a><br><div style="border: 1px solid #AAA; background-color: #FFF; margin-left: 10px; padding: 5px;"><div style="margin-bottom: 10px;">Anne-Gaelle is right.<wbr> As I check it out through KFDA, Hugel's botulinum Toxin A " Botulax " got BE approval as a registered indication from KFDA as of March 17, 2010.<wbr> </div><div style="margin-bottom: 10px;">There is no recent clinical study for EB completed these days.<wbr> </div><div>However, Hugel has been doing phase III study for CP in Korea to add new indication since mid of 2012 and will finish within 2013.<wbr> </div></div><a name="Neurology6830c"></a><div style="border: 1px solid #AAA; background-color: #FFF; margin-left: 10px; padding: 5px;"><div style="margin-bottom: 10px;">I found a study in clintrialtrials.<wbr>gov run in EB N<A href="http://clinicaltrials.gov/ct2/show/NCT01791881?term=01791881&amp;rank=1">CT01791881 </A>which is a confirmatory Phase 3.<wbr> Endpoints and duration of the trial would likely not support registration in the USA when compared to the recent approval of Xeomin in this country.<wbr> </div><div>Their strategy is maybe to gain registration in Latin America? </div></div></div><a name="Neurology6813c"></a><div style="border: 1px solid #AAA; background-color: #FFF; margin-left: 10px; padding: 5px;"><div>Its a relatively small study - I would'nt have thought they'd be enough patients to statistically show non-inferiority, therefore not sure if it has a regulatory purpose.<wbr> A quick look at clintrial.<wbr>gov showed anther Korean toxin did a similar thing with an even smaller study (60 patients - NCT00682760 KbtxA, Pacific Pharmaceuticals, Korea) - will check to see if LRA are aware of any sort of local requirement ? </div></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20130431&edate=20130101&rec=6810">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-02-19T18:24:33+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-02-19T18:24:33+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>ASCO GU - Key Intelligence On Enzalutamide</title>
	<pubDate>2013-02-19T12:13:03+01:00</pubDate>
	<wp:post_id>4137</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;"><SPAN lang="EN-US" style="FONT-FAMILY: 'Arial','sans-serif'; FONT-SIZE: 11pt"></SPAN> </div><div style="margin-bottom: 10px;"><SPAN lang="EN-US" style="FONT-FAMILY: 'Arial','sans-serif'; FONT-SIZE: 11pt"></SPAN> </div><div style="margin-bottom: 10px;"><B style="mso-bidi-font-weight: normal"><SPAN lang="EN-US" style="FONT-FAMILY: 'Arial','sans-serif'; FONT-SIZE: 11pt">Enzalutimide</SPAN></B> </div><div style="margin-bottom: 10px;"><B style="mso-bidi-font-weight: normal"><SPAN lang="EN-US" style="FONT-FAMILY: 'Arial','sans-serif'; FONT-SIZE: 11pt">Impact of on-study corticosteroid use on efficacy and safety in the phase III AFFIRM study of enzalutamide</SPAN></B> </div><div style="margin-bottom: 10px;"><SPAN lang="EN-US" style="FONT-FAMILY: 'Arial','sans-serif'; FONT-SIZE: 11pt">A growing body of evidence suggests that corticosteroids may stimulate prostate cancer growth.<wbr> A variety of mechanisms have been proposed: </SPAN> </div><div style="margin-bottom: 10px;"><SPAN lang="EN-US" style="FONT-FAMILY: Wingdings; FONT-SIZE: 11pt; mso-fareast-font-family: Wingdings; mso-bidi-font-family: Wingdings"><SPAN style="mso-list: Ignore">§ </SPAN></SPAN><SPAN lang="EN-US" style="FONT-FAMILY: 'Arial','sans-serif'; FONT-SIZE: 11pt">Activating promiscuous ARs</SPAN> </div><div style="margin-bottom: 10px;"><SPAN lang="EN-US" style="FONT-FAMILY: Wingdings; FONT-SIZE: 11pt; mso-fareast-font-family: Wingdings; mso-bidi-font-family: Wingdings"><SPAN style="mso-list: Ignore">§ </SPAN></SPAN><SPAN lang="EN-US" style="FONT-FAMILY: 'Arial','sans-serif'; FONT-SIZE: 11pt">Stimulating human SGK1 gene expression</SPAN> </div><div style="margin-bottom: 10px;"><SPAN lang="EN-US" style="FONT-FAMILY: Wingdings; FONT-SIZE: 11pt; mso-fareast-font-family: Wingdings; mso-bidi-font-family: Wingdings"><SPAN style="mso-list: Ignore">§ </SPAN></SPAN><SPAN lang="EN-US" style="FONT-FAMILY: 'Arial','sans-serif'; FONT-SIZE: 11pt">Promoting expression of IL-6</SPAN> </div><div style="margin-bottom: 10px;"><SPAN lang="EN-US" style="FONT-FAMILY: Wingdings; FONT-SIZE: 11pt; mso-fareast-font-family: Wingdings; mso-bidi-font-family: Wingdings"><SPAN style="mso-list: Ignore">§ </SPAN></SPAN><SPAN lang="EN-US" style="FONT-FAMILY: 'Arial','sans-serif'; FONT-SIZE: 11pt">Activating GR signaling</SPAN> </div><div style="margin-bottom: 10px;"><SPAN lang="EN-US" style="FONT-FAMILY: 'Arial','sans-serif'; FONT-SIZE: 11pt">As such, the investigators of the AFFIRM (post-chemo) study hypothesized that corticosteroid use may adversely affect survival.<wbr> </SPAN> </div><div style="margin-bottom: 10px;"><SPAN lang="EN-US" style="FONT-FAMILY: 'Arial','sans-serif'; FONT-SIZE: 11pt">An unplanned, post-hoc analysis exploring the relationship of corticosteroid use to survival and if potentially associated, whether patients still benefit from enzalutimde is detailed in the following slides.<wbr> </SPAN> </div><div style="margin-bottom: 10px;"><SPAN lang="EN-US" style="FONT-FAMILY: 'Arial','sans-serif'; FONT-SIZE: 11pt">In the P3 AFFIRM study, corticosteroids were permitted at entry but not required.<wbr> Results showed a prolonged survival median of 4.<wbr>8 months, translating into a 37% reduction in risk of death.<wbr></SPAN> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8790_1_ScreenCapture1.jpg"> </div><div style="margin-bottom: 10px;"><SPAN lang="EN-US" style="FONT-FAMILY: 'Arial','sans-serif'; FONT-SIZE: 11pt">In the P3 AFFIRM trial, baseline corticosteroid use was associated with an inferior OS independent of study treatment</SPAN> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8790_2_ScreenCapture2.jpg"> </div><div style="margin-bottom: 10px;"><SPAN lang="EN-US" style="FONT-FAMILY: 'Arial','sans-serif'; FONT-SIZE: 11pt">Corticosteroid use varied widely in AFFIRM from some pts receiving none at all, some pts came on at baseline and some added corticosteroids while on study.<wbr> </SPAN> </div><div style="margin-bottom: 10px;"><SPAN lang="EN-US" style="FONT-FAMILY: 'Arial','sans-serif'; FONT-SIZE: 11pt">In total, 30% of pts were on corticosteroids at study start and all patients had received corticosteroid along side first line docetaxel </SPAN> </div><div style="margin-bottom: 10px;"><P style="MARGIN: 0cm 0cm 0pt"><SPAN lang="EN-US" style="FONT-FAMILY: 'Arial','sans-serif'; FONT-SIZE: 11pt">The following slides detail the output from baseline use at study entry.<wbr></SPAN></P> </div><div style="margin-bottom: 10px;"><SPAN lang="EN-US" style="FONT-FAMILY: 'Arial','sans-serif'; FONT-SIZE: 11pt; mso-no-proof: yes">Statistical methods for the post-hoc analysis were applied</SPAN> </div><div style="margin-bottom: 10px;"><SPAN lang="EN-US" style="FONT-FAMILY: 'Arial','sans-serif'; FONT-SIZE: 11pt"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8790_3_ScreenCapture3.jpg"> </SPAN> </div><div style="margin-bottom: 10px;"><SPAN lang="EN-US" style="FONT-FAMILY: 'Arial','sans-serif'; FONT-SIZE: 11pt">A number of factors were pre-specified to develop a multivariate model for the question</SPAN> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8790_4_ScreenCapture4.jpg"> </div><div style="margin-bottom: 10px;"><SPAN lang="EN-US" style="FONT-FAMILY: 'Arial','sans-serif'; FONT-SIZE: 11pt">The multivariate analysis suggests that baseline corticosteroid use is an independent predictor of OS.<wbr> </SPAN> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8790_5_ScreenCapture5.jpg"> </div><div style="margin-bottom: 10px;"><SPAN lang="EN-US" style="FONT-FAMILY: 'Arial','sans-serif'; FONT-SIZE: 11pt; mso-fareast-font-family: 'MS Mincho'; mso-fareast-theme-font: minor-fareast; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA">A summary of the post-hoc analysis of baseline corticosteroid use in AFFIRM is addressed below: </SPAN> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8790_6_ScreenCapture6.jpg"> </div><div style="margin-bottom: 10px;"><SPAN lang="EN-US" style="FONT-FAMILY: 'Arial','sans-serif'; FONT-SIZE: 11pt">Next, the speaker reviewed the relation of baseline use as well as on study use of corticosteroids in relations to survival<SPAN style="mso-no-proof: yes">.<wbr> </SPAN>These patients had corticosteroids added at some point during the study.<wbr> 47% were on for 6+ months, 59% for 3+ months.<wbr> Overall, this represents an increase of 16% of the patient population.<wbr></SPAN> </div><div style="margin-bottom: 10px;"><SPAN lang="EN-US" style="FONT-FAMILY: 'Arial','sans-serif'; FONT-SIZE: 11pt"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8790_7_ScreenCapture7.jpg"></SPAN> </div><div style="margin-bottom: 10px;"><SPAN lang="EN-US" style="FONT-FAMILY: 'Arial','sans-serif'; FONT-SIZE: 11pt">The frequency and type of corticosteroid used was similar between the two groups of which prednisone and dexamethasone were the most common.<wbr> Pts who received corticosteroids were generally sicker and had more advanced disease.<wbr></SPAN> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8790_8_ScreenCapture8.jpg"> </div><div style="margin-bottom: 10px;"><P style="MARGIN: 0cm 0cm 0pt"><SPAN lang="EN-US" style="FONT-FAMILY: 'Arial','sans-serif'; FONT-SIZE: 11pt">Patients receiving corticosteroids had worse survival times and progressed more rapidly</SPAN></P> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8790_9_ScreenCapture9.jpg"> </div><div style="margin-bottom: 10px;"><SPAN lang="EN-US" style="FONT-FAMILY: 'Arial','sans-serif'; FONT-SIZE: 11pt">Survival times, rPFS and time to PSA progression with enzalutimide were superior to placebo in both the no corticosteroid and corticosteroid treated groups </SPAN> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8790_10_ScreenCapture10.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8790_11_ScreenCapture11.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8790_12_ScreenCapture12.jpg"> </div><div style="margin-bottom: 10px;"><SPAN lang="EN-US" style="FONT-FAMILY: 'Arial','sans-serif'; FONT-SIZE: 11pt">Use of corticosteroids on study was associated with more pts reporting grade 3-4 adverse events relative to the no corticosteroid group </SPAN> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8790_13_ScreenCapture13.jpg"> </div><div style="margin-bottom: 10px;">To conclude:- </div><div><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8790_14_ScreenCapture14.jpg"> </div><!-- Comment details --><a name="oncology8790attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8790_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(77,2 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8790_2_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(84 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8790_3_ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(47,8 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8790_4_ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(89 KB)<br>&nbsp;&nbsp;5.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8790_5_ScreenCapture5.jpg">ScreenCapture5.jpg</a>&nbsp;&nbsp;(93,7 KB)<br>&nbsp;&nbsp;6.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8790_6_ScreenCapture6.jpg">ScreenCapture6.jpg</a>&nbsp;&nbsp;(82,3 KB)<br>&nbsp;&nbsp;7.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8790_7_ScreenCapture7.jpg">ScreenCapture7.jpg</a>&nbsp;&nbsp;(98,1 KB)<br>&nbsp;&nbsp;8.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8790_8_ScreenCapture8.jpg">ScreenCapture8.jpg</a>&nbsp;&nbsp;(116,1 KB)<br>&nbsp;&nbsp;9.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8790_9_ScreenCapture9.jpg">ScreenCapture9.jpg</a>&nbsp;&nbsp;(89,3 KB)<br>&nbsp;&nbsp;10.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8790_10_ScreenCapture10.jpg">ScreenCapture10.jpg</a>&nbsp;&nbsp;(124,2 KB)<br>&nbsp;&nbsp;11.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8790_11_ScreenCapture11.jpg">ScreenCapture11.jpg</a>&nbsp;&nbsp;(130,8 KB)<br>&nbsp;&nbsp;12.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8790_12_ScreenCapture12.jpg">ScreenCapture12.jpg</a>&nbsp;&nbsp;(117,2 KB)<br>&nbsp;&nbsp;13.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8790_13_ScreenCapture13.jpg">ScreenCapture13.jpg</a>&nbsp;&nbsp;(82,4 KB)<br>&nbsp;&nbsp;14.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8790_14_ScreenCapture14.jpg">ScreenCapture14.jpg</a>&nbsp;&nbsp;(102,2 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20130431&edate=20130101&rec=8790">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-02-19T12:13:03+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-02-19T12:13:03+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>New Therapeutic Target in Prostate Cancer</title>
	<pubDate>2013-02-19T12:01:40+01:00</pubDate>
	<wp:post_id>4138</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Dr Ramesh Narayanan (Director, Drug Discovery for GTx Inc) presented preclinical data indicating that AKR1C3, a steroidogenic enzyme, is an androgen receptor-selective coactivator and promoter of growth in prostate cancer cells and CRPC, and may present the 1st nuclear hormone receptor coactivator that can be pharmacologocally targeted in the treatment of advanced prostate cancer.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>ASCO GU Presentation</STRONG> (Feb 14 2013) Abstract ID 100 </div><div style="margin-bottom: 10px;">CRPC may occur by several mechanisms, including up-regulation of the androgen receptor, coactivators and steroidogenic enzymes, including AKR1C3.<wbr> </div><div style="margin-bottom: 10px;"><I>In vitro </I>cellular and molecular biological techniques and novel AKR1C3-selective inhibitors developed by GTx facilitated the identification of AKR1C3 as a unique androgen receptor-selective coactivator that promotes prostate cancer growth.<wbr> </div><div>Over expression of AKR1C3 promotes both androgen-dependent prostate cancer and CRPC growth with concomitant reactivation of androgen signaling in xenograft models.<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20130431&edate=20130101&rec=8789">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-02-19T12:01:40+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-02-19T12:01:40+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Key Messages from GTx' Analyst Event</title>
	<pubDate>2013-02-19T11:48:38+01:00</pubDate>
	<wp:post_id>4139</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: The company reviewed data from previous and current Ph2 of Capesaris, and the next steps.<wbr> Some questions arising in patients with CRPC and hormone sensitive prostate cancer were treated by Ph Kantoff, as well as where could GTx-758 fit in.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">- Presented by Philip Kantoff, MD (Dana-Farber Cancer Institute Harvard Medical School).<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8788_1_ScreenCapture1.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8788_2_ScreenCapture2.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8788_3_ScreenCapture3.jpg"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Presented by Evan Yu, MD (Fred Hutchinson Cancer Research).<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8788_8_ScreenCapture8.jpg"> </div><div style="margin-bottom: 10px;"><STRONG>Details of the 710 and 705 studies</STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8788_9_ScreenCapture9.jpg"> </div><div style="margin-bottom: 10px;"><U>Focus on the 705</U> </div><div style="margin-bottom: 10px;">Capesaris data from earlier trials (at higher doses) showed statistically significant lower rates of hot flashes than Lupron, improved markers of bone turnover and lowered levels of IGF-1.<wbr> At 1000 mg, the rate of hot flashes was 18.<wbr>6%; at 2000 mg, it was 5.<wbr>6%, compared to 80.<wbr>9% of men receiving Lupron.<wbr> </div><div style="margin-bottom: 10px;">Similarly, men receiving the 1000 mg and 2000 mg doses of GTx-758 had C-terminal telopeptide declines of -56.<wbr>9% and -54.<wbr>8%, respectively, as compared with an increase of 46.<wbr>0% in the men receiving Lupron.<wbr> </div><div style="margin-bottom: 10px;">Bone specific alkaline phosphatase levels were also lower in men treated with GTx-758, with mean percentage changes of-28.<wbr>5% and -19.<wbr>8%, in the treated arms, compared with an increase of 8.<wbr>1% in the Luprontreated group.<wbr> </div><div style="margin-bottom: 10px;">Serum IGF-1 levels dropped by a mean of &gt;50% in Capesaris-treated patients, while Lupron-treated patients saw IGF-1 levels stay the same or increase.<wbr> All these indicators favor an improvement quality of life for patients receiving Capesaris compared to Lupron.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8788_10_ScreenCapture10.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8788_11_ScreenCapture11.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8788_4_ScreenCapture4.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8788_5_ScreenCapture5.jpg"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Presented by Thomas Flaig, MD U.<wbr> of Colorado School of Medicine) </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8788_6_ScreenCapture6.jpg"> </div><div><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8788_7_ScreenCapture7.jpg"> </div><!-- Comment details --><a name="oncology8788attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8788_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(75,1 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8788_2_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(51,9 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8788_3_ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(56,9 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8788_4_ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(49,2 KB)<br>&nbsp;&nbsp;5.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8788_5_ScreenCapture5.jpg">ScreenCapture5.jpg</a>&nbsp;&nbsp;(37,7 KB)<br>&nbsp;&nbsp;6.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8788_6_ScreenCapture6.jpg">ScreenCapture6.jpg</a>&nbsp;&nbsp;(44,4 KB)<br>&nbsp;&nbsp;7.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8788_7_ScreenCapture7.jpg">ScreenCapture7.jpg</a>&nbsp;&nbsp;(47,4 KB)<br>&nbsp;&nbsp;8.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8788_8_ScreenCapture8.jpg">ScreenCapture8.jpg</a>&nbsp;&nbsp;(53,3 KB)<br>&nbsp;&nbsp;9.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8788_9_ScreenCapture9.jpg">ScreenCapture9.jpg</a>&nbsp;&nbsp;(71 KB)<br>&nbsp;&nbsp;10.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8788_10_ScreenCapture10.jpg">ScreenCapture10.jpg</a>&nbsp;&nbsp;(42,9 KB)<br>&nbsp;&nbsp;11.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8788_11_ScreenCapture11.jpg">ScreenCapture11.jpg</a>&nbsp;&nbsp;(55 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20130431&edate=20130101&rec=8788">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-02-19T11:48:38+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-02-19T11:48:38+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>re: New Sequential Design Study In pNET</title>
	<pubDate>2013-02-18T17:25:54+01:00</pubDate>
	<wp:post_id>4140</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="border-left: 2px solid #8B1010; padding: 0px 0px 5px 12px; margin-bottom: 3px;"><span style="font-weight: bold; font-size: 14px;">New Sequential Design Study In pNET</span>&nbsp;<br><span style="font-size: 12px;">Comment: Thanks to Eva Pineda, we were recently able to access a presentation 
given by Marianne Pavel to the VIII International GETNE Symposium.<wbr> The slides 
interestingly refer to a new upcoming Novartis GETNE co-sponsored 
study looking at sequential chemo/<wbr>mTOR therapy in a study callled 
SEQTOR.<wbr></span>&nbsp;&nbsp;<a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20130431&edate=20130101&rec=7264">...</a><br></div><div style="margin-bottom: 10px;">Combinability of drugs for the management of NET is indeed an open question and has also been considered at Ipsen with the SUNLAND study.<wbr> </div><div>This european ESS is coordinated by GERCORupported by ENETS .<wbr> It is fully granted by Ipsen and Pfizer through a global /<wbr> european partnership between both companies aiming at joining both expertises in this dynamic field and trying to address to enroll more than 100 patients.<wbr> The first 2 patients have been enrolled in January 2013.<wbr> </div><!-- Comment details --><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20130431&edate=20130101&rec=7271">Add a Comment on this Article</a><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7264">View thread  Endocrinology7264: New Sequential Design Study In pNET</a>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-02-18T17:25:54+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-02-18T17:25:54+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category endocrinology > <![CDATA[Endocrinology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>New Trials with Aragon's ARN-509 for Prostate Cancer</title>
	<pubDate>2013-02-18T17:20:03+01:00</pubDate>
	<wp:post_id>4141</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Aragon started two new combination trials this month.<wbr> A Ph2 RCT to study the effects of 12 months of treatment with ARN-509 alone or in combination with an LHRH agonist in men with a rapidly rising serum PSA after prior definitive local therapy for prostate cancer.<wbr> PE will assess mean change in QoL.<wbr> A Ph1b open label trial to assess ARN-509 in combination with abiraterone + prednisone for mCRPC.<wbr> PE will measure MTD.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG><A href="http://clinicaltrials.gov/ct2/show/NCT01790126?recr=Open&amp;no_unk=Y&amp;phase=012&amp;fund=2&amp;rcv_s=01%2F14%2F2013&amp;rank=68"><STRONG></STRONG></A> </div><div style="margin-bottom: 10px;"><P class="color-bullet" style="MARGIN-TOP: 0.7ex">Start date: Feb 2013 - Completion dates: Feb 2015 /<wbr> Feb 2018</P> </div><div style="margin-bottom: 10px;">Recruitment: approx 90 men </div><div style="margin-bottom: 10px;"><P style="MARGIN-TOP: 0ex; MARGIN-BOTTOM: 1ex">Inclusion Criteria:</P> </div><div style="margin-bottom: 10px;"><UL style="MARGIN-TOP: 1ex; MARGIN-BOTTOM: 1ex"><LI class="color-bullet" style="MARGIN-TOP: 0.7ex">Histologically proven adenocarcinoma of the prostate</LI>
<LI class="color-bullet" style="MARGIN-TOP: 0.7ex">Rising PSA after prior definitive local therapy (radical prostatectomy, external beam radiation, or brachytherapy) or combination of radical prostatectomy and radiotherapy with curative intent</LI>
<LI class="color-bullet" style="MARGIN-TOP: 0.7ex">PSA doubling time less than or equal to 12 months</LI>
<LI class="color-bullet" style="MARGIN-TOP: 0.7ex">No evidence of metastatic disease by CT/<wbr>MRI abdomen/<wbr>pelvis and whole body bone scan</LI>
<LI class="color-bullet" style="MARGIN-TOP: 0.7ex">Minimum PSA 1.<wbr>0 ng/<wbr>mL if prior radical prostatectomy +/<wbr>- adjuvant or salvage radiation; nadir + 2.<wbr>0 ng/<wbr>mL if prior RT without prior radical prostatectomy</LI>
<LI class="color-bullet" style="MARGIN-TOP: 0.7ex">No androgen deprivation therapy or anti-androgen (i.<wbr>e.<wbr> bicalutamide) within 12 months of study entry</LI>
<LI class="color-bullet" style="MARGIN-TOP: 0.7ex">No prior androgen deprivation therapy (ADT) or anti-androgen for biochemical relapse</LI>
<LI class="color-bullet" style="MARGIN-TOP: 0.7ex">Serum testosterone &gt; 150 ng/<wbr>dL at study entry</LI>
<LI class="color-bullet" style="MARGIN-TOP: 0.7ex">No history of seizures or medical conditions which may lower seizure threshold</LI>
</UL> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Start date: Feb 2013 - Completion dates: Feb 2014 </div><div style="margin-bottom: 10px;">Recruitment: approx 21 men </div><div style="margin-bottom: 10px;"><P style="MARGIN-TOP: 0ex; MARGIN-BOTTOM: 1ex">Inclusion Criteria:</P> </div><div style="margin-bottom: 10px;"><UL style="MARGIN-TOP: 1ex; MARGIN-BOTTOM: 1ex"><LI class="color-bullet" style="MARGIN-TOP: 0.7ex">Participants must have histologically confirmed prostate cancer.<wbr></LI>
<LI class="color-bullet" style="MARGIN-TOP: 0.7ex">Radiographic evidence of metastatic disease, detectable by bone scan, CT scan, or MRI.<wbr> At least one site of metastatic disease must be amenable to needle biopsy.<wbr></LI>
<LI class="color-bullet" style="MARGIN-TOP: 0.7ex">Castrate levels of testosterone (testosterone &lt; 50 ng/<wbr>dL) on androgen deprivation therapy (ADT).<wbr> Patients who have not undergone orchiectomy will continue gonadotropin releasing hormone (GnRH) agonist or antagonist therapy.<wbr></LI>
<LI class="color-bullet" style="MARGIN-TOP: 0.7ex">Age &gt; 18 years</LI>
<LI class="color-bullet" style="MARGIN-TOP: 0.7ex">ECOG performance status &lt; 2</LI>
<LI class="color-bullet" style="MARGIN-TOP: 0.7ex">Evidence of disease progression on ADT.<wbr> Patients must have two serial rises in PSA from nadir, with at least 1 week between PSA measurements, with a minimum PSA of 2 ng/<wbr>mL, OR patients must have radiographic evidence of progression.<wbr> Nadir is defined as the lowest PSA value after beginning the most recent therapy for metastatic CRPC.<wbr></LI>
</UL> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div><H1><A href="http://clinicaltrials.gov/ct2/show/study/NCT01171898?term=NCT01171898&amp;rank=1"></A></H1> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20130431&edate=20130101&rec=8786">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-02-18T17:20:03+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-02-18T17:20:03+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Ghrelin Peptide Agonist to Enter POC Study for Constipation</title>
	<pubDate>2013-02-18T16:58:57+01:00</pubDate>
	<wp:post_id>4142</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Clinicaltrials.<wbr>gov is listing a new Ph2 RCT, sponsored by Rythm Pharm, to assess RM-31 for chronic constipation.<wbr> PE will assess the effect of the drug on colonic transit.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG><A href="http://clinicaltrials.gov/ct2/show/NCT01781104?recr=Open&amp;no_unk=Y&amp;phase=012&amp;fund=2&amp;rcv_s=01%2F14%2F2013&amp;rank=41"><STRONG></STRONG></A> </div><div style="margin-bottom: 10px;">Regimen/<wbr>Dosage : RM-131 (100 ug) will be delivered subcutaneously once daily for 14 days.<wbr> </div><div style="margin-bottom: 10px;">Recruitment: approx 48 </div><div style="margin-bottom: 10px;">Location: USA </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">RM-131 was derived from the natural ghrelin sequence and optimized for the properties of stimulating GI motility, weight gain, and anti-inflammatory activity—with enhanced stability and pharmacokinetics.<wbr> </div><div>Development Stage : RM-131 is in Ph2 clinical development for the treatment of diabetic gastroparesis.<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20130431&edate=20130101&rec=1875">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-02-18T16:58:57+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-02-18T16:58:57+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category gastroenterology > <![CDATA[gastroenterology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Sanofi to Refocus R&D Strategy on the Biology of Diseases</title>
	<pubDate>2013-02-18T16:07:34+01:00</pubDate>
	<wp:post_id>4143</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: As Novartis and Roche, Sanofi is shifting the company's focus toward disease biology to increase the quantity and quality of new drug discoveries.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Since becoming Sanofi's Head of R&amp;D in 2011, Elias Zerhouni has reduced the company's late-stage portfolio of experimental drugs to ensure that only the most  promising candidates are studied in clinical trials.<wbr> </div><div>Sanofi plans to hire about 20 new R&amp;D leaders.<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20130431&edate=20130101&rec=10321">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-02-18T16:07:34+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-02-18T16:07:34+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category pharma-news > <![CDATA[Pharma News]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Spain to Prepare New Drugs Reference Pricing Regulation</title>
	<pubDate>2013-02-18T15:47:38+01:00</pubDate>
	<wp:post_id>4144</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: The prospective decree is aimed at enhancing the stability of the national pharmaceutical system, encouraging fairer bidding practices for those companies wishing to sell drugs to the public healthcare system, and setting up fairer standards in relation to timeframes of payment from the government to companies involved in tendering in order to avoid the payment delays that occurred in 2011.<wbr> </div><div style="margin-bottom: 10px;">Spanish health minister Pilar Farjas has announced that the Ministry of Health (MoH) is working on implementing a new Royal Decree aimed at the regulation of the country's drug reference pricing system.<wbr> According to Farjas, cited by Europa Press, the measure is expected to be "a key instrument for fairer market access to Spain and a necessary element to foster pharmaceutical cost containment".<wbr> </div><div style="margin-bottom: 10px;">At the XVI Farmaindustria Forum that took place this week in Zaragoza, Farjas asked the pharmaceutical sector to maintain its loyalty to the public healthcare system.<wbr> According to the source, Farjas also stated that pharmaceutical companies doing business with Spain can trust the government in terms of repayment of debts contracted during the last two years as a "suppliers repayment plan" has been implemented under which the government has started paying off some debts in a bid to regain the trust of the industry.<wbr> Farjas also pointed out that the government is working towards clearer pharmacovigilance and pharmaco-surveillance regulations to avoid counterfeiting and other illegal activity.<wbr> This measure, together with the centralised drug purchase that was recently approved at the beginning of January, is expected to help the government save EUR1.<wbr>5 billion (USD2 billion).<wbr> No further details of when the regulation will come into force were disclosed.<wbr> </div><div style="margin-bottom: 10px;"><P class="bodyHeading2"><B>Outlook and implications</B></P> </div><div style="margin-bottom: 10px;">The regulation, when implemented, would mark an essential step towards regulating the price of drugs in the country as well as creating stronger guarantees for wholesaler enterprises operating in Spain.<wbr> The decree is aimed at enhancing the stability of the national pharmaceutical system, encouraging fairer bidding practices for those companies wishing to sell drugs to the public healthcare system, setting up fairer standards in relation to timeframes for payments from the government to companies involved in the tendering process, and avoiding the kinds of payment delays that occurred in 2011.<wbr> </div><div style="margin-bottom: 10px;">This new regulation is part of a wider wave of austerity measures that began in 2011 aimed at decreasing pharmaceutical expenditure in the country.<wbr> Specifically, this regulation is aimed at avoiding unnecessary spending while tendering for drugs entering the public healthcare system, as reference pricing regulations in Spain have been historically unreliable, depending on a host of different variables.<wbr> Therefore, the creation of a decree will benefit the pharmaceutical industry operating in the country as well as the government.<wbr> </div><div style="margin-bottom: 10px;">This measure, together with the recently approved centralised drug purchasing system, is expected to help the government with consistent savings.<wbr> The centralisation of drug purchases is also part of a wider emergency financial plan aimed at cutting healthcare expenditure.<wbr> </div><div style="margin-bottom: 10px;">The laws on drug purchases approved at the end of December fulfill the aims of Royal Decree 16/<wbr>2012 to guarantee the sustainability of the national health system, as well as improving drug supplies.<wbr> The centralised purchase is expected to also benefit pharmaceutical companies tendering for drugs as the MoH has recently established a new payment system for those firms providing drugs for the public healthcare system, offering payment to the companies within a set time period and a contract of up to three years.<wbr> </div><div>Source: GlobalInsight </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20130431&edate=20130101&rec=10319">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-02-18T15:47:38+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-02-18T15:47:38+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category pharma-news > <![CDATA[Pharma News]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Roche Acquires Rights To Octreolin in $595m Deal</title>
	<pubDate>2013-02-18T10:36:19+01:00</pubDate>
	<wp:post_id>4145</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Roche has entered into an agreement with Chiasma to develop and commercialise its proprietary oral octreotide formulation Octreolin for the treatment of acromegaly and NET.<wbr> The product is currently in phIII development for the treatment of acromegaly only.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Deal Terms</STRONG> </div><div style="margin-bottom: 10px;">Under the terms of the agreement, Roche receives a W/<wbr>W exclusive license to Octreolin, and will assume responsibility for the commercialization of Octreolin.<wbr>The arrangement includes an upfront payment to Chiasma of $65 million, future considerations of up to $530 million in development and commercial milestones, as well as tiered, double-digit royalties on Octreolin net sales.<wbr> </div><div style="margin-bottom: 10px;"><UL><LI>Genentech will market the product in the United States after US FDA approval.<wbr>
</LI>
<LI>Chiasma will continue development through completion of the pivotal phase 3 clinical trial for acromegaly.<wbr>
</LI>
<LI>The arrangement includes an upfront payment to Chiasma of $65 million, future considerations of up to $530 million in development and commercial milestones, as well as tiered, double-digit royalties on Octreolin net sales.<wbr>
</LI>
</UL> </div><div style="margin-bottom: 10px;"><STRONG>Deal Rational</STRONG> </div><div style="margin-bottom: 10px;">Roche is a large oncology player and probably views the NET therapy area as an attractive market in which to participate, however, hitherto it has no existing presence of previous experience of within this field.<wbr> </div><div style="margin-bottom: 10px;">It does have an existing presence within the Endocrinology market but only in the US through its growth hormone franchise (e.<wbr>g.<wbr> Nutropin).<wbr> </div><div style="margin-bottom: 10px;">There is currently ongoing a phIII study being undertaken by SWOG that is evaluating Avastin as a potential treatment for NET.<wbr> If the results are positive (due mid 2013), it may provide a basis for Roche to file for approval and an entry point to the NET market.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Octreolin's Profile</STRONG> </div><div style="margin-bottom: 10px;"><DIV style="widows: 2; text-transform: none; background-color: #ffffff; text-indent: 0px; font: 12px arial, sans-serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #222222; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;">Chiasma is a Biotech company without any commercial capabilities so it was always going to be in need of contact/<wbr>partnership with a pharma company for commercialisation purposes.<wbr></DIV> </div><div style="margin-bottom: 10px;"><DIV style="widows: 2; text-transform: none; background-color: #ffffff; text-indent: 0px; font: 12px arial, sans-serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #222222; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;">Regarding Octreolin, we see this product as a twice daily oral treatment potentially for well controlled Acromegalics (see comments below).<wbr></DIV> </div><div style="margin-bottom: 10px;"><DIV style="widows: 2; text-transform: none; background-color: #ffffff; text-indent: 0px; font: 12px arial, sans-serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #222222; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;">The first phase I/<wbr>II results on the drug were presented at the ENDO congresses 2011/<wbr>2012.<wbr> Highlighted was</DIV> </div><div style="margin-bottom: 10px;"><DIV style="widows: 2; text-transform: none; background-color: #ffffff; text-indent: 0px; font: 12px arial, sans-serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #222222; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;">Octreolin's low bio-availability due to the oral route of administration.<wbr> Potentially this could create some issues for the product in the presence of food or drugs such as PPIs, and it raises some concerns regarding long term safety profile because of the large quantities of active drug substance that have to be administered to achieve a therapeutic concentration and therefore reach the portal circulation in the liver.<wbr></DIV> </div><div style="margin-bottom: 10px;"><DIV style="widows: 2; text-transform: none; background-color: #ffffff; text-indent: 0px; font: 12px arial, sans-serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #222222; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;">A phase III study is currently in place for Acromegaly with 40 participating sites in EU countries and Mexico.<wbr> Chiasma claim that they will be able to use this unique study for registration in US despite the lack of participating centres in this country.<wbr></DIV> </div><div style="margin-bottom: 10px;"><DIV style="widows: 2; text-transform: none; background-color: #ffffff; text-indent: 0px; font: 12px arial, sans-serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #222222; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;">There is a possibilitiey that there may be a requirement for a futher study to address higher dose octreotide LAR patients and this could delay the registration process.<wbr></DIV> </div><div style="margin-bottom: 10px;"><DIV style="widows: 2; text-transform: none; background-color: #ffffff; text-indent: 0px; font: 12px arial, sans-serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #222222; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;">.<wbr></DIV> </div><div style="margin-bottom: 10px;"><DIV style="widows: 2; text-transform: none; background-color: #ffffff; text-indent: 0px; font: 12px arial, sans-serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #222222; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;">The target population for such drug appears as though it would be good responders to SSAs ( may be low dose patients 10-20 mg octreotide LAR).<wbr> There is some preliminary indication that needs to be confirmed that higher dose octreotide LAR patients may not be adequately controlled by twice daily Octreolin dosing.<wbr></DIV> </div><div style="margin-bottom: 10px;"><DIV style="widows: 2; text-transform: none; background-color: #ffffff; text-indent: 0px; font: 12px arial, sans-serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #222222; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;">From a regulatory stand point, Octreolin has FDA Orphan drug status, and Chiasma will file utilising the 5O52B regulatory route (an abreviated filing process for follow-on products).<wbr> In term of timelines, we assume that for Acromegaly , Octreolin could reach the EU market in Q1 2015, assuming that 1 study is sufficient for approval.<wbr> Regarding the US timelines could be similar.<wbr></DIV> </div><div><DIV style="widows: 2; text-transform: none; background-color: #ffffff; text-indent: 0px; font: 12px arial, sans-serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #222222; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;">Chiasma claim that they want to develop Octreolin within NET area but no study has been initiated yet, pushing potential approval timelines out towards 2020.<wbr></DIV> </div><!-- Comment details --><span style="font-weight: bold; font-style: italic;"><br>Comments</span><a name="Endocrinology7276c"></a><br><div style="border: 1px solid #AAA; background-color: #FFF; margin-left: 10px; padding: 5px;"><div style="margin-bottom: 10px;">Thanks to Kate Higgs (UK Medical Advisor) and a conversation she had with a UK endocrinologist participating in the Octreolin trial, we have learnt that Chiasma has been suggesting that the price of Octreolin should be higher than injectable therapy because of the "benefits" of oral administration.<wbr> This comment was not well received by the endocrinologist who perceived that such a price would cause funding and reimbursement issues.<wbr> </div><div style="margin-bottom: 10px;">The cost of goods associated with an oral therapy has always raised the possibility that the price of Octreolin would not be that low since the quantity of API required to achieve an acceptable level of bioavailability  is 200x the dose needed for injectable therapy.<wbr> </div><div>In addition to comments on price, the need for gastric acidity for the drug to be absorbed (i.<wbr>e.<wbr> it has to be taken on an empty stomach) and difficulties with co-administration with PPIs was also acknowledged but patients that have been treated with the drug have been positive about it.<wbr> </div></div><a name="Endocrinology7279c"></a><div style="border: 1px solid #AAA; background-color: #FFF; margin-left: 10px; padding: 5px;"><div style="margin-bottom: 10px;">Very interesting info indeed.<wbr> </div><div>The Octreolin trial involves a lot of patients with Acromegaly condition, leading to a significant loss of patients in our market places.<wbr> Can we have the details of countries /<wbr> centers per country /<wbr> number of patients per country involved ? Can we estimate the duration for investigating these patients under octreoloin ? </div></div><a name="Endocrinology7280c"></a><div style="border: 1px solid #AAA; background-color: #FFF; margin-left: 10px; padding: 5px;"><div style="margin-bottom: 10px;">You will find the full list of participating centers (as well as their recruitment status and names of PI) of the phase III study, following the link: <A href="http://clinicaltrials.gov/ct2/show/study/NCT01412424?term=Chiasma&amp;rank=1&amp;show_locs=Y#locn">http:/<wbr>/<wbr>clinicaltrials.<wbr>gov/<wbr>ct2/<wbr>show/<wbr>study/<wbr>NCT01412424?term=Chiasma&amp;rank=1&amp;show_locs=Y#locn</A> </div><div style="margin-bottom: 10px;"><A href="http://clinicaltrials.gov/ct2/show/study/NCT01412424?term=Chiasma&amp;rank=1&amp;show_locs=Y#locn"></A><SPAN style="line-height: 1.5em;">You can see that out of the 14 countries involved, 12 are active (i.<wbr>e.<wbr> all except the US and Slovenia): Germany, Hungary, Israel, Italy, Lithuania, Mexico, Netherlands, Poland, Romania, Serbia, Slovakia, United Kingdom.<wbr></SPAN> </div><div style="margin-bottom: 10px;">The phase III trial <EM>&ldquo;Efficacy and Safety of Oral Octreolin in Patients With Acromegaly Who Are Currently Receiving Parenteral Somatostatin Analogs&rdquo;</EM> is enrolling 150 patients.<wbr> We can&rsquo;t have access to the split per country /<wbr> center.<wbr> </div><div style="margin-bottom: 10px;">Treatment duration is 7 months, and estimated completion date is October 2013.<wbr> </div><div style="margin-bottom: 10px;">Inclusion criteria are: Subjects with acromegaly defined as documented evidence of GH-secreting pituitary tumor that is abnormally responsive to glucose who is currently receiving a somatostatin analog.<wbr> </div><div style="margin-bottom: 10px;">Do not hesitate to post comments on Traction related to this trial, e.<wbr>g.<wbr> recruitment status, investigators&rsquo; or nurses&rsquo; feed-back, communication plan, &hellip; </div><div>Each and every information gathered will be very useful to feed the Octreolin war game planned this year.<wbr> </div></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20130431&edate=20130101&rec=7265">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-02-18T10:36:19+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-02-18T10:36:19+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category endocrinology > <![CDATA[Endocrinology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Interest in Duchenne Muscular Dystrophy Hots Up</title>
	<pubDate>2013-02-15T17:50:14+01:00</pubDate>
	<wp:post_id>4146</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Daiichi Sankyo has announced that it will establish a new 
company, Orphan Disease Treatment Institute Co.<wbr>, Ltd.<wbr> with Innovation Network 
Corporation of Japan and Mitsubishi UFJ Capital Co.<wbr>, Ltd.<wbr> to 
collaborate on the development of a new treatment for Duchenne 
muscular dystrophy with the active ingredient ENA® oligonucleotide*.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>The Partnership Terms</STRONG> </div><div style="margin-bottom: 10px;"><P align="left">INCJ will underwrite third party allocation of new shares for the 
new company with a maximum investment of 1.<wbr>65 billion yen.<wbr> The new company will 
also issue new shares by third party allocation for a fund managed by MUC.<wbr> 
Daiichi Sankyo will invest in the new company and mainly conduct development 
with the goal of achieving POC for clinical drug development.<wbr></P> </div><div style="margin-bottom: 10px;"><P align="left"><STRONG>*ENA® oligonucleotides</STRONG></P> </div><div><P align="left">ENA® is an ethylene-bridged nucleic acid in which ethylene is 
bridged at the furanose sugar ring at 2'-<EM>O</EM> and 4'-<EM>C</EM> ends.<wbr> 
Short-chain nucleic acids and ENA® oligonucleotides found in ENA® demonstrate 
high binding force with complementary DNA and RNA as well as superior thermal 
stability and nuclease resistance.<wbr> </P> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20130431&edate=20130101&rec=6809">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-02-15T17:50:14+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-02-15T17:50:14+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Tokai's Galeterone Appears To Have A Differentiated Profile</title>
	<pubDate>2013-02-15T17:36:32+01:00</pubDate>
	<wp:post_id>4147</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Thanks to Phil Kaspryzk, we note that Tokai has published in poster 
form some interesting data at ASCO GU, demonstrating its differentiated CYP-17 
profile compared to Zytiga (abiraterone) and Orteronel (TAK-700).<wbr> The 
implications are that it may be have an improved safety profile versus these 
drugs and will not require concomitant prednisone administration.<wbr> </div><div style="margin-bottom: 10px;">A copy of the poster is attached for review but the important data is 
highlighted below: </div><div style="margin-bottom: 10px;">Tokai's galererone is the most postent Cyp17 inhibitor selective for CYP17 
Lyase, whereas its negligble effect on CYP17A1 hydroxylase means that it has 
little effect on cortisol levels.<wbr> The latter it suggest could explain phI 
clinical experience with the drug where no mineralocorticoid excess was observed 
or prednisone required.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8784_1_ScreenCapture1.jpg"> </div><div><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8784_2_ScreenCapture2.jpg"> </div><!-- Comment details --><a name="oncology8784attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8784_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(45,7 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8784_2_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(135,9 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8784_3_TOKAI%2d2013ASCOGUPoster.pdf">TOKAI-2013ASCOGUPoster.pdf</a>&nbsp;&nbsp;(296,3 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20130431&edate=20130101&rec=8784">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-02-15T17:36:32+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-02-15T17:36:32+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>How To Interpret The Value Of An Oncology Asset</title>
	<pubDate>2013-02-14T17:33:09+01:00</pubDate>
	<wp:post_id>4148</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;"><SPAN style="WIDOWS: 2; TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; DISPLAY: inline !important; FONT: 12px arial, sans-serif; WHITE-SPACE: normal; ORPHANS: 2; FLOAT: none; LETTER-SPACING: normal; COLOR: rgb(34,34,34); WORD-SPACING: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px">Comment: 
Phase III cancer drugs owned by micro-cap companies are almost assured of 
failure and thus will see a collapse in their share prices, according to an 
analysis (</SPAN><A href="http://jnci.oxfordjournals.org/content/early/2011/09/26/jnci.djr375.full" style="WIDOWS: 2; TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; FONT: 12px arial, sans-serif; WHITE-SPACE: normal; ORPHANS: 2; LETTER-SPACING: normal; COLOR: rgb(17,85,204); WORD-SPACING: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px" target="_blank">http:/<wbr>/<wbr>jnci.<wbr>oxfordjournals.<wbr><WBR>org/<wbr>content/<wbr>early/<wbr>2011/<wbr>09/<wbr>26/<wbr></WBR><WBR>jnci.<wbr>djr375.<wbr>full</WBR></A><SPAN style="WIDOWS: 2; TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; DISPLAY: inline !important; FONT: 12px arial, sans-serif; WHITE-SPACE: normal; ORPHANS: 2; FLOAT: none; LETTER-SPACING: normal; COLOR: rgb(34,34,34); WORD-SPACING: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px">) 
  published in the Journal of the National Cancer Institute.<wbr> The 
article suggests that cocmpanies with a market cap of less than $300m four 
months before data readout will ultimately fail to produce positive 
results.<wbr></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="WIDOWS: 2; TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; DISPLAY: inline !important; FONT: 12px arial, sans-serif; WHITE-SPACE: normal; ORPHANS: 2; FLOAT: none; LETTER-SPACING: normal; COLOR: rgb(34,34,34); WORD-SPACING: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px">This 
is likely not a reflection on the scientific expertise or the capabilities 
of the company, but rather a sign of how rare and sought-after good oncology 
assets are, leaving only the probable failures in the hands of small drug 
developers.<wbr> </SPAN> </div><div style="margin-bottom: 10px;"><STRONG><SPAN style="WIDOWS: 2; TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; DISPLAY: inline !important; FONT: 12px arial, sans-serif; WHITE-SPACE: normal; ORPHANS: 2; FLOAT: none; LETTER-SPACING: normal; COLOR: rgb(34,34,34); WORD-SPACING: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px">Waiting 
for validation</SPAN><BR></STRONG><BR><SPAN style="WIDOWS: 2; TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; DISPLAY: inline !important; FONT: 12px arial, sans-serif; WHITE-SPACE: normal; ORPHANS: 2; FLOAT: none; LETTER-SPACING: normal; COLOR: rgb(34,34,34); WORD-SPACING: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px">At 
the time their article was published in JNCI, 21 micro-cap companies had failed 
the test; by comparison, 21 of 27 trials reported by companies of greater than 
$1bn market cap had been successful.<wbr></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="WIDOWS: 2; TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; DISPLAY: inline !important; FONT: 12px arial, sans-serif; WHITE-SPACE: normal; ORPHANS: 2; FLOAT: none; LETTER-SPACING: normal; COLOR: rgb(34,34,34); WORD-SPACING: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px">The 
explanation is rather simple: based on earlier-stage data, investors have simply 
not had the belief in the company to drive prices any higher.<wbr> Furthermore, big 
pharma companies have not had the confidence to either in-license the drug or 
buy the company outright; either move would help validate the drug’s 
promise.<wbr></SPAN> </div><div><SPAN style="WIDOWS: 2; TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; DISPLAY: inline !important; FONT: 12px arial, sans-serif; WHITE-SPACE: normal; ORPHANS: 2; FLOAT: none; LETTER-SPACING: normal; COLOR: rgb(34,34,34); WORD-SPACING: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px">Source: 
Evaluate Pharma</SPAN><BR> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20130431&edate=20130101&rec=8783">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-02-14T17:33:09+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-02-14T17:33:09+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>New Sequential Design Study In pNET</title>
	<pubDate>2013-02-14T17:18:32+01:00</pubDate>
	<wp:post_id>4149</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Thanks to Eva Pineda, we were recently able to access a presentation 
given by Marianne Pavel to the VIII International GETNE Symposium.<wbr> The slides 
interestingly refer to a new upcoming Novartis GETNE co-sponsored 
study looking at sequential chemo/<wbr>mTOR therapy in a study callled 
SEQTOR.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7264_2_ScreenCapture2.jpg"> </div><div style="margin-bottom: 10px;">Below you will find a link to the presentation but it is worth highlighting a 
slide showing the current range of combination studies ongoing and some of 
Marianne Pavel's key conclusions about where we stand with the different types 
of therapies/<wbr>combinations available for the treatment of NET, both in terms of 
efficacy and safety.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7264_1_ScreenCapture1.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7264_3_ScreenCapture3.jpg"> </div><div>source: <A href="http://www.getne.org/LinkClick.aspx?fileticket=qTqmicDIrFw%3D&amp;tabid=174" style="WIDOWS: 2; TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; FONT: 12px arial, sans-serif; WHITE-SPACE: normal; ORPHANS: 2; LETTER-SPACING: normal; COLOR: rgb(17,85,204); WORD-SPACING: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px" target="_blank">http:/<wbr>/<wbr>www.<wbr>getne.<wbr>org/<wbr><WBR>LinkClick.<wbr>aspx?fileticket=</WBR><WBR>qTqmicDIrFw%3D&amp;tabid=174</WBR></A> </div><!-- Comment details --><span style="font-weight: bold; font-style: italic;"><br>Comments</span><a name="Endocrinology7271c"></a><br><div style="border: 1px solid #AAA; background-color: #FFF; margin-left: 10px; padding: 5px;"><div style="margin-bottom: 10px;">Combinability of drugs for the management of NET is indeed an open question and has also been considered at Ipsen with the SUNLAND study.<wbr> </div><div>This european ESS is coordinated by GERCORupported by ENETS .<wbr> It is fully granted by Ipsen and Pfizer through a global /<wbr> european partnership between both companies aiming at joining both expertises in this dynamic field and trying to address to enroll more than 100 patients.<wbr> The first 2 patients have been enrolled in January 2013.<wbr> </div></div><a name="endocrinology7264attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7264_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(131 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7264_2_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(78,8 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7264_3_ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(146,2 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20130431&edate=20130101&rec=7264">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-02-14T17:18:32+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-02-14T17:18:32+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category endocrinology > <![CDATA[Endocrinology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Medivation Signals Its Itent To Potentially Compete Head On With The GNRH-agonists</title>
	<pubDate>2013-02-14T14:39:51+01:00</pubDate>
	<wp:post_id>4150</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Medivation has reported phII data from its study of enzalutamide in 
hormone niave prostate cancer patients, demonstrating a significant PSA 
response.<wbr> These results are likely to pave the way for a phIII trial as 
Medivations's CFO alluded to during yesterday's Leerink Swann H/<wbr>C 
Conference.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Study Design</STRONG> </div><div style="margin-bottom: 10px;">A 25-wk, open-label, single-arm study of patients with hormone-naïve, 
histologically confirmed prostate cancer (all stages) requiring hormonal 
treatment, an ECOG PS score of 0, and a life expectancy &gt;1 y.<wbr> All patients 
received ENZA 160 mg/<wbr>d without concomitment castration.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Key Findings </STRONG> </div><div style="margin-bottom: 10px;">Among 67 men enrolled, the median age was 73y; 39% had metastases; 36% and 
24% had undergone prostatectomy or radiotherapy before study entry.<wbr> </div><div style="margin-bottom: 10px;">The PSA response rate (&gt;80% PSA decline at wk 25) was 93%, with a median 
decrease of −99% at wk 25.<wbr> Serum T and estrogen levels increased by a 
median  113% and 58% at wk 25, respectively, compared with baseline.<wbr> </div><div style="margin-bottom: 10px;">82% of men reported drug-related AEs (mostly Grade 1 or 2).<wbr> Most frequent 
treatment-emergent AEs included gynaecomastia (36%), fatigue (34%), and hot 
flush (18%).<wbr> 7% of men experienced SAEs; none were drug-related.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Commenting on these results Pat Mochado Chief Financial &amp; 
Business Officer stated</STRONG> </div><div style="margin-bottom: 10px;">"This data is very very robust and definitely in the same ballpark as one 
would expect to see with Lupron, which really is significat for us because from 
a clinical rational point of view Lupron is currently the first agent that 
physicians reach for.<wbr> And Lupron has good news and bad news.<wbr> The good news is 
it's pretty effective at controlling tumour growth for a certain period of time.<wbr> 
The bad news is that it reduces your testosterone to castrate levels to the 
equivalent of being physically castrated.<wbr> So if we could offer an option to 
patients of that stage of the disease that offered comparable tumour control 
without castratoin and the side-effects and libodo and muscle wasting and the 
various associated issues that follow with castration, we think that would be a 
fairly compelling proposition.<wbr> So the fact that the initial foray into this 
patient population generated PSA response data which are the same zip code as 
Lurpon's that to us is a very encouraging first sign.<wbr>" </div><div style="margin-bottom: 10px;"><STRONG>Pat Mochado also noted that he expects the R&amp;D budget to inflect 
upwards in 2013 as one or potentially more phIII studies are 
intitiated.<wbr></STRONG> He noted:- </div><div style="margin-bottom: 10px;">So the details of that are still being worked out, but I think if you just 
look at the spectrum of disease states , there are two substantial population.<wbr>.<wbr>.<wbr> 
We have done preliminary work in both of them but they certainly remain 
interesting targets for registration.<wbr> The first would be the M0 population, so 
non-metastatic CRPC, patients who have fialed Lupron but do not yet have 
metastatic disease.<wbr> That's a population that we think would be quite interesting 
and based on the data that we,ve seen so far, especially if PREVAIL reads out 
positively, as we expect, very strong clinical rational for going into that 
poplation.<wbr> </div><div style="margin-bottom: 10px;">The second would be the even earlier stage population, which is the 
hormone-naive patients who have had their prostatectomy or their radiation and 
are experiencing biochemical recurrence.<wbr> </div><div style="margin-bottom: 10px;">We are looking to expand our opportunity by pushing earlier into the disease 
state but an equally interesting way to expand the opportunity is to follow the 
Lupron template from initiation of biochemical recurrence until death.<wbr> Once the 
patient progresses you don't stop the Lupron you add a new agent onto it.<wbr> </div><div style="margin-bottom: 10px;">That is exactly the model we want to follow with XTANDI.<wbr> So one of the 
studies that we are actually in fairly late stages of finalizing would be a 
study that would look at exactly that.<wbr> If you take patients who've begun to 
progress on XTANDI, is there incremental benefit to keeping them on XTANDI and 
adding on Zytiga or whatever subseqeunt treatment the physician might think is 
appropriate and I think if we can show that answer to that as yes, that will be 
a further enhancement of the opportunity.<wbr> </div><div>Source: <A href="http://www.medivation.com">www.<wbr>medivation.<wbr>com</A> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20130431&edate=20130101&rec=8782">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-02-14T14:39:51+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-02-14T14:39:51+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Orphan Drug Designation Granted in EU to PROLOR's Longer-Acting hGH</title>
	<pubDate>2013-02-13T18:41:42+01:00</pubDate>
	<wp:post_id>4151</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: The EU Commission and the EMA have granted orphan drug designation (ODD) to hGH-CTP, a once-weekly version of human GH, in development for the treatment of GH deficiency.<wbr> This is the 1st time a GH drug has received ODD in Europe.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">- Market exclusivity: the ODD will prevent any other long-acting recombinant growth hormone from being marketed in Europe for 10 years after the launch of hGH-CTP.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Ph3 trial in growth hormone-deficient adults is scheduled to begin later this year.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">In Oct 2010 the drug received ODD in the US which provides 7 years of market exclusivity, reductions in regulatory fees, certain credits and additional regulatory support.<wbr> </div><div>Source: PROLOR </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20130431&edate=20130101&rec=7262">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-02-13T18:41:42+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-02-13T18:41:42+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category endocrinology > <![CDATA[Endocrinology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Recordati Business Update</title>
	<pubDate>2013-02-13T17:09:08+01:00</pubDate>
	<wp:post_id>4152</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Alongside its quarterly earnings, Recordati highlighted its strategy for growth commenting on the issues facing its primary care business and its main growth drivers, which include geographic diversification plus a focus on specialty and orphan products.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10316_9_ScreenCapture9.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10316_2_ScreenCapture2.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10316_1_ScreenCapture1.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10316_3_ScreenCapture3.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10316_4_ScreenCapture4.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10316_5_ScreenCapture5.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10316_6_ScreenCapture6.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10316_7_ScreenCapture7.jpg"> </div><div><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10316_8_ScreenCapture8.jpg"> </div><!-- Comment details --><a name="pharmaworld10316attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10316_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(81,4 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10316_2_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(76,5 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10316_3_ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(64,1 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10316_4_ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(99,3 KB)<br>&nbsp;&nbsp;5.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10316_5_ScreenCapture5.jpg">ScreenCapture5.jpg</a>&nbsp;&nbsp;(59,6 KB)<br>&nbsp;&nbsp;6.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10316_6_ScreenCapture6.jpg">ScreenCapture6.jpg</a>&nbsp;&nbsp;(65,5 KB)<br>&nbsp;&nbsp;7.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10316_7_ScreenCapture7.jpg">ScreenCapture7.jpg</a>&nbsp;&nbsp;(66,4 KB)<br>&nbsp;&nbsp;8.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10316_8_ScreenCapture8.jpg">ScreenCapture8.jpg</a>&nbsp;&nbsp;(50,1 KB)<br>&nbsp;&nbsp;9.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10316_9_ScreenCapture9.jpg">ScreenCapture9.jpg</a>&nbsp;&nbsp;(82,2 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20130431&edate=20130101&rec=10316">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-02-13T17:09:08+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-02-13T17:09:08+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category pharma-news > <![CDATA[Pharma News]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>re: Bayer/Algeta's Alpharadin Submitted to the EMA for CRPC Patients with Bone Metastases</title>
	<pubDate>2013-02-13T09:43:59+01:00</pubDate>
	<wp:post_id>4153</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="border-left: 2px solid #8B1010; padding: 0px 0px 5px 12px; margin-bottom: 3px;"><span style="font-weight: bold; font-size: 14px;">Bayer/<wbr>Algeta's Alpharadin Submitted to the EMA for CRPC Patients with Bone Metastases</span>&nbsp;<br><span style="font-size: 12px;">Comment: On August 20th, at last Bayer's Q2 financial results, management highlighted EU launch to occur in Q2/<wbr>Q3:13.<wbr> In Russia, the drug is expected to reach the market in the course of the next five years.<wbr></span>&nbsp;&nbsp;<a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20130431&edate=20130101&rec=8669">...</a><br></div><div style="margin-bottom: 10px;">Bayer has received notification from the FDA granting priority review of the NDA (filed in December 2012).<wbr> The application is under review for the treatment of CRPC patients with bone metastases.<wbr> </div><div style="margin-bottom: 10px;">FDA now has 8 months to complete its review (This suggests an estimated PDUFA action date of 13 August 2013).<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Analysts with Deutsche Bank "believe Alpharadin has blockbuster potential in prostate cancer alone, supported by use as an alternative to Taxotere and potential for use in combination with new oral anti-hormonals.<wbr> </div><div>Benefits on bone palliation are particularly important given additional potential for repeat use in patients with bone pain at the end of life.<wbr> In addition, our discussions with physicians suggest Taxotere is often used more for its palliative benefits than for its improvement in survival.<wbr> The data suggests Alpharadin could be competitive in this regard and further adds to its benefits which include an improvement in overall survival (14.<wbr>9 vs 11.<wbr>3 mo; HR=0.<wbr>695) and delay in time to skeletalrelated events (15.<wbr>6 vs 9.<wbr>8 mo;P&lt; 0.<wbr>001; HR = 0.<wbr>66; 95% CI: 0.<wbr>52-0.<wbr>83).<wbr>" </div><!-- Comment details --><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20130431&edate=20130101&rec=8780">Add a Comment on this Article</a><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology8669">View thread  Oncology8669: Bayer/<wbr>Algeta's Alpharadin Submitted to the EMA for CRPC Patients with Bone Metastases</a>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-02-13T09:43:59+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-02-13T09:43:59+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>re: Esmya(R) Granted EMA for Uterine Fibroids</title>
	<pubDate>2013-02-13T09:34:06+01:00</pubDate>
	<wp:post_id>4154</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="border-left: 2px solid #8B1010; padding: 0px 0px 5px 12px; margin-bottom: 3px;"><span style="font-weight: bold; font-size: 14px;">Esmya(R) Granted EMA for Uterine Fibroids</span>&nbsp;<br><span style="font-size: 12px;">Comment: The EC has granted marketing authorization to Richter/<wbr>PregLem's Esmya(R) 5mg tablet for pre-operative treatment of moderate to severe symptoms of uterine fibroids.<wbr></span>&nbsp;&nbsp;<a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20130431&edate=20130101&rec=8125">...</a><br></div><div>The Scottish Medicines Consortium (SMC) backed the use of Esmya on the NHS as the 1st oral treatment for uterine fibroids.<wbr> The licence from the SMC means the drug ca now be prescribed generally in treatment.<wbr> </div><!-- Comment details --><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20130431&edate=20130101&rec=8779">Add a Comment on this Article</a><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology8125">View thread  Oncology8125: Esmya(R) Granted EMA for Uterine Fibroids</a>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-02-13T09:34:06+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-02-13T09:34:06+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>New Ulcerative Colitis Therapy to be Marketed in the US</title>
	<pubDate>2013-02-12T18:12:55+01:00</pubDate>
	<wp:post_id>4155</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: The FDA has approved Warner Chilcott's 400mg mesalamine, to be marketed next month as Delzicol.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Delzicol delayed(release capsules are indicated to treat patients with mild to moderate UC, and to maintain remisssion of the disease.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Treat: 2 x 400mg capsules 3 times daily (2.<wbr>4g) for 6 wks </div><div>Maintain: 1.<wbr>6g daily </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20130431&edate=20130101&rec=1873">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-02-12T18:12:55+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-02-12T18:12:55+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category gastroenterology > <![CDATA[gastroenterology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Nasal Growth Hormone to Progress Phase 2/3 Studies</title>
	<pubDate>2013-02-12T16:06:50+01:00</pubDate>
	<wp:post_id>4156</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Latest Ph1 results with Critical Pharm.<wbr>'s CP024 showed that the drug was well tolerated, pharmacokinetics were highly reproducible, and IGF-1 was strongly induced.<wbr> The company is searching for a development and commercialization partner.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Dosage: 6 dose levels of CP024 (between 2-6 mg growth hormone) were administered to healthy subjects along with an infusion of octreotide to suppress the production of endogenous growth hormone.<wbr> </div><div style="margin-bottom: 10px;">Objectives: The objectives of the study were to measure the pharmacokinetics, pharmacodynamics and dose response relationship of CP024 compared to a subcutaneous dose of 0.<wbr>75 mg Omnitrope®.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Critical Pharmaceuticals’ proprietary CriticalSorb technology enhances the absorption of somatropin and thereby makes it possible to deliver the drug by nasal spray.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Pipeline</STRONG> </div><div><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7260_1_ScreenCapture1.jpg"> </div><!-- Comment details --><a name="endocrinology7260attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7260_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(24,8 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20130431&edate=20130101&rec=7260">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-02-12T16:06:50+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-02-12T16:06:50+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category endocrinology > <![CDATA[Endocrinology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>OncoGenex Expands OGX-427 Development Program for Bladder Cancer</title>
	<pubDate>2013-02-12T15:44:51+01:00</pubDate>
	<wp:post_id>4157</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: The Ph2 trial (Borealis-2) will investigate OGX-427¨+/<wbr>- docetaxel for the treatment of 2nde-line metastatic bladder cancer.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Currently, first-line platinum-based chemotherapy regimens result in a median overall survival of approximately 12-15 months.<wbr> Docetaxel is commonly used in second-line treatment, with a reported median overall survival of approximately six months.<wbr> </div><div style="margin-bottom: 10px;"><B>Rationale for 2nd/<wbr>3rd-line Treatment</B> </div><div style="margin-bottom: 10px;">Given acquired treatment resistance and these short survival times, there continues to be a high unmet need for additional therapeutic options for this patient population.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><U>Borealis-2</U> will be the second randomized, controlled clinical trial of OGX-427 in advanced bladder cancer.<wbr> </div><div style="margin-bottom: 10px;"><BLOCKQUOTE dir="ltr" style="MARGIN-RIGHT: 0px">
<P>o   Recruitment: approximately 200 patients</P>
<P>o   Protocol: OGX-427 plus docetaxel treatment or docetaxel treatment alone.<wbr> Patients may also continue weekly OGX-427 infusions as maintenance treatment until disease progression or unacceptable toxicity if they complete all 10 planned cycles of docetaxel or are discontinued from docetaxel due to docetaxel toxicity.<wbr> </P>
<P>o   The primary objective: overall survival</P>
<P>o   Location: 30 sites in the U.<wbr>S.<wbr> </P>
<P>o   Sponsors/<wbr>Investigators: Hoosier Oncology Group.<wbr> Dr.<wbr> Noah Hahn from the Indiana University Simon Cancer Center, Dr.<wbr> Toni Choueiri from the Dana-Farber Cancer Institute and Dr.<wbr> Jonathan Rosenberg from Memorial Sloan-Kettering Cancer Center will serve as the primary investigators on the study.<wbr> </P></BLOCKQUOTE> </div><div style="margin-bottom: 10px;"><U>Borealis-1</U> clinical trial is the OncoGenex-sponsored, randomized, placebo-controlled Phase 2 study designed to evaluate a potential survival benefit, safety and tolerability of combining OGX-427 with gemcitabine and cisplatin in the first-line treatment of patients with advanced bladder cancer.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div>If either Borealis trial shows a survival advantage, OncoGenex plans to initiate conversations with the Food and Drug Administration about the possibility of a Phase 3 study of OGX-427 in bladder cancer as part of the ORCA program.<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20130431&edate=20130101&rec=8778">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-02-12T15:44:51+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-02-12T15:44:51+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Survey Data Highlights Recent Trends In The CRPC Market</title>
	<pubDate>2013-02-12T14:19:56+01:00</pubDate>
	<wp:post_id>4158</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: A recent report from Baird equity research, highlights the results 
of two new surveys evaluating usage of new drugs in the CRPC market.<wbr> The surveys 
were undertaken in the US in October/<wbr>November 2012 by BioTrends and ICI 
community-oncology and included 191 participants.<wbr> Zytiga is more 
favourably perceived than Provenge but there are also indications that Xtandi is 
likely to be very well received.<wbr> </div><div style="margin-bottom: 10px;">BioTrends surveyed urologists and oncologists and included 52 urologists, 
whilst ICI's survey included 92 oncologists.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Key Findings</STRONG> </div><div style="margin-bottom: 10px;"><UL><LI>Both surveys show Zytiga increasing its footprint in the chemo-naive 
  patients segment.<wbr></LI>
</UL> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8777_3_ScreenCapture3.jpg"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8777_4_ScreenCapture5.jpg"> </div><div style="margin-bottom: 10px;"><UL><LI>Feedback from urologists (n=52) indicated that Provenge's share of the 
  asymptomatic /<wbr>minimally symtpomatic CRPC segment has increased steadily over 
  the last year, now 24%.<wbr></LI>
<LI>However, amongst oncologists (which account for 60% of 
  community-based sales)Provenge sales are flat</LI>
<LI>The view on sequencing Provenge and Zytiga remains split with about half 
  indicating that they will prescribe Zytiga only.<wbr></LI>
</UL> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8777_5_ScreenCapture6.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8777_6_ScreenCapture7.jpg"> </div><div style="margin-bottom: 10px;"><UL><LI>Oncologists also indicate a high degree of enthusiasm for Xtandi with 46% 
  citing it as a promising new treatment strategy for prostate cancer vs 5% for 
  Provenge and 30% for Zytiga</LI>
</UL> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8777_1_ScreenCapture1.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8777_2_ScreenCapture2.jpg"> </div><div style="margin-bottom: 10px;">For a full copy of the report please contact the CI Department.<wbr> </div><div>Source: Baird Analyst Report January 31st 2013 </div><!-- Comment details --><a name="oncology8777attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8777_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(113,1 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8777_2_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(138,9 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8777_3_ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(635 B)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8777_4_ScreenCapture5.jpg">ScreenCapture5.jpg</a>&nbsp;&nbsp;(86,4 KB)<br>&nbsp;&nbsp;5.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8777_5_ScreenCapture6.jpg">ScreenCapture6.jpg</a>&nbsp;&nbsp;(96,3 KB)<br>&nbsp;&nbsp;6.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8777_6_ScreenCapture7.jpg">ScreenCapture7.jpg</a>&nbsp;&nbsp;(126,4 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20130431&edate=20130101&rec=8777">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-02-12T14:19:56+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-02-12T14:19:56+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>re: Key Takeaways from IMCAS (Jan. 31 - Feb. 3)</title>
	<pubDate>2013-02-12T10:52:23+01:00</pubDate>
	<wp:post_id>4159</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="border-left: 2px solid #8B1010; padding: 0px 0px 5px 12px; margin-bottom: 3px;"><span style="font-weight: bold; font-size: 14px;">Key Takeaways from IMCAS (Jan.<wbr> 31 - Feb.<wbr> 3)</span>&nbsp;<br><span style="font-size: 12px;">Comment: General perspectives for the years to come will be guided by more sessions on Evidence Based Medicine (EBM), the importance of anatomy and muscle mass-based approaches.<wbr> Prolonged action (&gt; 6 months) was cited as a missing important characteristic for an ‘ideal toxin’.<wbr> If portfolios include products from prevention to enhancement, a question mark arised on whether to consider ‘diagnosis’ in the future.<wbr> Of note, Medy-Tox exhibited for the 1<SUP>st</SUP> time, and Merz did not hold a symposium, whereas Allergan’s one celebrated the 10<SUP>th</SUP> anniversary of Botox, and the launch of a new filler.<wbr> Highlights from the ‘New approaches for hyperhidrosis’ and 'The power of nanotechnology" sessions are provided below.<wbr></span>&nbsp;&nbsp;<a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20130431&edate=20130101&rec=6796">...</a><br></div><div><UL><LI><SPAN style="LINE-HEIGHT: 1.5em">It is important to mention that </SPAN><SPAN style="LINE-HEIGHT: 1.5em"><STRONG>BoNT-A is the best choice for the treatment of hyperhidrosis</STRONG> - (Dr Marc Heckman at the session "New approaches for Hyperhidrosis").<wbr></SPAN></LI>
<LI><SPAN style="LINE-HEIGHT: 1.5em">According to Juergen Frevert <EM>(Merz at Botulinum Toxins products : from characteristics to recommendations)</EM> and Philippe Bouchard <EM>(CEO - Merz at the Industry Tribune)</EM>, the goal of Merz is to develop new indications for Xeomin.<wbr></SPAN> </LI>
</UL> </div><!-- Comment details --><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20130431&edate=20130101&rec=6805">Add a Comment on this Article</a><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology6796">View thread  Neurology6796: Key Takeaways from IMCAS (Jan.<wbr> 31 - Feb.<wbr> 3)</a>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-02-12T10:52:23+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-02-12T10:52:23+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>re: Key Takeaways from IMCAS (Jan. 31 - Feb. 3)</title>
	<pubDate>2013-02-12T10:41:44+01:00</pubDate>
	<wp:post_id>4160</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="border-left: 2px solid #8B1010; padding: 0px 0px 5px 12px; margin-bottom: 3px;"><span style="font-weight: bold; font-size: 14px;">Key Takeaways from IMCAS (Jan.<wbr> 31 - Feb.<wbr> 3)</span>&nbsp;<br><span style="font-size: 12px;">Comment: General perspectives for the years to come will be guided by more sessions on Evidence Based Medicine (EBM), the importance of anatomy and muscle mass-based approaches.<wbr> Prolonged action (&gt; 6 months) was cited as a missing important characteristic for an ‘ideal toxin’.<wbr> If portfolios include products from prevention to enhancement, a question mark arised on whether to consider ‘diagnosis’ in the future.<wbr> Of note, Medy-Tox exhibited for the 1<SUP>st</SUP> time, and Merz did not hold a symposium, whereas Allergan’s one celebrated the 10<SUP>th</SUP> anniversary of Botox, and the launch of a new filler.<wbr> Highlights from the ‘New approaches for hyperhidrosis’ and 'The power of nanotechnology" sessions are provided below.<wbr></span>&nbsp;&nbsp;<a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20130431&edate=20130101&rec=6796">...</a><br></div><div style="margin-bottom: 10px;">With regard to the InPart Transdermal Delivery System: a more comprehensive presentation on their topical Botulinum toxin trial can be found at the company's website: <A href="http://www.transdermalcorp.com/clinical-studies">http:/<wbr>/<wbr>www.<wbr>transdermalcorp.<wbr>com/<wbr>clinical-studies</A> </div><div style="margin-bottom: 10px;">(Presentation can be downloaded when left-clicking on it).<wbr> </div><div>Slides 114-138 are most relevant to botulinum toxin trial.<wbr> </div><!-- Comment details --><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20130431&edate=20130101&rec=6804">Add a Comment on this Article</a><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology6796">View thread  Neurology6796: Key Takeaways from IMCAS (Jan.<wbr> 31 - Feb.<wbr> 3)</a>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-02-12T10:41:44+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-02-12T10:41:44+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Key Takeaways from IMCAS (Jan. 31 - Feb. 3)</title>
	<pubDate>2013-02-11T13:57:51+01:00</pubDate>
	<wp:post_id>4161</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: General perspectives for the years to come will be guided by more sessions on Evidence Based Medicine (EBM), the importance of anatomy and muscle mass-based approaches.<wbr> Prolonged action (&gt; 6 months) was cited as a missing important characteristic for an ‘ideal toxin’.<wbr> If portfolios include products from prevention to enhancement, a question mark arised on whether to consider ‘diagnosis’ in the future.<wbr> Of note, Medy-Tox exhibited for the 1<SUP>st</SUP> time, and Merz did not hold a symposium, whereas Allergan’s one celebrated the 10<SUP>th</SUP> anniversary of Botox, and the launch of a new filler.<wbr> Highlights from the ‘New approaches for hyperhidrosis’ and 'The power of nanotechnology" sessions are provided below.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">For this exceptional edition, IMCAS welcomed more than 4000 participants from 85 countries, 160 exhibitors, 350 international speakers, and about 900 oral presentations.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><STRONG>The Ideal Toxin</STRONG> </div><div style="margin-bottom: 10px;">G.<wbr> Monheit (dermatologist, US) and C-H Huh (<SPAN style="LINE-HEIGHT: 115%; FONT-FAMILY: 'Arial','sans-serif'; FONT-SIZE: 10pt; mso-fareast-font-family: Calibri; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA">)</SPAN> had a go on trying to describe the 'ideal toxin'.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6796_1_ScreenCapture1.jpg"> </div><div style="margin-bottom: 10px;"><STRONG>C-H Huh</STRONG> concluded his presentation entitled 'Focus on Chinese and Korean Toxins' by highlighting that Botulax/<wbr>Regenox/<wbr>Zentox from Hugel still lack clinical references.<wbr> He also warned the audience on the 'allergic reactions' (skin rash) and possibly bovine spongiform encephalopathy (BSE) linked with BTX-A/<wbr>Prosigne from Lanzhou Institute of Biological Products.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>'NEW APPROACHES FOR HYPERHIDROSIS' (HH)</STRONG> </div><div style="margin-bottom: 10px;">Although the title of this session was attractive, there was nothing new on the matter.<wbr> Below are some interesting points to note: </div><div style="margin-bottom: 10px;">The ‘Sweat’ market represents approx.<wbr> $10bn (EU: 45% - Americas: 30%).<wbr> </div><div style="margin-bottom: 10px;"><UL><LI>3% of the population in the world</LI>
<LI>80% who do not want to sweat </LI>
</UL> </div><div style="margin-bottom: 10px;">- Cause: neuronal overstimulation (neuregulin overexpressed) </div><div style="margin-bottom: 10px;">- Background: gene locus have been mapped </div><div style="margin-bottom: 10px;">- Diagnosis: "clinical signs and patients history are key".<wbr> </div><div style="margin-bottom: 10px;">Doris Hexsel (dermatologist, Brazil) outlined that as "sweating is connected to the brain, the placebo effect is important in this pathology".<wbr> She concluded her presentation outlining that BoNT-A injections is a very good option to optimize the effects of HH in various areas of the face and body.<wbr> Several recent publications have reinforced the efficacy of BoNT-A in many forms of the condition.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><STRONG>Nano Dermatology: Ethosomes (discovered by Pf E.<wbr> Touitou)</STRONG> </div><div style="margin-bottom: 10px;">Schlomit Halachmi (dermatologist, Israel) cited Ethosomes, as novel vesicular carriers for enhanced delivery.<wbr> The ethosomal system is composed of phospholipid, ethanol and water.<wbr> This carrier presents interesting features correlated with its ability to permeate intact through the human skin due to its high deformability.<wbr> Ethosomes are soft, malleable vesicles tailored for enhanced delivery of active agents.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>The InParT Transdermal Delivery System</STRONG> </div><div style="margin-bottom: 10px;"><U>Hyperhidrosis </U>/<wbr> Mark Nestor presented : </div><div style="margin-bottom: 10px;">The results from a prospective open label study for axillary and palmer hyperhidrosis in 24 patients (18-59) - <SPAN style="FONT-FAMILY: 'Times New Roman'; COLOR: white; mso-fareast-font-family: 굴림; mso-ascii-font-family: 'Times New Roman'; mso-bidi-font-family: +mn-cs; mso-ascii-theme-font: minor-latin; mso-bidi-theme-font: minor-bidi; mso-color-index: 1; mso-font-kerning: 12.0pt; text-shadow: auto; language: en-US; mso-effects-shadow-color: black; mso-effects-shadow-alpha: 100.0%; mso-effects-shadow-dpiradius: 3.0pt; mso-effects-shadow-angledirection: 2700000; mso-effects-shadow-dpidistance: 3.0pt; mso-effects-shadow-pctsx: 100.0%; mso-effects-shadow-pctsy: 100.0%; mso-effects-shadow-anglekx: 0; mso-effects-shadow-angleky: 0; mso-effects-shadow-align: topleft; mso-style-textfill-type: solid; mso-style-textfill-fill-themecolor: text1; mso-style-textfill-fill-color: white; mso-style-textfill-fill-alpha: 100.0%"></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="FONT-FAMILY: 'Times New Roman'; COLOR: white; mso-fareast-font-family: 굴림; mso-ascii-font-family: 'Times New Roman'; mso-bidi-font-family: +mn-cs; mso-ascii-theme-font: minor-latin; mso-bidi-theme-font: minor-bidi; mso-color-index: 1; mso-font-kerning: 12.0pt; text-shadow: auto; language: en-US; mso-effects-shadow-color: black; mso-effects-shadow-alpha: 100.0%; mso-effects-shadow-dpiradius: 3.0pt; mso-effects-shadow-angledirection: 2700000; mso-effects-shadow-dpidistance: 3.0pt; mso-effects-shadow-pctsx: 100.0%; mso-effects-shadow-pctsy: 100.0%; mso-effects-shadow-anglekx: 0; mso-effects-shadow-angleky: 0; mso-effects-shadow-align: topleft; mso-style-textfill-type: solid; mso-style-textfill-fill-themecolor: text1; mso-style-textfill-fill-color: white; mso-style-textfill-fill-alpha: 100.0%"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6796_9_ScreenCapture9.jpg"></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="FONT-FAMILY: 'Times New Roman'; COLOR: white; mso-fareast-font-family: 굴림; mso-ascii-font-family: 'Times New Roman'; mso-bidi-font-family: +mn-cs; mso-ascii-theme-font: minor-latin; mso-bidi-theme-font: minor-bidi; mso-color-index: 1; mso-font-kerning: 12.0pt; text-shadow: auto; language: en-US; mso-effects-shadow-color: black; mso-effects-shadow-alpha: 100.0%; mso-effects-shadow-dpiradius: 3.0pt; mso-effects-shadow-angledirection: 2700000; mso-effects-shadow-dpidistance: 3.0pt; mso-effects-shadow-pctsx: 100.0%; mso-effects-shadow-pctsy: 100.0%; mso-effects-shadow-anglekx: 0; mso-effects-shadow-angleky: 0; mso-effects-shadow-align: topleft; mso-style-textfill-type: solid; mso-style-textfill-fill-themecolor: text1; mso-style-textfill-fill-color: white; mso-style-textfill-fill-alpha: 100.0%"></SPAN><SPAN style="FONT-FAMILY: 'Times New Roman'; COLOR: white; mso-fareast-font-family: 굴림; mso-ascii-font-family: 'Times New Roman'; mso-bidi-font-family: +mn-cs; mso-ascii-theme-font: minor-latin; mso-bidi-theme-font: minor-bidi; mso-color-index: 1; mso-font-kerning: 12.0pt; text-shadow: auto; language: en-US; mso-effects-shadow-color: black; mso-effects-shadow-alpha: 100.0%; mso-effects-shadow-dpiradius: 3.0pt; mso-effects-shadow-angledirection: 2700000; mso-effects-shadow-dpidistance: 3.0pt; mso-effects-shadow-pctsx: 100.0%; mso-effects-shadow-pctsy: 100.0%; mso-effects-shadow-anglekx: 0; mso-effects-shadow-angleky: 0; mso-effects-shadow-align: topleft; mso-style-textfill-type: solid; mso-style-textfill-fill-themecolor: text1; mso-style-textfill-fill-color: white; mso-style-textfill-fill-alpha: 100.0%"></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="FONT-FAMILY: 'Times New Roman'; COLOR: white; mso-fareast-font-family: 굴림; mso-ascii-font-family: 'Times New Roman'; mso-bidi-font-family: +mn-cs; mso-ascii-theme-font: minor-latin; mso-bidi-theme-font: minor-bidi; mso-color-index: 1; mso-font-kerning: 12.0pt; text-shadow: auto; language: en-US; mso-effects-shadow-color: black; mso-effects-shadow-alpha: 100.0%; mso-effects-shadow-dpiradius: 3.0pt; mso-effects-shadow-angledirection: 2700000; mso-effects-shadow-dpidistance: 3.0pt; mso-effects-shadow-pctsx: 100.0%; mso-effects-shadow-pctsy: 100.0%; mso-effects-shadow-anglekx: 0; mso-effects-shadow-angleky: 0; mso-effects-shadow-align: topleft; mso-style-textfill-type: solid; mso-style-textfill-fill-themecolor: text1; mso-style-textfill-fill-color: white; mso-style-textfill-fill-alpha: 100.0%"></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="FONT-FAMILY: 'Times New Roman'; COLOR: white; mso-fareast-font-family: 굴림; mso-ascii-font-family: 'Times New Roman'; mso-bidi-font-family: +mn-cs; mso-ascii-theme-font: minor-latin; mso-bidi-theme-font: minor-bidi; mso-color-index: 1; mso-font-kerning: 12.0pt; text-shadow: auto; language: en-US; mso-effects-shadow-color: black; mso-effects-shadow-alpha: 100.0%; mso-effects-shadow-dpiradius: 3.0pt; mso-effects-shadow-angledirection: 2700000; mso-effects-shadow-dpidistance: 3.0pt; mso-effects-shadow-pctsx: 100.0%; mso-effects-shadow-pctsy: 100.0%; mso-effects-shadow-anglekx: 0; mso-effects-shadow-angleky: 0; mso-effects-shadow-align: topleft; mso-style-textfill-type: solid; mso-style-textfill-fill-themecolor: text1; mso-style-textfill-fill-color: white; mso-style-textfill-fill-alpha: 100.0%"></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="FONT-FAMILY: 'Times New Roman'; COLOR: white; mso-fareast-font-family: 굴림; mso-ascii-font-family: 'Times New Roman'; mso-bidi-font-family: +mn-cs; mso-ascii-theme-font: minor-latin; mso-bidi-theme-font: minor-bidi; mso-color-index: 1; mso-font-kerning: 12.0pt; text-shadow: auto; language: en-US; mso-effects-shadow-color: black; mso-effects-shadow-alpha: 100.0%; mso-effects-shadow-dpiradius: 3.0pt; mso-effects-shadow-angledirection: 2700000; mso-effects-shadow-dpidistance: 3.0pt; mso-effects-shadow-pctsx: 100.0%; mso-effects-shadow-pctsy: 100.0%; mso-effects-shadow-anglekx: 0; mso-effects-shadow-angleky: 0; mso-effects-shadow-align: topleft; mso-style-textfill-type: solid; mso-style-textfill-fill-themecolor: text1; mso-style-textfill-fill-color: white; mso-style-textfill-fill-alpha: 100.0%"></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="FONT-FAMILY: 'Times New Roman'; COLOR: white; mso-fareast-font-family: 굴림; mso-ascii-font-family: 'Times New Roman'; mso-bidi-font-family: +mn-cs; mso-ascii-theme-font: minor-latin; mso-bidi-theme-font: minor-bidi; mso-color-index: 1; mso-font-kerning: 12.0pt; text-shadow: auto; language: en-US; mso-effects-shadow-color: black; mso-effects-shadow-alpha: 100.0%; mso-effects-shadow-dpiradius: 3.0pt; mso-effects-shadow-angledirection: 2700000; mso-effects-shadow-dpidistance: 3.0pt; mso-effects-shadow-pctsx: 100.0%; mso-effects-shadow-pctsy: 100.0%; mso-effects-shadow-anglekx: 0; mso-effects-shadow-angleky: 0; mso-effects-shadow-align: topleft; mso-style-textfill-type: solid; mso-style-textfill-fill-themecolor: text1; mso-style-textfill-fill-color: white; mso-style-textfill-fill-alpha: 100.0%"></SPAN> </div><div style="margin-bottom: 10px;"><STRONG>HIGHLIGHTS FROM THE SYMPOSIUM</STRONG> </div><div style="margin-bottom: 10px;"><B>MYOSCIENCE</B> </div><div style="margin-bottom: 10px;">For the 1<SUP>st</SUP> time, Myoscience organized a symposium to introduce iovera, its Cold Therapy for dynamic wrinkles.<wbr> Speakers: B.<wbr> Ascher, J.<wbr> Sykes and D.<wbr> Cassuto.<wbr> </div><div style="margin-bottom: 10px;"><U>Key Messages</U> </div><div style="margin-bottom: 10px;"><UL type="disc"><LI>World’s first toxin free treatment of dynamic wrinkles</LI>
<LI>Not a competitor to toxins, but an opportunity to increase patient demand (2 to 5 times the number of botulinum toxin treated patients do not want a toxin)</LI>
<LI>Predictable (Treatment effect: Immediate results - Duration: 2 to 4 months; 90 days (minimum)</LI>
<LI>Repeatable (complete restoration of motor functions)</LI>
</UL> </div><div style="margin-bottom: 10px;"><B>ALLERGAN </B> </div><div style="margin-bottom: 10px;">Allergan celebrated the 10<SUP>th</SUP> anniversary of Botox, and the arrival of a newcomer in the "Juvederm dynasty": JUVEDERM VOLBELLA with lidocaine, which contains low molecular weight HA (&lt; 1 million Da).<wbr> </div><div style="margin-bottom: 10px;"><U>First Part</U> of the presentation was dedicated to Botox, listing its following characteristics: </div><div style="margin-bottom: 10px;"><UL><LI>The very first</LI>
<LI>The longest follow-up</LI>
<LI>The largest literature</LI>
<LI>The most widely used in the world</LI>
</UL> </div><div style="margin-bottom: 10px;">Supported by literature references </div><div style="margin-bottom: 10px;"><STRONG>Precision </STRONG>- <U>Study</U> De AlmeIda et al(2007) P1070228 Key Findings 6 month pilot study using a forehead anhydrotic model </div><div style="margin-bottom: 10px;"><STRONG>Rapid onset of effect</STRONG> -<U>Study</U> Beers et al(2011) VISTABEL provides rapid onset of response based on physician and subject assessments </div><div style="margin-bottom: 10px;"><STRONG>Long lasting effect</STRONG>: dynamic lines — <U>Study</U> Kane et al (2011) 84.<wbr>2% subjects identified as responsers at day 30; Median duration of efficacy was 120 days (95% CI 119-121) </div><div style="margin-bottom: 10px;"><STRONG>High patient satisfaction</STRONG> - <U>Study</U> Stotland et al(2007) Aesthetic treatment with AGN BoNTA significantly improved self perception of age by approx.<wbr> 5years </div><div style="margin-bottom: 10px;"><STRONG>Proven long term safety</STRONG> — <U>Study</U> Brin et al (2009) meata-analysis </div><div style="margin-bottom: 10px;"><U>Second Part</U> dedicated to Volbella ("Voluma's little brother") </div><div style="margin-bottom: 10px;"><UL><LI>Same Vycross technology HA 15 mg/<wbr>ml</LI>
<LI>Specifically designed for lips and perioral</LI>
<LI>Extremely soft and easy to mold</LI>
<LI>Less swelling</LI>
<LI>Reduced edema potential</LI>
<LI>Significantly increased longevity (12 months)</LI>
</UL> </div><div style="margin-bottom: 10px;"><B>MERZ Presence</B> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6796_8_ScreenCapture8.jpg"> </div><div style="margin-bottom: 10px;">Merz did not organize a symposium this year.<wbr> In addition to Bocouture, Radiesse and Belotero, the company exhibited Glytone “the dermal filler with a pharmaceutical heritage’ acquired from Pierre Fabre in Q3:12.<wbr> </div><div style="margin-bottom: 10px;">Glytone contains mannitol, a well-known radical scavenger.<wbr> </div><div style="margin-bottom: 10px;"><DIV class="identifier"><A href="http://clinicaltrials.gov/ct2/show/NCT00777803?term=NT201&amp;rank=6&amp;submit_fld_opt=">NCT00777803</A> - Results from a Ph3 comparison trial with Vistabel for GL (in press) were projected on the booth.<wbr> They show that:</DIV> </div><div style="margin-bottom: 10px;"><DIV class="identifier"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6796_3_ScreenCapture3.jpg"></DIV> </div><div style="margin-bottom: 10px;"><DIV class="identifier"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6796_4_ScreenCapture4.jpg"></DIV> </div><div style="margin-bottom: 10px;"><B>MEDY-TOX Presence </B> </div><div style="margin-bottom: 10px;">Medium-size booth presenting Neuramis and Neuronox.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6796_6_ScreenCapture6.jpg"> </div><div style="margin-bottom: 10px;">Medy-Tox claims that "Approximately a million Neuronox procedures have been administered globally since 2004" - data on file, Medy-Tox (source: Neuronox flyer) </div><div style="margin-bottom: 10px;">The company outlined four articles about Neuronox in the recent issue of 'Dermatology Surgery' (vol 39 Number 1 Part II, Jan 13) introducing "a novel Botulinum Toxin Preparation" </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6796_7_ScreenCapture7.jpg"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> (gathered by the Aesthetic Team) </div><div style="margin-bottom: 10px;">- J&amp; J's Mentor Purified Toxin (ex PurTox) will have a "low pre-marketing profile" (feedback from an ex J&amp;J employee), and its clinical profile may be considered as a "mee too" (feedback from a US dermatologist).<wbr> </div><div style="margin-bottom: 10px;">- Because biodisponibility is low, Revance has to increase the dose.<wbr> Is this going to arise safety concern with the US FDA ? </div><div>- Allergan message to increase the doses of Botox Cosmetic in GL in order to avoid underdosing (could be linked with the fact that Allergan recently reported it will focus on the Botox Cosmetic duration of action of 4 months vs.<wbr> 3 months in the Xeomin label after reintroduction of Xeomin in the US).<wbr> </div><!-- Comment details --><span style="font-weight: bold; font-style: italic;"><br>Comments</span><a name="Neurology6804c"></a><br><div style="border: 1px solid #AAA; background-color: #FFF; margin-left: 10px; padding: 5px;"><div style="margin-bottom: 10px;">With regard to the InPart Transdermal Delivery System: a more comprehensive presentation on their topical Botulinum toxin trial can be found at the company's website: <A href="http://www.transdermalcorp.com/clinical-studies">http:/<wbr>/<wbr>www.<wbr>transdermalcorp.<wbr>com/<wbr>clinical-studies</A> </div><div style="margin-bottom: 10px;">(Presentation can be downloaded when left-clicking on it).<wbr> </div><div>Slides 114-138 are most relevant to botulinum toxin trial.<wbr> </div></div><a name="Neurology6805c"></a><div style="border: 1px solid #AAA; background-color: #FFF; margin-left: 10px; padding: 5px;"><div><UL><LI><SPAN style="LINE-HEIGHT: 1.5em">It is important to mention that </SPAN><SPAN style="LINE-HEIGHT: 1.5em"><STRONG>BoNT-A is the best choice for the treatment of hyperhidrosis</STRONG> - (Dr Marc Heckman at the session "New approaches for Hyperhidrosis").<wbr></SPAN></LI>
<LI><SPAN style="LINE-HEIGHT: 1.5em">According to Juergen Frevert <EM>(Merz at Botulinum Toxins products : from characteristics to recommendations)</EM> and Philippe Bouchard <EM>(CEO - Merz at the Industry Tribune)</EM>, the goal of Merz is to develop new indications for Xeomin.<wbr></SPAN> </LI>
</UL> </div></div><a name="neurology6796attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6796_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(102,7 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6796_2_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(60,5 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6796_3_ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(77,2 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6796_4_ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(38,6 KB)<br>&nbsp;&nbsp;5.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6796_5_ScreenCapture5.jpg">ScreenCapture5.jpg</a>&nbsp;&nbsp;(46,3 KB)<br>&nbsp;&nbsp;6.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6796_6_ScreenCapture6.jpg">ScreenCapture6.jpg</a>&nbsp;&nbsp;(68,7 KB)<br>&nbsp;&nbsp;7.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6796_7_ScreenCapture7.jpg">ScreenCapture7.jpg</a>&nbsp;&nbsp;(56,2 KB)<br>&nbsp;&nbsp;8.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6796_8_ScreenCapture8.jpg">ScreenCapture8.jpg</a>&nbsp;&nbsp;(40,4 KB)<br>&nbsp;&nbsp;9.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6796_9_ScreenCapture9.jpg">ScreenCapture9.jpg</a>&nbsp;&nbsp;(97,4 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20130431&edate=20130101&rec=6796">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-02-11T13:57:51+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-02-11T13:57:51+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Study to Compare Botulax and Botox in Children with Cerebral Palsy</title>
	<pubDate>2013-02-08T19:12:20+01:00</pubDate>
	<wp:post_id>4162</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Hugel has started the Ph3 trial of its BoNT-A in approx.<wbr> 144 children (2 years to 10 years) in Korea (6 sites).<wbr> PE will assess rate of patients with an improvement more than two grade in Physician's Rating Scale score.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG><A href="http://clinicaltrials.gov/ct2/show/NCT01787344?recr=Open&amp;no_unk=Y&amp;phase=012&amp;fund=2&amp;rcv_s=01%2F08%2F2013&amp;rank=108"><STRONG></STRONG></A> </div><div style="margin-bottom: 10px;">Completion dates: July 2013 /<wbr> Nov.<wbr> 2013 </div><div style="margin-bottom: 10px;">PI: Jeong-yi Kwon, MD <TD style="PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 1em; PADDING-TOP: 1ex">Samsung Medical Center -Seoul</TD> </div><div style="margin-bottom: 10px;"><STRONG>Protocol</STRONG> </div><div><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6795_1_ScreenCapture1.jpg"> </div><!-- Comment details --><a name="neurology6795attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6795_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(169,4 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20130431&edate=20130101&rec=6795">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-02-08T19:12:20+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-02-08T19:12:20+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>microRNAs as Biomarker to Predict the Progression of Bladder Urothelial Carcinoma</title>
	<pubDate>2013-02-08T14:17:34+01:00</pubDate>
	<wp:post_id>4163</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: The conclusion of the study, published in the <EM>British Journal of Urology</EM>, shows that microRNA can be useful biomarkers for prognosis in patients with urothelial carcinoma and that the expression levels of several microRNAs, including miR-29c, identified high- and low-risk groups.<wbr>  </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8770_1_ScreenCapture1.jpg"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">According to Kenneth A.<wbr> Berlin (CEO of <STRONG>Rosetta Genomics</STRONG>), ".<wbr>.<wbr>.<wbr> This publication adds to the growing body of clinical data demonstrating the utility of microRNA expression for predicting progression of disease, and for stratification of patients with bladder cancer .<wbr>.<wbr>.<wbr>".<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8770_2_ScreenCapture2.jpg"> </div><div><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8770_3_ScreenCapture3.jpg"> </div><!-- Comment details --><a name="oncology8770attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8770_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(69,4 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8770_2_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(65,1 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8770_3_ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(116,9 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20130431&edate=20130101&rec=8770">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-02-08T14:17:34+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-02-08T14:17:34+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>re: Allergan Reports Botox Sales in Q4 were the "Highest Ever"</title>
	<pubDate>2013-02-08T12:51:13+01:00</pubDate>
	<wp:post_id>4164</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="border-left: 2px solid #8B1010; padding: 0px 0px 5px 12px; margin-bottom: 3px;"><span style="font-weight: bold; font-size: 14px;">Allergan Reports Botox Sales in Q4 were the "Highest Ever"</span>&nbsp;<br><span style="font-size: 12px;">Comment: Management reported that FY12 therapeutic sales accounted for about 52% of total Botox®, an increase of 13% compared to 2011.<wbr> FY12 aesthetic sales accounted for approx.<wbr> 48% of total Botox® sales (an increased of 8% compared to 2011).<wbr> <SPAN style="BACKGROUND-COLOR: #ffffff">At the IMCAS conference in Paris, </SPAN><SPAN style="BACKGROUND-COLOR: #ffffff">Allergan launched Volbella (with lidocaine), a new filler based on the VYCROSS technology, indicated for the lips and the perioral area</SPAN>.<wbr></span>&nbsp;&nbsp;<a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20130431&edate=20130101&rec=6781">...</a><br></div><div style="margin-bottom: 10px;">Additional information arising from the earnings call highlights the point that due to rapidly increasing sales and workloads in neurology and urology, Allergan over the summer of 2012 created dedicated sales teams for neuro-rehabilitation, covering cervical dsytonia and upper limb spasticity, Hence it now has four focused sales team: chronic migraine, neuro-rehab, urology and a hospital team covering all indications.<wbr> <SPAN style="line-height: 1.5em;">Additional country approvals were also mentioned,</SPAN> </div><div style="margin-bottom: 10px;"><STRONG><SPAN style="line-height: 1.5em;">New Approvals</SPAN></STRONG> </div><div style="margin-bottom: 10px;"><OL><LI><SPAN style="line-height: 1.5em;">Russia and Austria for chronic migraine, </SPAN>
</LI>
<LI><SPAN style="line-height: 1.5em;">Russia, Saudi Arabia, Egypt , Kuwait and Argentina for neurogenic bladder;</SPAN>
</LI>
<LI><SPAN style="line-height: 1.5em;">Germany, Austria , Finland and Estonia for iOAB in addition to the Irish reference member state approval; and</SPAN>
</LI>
<LI><SPAN style="line-height: 1.5em;">Hyperhydrosis for GSK in Japan</SPAN>
</LI>
</OL> </div><div>
In terms of Xeomin re-entry to the US market, Allergan does state that it expects to lose some share to Xeomin but in terms of messaging it will focus on the Botox cosmetic label which specifies a duration of action of four months versus three months in the Xeomin label.<wbr> </div><!-- Comment details --><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20130431&edate=20130101&rec=6794">Add a Comment on this Article</a><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology6781">View thread  Neurology6781: Allergan Reports Botox Sales in Q4 were the "Highest Ever"</a>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-02-08T12:51:13+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-02-08T12:51:13+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Acorda Highlights New Stroke Data</title>
	<pubDate>2013-02-08T10:56:43+01:00</pubDate>
	<wp:post_id>4165</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Acorda Therapeutics has presented data at a recent stroke 
conference demonstrating Glial Growth Factor 2 (GGF2) can enhance recovery 
of sensorimotor function in a preclinical model of stroke.<wbr> </div><div style="margin-bottom: 10px;">The data were featured as a late-breaking poster presentation at the 
<ORG>American Heart Association/<wbr>American Stroke Association International Stroke 
Conference</ORG> in <LOCATION value="LU/us.hi.honolu">Honolulu, HI</LOCATION>.<wbr> </div><div style="margin-bottom: 10px;">Commenting on the data Anthony Caggiano VP of R&amp;D stated “These data 
confirm earlier preclinical study results showing that GGF2 can improve recovery 
of function following stroke.<wbr> They also provide valuable information about 
varying dosing regimens that will contribute to the further development of 
GGF2.<wbr>" </div><div style="margin-bottom: 10px;">He went onto say "Previous studies have shown that GGF2 can be effective 
in restoring function when initiating therapy as long as seven days following a 
stroke.<wbr> Currently approved stroke interventions need to be administered within a 
few hours of an event, which limits therapy to a small minority of people who 
experience a stroke.<wbr> Early data on GGF2 suggest a longer time window to 
administer treatment, which represents a potentially critical advance.<wbr>” </div><div style="margin-bottom: 10px;"><STRONG>Key Study Findings</STRONG> </div><div style="margin-bottom: 10px;">The poster, entitled “Optimized Dosing of Glial Growth Factor 2 in a Middle 
Cerebral Artery Occlusion Model Increases GAP43 Expression,” reviewed data from 
study groups receiving differing doses of GGF2 to determine which dose was most 
effective in enhancing recovery of sensorimotor function after stroke.<wbr> This was 
measured by several sensorimotor function tests, including limb placement.<wbr> 
Treatment was initiated 24 hours after the stroke.<wbr> The study showed significant 
improvements in sensorimotor recovery with GGF2 that were related to dose and 
frequency of treatment.<wbr> As was seen in previous studies, improvements were not 
associated with reduced lesion volume, but in this study were shown to be 
associated with increased expression of the growth associated protein, GAP43, 
within the brain, both close to and distant from the area of injury.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>What is GGF2</STRONG> </div><div style="margin-bottom: 10px;">GGF2 is the leading development candidate from the Company’s neuregulin 
program.<wbr> Neuregulins are a class of naturally occurring protein growth factors 
that have multiple effects on the nervous and cardiovascular systems.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Next Steps</STRONG> </div><div>Acorda is currently conducting a clinical program for GGF2 in heart failure 
and preclinical development in a number of neurological indications, including 
peripheral nerve injury and stroke.<wbr> The first clinical trial of GGF2, a Phase 1 
study of GGF2 in patients with heart failure, was completed in late 2012.<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20130431&edate=20130101&rec=6793">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-02-08T10:56:43+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-02-08T10:56:43+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>A Ph2 of LHRH +/- Zytiga (abiraterone) Has Started in Men with Prostate Cancer</title>
	<pubDate>2013-02-07T17:53:18+01:00</pubDate>
	<wp:post_id>4166</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: The goal of the study is to learn if treatment with HT (Zoladex, Lupron, Degarelix) +/<wbr>- abiraterone and prednisone for 8 months controls the disease better than treatment with HT alone.<wbr> Primary endpoint will assess PSA Free Survival.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG><A href="http://clinicaltrials.gov/ct2/show/NCT01786265?recr=Open&amp;no_unk=Y&amp;phase=012&amp;fund=2&amp;rcv_s=01%2F07%2F2013&amp;rank=230"><STRONG></STRONG></A> </div><div style="margin-bottom: 10px;">Sponsor: M.<wbr>D Anderson Cancer Center - Collaborator: Janssen Services LLC </div><div style="margin-bottom: 10px;">Recruitment: approx 200 men with prostate cancer who have PSA progression after prostatectomy and/<wbr>or radiotherapy.<wbr> </div><div style="margin-bottom: 10px;">Start date: Feb 2013 - Completion date: Feb 2017 </div><div>PI: Christopher Logothetis, MD </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20130431&edate=20130101&rec=8768">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-02-07T17:53:18+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-02-07T17:53:18+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>re: Rhenovia Initiates Drug Research Program in Huntington's Disease (HD)</title>
	<pubDate>2013-02-07T14:20:16+01:00</pubDate>
	<wp:post_id>4167</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="border-left: 2px solid #8B1010; padding: 0px 0px 5px 12px; margin-bottom: 3px;"><span style="font-weight: bold; font-size: 14px;">Rhenovia Initiates Drug Research Program in Huntington's Disease (HD)</span>&nbsp;<br><span style="font-size: 12px;">Comment: The company has started to develop the use of biostimulation as a novel approach for drug development in HD.<wbr></span>&nbsp;&nbsp;<a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20130431&edate=20130101&rec=6305">...</a><br></div><div style="margin-bottom: 10px;">After the 1st round of seed funding of &euro;350,000 in 2009, Rhenovia is preparing a second round of &euro;2.<wbr>5M to accelerate its development.<wbr> The company plans to recruit about 20 new employees in France over the next 5 years.<wbr> </div><div style="margin-bottom: 10px;">Rhenovi announced yesterday it has had its position confirmed as world leader in the field of biosimulation for research into drugs for the treatment of diseases of the CNS.<wbr> </div><div>Source: Company PR </div><!-- Comment details --><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20130431&edate=20130101&rec=6792">Add a Comment on this Article</a><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology6305">View thread  Neurology6305: Rhenovia Initiates Drug Research Program in Huntington's Disease (HD)</a>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-02-07T14:20:16+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-02-07T14:20:16+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Addex to Focus Resources on Clinical Pipeline for Rare Diseases</title>
	<pubDate>2013-02-07T10:56:35+01:00</pubDate>
	<wp:post_id>4168</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: B.<wbr> Chowrira (CEO) reported that value drivers for 2013 include the initiation of a POC trial of dipraglurant in rare dystonias, the completion of GABA(B)-RPAM Ph1 testing for Charcot-Marie-Tooth neuropathy.<wbr> To improve the Company's liquidity and long term outlook, Addex will secure a listing on a US stock exchange.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Addex will advance current clinical and pre-IND programs in certain diseases where orphan drug designation can be reasonably achieved in the major commercial markets - U.<wbr>S.<wbr>, Europe and Japan.<wbr> </div><div style="margin-bottom: 10px;">In executing this strategy and to maximize potential clinical success in at least two programs over the next 12 months, the company will reduce its overall cost structure, particularly around its early-stage discovery efforts, while maintaining its core competency and expertise in allosteric modulation.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6791_3_ScreenCapture3.jpg"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6791_1_ScreenCapture1.jpg"> </div><div><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6791_2_ScreenCapture2.jpg"> </div><!-- Comment details --><a name="neurology6791attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6791_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(4,3 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6791_2_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(66,7 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6791_3_ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(73,2 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20130431&edate=20130101&rec=6791">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-02-07T10:56:35+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-02-07T10:56:35+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Aduro Biotech to Advance Portfolio of Combination Vaccine Treatments</title>
	<pubDate>2013-02-06T11:09:54+01:00</pubDate>
	<wp:post_id>4169</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Aduro, a clinical-stage immunotherapy company located in Berkeley (California), has acquired all GVAX assets from BioSante Pharm.<wbr>.<wbr> End of last month, the company completed an equity financing of $6.<wbr>5M (€4.<wbr>8M).<wbr> Management believes that combinations will become the standard for the next generation immunotherapies.<wbr> Of note, the sequential administration of GVAX Pancreas and the <I>Listeria</I>-based CRS-207 is currently assessed in a randomized, controlled Phase 2 trial in patients with metastatic pancreatic cancer.<wbr> (interim analysis planned H1:13).<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">- synergy between listeria and other vaccine technologies would improve efficacy.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8766_3_ScreenCapture3.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8766_2_ScreenCapture2.jpg"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">The company previously licensed 2 GVAX vaccines (GVAX Pancreas and GVAX Prostate), for use in combination with its Listeria-based vaccines.<wbr> </div><div style="margin-bottom: 10px;">See <a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20130431&edate=20130101&rec=7339" class="defaultlink">Oncology7339: Aduro BioTech Licenses GVAX Cancer Vaccines from BioSante</a>.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">- covers all uses and includes additional vaccines for multiple myeloma, breast and colon cancers.<wbr> </div><div style="margin-bottom: 10px;">- assumes rights to the existing license agreement for GVAX Melanoma.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">- based on human cancer cell lines that are genetically modified to secrete granulocyte-macrophage colony-stimulating factor (GM-CSF), an immune-stimulatory cytokine.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8766_4_ScreenCapture4.jpg"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><U>Platform</U> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8766_1_ScreenCapture1.jpg"> </div><div style="margin-bottom: 10px;"><U>Pipeline - Available for partnering</U> </div><div><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8766_5_ScreenCapture5.jpg"> </div><!-- Comment details --><a name="oncology8766attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8766_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(45,2 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8766_2_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(43,9 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8766_3_ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(30,6 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8766_4_ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(93,4 KB)<br>&nbsp;&nbsp;5.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8766_5_ScreenCapture5.jpg">ScreenCapture5.jpg</a>&nbsp;&nbsp;(54,7 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20130431&edate=20130101&rec=8766">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-02-06T11:09:54+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-02-06T11:09:54+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Novo Nordisk - The 'Experts in Protein Technology'</title>
	<pubDate>2013-02-05T18:20:44+01:00</pubDate>
	<wp:post_id>4170</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment:  Novo Nordisk outlines five key strategic focus areas including Diabetes, Obesity, Haemophilia, Growth Disorders and Inflammation.<wbr> </div><div style="margin-bottom: 10px;"><SPAN style="line-height: 1.5em;">Novo Nordisk  published their 2012 annual report this week, defining themselves as experts in protein technology, not just a &lsquo;diabetes company&rsquo;.<wbr>  </SPAN> </div><div style="margin-bottom: 10px;">There may be a long term goal to diversify but, they are the world's largest insulin producer and had a total sales growth of 18% in 2012 ($14 billion) -  due to the strong sales from their diabetes franchise.<wbr>  Sales growth for 2013 is a projected 8-11%.<wbr> </div><div style="margin-bottom: 10px;">The report centred around five key strategic focus areas of 2012 which will be continued and further developed in 2013: </div><div><UL><LI><SPAN style="line-height: 1.5em;">Expand its leadership in Diabetes Care</SPAN>
</LI>
<LI><SPAN style="line-height: 1.5em;">Establish a presence in Obesity</SPAN>
</LI>
<LI><SPAN style="line-height: 1.5em;">Pursue a leadership position in Haemophilia</SPAN>
<UL><LI><SPAN style="line-height: 1.5em;">In October 2012, turoctocog alfa &ndash; a recombinant factor VIII therapy &ndash; was filed for approval in Europe</SPAN>
</LI>
<LI><SPAN style="line-height: 1.5em;">US.<wbr> Long-acting versions of recombinant factor VII and factor IX are in Phase III development</SPAN>
</LI>
<LI><SPAN style="line-height: 1.5em;">Novo Nordisk did suffer a setback in 2012 with vatreptacog alfa, a fast-acting recombinant factor VIIa analogue whereby some patients in the trial developed anti-drug antibodies and chose to discontinue development</SPAN>
</LI>
</UL>
</LI>
<LI><SPAN style="line-height: 1.5em;">Build its Growth Disorders franchise by providing new convenient products and devices</SPAN>
<UL><LI><SPAN style="line-height: 1.5em;">Novo Nordisk is developing a long-acting growth hormone formulation, currently in Phase I trials</SPAN>
</LI>
</UL>
</LI>
<LI><SPAN style="line-height: 1.5em;">Establish a presence in inflammation using its expertise in protein design</SPAN>
<UL><LI><SPAN style="line-height: 1.5em;">3 candidates in Phase II development</SPAN>
</LI>
</UL>
</LI>
</UL> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20130431&edate=20130101&rec=10309">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-02-05T18:20:44+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-02-05T18:20:44+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category pharma-news > <![CDATA[Pharma News]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Ph3 Trial of Revance's RT001 Topical Toxin for Crow's Feet Lines (CFL)</title>
	<pubDate>2013-02-05T18:07:28+01:00</pubDate>
	<wp:post_id>4171</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Clinicaltrials.<wbr>gov is listed the new Ph3, which will assess the efficacy and safety of the drug compared to placebo for moderate to severe CFL.<wbr> Primary endpoint will measure composite endpoint based upon the investigator global assessment and patient assessment of severity of lateral canthal lines.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG><A href="http://clinicaltrials.gov/ct2/show/NCT01776606?recr=Open&amp;no_unk=Y&amp;phase=012&amp;fund=2&amp;rcv_s=01%2F05%2F2013&amp;rank=37"><STRONG></STRONG></A><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Recruitment: about 240 (both genders - 18 to 65 years) </div><div style="margin-bottom: 10px;">Started Dec 2012 - completion date Feb 2013 /<wbr> March 2013 </div><div style="margin-bottom: 10px;">Location: Dermatology Research Institute (Florida) </div><div style="margin-bottom: 10px;"><STRONG>Product Description</STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6784_1_ScreenCapture1.jpg"> </div><div style="margin-bottom: 10px;">Proprietary 150kD neurotoxin molecule with TransMTS peptide </div><div style="margin-bottom: 10px;">- reconstituted with poloxamer gel </div><div style="margin-bottom: 10px;">Liquid at refrigerated temperatures; gels at room temperature </div><div style="margin-bottom: 10px;">Applied in the physician's office </div><div style="margin-bottom: 10px;">Gel stays on skin for 30 minutes </div><div>- easily wiped clean with water </div><!-- Comment details --><a name="neurology6784attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6784_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(19,8 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20130431&edate=20130101&rec=6784">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-02-05T18:07:28+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-02-05T18:07:28+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Allergan Reports Botox Sales in Q4 were the "Highest Ever"</title>
	<pubDate>2013-02-05T15:55:29+01:00</pubDate>
	<wp:post_id>4172</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Management reported that FY12 therapeutic sales accounted for about 52% of total Botox®, an increase of 13% compared to 2011.<wbr> FY12 aesthetic sales accounted for approx.<wbr> 48% of total Botox® sales (an increased of 8% compared to 2011).<wbr> <SPAN style="BACKGROUND-COLOR: #ffffff">At the IMCAS conference in Paris, </SPAN><SPAN style="BACKGROUND-COLOR: #ffffff">Allergan launched Volbella (with lidocaine), a new filler based on the VYCROSS technology, indicated for the lips and the perioral area</SPAN>.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><UL><LI><SPAN style="BACKGROUND-COLOR: #ffffff">In Q4 12, Allergan sales grew vs.<wbr> </SPAN><SPAN style="BACKGROUND-COLOR: #ffffff">Q4 11 by 8.<wbr>1% in lc.<wbr></SPAN></LI>
<LI><SPAN style="BACKGROUND-COLOR: #ffffff">FY12 sales increased by 9.<wbr>1% in lc vs.<wbr> FY</SPAN><SPAN style="BACKGROUND-COLOR: #ffffff">11</SPAN><SPAN style="BACKGROUND-COLOR: #ffffff">.<wbr></SPAN></LI>
</UL> </div><div style="margin-bottom: 10px;"><SPAN style="BACKGROUND-COLOR: #ffffff"></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="BACKGROUND-COLOR: #ffffff">Management outlined that " .<wbr>.<wbr>.<wbr> <SPAN style="BACKGROUND-COLOR: #ffffff">Botox® sales in Q4 were the highest ever at $475 million </SPAN><SPAN style="BACKGROUND-COLOR: #ffffff">benefiting from the normal high aesthetics and an accelerating </SPAN><SPAN style="BACKGROUND-COLOR: #ffffff">trend in therapeutics.<wbr> </SPAN><SPAN style="BACKGROUND-COLOR: #ffffff">Sales grew vs.<wbr> the Fourth Quarter of 2011 by 14.<wbr>7% </SPAN><SPAN style="BACKGROUND-COLOR: #ffffff">to local currencies and 14.<wbr>3% in dollars.<wbr> </SPAN></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="BACKGROUND-COLOR: #ffffff"><SPAN style="BACKGROUND-COLOR: #ffffff">For the full year, Botox® sales increased 12.<wbr>7% in </SPAN><SPAN style="BACKGROUND-COLOR: #ffffff">local currencies and 10.<wbr>7% in dollars.<wbr> </SPAN><SPAN style="BACKGROUND-COLOR: #ffffff">The therapeutic indications grew approximately 13% </SPAN><SPAN style="BACKGROUND-COLOR: #ffffff">in dollars and the aesthetics sales grew approximately </SPAN><SPAN style="BACKGROUND-COLOR: #ffffff">8% in dollars with local currency growth for both franchises </SPAN><SPAN style="BACKGROUND-COLOR: #ffffff">being greater in local currencies by approximately 200 basis points".<wbr></SPAN></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="BACKGROUND-COLOR: #ffffff"><STRONG></STRONG></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="BACKGROUND-COLOR: #ffffff"><SPAN style="BACKGROUND-COLOR: #ffffff">For the FY12, Allergan spent $927 million on R &amp; </SPAN><SPAN style="BACKGROUND-COLOR: #ffffff">D, an increase of 8.<wbr>1% over 2011</SPAN>.<wbr></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="BACKGROUND-COLOR: #ffffff">Management indicated that : " .<wbr>.<wbr>.<wbr> <SPAN style="BACKGROUND-COLOR: #ffffff">As we reviewed our urology R &amp; D portfolio we have </SPAN><SPAN style="BACKGROUND-COLOR: #ffffff">determine which products to fund for late stage development.<wbr> </SPAN><SPAN style="BACKGROUND-COLOR: #ffffff">Given positive Phase III data SER120, development </SPAN><SPAN style="BACKGROUND-COLOR: #ffffff">in cooperation with our partner Serenity, Allergan </SPAN><SPAN style="BACKGROUND-COLOR: #ffffff">has decided to fund a confirmatory Phase III trial.<wbr> </SPAN><SPAN style="BACKGROUND-COLOR: #ffffff">With mixed efficacy data Botox® for benign hyper static </SPAN><SPAN style="BACKGROUND-COLOR: #ffffff">hyperplasia we have decided to terminate this program".<wbr> </SPAN><BR><BR></SPAN> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">The company expects to execute a signed agreement in H1:13.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Total product net sales between $5,900 million and $6,200 million, which excludes the obesity intervention business.<wbr> </div><div style="margin-bottom: 10px;"><UL><LI>Botox® product net sales between $1,900 million and $2,000 million.<wbr> </LI>
<LI>LATISSE® product net sales at approximately $110 million.<wbr> </LI>
<LI>Facial aesthetics product net sales between $410 million and $440 million.<wbr></LI>
</UL> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">- <U><STRONG>Botox® in OAB</STRONG></U> " .<wbr>.<wbr>.<wbr> <SPAN style="BACKGROUND-COLOR: #ffffff">if we compare and contrast to chronic migraine, it was clear to us from the very </SPAN><SPAN style="BACKGROUND-COLOR: #ffffff">beginning that urology would move much quicker.<wbr> </SPAN><SPAN style="BACKGROUND-COLOR: #ffffff">Urologists are really procedure-based physicians.<wbr> </SPAN><SPAN style="BACKGROUND-COLOR: #ffffff">They like doing things like this.<wbr> </SPAN><SPAN style="BACKGROUND-COLOR: #ffffff">Obviously from my remarks once we've trained urologists </SPAN><SPAN style="BACKGROUND-COLOR: #ffffff">how to deploy a scope and use the bladder injections </SPAN><SPAN style="BACKGROUND-COLOR: #ffffff">to go from 200 units for NDO to a hundred for idiopathic </SPAN><SPAN style="BACKGROUND-COLOR: #ffffff">overactive bladder is pretty simple.<wbr> </SPAN><SPAN style="BACKGROUND-COLOR: #ffffff">Coupled with that, the reimbursement codes is relatively </SPAN><SPAN style="BACKGROUND-COLOR: #ffffff">complicated but it depends on site of care but I would </SPAN><SPAN style="BACKGROUND-COLOR: #ffffff">say not only favorable in our point of view but also </SPAN><SPAN style="BACKGROUND-COLOR: #ffffff">the point of view of the urology practices.<wbr> </SPAN><SPAN style="BACKGROUND-COLOR: #ffffff">.<wbr>.<wbr>.<wbr> in terms of training, this will continue to </SPAN><SPAN style="BACKGROUND-COLOR: #ffffff">pick up in terms of those that still have not yet been </SPAN><SPAN style="BACKGROUND-COLOR: #ffffff">trained and certainly, we heard prior to the approval </SPAN><SPAN style="BACKGROUND-COLOR: #ffffff">of the latest indication, a lot of doctors were already </SPAN><SPAN style="BACKGROUND-COLOR: #ffffff">thinking about the patients if you like they had in </SPAN><SPAN style="BACKGROUND-COLOR: #ffffff">their practice just waiting for approval and of course </SPAN><SPAN style="BACKGROUND-COLOR: #ffffff">that meant really access to reimbursement, so I think </SPAN><SPAN style="BACKGROUND-COLOR: #ffffff">adding all those factors together, the over active </SPAN><SPAN style="BACKGROUND-COLOR: #ffffff">bladder launch which by the way still has not formally </SPAN><SPAN style="BACKGROUND-COLOR: #ffffff">occurred, this will be right around the corner, should be pretty quick"</SPAN>.<wbr> </div><div>- <U><STRONG>Botox® growth in 2013</STRONG></U>, " .<wbr>.<wbr>.<wbr> <SPAN style="BACKGROUND-COLOR: #ffffff">the growth will be higher on the therapeutic </SPAN><SPAN style="BACKGROUND-COLOR: #ffffff">side than the aesthetic .<wbr>.<wbr>.<wbr></SPAN> <SPAN style="BACKGROUND-COLOR: #ffffff">If we look at the cosmetic side, we think the market </SPAN><SPAN style="BACKGROUND-COLOR: #ffffff">in the US is growing pretty close to 10%.<wbr> </SPAN><SPAN style="BACKGROUND-COLOR: #ffffff">The European market is also very healthy.<wbr> </SPAN><SPAN style="BACKGROUND-COLOR: #ffffff">I gave you some very specific numbers on fillers where </SPAN><SPAN style="BACKGROUND-COLOR: #ffffff">it's easier for us to get behind it and the issue we </SPAN><SPAN style="BACKGROUND-COLOR: #ffffff">always have with BOTOX Europe is how do we split therapeutic </SPAN><SPAN style="BACKGROUND-COLOR: #ffffff">and aesthetic even ourselves because of lots of shipments </SPAN><SPAN style="BACKGROUND-COLOR: #ffffff">that go around from one country to another and then of course trying to do that for our competitors becomes like an even greater defining process when we have </SPAN><SPAN style="BACKGROUND-COLOR: #ffffff">our own data but stepping back from all of that I think </SPAN><SPAN style="BACKGROUND-COLOR: #ffffff">you can see pretty healthy consumer facing market demand </SPAN><SPAN style="BACKGROUND-COLOR: #ffffff">and hence why we feel pretty good about BOTOX and its </SPAN><SPAN style="BACKGROUND-COLOR: #ffffff">entirety for 2013".<wbr></SPAN> </div><!-- Comment details --><span style="font-weight: bold; font-style: italic;"><br>Comments</span><a name="Neurology6794c"></a><br><div style="border: 1px solid #AAA; background-color: #FFF; margin-left: 10px; padding: 5px;"><div style="margin-bottom: 10px;">Additional information arising from the earnings call highlights the point that due to rapidly increasing sales and workloads in neurology and urology, Allergan over the summer of 2012 created dedicated sales teams for neuro-rehabilitation, covering cervical dsytonia and upper limb spasticity, Hence it now has four focused sales team: chronic migraine, neuro-rehab, urology and a hospital team covering all indications.<wbr> <SPAN style="line-height: 1.5em;">Additional country approvals were also mentioned,</SPAN> </div><div style="margin-bottom: 10px;"><STRONG><SPAN style="line-height: 1.5em;">New Approvals</SPAN></STRONG> </div><div style="margin-bottom: 10px;"><OL><LI><SPAN style="line-height: 1.5em;">Russia and Austria for chronic migraine, </SPAN>
</LI>
<LI><SPAN style="line-height: 1.5em;">Russia, Saudi Arabia, Egypt , Kuwait and Argentina for neurogenic bladder;</SPAN>
</LI>
<LI><SPAN style="line-height: 1.5em;">Germany, Austria , Finland and Estonia for iOAB in addition to the Irish reference member state approval; and</SPAN>
</LI>
<LI><SPAN style="line-height: 1.5em;">Hyperhydrosis for GSK in Japan</SPAN>
</LI>
</OL> </div><div>
In terms of Xeomin re-entry to the US market, Allergan does state that it expects to lose some share to Xeomin but in terms of messaging it will focus on the Botox cosmetic label which specifies a duration of action of four months versus three months in the Xeomin label.<wbr> </div></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20130431&edate=20130101&rec=6781">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-02-05T15:55:29+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-02-05T15:55:29+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>New Drug Pricing Regulations Come into Effect in Greece</title>
	<pubDate>2013-02-05T15:22:38+01:00</pubDate>
	<wp:post_id>4173</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: New regulations governing the price of medicines have been published in a Ministerial Decision by Greece's deputy minister of health, Marios Salmas, with the order that the decision be published in the Greek government gazette, thus bringing its regulations into law.<wbr> The regulations in the Ministerial Decision are numerous and many are technical in nature, but there are a number of important changes that have immediate implications for pharmaceutical companies.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><UL style="WIDOWS: 2; TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; FONT: 13px arial, sans-serif; WHITE-SPACE: normal; ORPHANS: 2; LETTER-SPACING: normal; COLOR: rgb(34,34,34); WORD-SPACING: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px" type="disc"><LI style="MARGIN-LEFT: 15px"></LI>
<LI style="MARGIN-LEFT: 15px"></LI>
<LI style="MARGIN-LEFT: 15px"></LI>
<LI style="MARGIN-LEFT: 15px"></LI>
</UL> </div><div style="margin-bottom: 10px;"><P style="WIDOWS: 2; TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; FONT: 13px arial, sans-serif; WHITE-SPACE: normal; ORPHANS: 2; LETTER-SPACING: normal; COLOR: rgb(34,34,34); WORD-SPACING: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"></P> </div><div style="margin-bottom: 10px;"><UL style="WIDOWS: 2; TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; FONT: 13px arial, sans-serif; WHITE-SPACE: normal; ORPHANS: 2; LETTER-SPACING: normal; COLOR: rgb(34,34,34); WORD-SPACING: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px" type="disc"><LI style="MARGIN-LEFT: 15px"></LI>
<LI style="MARGIN-LEFT: 15px"></LI>
</UL> </div><div style="margin-bottom: 10px;"><P style="WIDOWS: 2; TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; FONT: 13px arial, sans-serif; WHITE-SPACE: normal; ORPHANS: 2; LETTER-SPACING: normal; COLOR: rgb(34,34,34); WORD-SPACING: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"></P> </div><div style="margin-bottom: 10px;"><P style="WIDOWS: 2; TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; FONT: 13px arial, sans-serif; WHITE-SPACE: normal; ORPHANS: 2; LETTER-SPACING: normal; COLOR: rgb(34,34,34); WORD-SPACING: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"></P> </div><div style="margin-bottom: 10px;"><P style="WIDOWS: 2; TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; FONT: 13px arial, sans-serif; WHITE-SPACE: normal; ORPHANS: 2; LETTER-SPACING: normal; COLOR: rgb(34,34,34); WORD-SPACING: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"></P> </div><div><P style="WIDOWS: 2; TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; FONT: 13px arial, sans-serif; WHITE-SPACE: normal; ORPHANS: 2; LETTER-SPACING: normal; COLOR: rgb(34,34,34); WORD-SPACING: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"></P> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20130431&edate=20130101&rec=10306">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-02-05T15:22:38+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-02-05T15:22:38+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category pharma-news > <![CDATA[Pharma News]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Key Messages from Takeda's 9-Month Results</title>
	<pubDate>2013-02-05T09:36:55+01:00</pubDate>
	<wp:post_id>4174</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Overall sales in the period (ended December 2012) increased by 5.<wbr>5% to $12.<wbr>9bn.<wbr> Revenue from Leuplin (leuprorelin) decreased 5.<wbr>5% to $944M, and dropped 4.<wbr>9% to $326M for the third quarter.<wbr> Of note, Management reported that the Ph3 results from TAK-700 /<wbr> Orteronel in post-docetaxel setting (<A href="http://clinicaltrials.gov/ct2/show/NCT01193257?term=21005&amp;rank=2">NCT01193257</A>) will be presented at ASCO and ESMO this year.<wbr> Approvals are expected next year in the US, and FY15-FY16 (JP/<wbr>EU).<wbr> FY2012 forecasts remain unchanged from the latest announcement.<wbr> Key figures are provided below.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8765_1_ScreenCapture1.jpg"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8765_4_ScreenCapture4.jpg"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8765_2_ScreenCapture2.jpg"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Thanks to the acquisitions of Nycomed and Multilab the sales increased about 2.<wbr>3 times over year to reach JPY151.<wbr>1bn (14% of the total ethical drug sales of Takeda).<wbr> </div><div><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8765_3_ScreenCapture3.jpg"> </div><!-- Comment details --><a name="oncology8765attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8765_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(41,1 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8765_2_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(132,1 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8765_3_ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(128,2 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8765_4_ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(158 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20130431&edate=20130101&rec=8765">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-02-05T09:36:55+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-02-05T09:36:55+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>re: SPA for Tivantinib in 2nde-Line Ph3 Trial in MET-High HCC Patients</title>
	<pubDate>2013-02-04T18:59:53+01:00</pubDate>
	<wp:post_id>4175</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="border-left: 2px solid #8B1010; padding: 0px 0px 5px 12px; margin-bottom: 3px;"><span style="font-weight: bold; font-size: 14px;">SPA for Tivantinib in 2nde-Line Ph3 Trial in MET-High HCC Patients</span>&nbsp;<br><span style="font-size: 12px;">Comment: Daiichi and ArQule have announced a SPA agreement with the FDA for the design of the Ph3.<wbr> Details of the trial as well as ongoing development program with the drug are provided below.<wbr></span>&nbsp;&nbsp;<a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20130431&edate=20130101&rec=8545">...</a><br></div><div style="margin-bottom: 10px;">The first patient has been enrolled in the pivotal Phase 3 METIV-HCC (<STRONG>MET</STRONG>-high patients with <STRONG>tiv</STRONG>antinib in HCC) trial of tivantinib (ARQ 197).<wbr> PE will assess Overall survival (OS) in Intent to Treat (ITT) population.<wbr> </div><div style="margin-bottom: 10px;">The <a href="http://www.clinicaltrials.gov/ct2/show/NCT01755767?term=metiv&rank=1" class="defaultlink">METIV-HCC</a> trial is a randomized, double-blinded, controlled study of previously treated patients with MET-high inoperable HCC who will receive tivantinib or placebo.<wbr> The primary endpoint is overall survival (OS), and the secondary endpoint is progression-free survival (PFS).<wbr> Approximately 300 patients are planned to be enrolled at approximately 120 clinical centers worldwide.<wbr> </div><div>Tivantinib, an investigational selective inhibitor of MET, a receptor tyrosine kinase, is being evaluated for the treatment of patients diagnosed with hepatocellular carcinoma (HCC) who have received one or two prior systemic anti-cancer therapies.<wbr> </div><!-- Comment details --><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20130431&edate=20130101&rec=8763">Add a Comment on this Article</a><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology8545">View thread  Oncology8545: SPA for Tivantinib in 2nde-Line Ph3 Trial in MET-High HCC Patients</a>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-02-04T18:59:53+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-02-04T18:59:53+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Aesthetics Leadership Change at Merz in the US</title>
	<pubDate>2013-02-04T18:54:12+01:00</pubDate>
	<wp:post_id>4176</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Jim Hartman has been appointed to VP President of the US Aesthetics Business Unit, which includes Xeomin, Radiesse and Belotero.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Hired in June 2012 to lead the US Dermatology Business Unit, which includes Naftin, Mederma and Onmel.<wbr> </div><div style="margin-bottom: 10px;">Prior to join Merz, he was the VP, Global Marketing &amp; Business Development at Obagi Medical Products.<wbr> </div><div style="margin-bottom: 10px;">Previously, he was Senior VP of US Commercial Operations, and Vice President of US Marketing for Stiefel Laboratories, a leader in global dermatology and skin health.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><STRONG>Mikael Svensson</STRONG> will now report directly to Mr.<wbr> Hartman.<wbr> </div><div style="margin-bottom: 10px;">Svensson will assume responsibility for marketing our aesthetic filler franchise which includes BELOTERO BALANCE<SUP>®</SUP> Dermal Filler and RADIESSE<SUP>®</SUP> Volumizing Filler in his new role, Director of Marketing Filler Franchise.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Liz Newman</STRONG> will continue in her role as Director of Marketing, maintaining responsibility for marketing our aesthetic toxin /<wbr> phlebology franchise which includes XEOMIN<SUP>®</SUP> (incobotulinumtoxinA) and Asclera<SUP>®</SUP> (polidocanol) Injection.<wbr> </div><div>Source: Merz </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20130431&edate=20130101&rec=6780">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-02-04T18:54:12+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-02-04T18:54:12+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>re: Theratechnologies' Second Generation GRF Peptide Enters PC Phase</title>
	<pubDate>2013-02-04T18:32:43+01:00</pubDate>
	<wp:post_id>4177</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="border-left: 2px solid #8B1010; padding: 0px 0px 5px 12px; margin-bottom: 3px;"><span style="font-weight: bold; font-size: 14px;">Theratechnologies' Second Generation GRF Peptide Enters PC Phase</span>&nbsp;<br><span style="font-size: 12px;">Comment: According to the company, TH1173 exhibits superior pharmaceutical properties than tesamorelin.<wbr> It is a shorter peptide with better physical and chemical stability.<wbr> FIM is planned in Q1 2013.<wbr> Potential future indication could include growth hormone replacement in growth hormone deficient patient populations.<wbr></span>&nbsp;&nbsp;<a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20130431&edate=20130101&rec=6922">...</a><br></div><div style="margin-bottom: 10px;">The US Patent and Trademark Office (USPTO) has granted a patent for the drug, providing for patent protection &gt;2030.<wbr> Of note, TH1173 is unpartnered.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Drug Clinical Program</STRONG> </div><div>The PC phase is completed.<wbr> Results, including those from 7-day and 28-day toxicology trials, warrent the pursuit of clinical stage.<wbr> </div><!-- Comment details --><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20130431&edate=20130101&rec=7259">Add a Comment on this Article</a><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology6922">View thread  Endocrinology6922: Theratechnologies' Second Generation GRF Peptide Enters PC Phase</a>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-02-04T18:32:43+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-02-04T18:32:43+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category endocrinology > <![CDATA[Endocrinology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Epidemiology of Acromegaly in Denmark</title>
	<pubDate>2013-02-04T17:18:21+01:00</pubDate>
	<wp:post_id>4178</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Aarhus U.<wbr> Hospital, the sponsor of this observational study, will focus on the comparison between the outcome of surgery alone vs.<wbr> medical treatment with SSA.<wbr> Primary outcome measure will assess mortality.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><A href="http://clinicaltrials.gov/ct2/show/NCT01752621?term=acromegaly&amp;recr=Open&amp;no_unk=Y&amp;rank=1&amp;submit_fld_opt=">NCT01752621</A> Incidence and late prognosis of acromegaly in Denmark from 1991 - 2010 Twenty years of medical treatment.<wbr> </div><div style="margin-bottom: 10px;">Recruitment: about 500 patients diagnosed with acromegaly in years 1991 - 2010.<wbr> </div><div style="margin-bottom: 10px;">Start date: Feb 2013 - Completion date: March 2015.<wbr> </div><div style="margin-bottom: 10px;">Status: Active but not yet open for recruitment.<wbr> </div><div style="margin-bottom: 10px;">Two cohorts: surgery treatment (acromegaly treated with surgery) and medical treatment (acromegaly treated with somatostatin).<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div>Denmark holds a unique position in terms of epidemiological studies due to the existence of well organized databases which include all its inhabitants.<wbr> A recognised problem with epidemiological surveys from specialised centres is whether the figures are representative for the general population.<wbr> A nationwide Danish study will profit from the fact that every Danish citizen holds a unique ID number that makes it easy to retrieve and combine pertinent data regarding health, disease and death from different registries.<wbr> The investigators have previously used this for a landmark survey of another rare endocrine disease, i.<wbr>e.<wbr> Cushing's syndrome.<wbr> This publication has been cited more than 100 times.<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20130431&edate=20130101&rec=7257">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-02-04T17:18:21+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-02-04T17:18:21+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category endocrinology > <![CDATA[Endocrinology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>ESOU 2013 - Highlights in Prostate Cancer</title>
	<pubDate>2013-02-04T15:52:40+01:00</pubDate>
	<wp:post_id>4179</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: We are grateful to Amauri Soares for forwarding the slides to be shared with all Traction users.<wbr> They present an up-to-date picture of what stage each competitor has reached, and how the data compares.<wbr> </div><div>Please see <a href="http://ci.beaufour-ipsen.com/traction?type=np&proj=*&sdate=20130431&edate=20130101&rs=/link%20Oncology8764%401" class="defaultlink">@1</a> </div><!-- Comment details --><a name="oncology8762attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8762_1_ESOU2013%2dProstate.pptx">ESOU2013-Prostate.pptx</a>&nbsp;&nbsp;(2,6 MB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20130431&edate=20130101&rec=8762">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-02-04T15:52:40+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-02-04T15:52:40+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Intelligence from Spain Brings Additional Details on Lexicon's Ph3 for Carcinoid Syndrome</title>
	<pubDate>2013-02-04T14:47:57+01:00</pubDate>
	<wp:post_id>4180</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Thanks to Eva Pineda (Medical Adviser), we have learnt that the Ph3 study is not only recruiting in the US but in Spain as well.<wbr> Six Spanish NET specialists/<wbr>KOLs will participate in the trial.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Recruitment in Spain: expected to start in April 2013.<wbr> </div><div style="margin-bottom: 10px;">According to the clinical study protocol, 50 international centers will participate to include 104 patients.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div><DIV class="i" id="endocrinology7077.01i">
<DIV class="ii" id="endocrinology7077.01ii"><STRONG>TELESTAR</STRONG> (Telotristat Etiprate for Somatostatin Analogue Refractory Carcinoid Syndrome) - <A class="defaultlink" href="http://clinicaltrials.gov/ct2/show/NCT01677910?recr=Open&amp;fund=2&amp;rcv_s=08%2F21%2F2012&amp;rank=11"><STRONG>NCT01677910</STRONG></A> 
<P>- <STRONG>Design</STRONG>: randomized, placebo-controlled, parallel group, multicenter, double-blind study </P>
<P>- <STRONG>Recruitment</STRONG>: approx.<wbr><WBR> 105 participants with carcinoid syndrome refractory to SSA therapy.<wbr></WBR><WBR> </WBR></P>
<P>- <STRONG>Primary outcome</STRONG> measures will assess change from baseline in number of daily bowel movements.<wbr></P>
<P>- <STRONG>Timelines</STRONG>: study started in October 2012 and is expected to complete in April 2015.<wbr></P></DIV></DIV> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20130431&edate=20130101&rec=7253">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-02-04T14:47:57+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-02-04T14:47:57+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category endocrinology > <![CDATA[Endocrinology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Import and Sale of Animal Tested Cosmetic Product to be Banned in EU Soon</title>
	<pubDate>2013-02-01T20:39:01+01:00</pubDate>
	<wp:post_id>4181</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: G.<wbr> Asta (Public Affairs) commented this recent news.<wbr> As of March 2013 animal testing will be banned for comsetics, due to the implementation in EU countries of the EU Cosmetic Products Directive (76/<wbr>768/<wbr>EEC, as amended).<wbr> In spite of repeated attempts by Animal Rights Activists each time the legislation is amended, this ban does not apply to BoNTA used in aesthetic medicine.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Products containing substances intended to be injected in the human body do not come under the field of cosmetics, and are therefore not covered by the provision of this directive.<wbr> </div><div style="margin-bottom: 10px;">For any question you may get re animal welfare, please contact Ipsen's Animal Welfare WG (<A href="mailto:law@ipsen.com">law@ipsen.<wbr>com</A>).<wbr> </div><div>Original news please click <A href="http://www.prnewswire.com/news-releases/eu-set-to-ban-animal-testing-for-cosmetics-forever-189013971.html">here</A> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20130431&edate=20130101&rec=6779">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-02-01T20:39:01+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-02-01T20:39:01+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>MAP Pharm Investor is Suing to Block Allergan's Acquisition</title>
	<pubDate>2013-02-01T20:17:06+01:00</pubDate>
	<wp:post_id>4182</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: The investor claims that the $958M offer is too low, depriving investors of future earnings.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">LEVADEX "is likely to become a blockbuster" according to R.<wbr> Corwin, who is seeking to represent all MAP shareholders.<wbr> </div><div>Background Please click <A href="http://ci.beaufour-ipsen.com/traction#/single&amp;proj=Endocrinology&amp;rec=7239">here</A> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20130431&edate=20130101&rec=6778">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-02-01T20:17:06+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-02-01T20:17:06+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>The FDA Intesifies Its Efforts To Understand & Address The Issues Facing ALS Patients</title>
	<pubDate>2013-02-01T19:02:18+01:00</pubDate>
	<wp:post_id>4183</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: The FDA will hold a public hearing on Feb 25th to obtain stakeholder 
input on the needs and preferencese of ALS patients, as well input on how to be 
responsive to those needs.<wbr> </div><div style="margin-bottom: 10px;">The agency believes it needs input on ways to regulate the scientific 
evaluation, marketing authorisation and postmarketing surveillance of potential 
products to treat and diagnose ALS.<wbr> Comments are due by March 25th.<wbr> </div><div style="margin-bottom: 10px;">The last therapy to be approved for ALS was Riluteck in 1996 based on a 
survival endpoint thus unmet need remains high.<wbr> However the disease is poorly 
understood, heterogenouse in presentation and progression and there are 
currently no markers of progression or treatment response.<wbr> </div><div style="margin-bottom: 10px;">Biogen-Idec recent disappointing phIII data sparked and interesting review of 
drugs in development for ALS, with a number of companies now claiming they 
believe they have identified ways to improve the odds of clinical success.<wbr> 
Companies taking a more optimistic view include Cytokinetics, Newron 
Pharmaceuticals and Neuraltus Pharmaceuticals.<wbr> For those interested in a copy of 
the full 6-page article please contact the CI Dept.<wbr> </div><div>Source: <a href="http://www.biocentury.com" class="defaultlink" title="www.biocentury.com">biocentury.com</a> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20130431&edate=20130101&rec=6777">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-02-01T19:02:18+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-02-01T19:02:18+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>XTANDI (enzalutamide) Starts To Perform Well In The CRPC Market</title>
	<pubDate>2013-02-01T17:28:35+01:00</pubDate>
	<wp:post_id>4184</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: During its Q3 figures Astellas noted that sales of XTANDI enzalutamide during its first quarter on the US market (launched in September) reached $71m (ahead of company internal expectations).<wbr> EU approval for postchemotherapy CRPC is awaited, whilst the first data on usage in hormone naive patients will be presented at the upcoming ASCO GU.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Oncology Sales</STRONG> </div><div style="margin-bottom: 10px;">Tarceva-related revenue grew by 2.<wbr>7% year-over-year to reach $329 million.<wbr> Whilst Eligard in Europe, year-over-year it grew by 10.<wbr>4%, to reach €106 million.<wbr> Eligard, in October, was approved in Hong Kong.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8758_1_ScreenCapture1.jpg"> </div><div style="margin-bottom: 10px;">The group's other oncology drug that continues to make good progress is <STRONG>Tivozanib</STRONG> (see below).<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8758_2_ScreenCapture2.jpg"> </div><div><EM>Source: <a href="http://www.astellas.com" class="defaultlink" title="http://www.astellas.com">astellas.com</a></EM> </div><!-- Comment details --><a name="oncology8758attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8758_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(209,5 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8758_2_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(199,6 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20130431&edate=20130101&rec=8758">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-02-01T17:28:35+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-02-01T17:28:35+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Spectrum Reacquires Rights To Bladder Cancer Drug From Allergan</title>
	<pubDate>2013-02-01T11:13:41+01:00</pubDate>
	<wp:post_id>4185</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Spectrum has announced that it is to acquire all rights to Apaziquone in the US, Europe and other territories from Allergan with the expectation that it will soon file an NDA for the the treatment of NIMBC.<wbr> In return Allergan will receive a royalty on sales.<wbr> </div><div style="margin-bottom: 10px;">Spectrum's decision to file is based on a recent meeting it had with the FDA to discuss the results of the phIII trials.<wbr> Based on the discussion Spectrum understands that the FDA will accept a filing based on current PhIII data and will convene an Advisory meeting to review the data.<wbr> It also agreed to conduct one additional phIII study following consultation with the FDA on design.<wbr> </div><div style="margin-bottom: 10px;">Spectrum views the acquisition of apaziquone rights as essential to advancing the durg's commercialisation throughout the US, Europe and other key territories and especially to expanding its footprint within the US market.<wbr> </div><div style="margin-bottom: 10px;"><P align="left"><STRONG>Apaziquone's Profile</STRONG></P> </div><div style="margin-bottom: 10px;"><P align="left">Apaziquone is a pro-drug of a cytotoxic alkylating agent.<wbr> Spectrum has conducted two multi-centre randomised single dose phIII studies with the drug which did not meet their primary endpoint of a statistically significant differennce in the rate of tumour recuurence at 2 years However, analysis of the pooled data did reach statistical significance for this endpoint and key secondary endpoints.<wbr></P> </div><div style="margin-bottom: 10px;"><P align="left"><STRONG>What is NIMBC</STRONG></P> </div><div style="margin-bottom: 10px;"><P align="left">It is a form of bladder cancer localized in the surgace layers of the bladder that has not spread to the deeper muscle layer.<wbr> Appoximately 70% of all newly diagnosed patients have this form of baldder cancer (more than one million in the US and Europe alone) which is primarily treated by urologists.<wbr></P> </div><div>Source: <a href="http://www.spectrum.com" class="defaultlink" title="http://www.spectrum.com">spectrum.com</a> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20130431&edate=20130101&rec=8757">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-02-01T11:13:41+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-02-01T11:13:41+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Botox Assessed in Ph2/Ph3 for Non-Relaxing Puborectalis Syndrome (NRPS)</title>
	<pubDate>2013-01-31T21:49:00+01:00</pubDate>
	<wp:post_id>4186</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">omment: American Urogynecologic Society and Allergan collaborate on this study.<wbr> Approx.<wbr> 30 women will be recruited.<wbr> Primary endpoint will measure change in symptoms based on scores using the PAC-SYM and Wexner Constipation questionnaires.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Non-relaxing puborectalis syndrome (NRPS) is an obstructive defecatory disorder that presents with chronic constipation, anismus, or a sensation of incomplete rectal emptying.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">The etiology of NRPS is unknown.<wbr> Previous therapies for this syndrome have included biofeedback, pelvic floor physical therapy, dietary changes, laxatives, enemas, and surgical division of the puborectalis muscle.<wbr> However, responses to these treatments have been variable at best.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">to determine the efficacy of ultrasound and EMG guided Botox injections into the puborectalis muscle in women with NRPS.<wbr> </div><div>Study Details <A href="http://clinicaltrials.gov/ct2/show/NCT01780636?recr=Open&amp;no_unk=Y&amp;phase=012&amp;fund=2&amp;rcv_s=12%2F31%2F2012&amp;rank=207">NCT01780636</A> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20130431&edate=20130101&rec=6776">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-01-31T21:49:00+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-01-31T21:49:00+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Patient Enrollment Completion for Provenge Plus Indoximod Trial</title>
	<pubDate>2013-01-31T18:04:57+01:00</pubDate>
	<wp:post_id>4187</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: The Phase II indoximod with Provenge (sipuleucel-T) Prostate cancer study will conclude its patient enrollment in 2014 </div><div style="margin-bottom: 10px;">Cancer therapeutics developer NewLink Genetics aims to raise $42.<wbr>5m to finance a slew of cancer immunotherapy trials, selling over four million in common stock for its HyperAcute immunotherapy and IDO pathway inhibitor technology.<wbr> </div><div style="margin-bottom: 10px;">NewLink's lead product candidate using the HyperAcute immunotherapy is HyperAcute Pancreas cancer immunotherapy (algenpantucel-L), in phase III trials with surgically-resected pancreatic cancer patients.<wbr> </div><div style="margin-bottom: 10px;"><SPAN style="line-height: 1.5em;">Other trials utilizing this technology include:</SPAN> </div><div style="margin-bottom: 10px;"><UL><LI><SPAN style="line-height: 1.5em;">Phase IIb/<wbr>III clinical trial for HyperAcute Lung (tergenpumatucel-L)</SPAN>
</LI>
<LI><SPAN style="line-height: 1.5em;">Phase II HyperAcute Melanoma trial</SPAN>
</LI>
<LI><SPAN style="line-height: 1.5em;">Phase I renal cell cancer HyperAcute study</SPAN>
</LI>
</UL> </div><div><SPAN style="line-height: 1.5em;">With regards to their indoleamine-(2,3)-dioxygenase (IDO) pathway technology, t</SPAN><SPAN style="line-height: 1.5em;">he lead programme - indoximod (d-1-methyltryptophan) which is currently in phase II for second-line metastatic solid tumor studies (updates on data expected by mid 2013) and patient enrollment in a phase II prostate cancer study which combines indoximod with Provenge (sipuleucel-T) will conclude in 2014 - </SPAN><STRONG style="line-height: 1.5em;">ClinicalTrials.<wbr>gov Identifier:</STRONG><SPAN style="line-height: 1.5em;">NCT01560923</SPAN> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20130431&edate=20130101&rec=8754">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-01-31T18:04:57+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-01-31T18:04:57+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>SciClone Pharmaceuticals Continues To Promote Sanofi Products in China</title>
	<pubDate>2013-01-31T17:52:01+01:00</pubDate>
	<wp:post_id>4188</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment:  SciClone Pharmaceuticals will continue with its agreement to promote Sanofi's products in China, including Xatral for the treatment of BPH </div><div style="margin-bottom: 10px;">SciClone Pharmaceuticals has renewed its agreement with Sanofi to continue to promote four products in China.<wbr>  The agreement has been extended until the 31 December 2013 with a possibility for a longer-term collaboration.<wbr> </div><div style="margin-bottom: 10px;"><SPAN style="line-height: 1.5em;">The four products included in the agreement are:</SPAN> </div><div><UL><LI> <SPAN style="line-height: 1.5em;">Depakine (sodium valproate) for the treatment of epilepsy</SPAN>
</LI>
<LI><SPAN style="line-height: 1.5em;">Stilnox (zolpidem) for the treatment of insomnia</SPAN><SPAN style="line-height: 1.5em;"> and some brain disorders</SPAN>
</LI>
<LI><SPAN style="line-height: 1.5em;">Tritace (ramipril) for the treatment of hypertension</SPAN>
</LI>
<LI><SPAN style="line-height: 1.5em;">Xatral (alfuzosine HCl) for the treatment of  benign prostatic hyperplasia</SPAN>
</LI>
</UL> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20130431&edate=20130101&rec=10305">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-01-31T17:52:01+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-01-31T17:52:01+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category pharma-news > <![CDATA[Pharma News]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>JV Formed to Develop Peptide Injectable Drugs for Cancer</title>
	<pubDate>2013-01-31T10:53:56+01:00</pubDate>
	<wp:post_id>4189</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: ScinoPharm, a Taiwanese API manufacturer, and Foresee, a US drug delivery company, have formed a JV that will initially focus on developing a controlled-release formulation of leuprolide for prostate cancer.<wbr> Of note, Foresee Pharm's pipeline is listing 2 drugs in PC for prostate cancer (once-6month dosing) and <A href="http://www.foreseepharma.com/Product-Pipeline.html#acromegalycarcinoidtumorsdiabeticretinopathy">acromegaly</A>.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">ScinoPharm will invest $3.<wbr>6M for a minority stake in the JV </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">The companies plan to start a Ph3 trial of the injectable leuprolide late 2013.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">To submit a NDA under the section 505(b)(2) of the FDA.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Pipeline : <A href="http://www.foreseepharma.com/Product-Pipeline.html">http:/<wbr>/<wbr>www.<wbr>foreseepharma.<wbr>com/<wbr>Product-Pipeline.<wbr>html</A> </div><div style="margin-bottom: 10px;">Technology: <A href="http://www.foreseepharma.com/Technology.html">http:/<wbr>/<wbr>www.<wbr>foreseepharma.<wbr>com/<wbr>Technology.<wbr>html</A> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8751_1_ScreenCapture1.jpg"> </div><div style="margin-bottom: 10px;">Partnership: <A href="http://www.foreseepharma.com/Technology.html">http:/<wbr>/<wbr>www.<wbr>foreseepharma.<wbr>com/<wbr>Technology.<wbr>html</A> </div><div style="margin-bottom: 10px;">In collaboration with <A href="http://www.nangkuang.com.tw/index.php?lang=en">Nang Kuang Pharm </A>Inc.<wbr>, Foresee are developing FP-001 the treatment of advanced stage prostate Cancer.<wbr> This long-acting release formulation has the potential to provide important therapeutic benefits in a once-6 months dosing regimen.<wbr> </div><div style="margin-bottom: 10px;"><UL><LI>Foresee is responsible for developing potential long-acting formulations of FP-001, conducts its preclinical toxicology testing and clinical trial, and obtains regulatory approval.<wbr> </LI>
<LI>NanKuang is responsible for the cGMP compliant manufacturing of injectable FP-001 for supporting development and commercial manufacturing.<wbr></LI>
</UL> </div><div>Source: Cos websites </div><!-- Comment details --><a name="oncology8751attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8751_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(39,8 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20130431&edate=20130101&rec=8751">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-01-31T10:53:56+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-01-31T10:53:56+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>AbbVie Issues FY12 Performance</title>
	<pubDate>2013-01-30T17:54:53+01:00</pubDate>
	<wp:post_id>4190</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Portfolio of marketed products delivered solid growth in 2012, driven by double-digit growth from HUMIRA and AndroGel.<wbr> Management expects flat Lupron sales in 2013, compared with 2012.<wbr> Elagolix is reported to be one of AbbVie's key priorities.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><STRONG>Summary of Q4:12</STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8749_1_ScreenCapture1.jpg"> </div><div style="margin-bottom: 10px;"><STRONG>Summary of FY12</STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8749_2_ScreenCapture2.jpg"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div>This year, the company is planning to start a Ph2b of elagolix for UF (Ph2a data est.<wbr> Q1:13).<wbr> </div><!-- Comment details --><a name="oncology8749attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8749_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(40,2 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8749_2_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(41,8 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20130431&edate=20130101&rec=8749">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-01-30T17:54:53+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-01-30T17:54:53+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Pfizer May Split Drug Units in Emerging Markets</title>
	<pubDate>2013-01-30T10:32:14+01:00</pubDate>
	<wp:post_id>4191</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Alongside Q4 results presentation, management reported that the company may consider operating its branded medicines and generic products units as seprate businesses, with separate management.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">- To do the same way as in developed markets, where Pfizer's operations are already structured into separate units for brand-name and generic products.<wbr> </div><div style="margin-bottom: 10px;">- To offer stakeholders the opportunity to invest in 2 separate companies or not.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div>Analyst with Goldman Sachs forecasts Pfizers new business to have about $369bn sales in 2013, and generic medicines line $17bn.<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20130431&edate=20130101&rec=10304">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-01-30T10:32:14+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-01-30T10:32:14+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category pharma-news > <![CDATA[Pharma News]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Pfizer's Somavert - One Amongst A Group Of 12 Products In its Portfolio Reigstering Double-Digit Growth</title>
	<pubDate>2013-01-29T15:09:20+01:00</pubDate>
	<wp:post_id>4192</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Pfizer in its Q4 performance review, has started once again reporting more detailed sales figures for Somavert.<wbr> Full year global sales were $197m +14% with all geographic territories registering strong growth.<wbr> The geographic sales breakdown is shown below together with sales of Genotropin.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Somavert (Registering Strong Growth)</STRONG> </div><div style="margin-bottom: 10px;"><UL><LI><STRONG>Worldwide - </STRONG>FY $197m +14%(l.<wbr>c.<wbr>) Q4 $55m +16% </LI>
<LI><STRONG>US</STRONG> - FY $46m +18% Q4 $13m +8% </LI>
<LI><STRONG>Developed Europe</STRONG> - FY $123m +10% (l.<wbr>c.<wbr>) Q4 $34 +13% (l.<wbr>c.<wbr>) </LI>
<LI><STRONG>Developed ROW</STRONG> - FY $17m +23% (l.<wbr>c.<wbr>) Q4 $5m +25% (l.<wbr>c.<wbr>) </LI>
<LI><STRONG>Emerging Markets -</STRONG> FY $11m +33% (l.<wbr>c.<wbr>) Q4 $3m flat </LI>
</UL> </div><div style="margin-bottom: 10px;"><STRONG>Genotropin (Struggling in the face of competition from biosimilars)</STRONG> </div><div style="margin-bottom: 10px;"><UL><LI><STRONG>Worldwide - </STRONG>FY $842m -4%(l.<wbr>c.<wbr>) Q4 $213m -7% (l.<wbr>c.<wbr>) </LI>
<LI><STRONG>US</STRONG> - FY $204m flat Q4 $54m -11% </LI>
<LI><STRONG>Developed Europe</STRONG> - FY $295m -12% (l.<wbr>c.<wbr>) Q4 $71 -17% (l.<wbr>c.<wbr>) </LI>
<LI><STRONG>Developed ROW</STRONG> - FY $224m flat Q4 $58m flat </LI>
<LI><STRONG>Emerging Markets -</STRONG> FY $109m +8% (l.<wbr>c.<wbr>) Q4 $30m +23% (l.<wbr>c.<wbr>) </LI>
</UL> </div><div>Source: <A href="http://www.pfizer.com/">www.<wbr>pfizer.<wbr>com</A> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20130431&edate=20130101&rec=7250">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-01-29T15:09:20+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-01-29T15:09:20+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category endocrinology > <![CDATA[Endocrinology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Highlights of Leerink Swann's 4Q Cosmetic Survey Results</title>
	<pubDate>2013-01-29T14:49:38+01:00</pubDate>
	<wp:post_id>4193</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: The survey polled 32 U.<wbr><WBR>S based dermatologists and 31 plastic surgeons.<wbr> Respondents expect Botox to capture &gt;70%+ of the overall market in 2014 despite the return of Merz' Xeomin, and forecast stable Q/<wbr>Q growth for toxins and fillers in Q1:13.<wbr> Physicians' most cited interest area is injectable fat reduction technology (for "double-chin").<wbr> Key results are provided below.<wbr></WBR> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6771_3_ScreenCapture3.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6771_1_ScreenCapture1.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6771_2_ScreenCapture2.jpg"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Please see <a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20130431&edate=20130101&rec=6626" class="defaultlink">Neurology6626: Highlights of Leerink Swann's 3Q Cosmetic Survey Results</a>.<wbr> </div><div style="margin-bottom: 10px;"><DIV class="i hovered" id="neurology6626.08i">
<DIV class="ii" id="neurology6626.08ii"></DIV>
<DIV class="ii">
 </div><div style="margin-bottom: 10px;"><P><STRONG></STRONG></P>
 </div><div style="margin-bottom: 10px;"><P>If approved, ATX-101 will be the 1st and only drug product for the reduction of submental fat.<wbr> Bayer has rights outside US and Canada.<wbr></P>
 </div><div style="margin-bottom: 10px;"><P>During IMCAS (Jan31 - Feb3, Paris), Bayer will be dedicating its symposium to ATX-101.<wbr></P>
 </div><div style="margin-bottom: 10px;"><P><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6771_5_ScreenCapture5.jpg"></P>
 </div><div><P><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6771_4_ScreenCapture4.jpg"></P></DIV></DIV> </div><!-- Comment details --><a name="neurology6771attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;4.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6771_4_ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(51,3 KB)<br>&nbsp;&nbsp;5.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6771_5_ScreenCapture5.jpg">ScreenCapture5.jpg</a>&nbsp;&nbsp;(38,5 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20130431&edate=20130101&rec=6771">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-01-29T14:49:38+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-01-29T14:49:38+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Injecting Botox Into The Stomach Does Not Promote Weight Loss</title>
	<pubDate>2013-01-29T14:33:45+01:00</pubDate>
	<wp:post_id>4194</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: The February issue of Clinical Gastroenterology &amp; 
Hepatology highlights a study which indicates that Botox injections are not 
helpful when it comes to treating obesity.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Study Methodology</STRONG> </div><div style="margin-bottom: 10px;">Botox was evaluated by Mark Topazian and team at the Mayo Clinic in 
Rochester Minessota.<wbr> as a means of possibly slowing gastric 
emptying.<wbr>  They compared the effects of injecting different doses 
of BTA into the stomachs of 60 individuals with mild-to-moderate obesity.<wbr> </div><div style="margin-bottom: 10px;">Study participants were each given 1 injection of BTA (100, 300, or 500 U), 
or placebo, in the gastric antral muscularis propria, guided by endoscopic 
ultrasound.<wbr> </div><div style="margin-bottom: 10px;">Gastric emptying of solids was measured by scintigraphy 
and participants' body weight was recorded every 2 weeks, as well as 
satiation, calorie intake, gastrointestinal symptoms, and psychological aspects 
of eating.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Key Findings</STRONG> </div><div style="margin-bottom: 10px;">Two weeks after the injections, the mean half-time for gastric emptying of 
solids increased by 0.<wbr>8, 14, 24, and 14 minutes among subjects given placebo, 
100, 300, or 500 U BTA, respectively.<wbr> </div><div style="margin-bottom: 10px;">Sixteen weeks after the injections, mean body weights were reduced by 2.<wbr>2, 
0.<wbr>2, 2.<wbr>3, and 3.<wbr>0 kg in these groups, respectively -- not a statistically 
significant difference.<wbr> </div><div style="margin-bottom: 10px;">Nor were there significant differences among groups in satiation volume, 
caloric intake, gastrointestinal symptoms, or psychological aspects of eating 
among groups.<wbr> </div><div>So, although stomach injection of BTA slows gastric emptying, it does not 
increase the feeling of fullness or lead to loss of body weight.<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20130431&edate=20130101&rec=6770">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-01-29T14:33:45+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-01-29T14:33:45+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Addex' Dipraglurant As a Novel Treatment for Dystonia</title>
	<pubDate>2013-01-29T10:28:51+01:00</pubDate>
	<wp:post_id>4195</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: The company has reported positive PC data for its mGlu5 NAM in a validated rodent model of dystonia.<wbr> These data are consistent with earlier findings in a Ph2a trial assessing LID in Parkinson's patients as well as a non-human primate model of Parkinson's-related dystonia.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">On track for Ph2 clinical testing in H2:13.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">May be a valuable new strategy for treating PD, LID in PD, anxiety, depression, pain, tardive dyskinesia, dystonia, addiction, autism and Fragile X syndrome.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div>Addex continues to seek a partner to advance dipraglurant in Parkinson's LID.<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20130431&edate=20130101&rec=6769">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-01-29T10:28:51+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-01-29T10:28:51+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Aileron's Stappled Peptide Technology Has Entered Ph1 for GHD</title>
	<pubDate>2013-01-28T17:49:48+01:00</pubDate>
	<wp:post_id>4196</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: The FIM study started this month, and is evalutating approx.<wbr> 48 adult participants for growth hormone deficiency (GHD).<wbr> Primary outcome will assess incidence of AEs.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG><A href="http://clinicaltrials.gov/ct2/show/NCT01775358?term=aileron&amp;recr=Open&amp;no_unk=Y&amp;phase=012&amp;fund=2&amp;rcv_s=12%2F28%2F2012&amp;rank=1"><STRONG></STRONG></A> </div><div style="margin-bottom: 10px;">Completion date: June 2013 </div><div style="margin-bottom: 10px;">PI: Bradley D.<wbr> Vince </div><div style="margin-bottom: 10px;">Study Director: Hubert C.<wbr> Chen </div><div style="margin-bottom: 10px;">Location: US (1 site) </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Aileron's Stapled Peptide therapeutics provide the opportunity to greatly expand the number of "druggable" targets by targeting the thousands of intracellular and extracellular protein-protein interactions that cannot be functionally modulated by current therapeutics.<wbr> </div><div style="margin-bottom: 10px;">Leveraging these attributes, Aileron is creating a new paradigm in drug discovery and development.<wbr> </div><div><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7245_1_ScreenCapture1.jpg"> <STRONG>Reference in Traction CI</STRONG> Please see <a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20130431&edate=20130101&rec=9557" class="defaultlink">PharmaWorld9557: Permeon Biologics Technology Platform Focuses On Intracellular Delivery of Biologic Macromolecules</a>.<wbr> </div><!-- Comment details --><a name="endocrinology7245attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7245_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(56,1 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20130431&edate=20130101&rec=7245">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-01-28T17:49:48+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-01-28T17:49:48+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category endocrinology > <![CDATA[Endocrinology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>re: Lilly Announces Positive Results For Ramucirumab in Phase III Gastric Cancer Trial</title>
	<pubDate>2013-01-28T12:43:21+01:00</pubDate>
	<wp:post_id>4197</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="border-left: 2px solid #8B1010; padding: 0px 0px 5px 12px; margin-bottom: 3px;"><span style="font-weight: bold; font-size: 14px;">Lilly Announces Positive Results For Ramucirumab in Phase III Gastric Cancer Trial</span>&nbsp;<br><span style="font-size: 12px;">Comment: Eli Lilly has announced today positive top-line results from 
the REGARD trial, a Phase III study of ramucirumab (IMC-1121B) in patients with 
metastatic gastric cancer.<wbr> The study met its primary endpoint of 
improved overall survival and also showed prolonged progression-free survival.<wbr></span>&nbsp;&nbsp;<a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20130431&edate=20130101&rec=8528">...</a><br></div><div style="margin-bottom: 10px;"><P align="left">Ramucirumab a drug according to Goldman Sachs analysts with "game changing commercial potential not widely recognised in brokers forecasts " and highlighted as one of 10 in a recent report in Scrip, has reported additional data from the phIII REGARD study in gastric cancer at the recent ASCO Gastrointestinal Cancer Symposium in San Franscisco.<wbr></P> </div><div><P align="left">The double-blind, international Phase III REGARD trial in 355 patients with metastatic gastric or gastroesophageal junction adenocarcinoma following disease progression on first-line platinum or fluoropyrimidine-containing combination therapy showed that 8 mg/<wbr>kg IV ramucirumab every 2 weeks plus best supportive care (BSC) led to a median OS, the primary endpoint, of 5.<wbr>2 months vs.<wbr> 3.<wbr>8 months for placebo plus BSC (p=0.<wbr>0473).<wbr> On secondary endpoints, ramucirumab plus BSC led to a median PFS of 2.<wbr>1 months vs.<wbr> 1.<wbr>3 months for placebo plus BSC (p&lt;0.<wbr>0001).<wbr> Additionally, ramucirumab led to a 12-week PFS rate of 40% vs.<wbr> 16% for placebo and an ORR of 3.<wbr>4% vs.<wbr> 2.<wbr>6% for placebo.<wbr> Furthermore, ramucirumab led to a disease control rate (DCR) of 49% vs.<wbr> 23% for placebo (p&lt;0.<wbr>0001).<wbr> BSC included anti-emetic agents, opiate and non-opiate analgesic agents, appetite stimulants, and granulocyte and erythroid growth factors.<wbr> Data were presented at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium in San Francisco.<wbr></P> </div><!-- Comment details --><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20130431&edate=20130101&rec=8748">Add a Comment on this Article</a><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology8528">View thread  Oncology8528: Lilly Announces Positive Results For Ramucirumab in Phase III Gastric Cancer Trial</a>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-01-28T12:43:21+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-01-28T12:43:21+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>re: Recordati Enters Into Asset Purchase Agreement To Strengthen US Business</title>
	<pubDate>2013-01-28T12:30:17+01:00</pubDate>
	<wp:post_id>4198</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="border-left: 2px solid #8B1010; padding: 0px 0px 5px 12px; margin-bottom: 3px;"><span style="font-weight: bold; font-size: 14px;">Recordati Enters Into Asset Purchase Agreement To Strengthen US Business</span>&nbsp;<br><span style="font-size: 12px;">Comment: Recordati has acquired a portfolio of non-core products from Lundbeck, aimed at strengthen its US operations and its rare disease portfolio.<wbr> Lundbeck, meanwhile, wishes to exit these areas to focus on its core CNS business.<wbr></span>&nbsp;&nbsp;<a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20130431&edate=20130101&rec=10260">...</a><br></div><div>Recordati has completed its acquisition of a portfolio of H.<wbr> Lundbeck&rsquo;s non-core products.<wbr> Recordati paid Lundbeck $80 million at closing.<wbr> Recordati said it expects 2013 revenues for the acquired portfolio to be about $40 million.<wbr> </div><!-- Comment details --><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20130431&edate=20130101&rec=10303">Add a Comment on this Article</a><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10260">View thread  PharmaWorld10260: Recordati Enters Into Asset Purchase Agreement To Strengthen US Business</a>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-01-28T12:30:17+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-01-28T12:30:17+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category pharma-news > <![CDATA[Pharma News]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Venom Peptide Therapeutic In-licensed By Kineta For Treatment Of Chronic Pain</title>
	<pubDate>2013-01-25T17:03:53+01:00</pubDate>
	<wp:post_id>4199</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Kineta has secured exclusive, worldwide development rights from 
the University of Utah Research Foundation to a portfolio of drug candidates 
based on the Conotoxin Rg1a for the non-narcotic treatment of chronic pain.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Peptide Scource</STRONG> </div><div style="margin-bottom: 10px;">Derived from the Rg1a peptide found in the venom of cone snails, these 
molecules were discovered in the laboratory of Baldomero Olivera, Ph.<wbr>D.<wbr> and 
are featured in an article in the February issue of <I>National Geographic 
magazine</I>.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Leveraging Its Core Competency</STRONG> </div><div style="margin-bottom: 10px;">“This is a tremendous opportunity for Kineta to leverage its expertise in 
venom peptide therapeutics to provide a medical solution to an emergent need.<wbr> We 
have in our hands the potential to replace some of the most dangerous and abused 
prescription drugs on the market - opioid analgesics including morphine and 
oxycontin.<wbr> It is imperative that our industry develop treatments for chronic 
pain that are potent and effective without producing the destructive, sometimes 
deadly side-effects of opioid drugs,” said Shawn P.<wbr> Iadonato, Ph.<wbr>D.<wbr>, Kineta's 
Chief Scientific Officer and Executive Vice President.<wbr> Dr.<wbr> Olivera has an 
established record of discovering successful conotoxin-derived molecules; the 
FDA approved non-narcotic pain medicine Prialt® (Zicoconotide) is based on his 
laboratory's seminal work.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Press Coverage</STRONG> </div><div style="margin-bottom: 10px;">The <I>National Geographic</I> story is a scientific overview of the 
therapeutic potential of venom that also features a second Kineta drug 
candidate, ShK-186.<wbr> Derived from a venom peptide of the Caribbean Sea anemone, 
ShK-186 is Kineta's lead clinical stage autoimmune drug candidate.<wbr> The 
<I>National Geographic </I>article highlights its ability to suppress 
self-reactive inflammatory processes in autoimmune diseases such as multiple 
sclerosis and lupus without shutting down the entire immune system.<wbr> ShK-186 was 
originally developed in the lab of K.<wbr> George Chandy, M.<wbr>D.<wbr>, Ph.<wbr>D.<wbr> at the 
University of California, Irvine who is quoted in the article as saying “¦ 
anecdotal reports from patients in the field have been inspiring to my team, and 
encourage us to fully explore venom as a wellspring of potential new therapies.<wbr>” 
Kineta obtained development rights and has advanced ShK-186 into Phase 1 human 
clinical trials.<wbr> </div><div>Source:www.<wbr>kineta.<wbr>com </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20130431&edate=20130101&rec=6768">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-01-25T17:03:53+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-01-25T17:03:53+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>The Success Of Yervoy - Next Indications For Which Potentially Include CRPC</title>
	<pubDate>2013-01-25T15:17:06+01:00</pubDate>
	<wp:post_id>4200</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: During its Q4 earnings call BMS focused on the success of Yervoy 
(ipilumumab), sales of which topped $700m in 2012, making the drug one of the 
best oncology launches over the last decade behind that of Zytiga 
(abiraterone).<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Yervoy Sales</STRONG> </div><div style="margin-bottom: 10px;">Yervoy is commercialised both in the US and Europe for the treatment of 
metastatic melanoma.<wbr> Quarterly sales are now running at $211m +18% sequentially 
vs.<wbr> Q3 with $141m generated from sales in the US.<wbr> Geographic roll-out within 
Europe is ongoing.<wbr> The product is selling well in the UK and Germany whilst 
formulary access in other countries continues to expand.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Next Indications</STRONG> </div><div style="margin-bottom: 10px;">With regard to follow-on indications the following comments were made:- </div><div style="margin-bottom: 10px;">"We do have Phase III trials in multiple indications including adjuvant 
melanoma, two trials in prostate cancer and you mentioned yes, one of them 
should have data internally at BMS in H1 and hopefully we’ll find a way to 
present that this year at a conference.<wbr> And the one the will be coming due first 
is a Phase III trial in castrate-resistant post-docetaxel prostate cancer.<wbr> And 
these are patients who have progressed on that taxane.<wbr> It was initiated in 2009, 
we project to have the number of events to analyze and present this year.<wbr> </div><div style="margin-bottom: 10px;"><P class="pwrapper">"The other trial (chemonaive CRPC) will take longer.<wbr> We 
have two trials also in lung cancer, one in non-small cell lung cancer, one in 
small cell lung cancer.<wbr> We are doing combination therapy with other chemotherapy 
agents and we are actively exploring studies in other tumor types with the 
National Cancer Institute.<wbr>"</P> </div><div><P class="pwrapper">Source: <A href="http://www.bms.com">www.<wbr>bms.<wbr>com</A></P> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20130431&edate=20130101&rec=8747">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-01-25T15:17:06+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-01-25T15:17:06+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Threshold and Merck KGaA Progress with Their Pancreatic Cancer Program</title>
	<pubDate>2013-01-25T10:32:15+01:00</pubDate>
	<wp:post_id>4201</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Merck initiated the global Ph3 MAESTRO trial assessing TH-302 + gemcitabine in patients with previously untreated, locally advanced unresectable or metastatic pancreatic adenocarcinoma.<wbr> The study is conducted under a SPA with the US FDA.<wbr> The primary endpoint is OS.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Title: <STRONG>M</STRONG>etast<STRONG>A</STRONG>tic or unr<STRONG>ES</STRONG>ectable pancrea<STRONG>T</STRONG>ic adenoca<STRONG>R</STRONG>cin<STRONG>O</STRONG>ma </div><div style="margin-bottom: 10px;">Design: randomized, placebo-controlled, international multi-center, double-blind </div><div style="margin-bottom: 10px;">Recruitment: approx.<wbr> 660 </div><div style="margin-bottom: 10px;">Secondary endpoints include efficacy measured by PFS, ORR and disease controlrate, as well as assessments of safety and tolerability, PK and biomarkers.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">See <a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20130431&edate=20130101&rec=8475" class="defaultlink">Oncology8475: OS Advantage Remains Elusive In Pancreatic Cancer Study But Threshold Blames Trial Design</a>.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div>Feb.<wbr> 2012 - Merck KGaA signed a global license and co-development agreement for TH-302 with Threshold, which includes an option for Threshold to co-commercialize in the US.<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20130431&edate=20130101&rec=8746">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-01-25T10:32:15+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-01-25T10:32:15+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>US Defence Funding For Acorda's New Spinal Cordy Injury Drug</title>
	<pubDate>2013-01-24T18:13:32+01:00</pubDate>
	<wp:post_id>4202</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Acorda Therapeutics, has been awareded a $2.<wbr>67m research grant 
by  the U.<wbr>S.<wbr> Army Medical Research and Material Command (USAMRMC) to 
support development of AC105, a propriety magnesium formulation being studied as 
a treatment for acute spinal cord injury.<wbr> </div><div style="margin-bottom: 10px;">The contract will help support a Phase 2 clinical trial designed primarily to 
assess the safety and tolerability of AC105 in people with acute SCI.<wbr> The 
Company plans to open enrollment for this study in the first half of 2013.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Basis For Funding</STRONG> </div><div style="margin-bottom: 10px;">In preclinical studies, AC105 demonstrated neuroprotective properties and 
improvement of locomotor function in SCI when therapy was initiated within 
several hours of injury.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Next Steps</STRONG> </div><div style="margin-bottom: 10px;">The US FDA has granted the drug Fast Track designation to 
improve functional recovery of acute SCI patients.<wbr> Acorda expects to apply for 
FDA orphan drug designation for the acute treatment of SCI and will explore 
orphan drug designations in Europe and in other parts of the world.<wbr> </div><div style="margin-bottom: 10px;"><B>About Spinal Cord Injury (SCI)</B> </div><div style="margin-bottom: 10px;">Spinal cord injury (SCI) refers to any injury to the spinal cord that is 
caused by trauma, such as a motor vehicle accident, fall or sports injury.<wbr> 
According to the National Spinal Cord Injury Statistical Center (NSCISC), there 
are approximately 270,000 people in the United States living with a spinal cord 
injury.<wbr> Each year, there are approximately 12,000 new injuries reported in the 
United States, the majority of which are males.<wbr> Spinal cord injuries primarily 
affect young people, with 50-70% occurring in those aged 15-35.<wbr> </div><div style="margin-bottom: 10px;">The costs of living with SCI can be considerable and can vary greatly with 
the severity of injury.<wbr> Long-term complications from SCI can include neurologic 
impairments in any body system controlled by the affected nerves.<wbr> Average annual 
medical cost for an SCI patient ranges from $40,000-$178,000 depending on the 
extent of the injury.<wbr> </div><div style="margin-bottom: 10px;">There are currently no FDA-approved therapies indicated to treat, mitigate, 
or reverse SCI.<wbr> </div><div>Source: <A href="http://www.acorda.com">www.<wbr>acorda.<wbr>com</A> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20130431&edate=20130101&rec=6767">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-01-24T18:13:32+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-01-24T18:13:32+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>re: Watson on Track to Buy European-Based Actavis for Around $6bn</title>
	<pubDate>2013-01-24T18:01:18+01:00</pubDate>
	<wp:post_id>4203</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="border-left: 2px solid #8B1010; padding: 0px 0px 5px 12px; margin-bottom: 3px;"><span style="font-weight: bold; font-size: 14px;">Watson on Track to Buy European-Based Actavis for Around $6bn</span>&nbsp;<br><span style="font-size: 12px;">Comment: The deal would further diversify Watson's generic footprint in the EU, and help the company to compete more effectively against Teva and Sandoz.<wbr></span>&nbsp;&nbsp;<a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20130431&edate=20130101&rec=9837">...</a><br></div><div style="margin-bottom: 10px;">Watson Pharmaceuticals has announced that the company has adopted Actavis, Inc.<wbr> as its new global name and will today begin trading under the symbol — ACT — on the New York Stock Exchange.<wbr> The combination created the world's 3rd largest generic pharmaceutical company, with anticipated pro forma combined 2012 revenues in excess of $8 billion.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">On Jan 23rd, Watson completed the acquisition of <LOCATION value="LC/be;LB/weur">Belgium</LOCATION>-based <ORG>Uteron Pharma SA</ORG> for <MONEY>$150M</MONEY> in cash up front, and up to <MONEY>$155 million</MONEY> in potential future milestone payments.<wbr> </div><div style="margin-bottom: 10px;"><U>Rationale</U> </div><div style="margin-bottom: 10px;">The acquisition of Uteron expands Watson's <ORG>Global Brands</ORG> pipeline of Women's Health products including two potential near term global commercial opportunities in contraception and infertility, and one novel oral contraceptive, projected to launch globally in 2018.<wbr>  Several additional products in earlier stages of development are also included in the acquisition.<wbr> </div><div>Source: Actavis; Watson </div><!-- Comment details --><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20130431&edate=20130101&rec=10298">Add a Comment on this Article</a><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld9837">View thread  PharmaWorld9837: Watson on Track to Buy European-Based Actavis for Around $6bn</a>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-01-24T18:01:18+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-01-24T18:01:18+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category pharma-news > <![CDATA[Pharma News]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Key Takeaways from Amgen Q4:12 and FY:12 Results</title>
	<pubDate>2013-01-24T11:43:35+01:00</pubDate>
	<wp:post_id>4204</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Product sales grew 9% for the full year and 11% for the fourth quarter, driven by the solid contributions of Enbrel (the clear outperformer).<wbr> On the plus side, XGEVA/<wbr>Prolia re-accelerated with 19% QoQ growth to $369MM.<wbr> R&amp;D strategy will be disclosed on Feb 7 at the company's upcoming business review.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">When it comes to <STRONG>XGEVA</STRONG>, management reported that ".<wbr>.<wbr>.<wbr> as we approach the patent expirey for zoledronic acid, we expect there'll be some temporary disruption in the marketplace, both as a result of competitive activities and some reimbursement considerations.<wbr> But we continue to be very confident on XGEVA's superior clinical profile and the benefit that it actually delivers to patients".<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8744_1_ScreenCapture1.jpg"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">In the EU, the launch is continuing strongly with 23% QoQ growth to $37MM bolstered by recent reimbursement approvals in France, Italy and Spain.<wbr> </div><div style="margin-bottom: 10px;">Generic Zometa (in H:2 13) remains a near term risk although preference for XGEVA’s subQ administration over IV may offer a near-term buffer to erosion.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8744_2_ScreenCapture2.jpg"> </div><div><STRONG></STRONG> </div><!-- Comment details --><a name="oncology8744attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8744_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(106 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8744_2_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(49,2 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20130431&edate=20130101&rec=8744">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-01-24T11:43:35+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-01-24T11:43:35+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Novartis Q4 Figures - Key Takeaways</title>
	<pubDate>2013-01-23T14:50:20+01:00</pubDate>
	<wp:post_id>4205</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Demonstrating resilience in the face of its patent cliff, Novartis has reported a solid set of year-end figures with sales flat in constant currencies and operating income and net income down 2% and up 7% respectively.<wbr> The resignation of Chariman Danielle Vasella from the board is also noteworthy as is yet further confirmation that the group expects FDA action on Signfor for acromegaly in 2H13.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>2012 Business Profile</STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7241_1_ScreenCapture1.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7241_2_ScreenCapture2.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7241_3_ScreenCapture3.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7241_4_ScreenCapture4.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7241_5_ScreenCapture5.jpg"> </div><div style="margin-bottom: 10px;"><STRONG>Pharmaceutical Business Highlights</STRONG> </div><div style="margin-bottom: 10px;">Sandostatin sales for the full year increased by 8% ar CC to$1.<wbr>512bn with sales up 13% in the US to $649m and up 5% outside the US to $863m.<wbr> </div><div style="margin-bottom: 10px;">Novartis claims that there are now 29 countries that have an amended label for Sandostatin LAR including delay of disease progression in patients with advanced NET of mid-gut or unknown origin and that its new formulation of the drug is approved in 26 countries </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7241_6_ScreenCapture6.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7241_7_ScreenCapture7.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7241_8_ScreenCapture8.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7241_9_ScreenCapture9.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7241_10_ScreenCapture10.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7241_11_ScreenCapture11.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7241_14_ScreenCapture14.jpg"> </div><div style="margin-bottom: 10px;">Group Outlook </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7241_12_ScreenCapture12.jpg"> </div><div><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7241_13_ScreenCapture13.jpg"> </div><!-- Comment details --><a name="endocrinology7241attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7241_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(99,1 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7241_2_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(79,7 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7241_3_ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(72,2 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7241_4_ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(86,3 KB)<br>&nbsp;&nbsp;5.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7241_5_ScreenCapture5.jpg">ScreenCapture5.jpg</a>&nbsp;&nbsp;(98,5 KB)<br>&nbsp;&nbsp;6.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7241_6_ScreenCapture6.jpg">ScreenCapture6.jpg</a>&nbsp;&nbsp;(80 KB)<br>&nbsp;&nbsp;7.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7241_7_ScreenCapture7.jpg">ScreenCapture7.jpg</a>&nbsp;&nbsp;(94 KB)<br>&nbsp;&nbsp;8.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7241_8_ScreenCapture8.jpg">ScreenCapture8.jpg</a>&nbsp;&nbsp;(77,7 KB)<br>&nbsp;&nbsp;9.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7241_9_ScreenCapture9.jpg">ScreenCapture9.jpg</a>&nbsp;&nbsp;(101 KB)<br>&nbsp;&nbsp;10.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7241_10_ScreenCapture10.jpg">ScreenCapture10.jpg</a>&nbsp;&nbsp;(118,9 KB)<br>&nbsp;&nbsp;11.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7241_11_ScreenCapture11.jpg">ScreenCapture11.jpg</a>&nbsp;&nbsp;(103,4 KB)<br>&nbsp;&nbsp;12.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7241_12_ScreenCapture12.jpg">ScreenCapture12.jpg</a>&nbsp;&nbsp;(80,1 KB)<br>&nbsp;&nbsp;13.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7241_13_ScreenCapture13.jpg">ScreenCapture13.jpg</a>&nbsp;&nbsp;(129,8 KB)<br>&nbsp;&nbsp;14.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7241_14_ScreenCapture14.jpg">ScreenCapture14.jpg</a>&nbsp;&nbsp;(192,5 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20130431&edate=20130101&rec=7241">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-01-23T14:50:20+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-01-23T14:50:20+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category endocrinology > <![CDATA[Endocrinology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>NICE is Still not Backing Pierre Fabre's Javlor</title>
	<pubDate>2013-01-23T13:28:13+01:00</pubDate>
	<wp:post_id>4206</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: NICE made the same decision in November 2012, but Pierre Fabre won a partial appeal against this decision.<wbr> However NICE still did not find in favour of Javlor (for advanced/<wbr>metastatic transitional cell carcinoma of the urothelial tract).<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div>Javlor, compared with best supportive care (BSC), would have a QALY in excess of £120,000 (far higher than the normal threshold of £20,000-£30,000 per QALY gained).<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20130431&edate=20130101&rec=8742">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-01-23T13:28:13+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-01-23T13:28:13+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Progenics To Buy Radiopharmaceutical Company Molecular Insight</title>
	<pubDate>2013-01-23T13:04:59+01:00</pubDate>
	<wp:post_id>4207</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: In an all-stock transaction, Progenics Pharma has acquired Molecular Insight Pharmaceuticals, Inc.<wbr> a private company specialising in radiopharmaceutical products for the treatment/<wbr>diagnosis of prostate and adrenal cancer (phaeochromocytoma).<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Deal Rational</STRONG> </div><div style="margin-bottom: 10px;">The acquisition broadens Progenics oncology pipeline adding later-stage assets and deepening the company's strategic focus on the PSMA antigen, which it believes shows great promise as an oncology target.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Company Profiles</STRONG> </div><div style="margin-bottom: 10px;"><STRONG>Progenics </STRONG>is a US biopharmaceutical company that in 2011 had revenues of $84m.<wbr> It has one commercialised product Relistor which was outlicenced for commercialisation purposes to Salix Pharmaceuticals.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Molecular Insight</STRONG> is a US clinical stage biopharmaceuticalo company that exited Chapter 11 in May 2011 as a private company with a new board.<wbr> Strategically it realligned its business to focus on the discovery development and commercialisation of radiopharmaceutical for molecular imaging and targeted radiotherapy of prostate cancer.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><I><STRONG>Azedra™ radiotherapy for pheochromocytoma and potential other neuroendocrine indications</STRONG></I> </div><div style="margin-bottom: 10px;"><UL><LI>"Compelling data" obtained from a phase 2 registrational trial for pheochromocytoma, an ultra-orphan adrenal tumor indication</LI>
<LI>Is in development under a Special Protocol Assessment with the <ORG>U.<wbr>S.<wbr> Food and Drug Administration</ORG> using a surrogate marker registrational endpoint</LI>
<LI>Potential for use in neuroblastoma and other neuroendicrine diseases</LI>
</UL> </div><div style="margin-bottom: 10px;"><I><STRONG>Trofex™ imaging agent with potential to alter clinical practice in treating prostate cancer </STRONG></I> </div><div style="margin-bottom: 10px;"><UL><LI>Phase 2 study ongoing in metastatic prostate cancer</LI>
<LI>Highly sensitive and selective radioisotope small molecule targeting PSMA uses technetium-99m for metastatic and localized prostate cancer imaging and detection</LI>
<LI>Designed as an improved imaging agent that identifies cancer cells in soft tissue and bone, where current agents are insufficient</LI>
</UL> </div><div style="margin-bottom: 10px;">Commenting on this Product Robert Israel Senior VP-Medical Affairs &amp; Clinical Research stated: "Results thus far suggest that this agent may have sensitivity and specificity substantially beyond currently available options.<wbr> We expect this imaging product to complement our PSMA ADC program by facilitating its path to market and enhancing its value once marketed.<wbr>" </div><div style="margin-bottom: 10px;"><I><STRONG>MIP-1466 small molecule therapeutic for metastatic prostate cancer and other PSMA-expressing cancers </STRONG></I> </div><div style="margin-bottom: 10px;"><UL><LI>Targets the PSMA antigen with a radioactive payload</LI>
<LI>In preclinical development with evidence of dose-dependent enhanced tumor kill and prolonged survival in animal models of human prostate cancer</LI>
<LI>Investigator-initiated study in <LOCATION value="LC/de">Germany</LOCATION> of men with late-stage metastatic prostate cancer demonstrated tumor reduction for more than 14 days and a greater than 50% decrease in PSA levels in eight of 14 evaluable patients.<wbr></LI>
</UL> </div><div style="margin-bottom: 10px;"><STRONG>Deal Terms</STRONG> </div><div style="margin-bottom: 10px;">Under the terms of the all-stock transaction, Progenics exchanged 4,566,210 shares of its common stock (8.<wbr>9% of the total outstanding post-transaction shares) for all of the outstanding shares of Molecular Insight, which will become a wholly-owned subsidiary of Progenics.<wbr> Molecular Insight has no debt.<wbr> Progenics may make additional milestone payments to the former owners of Molecular Insight based on future commercial sales of the company's compounds.<wbr> No royalties are due to the former owners of Molecular Insight.<wbr> </div><div>Source:www.<wbr>progenics.<wbr>com </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20130431&edate=20130101&rec=8741">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-01-23T13:04:59+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-01-23T13:04:59+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Allergan Enhances Position in Migraine with MAP Pharma Buy</title>
	<pubDate>2013-01-23T11:41:56+01:00</pubDate>
	<wp:post_id>4208</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: MAP Pharma is developing LEVADEX, an orally inhaled drug for migraine in adults.<wbr> The drug is currently under review with the FDA (decision around April 15th).<wbr> Allergan expects to fund the deal (about $598M) with a combination of cash on hand, cash equivalents and short-term borrowing.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">The per share cash offer price ($25.<wbr>00) represents: </div><div style="margin-bottom: 10px;"><UL><LI>60% premium over MAP's closing stock price on the NASDAQ of $15.<wbr>5 (on Jan.<wbr> 22, 2013).<wbr></LI>
<LI>total equity value of approx.<wbr> $958M</LI>
</UL> </div><div style="margin-bottom: 10px;">Close date of the acquisition: Q2:13.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><UL><LI>To capitalize on specialty business (neurology and pain specialists)</LI>
<LI>To complement BOTOX® migraine franchise (Allergan has received regulatory approvals in 56 countries for BOTOX® for chronic migraine)</LI>
<LI>To use MAP's proprietary drug particles and inhalation technologies to generate new pipeline opportunities (D2/<wbr>D3 agonist for PD and for epilepsy)</LI>
</UL> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Assuming this transaction closes as planned, and approval of LEVADEX® occurs on or before the PDUFA date of April 15<SUP>th</SUP>, 2013, Allergan anticipates that this transaction will be dilutive to 2013 earnings per share by approximately $0.<wbr>07 and accretive to earnings per share by the second half of 2014.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Management indicated launch of LEVADEX 'would be quicker than Botox.<wbr> <SPAN style="BACKGROUND-COLOR: #ffffff">The reason being on the Botox side being an injectable, </SPAN><SPAN style="BACKGROUND-COLOR: #ffffff">we actually to have train the physicians how to administer </SPAN><SPAN style="BACKGROUND-COLOR: #ffffff">the product, where as in the case of this product it </SPAN><SPAN style="BACKGROUND-COLOR: #ffffff">is prescribed, and, of course, really the only education </SPAN><SPAN style="BACKGROUND-COLOR: #ffffff">piece is making sure then the patients know how to </SPAN><SPAN style="BACKGROUND-COLOR: #ffffff">fire the Tempo inhaler, which isn't that complicated, </SPAN><SPAN style="BACKGROUND-COLOR: #ffffff">but still is something we would pay attention to'.<wbr> </SPAN> </div><div style="margin-bottom: 10px;">When questionned on the launch of LEVADEX in interational markets, management reported that '<SPAN style="BACKGROUND-COLOR: #ffffff">Canada is the largest </SPAN><SPAN style="BACKGROUND-COLOR: #ffffff">market for Allergan outside the United States.<wbr> </SPAN><SPAN style="BACKGROUND-COLOR: #ffffff">And also we're in full launch phase of Botox, private </SPAN><SPAN style="BACKGROUND-COLOR: #ffffff">pay space, which is actually for myself, even larger </SPAN><SPAN style="BACKGROUND-COLOR: #ffffff">than I had initially assumed.<wbr> </SPAN><SPAN style="BACKGROUND-COLOR: #ffffff">And then, of course, will you all know from any drug </SPAN><SPAN style="BACKGROUND-COLOR: #ffffff">launch in Canada it takes awhile to he get through </SPAN><SPAN style="BACKGROUND-COLOR: #ffffff">all the different provincial formularies.<wbr> </SPAN><SPAN style="BACKGROUND-COLOR: #ffffff">If we look further afield, particularly to Europe, </SPAN><SPAN style="BACKGROUND-COLOR: #ffffff">the real issue is will public payers be willing to </SPAN><SPAN style="BACKGROUND-COLOR: #ffffff">pay for such a technology, and there we've started doing some work.<wbr> </SPAN><SPAN style="BACKGROUND-COLOR: #ffffff">I would say, however, I put a note of caution on that, </SPAN><SPAN style="BACKGROUND-COLOR: #ffffff">given what's going on with reimbursement in Europe, </SPAN><SPAN style="BACKGROUND-COLOR: #ffffff">and I won't refer to all the various I am ped did Iments.<wbr> </SPAN><SPAN style="BACKGROUND-COLOR: #ffffff">So we'll look at it carefully but I would say this </SPAN><SPAN style="BACKGROUND-COLOR: #ffffff">will be relative to other programs or products launched </SPAN><SPAN style="BACKGROUND-COLOR: #ffffff">by Allergan much more skewed to North America than is normal'.<wbr></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="BACKGROUND-COLOR: #ffffff">When it comes to intellectual property, D.<wbr> Pyott highlighted that '<SPAN style="BACKGROUND-COLOR: #ffffff">the patents go out to 2028.<wbr> This is the </SPAN><SPAN style="BACKGROUND-COLOR: #ffffff">case where this whole inhalation technology is quite </SPAN><SPAN style="BACKGROUND-COLOR: #ffffff">unique, quite complex, and therefore we feel really </SPAN><SPAN style="BACKGROUND-COLOR: #ffffff">good about its protectability'</SPAN>.<wbr> </SPAN> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Recent article in TRACTION CI, please See <a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20130431&edate=20130101&rec=6660" class="defaultlink">Neurology6660: MAP Resubmission Accepted By The FDA</a>.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7239_1_ScreenCapture1.jpg"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Jan.<wbr> 2011 Allergan and MAP were to co-promote LEVADEX to neurologists and pain specialists in U.<wbr>S.<wbr> and share profits 50-50 from U.<wbr>S neurologist and pain specialist sales (MAP would retain U.<wbr>S.<wbr> primary care and all ex-U.<wbr>S.<wbr> rights).<wbr> Allergan was to record its share of net profits in “other revenues.<wbr> </div><div>Source: Allergan; MAP Pharm.<wbr>; ThomsonOne </div><!-- Comment details --><a name="endocrinology7239attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7239_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(55,3 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20130431&edate=20130101&rec=7239">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-01-23T11:41:56+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-01-23T11:41:56+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category endocrinology > <![CDATA[Endocrinology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>JNJ - Q4 Results Key Takeaways</title>
	<pubDate>2013-01-22T16:25:47+01:00</pubDate>
	<wp:post_id>4209</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Full year sales advanced 3.<wbr>4% to $65bn (+6.<wbr>1% CER) with growth driven by Pharmaceuticals +6.<wbr>8% and Medical Devices ~&amp; Diagnostics (+8.<wbr>7%) whilst consumer sales remained flat.<wbr> Zytiga (abiraterone) was a strong contributer to Pharmaceutical growth with sales in the full year reaching $961m.<wbr> With both post and pre-chemotherapy usage now approved, the next indication JNJ is looking to tackly is hormone niave metastatic patients in combination with androgen deprivation therapy.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Business Profile</STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8739_1_ScreenCapture1.jpg"> </div><div style="margin-bottom: 10px;">Primary contributors to operational sales growth were REMICADE&reg; (infliximab), a biologic approved for the treatment of a number of immune-mediated, inflammatory diseases; VELCADE&reg; (bortezomib), a treatment for multiple myeloma; PREZISTA&reg; (darunavir), a treatment for HIV; and a number of recently launched products including Zytiga (abirarterone).<wbr> </div><div style="margin-bottom: 10px;">Zytiga achieved operation sales growth or over 75%, with US sales growing 34.<wbr>1% and sales outside the US more than doubling.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8739_2_ScreenCapture2.jpg"> </div><div style="margin-bottom: 10px;"><STRONG>Key Pipeline Developments</STRONG> </div><div style="margin-bottom: 10px;">Focusing on innovation JNJ also highlighted its late stage pipeline (see below) which as you will note includes a development plan for Zytiga in hormone naive patients with metasatic disease.<wbr> </div><div style="margin-bottom: 10px;"><DIV class="body3">
<P style="margin-top: 1ex; margin-bottom: 1ex;">The purpose of this study NCT01715285 is to determine if newly diagnosed (within previous 3 months) patients with metastatic hormone-naive prostate cancer (mHNPC) who have high-risk prognostic factors will benefit from the addition of abiraterone acetate and low-dose prednisone to androgen deprivation therapy.<wbr> The study will recruit 1270 patients starting this year and scheduled to complete in terms of primary endpoint (overall survival) in July 2018.<wbr> The study will be an international study run outside of the US.<wbr></P>
</DIV> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8739_3_ScreenCapture3.jpg"> </div><div style="margin-bottom: 10px;">With regard to its R&amp;D spend, Alex Gorsky Vice Chairman Executive Committee </div><div style="margin-bottom: 10px;">"The R&amp;D spending is at the higher end of the industry norm although there are other innovators in pharma that also spend at that high level.<wbr> So we view ourselves as an innovator in pharma and for that, you should expect us to be spending at the higher level and quite frankly, with the productivity that our R&amp;D organization in pharma has been able to deliver, that&rsquo;s a fantastic investment from my point of view.<wbr> Overall, for the enterprise, we tend to average an R&amp;D spend as a percent of sales higher than our competitive set blended.<wbr> Again, that&rsquo;s a much more capital-efficient way of growing our business.<wbr> As long as that&rsquo;s productive, we&rsquo;re happy to invest at higher levels than our competitors.<wbr> We&rsquo;ve got to find ways to fund that and you saw that that&rsquo;s what we did by a significant reduction in the SG&amp;A costs.<wbr> So as long as our R&amp;D is productive and we can bring innovation to the marketplace, we&rsquo;re happy to spend more than the industry in that regard and then obviously then to hopefully grow at a rate faster than our competitors as well.<wbr>" </div><div style="margin-bottom: 10px;">Interestingly, the group plans to host a Pharmaceutical Business Review in the spring on May 23rd.<wbr> </div><div>Source: <A href="http://www.jnj.com">www.<wbr>jnj.<wbr>com</A> </div><!-- Comment details --><a name="oncology8739attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8739_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(90 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8739_2_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(142,2 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8739_3_ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(178,2 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20130431&edate=20130101&rec=8739">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-01-22T16:25:47+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-01-22T16:25:47+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Takeda Reinforces Business Structure in China</title>
	<pubDate>2013-01-22T11:09:01+01:00</pubDate>
	<wp:post_id>4210</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Takeda has launched a new trading company, which began operations this month.<wbr> Takeda China Internation Trading Co.<wbr>, Ltd (TCIT) will serve as a central hub for importing Takeda products from the company's global manufacturing sites.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Local integration of Nycomed.<wbr> </div><div style="margin-bottom: 10px;">To complete liquidation of Nycomed Shanghai (end of March 2015).<wbr> </div><div style="margin-bottom: 10px;">China is Takeda's seventh largest market by revenue, and a cornerstone of the company's strategy to grow in emerging markets.<wbr> It is expected to be second largest globally by 2016.<wbr> </div><div style="margin-bottom: 10px;">Takeda is outpacing the market growth in China, with the highest market share among Japanese pharmaceutical companies in the country.<wbr> The Company aims to achieve top line growth of 29% CAGR between 2012-2016.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Will import finished products from Takeda global manufacturing sites and transfer them to TCIT.<wbr> </div><div style="margin-bottom: 10px;"><UL><LI>Establishment: September 2012 (capital paid in October 2012)
</LI>
<LI>Start of operation: January 2013
</LI>
<LI>Location: Shanghai Waigaoqiao Free Trade Zone
</LI>
<LI>Capital Stock: 8.<wbr>4 million USD
</LI>
</UL> </div><div>Source: Takeda </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20130431&edate=20130101&rec=10294">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-01-22T11:09:01+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-01-22T11:09:01+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category pharma-news > <![CDATA[Pharma News]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Health Canada to Request Revision of Product Labels for Botulinum Toxin Products</title>
	<pubDate>2013-01-22T10:43:52+01:00</pubDate>
	<wp:post_id>4211</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: To help prevent medication errors, all manufacturer of botulinum products are to revise their product labels to reflect that each product has its own individual potency and as such is not interchangeable with other botulinum products.<wbr> Manufacturers will have one year to comply with the labelling change requests.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6762_1_ScreenCapture1.jpg"> </div><div><UL><LI><STRONG>Botox </STRONG>is indicated for the treatment of severe muscle spasm in the neck, eye and foot, for chronic migraines, incontinence, and for excessive sweating.<wbr> </LI>
<LI><STRONG>Botox Cosmetic</STRONG> is indicated for cosmetic purposes, to treat facial wrinkling.<wbr></LI>
<LI><STRONG>Dysport</STRONG> is indicated for the temporary improvement in the appearance of moderate to severe wrinkles in adult patients less than 65 years of age.<wbr></LI>
<LI><STRONG>Xeomin</STRONG> is indicated for severe muscle spasm in the neck, eye and arm.<wbr> </LI>
<LI><STRONG>Xeomin Cosmetic</STRONG> is indicated for the temporary improvement of moderate to severe frown lines in adult patients.<wbr></LI>
<LI><STRONG>Myobloc</STRONG> is indicated for the treatment of adult patients with severe muscle spasm in the neck.<wbr></LI>
</UL> </div><!-- Comment details --><a name="neurology6762attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6762_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(23,6 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20130431&edate=20130101&rec=6762">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-01-22T10:43:52+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-01-22T10:43:52+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>GSK to Boost Innovative Drug Production in China</title>
	<pubDate>2013-01-22T10:23:53+01:00</pubDate>
	<wp:post_id>4212</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"><SPAN style="TEXT-ALIGN: justify; WIDOWS: 2; TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; DISPLAY: inline !important; FONT: 12px Arial, Helvetica, sans-serif; WHITE-SPACE: normal; ORPHANS: 2; FLOAT: none; LETTER-SPACING: normal; COLOR: rgb(0,0,0); WORD-SPACING: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="TEXT-ALIGN: justify; WIDOWS: 2; TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; DISPLAY: inline !important; FONT: 12px Arial, Helvetica, sans-serif; WHITE-SPACE: normal; ORPHANS: 2; FLOAT: none; LETTER-SPACING: normal; COLOR: rgb(0,0,0); WORD-SPACING: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"></SPAN><SPAN style="TEXT-ALIGN: justify; WIDOWS: 2; TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; DISPLAY: inline !important; FONT: 12px Arial, Helvetica, sans-serif; WHITE-SPACE: normal; ORPHANS: 2; FLOAT: none; LETTER-SPACING: normal; COLOR: rgb(0,0,0); WORD-SPACING: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"></SPAN> </div><div><SPAN style="TEXT-ALIGN: justify; WIDOWS: 2; TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; DISPLAY: inline !important; FONT: 12px Arial, Helvetica, sans-serif; WHITE-SPACE: normal; ORPHANS: 2; FLOAT: none; LETTER-SPACING: normal; COLOR: rgb(0,0,0); WORD-SPACING: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"></SPAN> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20130431&edate=20130101&rec=10291">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-01-22T10:23:53+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-01-22T10:23:53+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category pharma-news > <![CDATA[Pharma News]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Approval of New Gablofen® Prefilled Syringe</title>
	<pubDate>2013-01-21T15:40:42+01:00</pubDate>
	<wp:post_id>4213</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Mallinckrodt's Gablofen prefilled syringes will be available in February 2013.<wbr> Gablofen is currently available in ready-to-use vials.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">The Gablofen prefilled syringe was created to reduce preparation steps, helping to simplify the pump refill process for patients receiving ITB Therapy<SUP>SM</SUP> (Intrathecal Baclofen Therapy) to treat severe spasticity of cerebral and spinal origin.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div>Please see <a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20130431&edate=20130101&rec=6577" class="defaultlink">Neurology6577: Mallinckrodt to Acquire CNS Therapeutics for $100M</a>.<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20130431&edate=20130101&rec=6760">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-01-21T15:40:42+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-01-21T15:40:42+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>re: Impax Pharmaceuticals Announces Extension of RytaryTM FDA Review Date</title>
	<pubDate>2013-01-21T15:33:31+01:00</pubDate>
	<wp:post_id>4214</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="border-left: 2px solid #8B1010; padding: 0px 0px 5px 12px; margin-bottom: 3px;"><span style="font-weight: bold; font-size: 14px;">Impax Pharmaceuticals Announces Extension of RytaryTM FDA Review Date</span>&nbsp;<br><span style="font-size: 12px;">Comment: Impax Pharmaceuticals has announced that the <ORG>U.<wbr>S </ORG><ORG>FDA 
has extended the PDUFA date for its review of the Rytary<SUP>TM</SUP> 
(IPX066) NDA from <CHRON>October 21, 2012</CHRON>, to <CHRON>January 21, 
2013 due to the submission by Impax of information on an excipient in the 
Rytary<SUP>TM</SUP> formulation.<wbr></CHRON></ORG></span>&nbsp;&nbsp;<a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20130431&edate=20130101&rec=6611">...</a><br></div><div style="margin-bottom: 10px;">Impax failed to win U.<wbr>S.<wbr> approval for a new version of an extended-release drug used to relieve spasms in patients with Parkinson&rsquo;s disease.<wbr> The US Agency requires a re-inspection of a plant involved in the development of Rytary, which combines standard Parkinson&rsquo;s medications in a new sustained release formulation.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Piper Jaffray Forecasts</STRONG> </div><div style="margin-bottom: 10px;">The medication would likely be used most among patients for whom the standard medicines, levodopa and carbidopa, have stopped working as reliably </div><div>Analyst with Piper Jaffray &amp; Co.<wbr> predicts Rytary could generate peak sales of $200 million to $300 million.<wbr> </div><!-- Comment details --><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20130431&edate=20130101&rec=6759">Add a Comment on this Article</a><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology6611">View thread  Neurology6611: Impax Pharmaceuticals Announces Extension of RytaryTM FDA Review Date</a>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-01-21T15:33:31+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-01-21T15:33:31+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>FDA Approves New Ulcerative Colitis Drug</title>
	<pubDate>2013-01-21T12:54:14+01:00</pubDate>
	<wp:post_id>4215</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;"><DIV style="WIDOWS: 2; TEXT-TRANSFORM: none; TEXT-INDENT: 0px; FONT: small arial; WHITE-SPACE: normal; ORPHANS: 2; LETTER-SPACING: normal; COLOR: rgb(0,0,0); WORD-SPACING: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px">Comment: The 
FDA has approved an NDA from Santarus for Uceris budesonide to induce 
remission of mild to moderate active ulcerative colitis.<wbr></DIV> </div><div style="margin-bottom: 10px;"><DIV style="WIDOWS: 2; TEXT-TRANSFORM: none; TEXT-INDENT: 0px; FONT: small arial; WHITE-SPACE: normal; ORPHANS: 2; LETTER-SPACING: normal; COLOR: rgb(0,0,0); WORD-SPACING: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px">Santarus 
said it plans to launch Uceris in the U.<wbr>S.<wbr> in March.<wbr> </DIV> </div><div style="margin-bottom: 10px;"><DIV style="WIDOWS: 2; TEXT-TRANSFORM: none; TEXT-INDENT: 0px; FONT: small arial; WHITE-SPACE: normal; ORPHANS: 2; LETTER-SPACING: normal; COLOR: rgb(0,0,0); WORD-SPACING: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px">The 
company has not yet determined the price but estimates Uceris will cost</DIV> </div><div style="margin-bottom: 10px;"><DIV style="WIDOWS: 2; TEXT-TRANSFORM: none; TEXT-INDENT: 0px; FONT: small arial; WHITE-SPACE: normal; ORPHANS: 2; LETTER-SPACING: normal; COLOR: rgb(0,0,0); WORD-SPACING: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px">around 
$40 a day.<wbr> Santarus has U.<wbr>S.<wbr> rights from Italian company Cosmo to the 
product which is budesonide delivered using Cosmo’s MMX multi-matrix 
system</DIV> </div><div style="margin-bottom: 10px;"><DIV style="WIDOWS: 2; TEXT-TRANSFORM: none; TEXT-INDENT: 0px; FONT: small arial; WHITE-SPACE: normal; ORPHANS: 2; LETTER-SPACING: normal; COLOR: rgb(0,0,0); WORD-SPACING: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px">technology.<wbr></DIV> </div><div style="margin-bottom: 10px;"><DIV style="WIDOWS: 2; TEXT-TRANSFORM: none; TEXT-INDENT: 0px; FONT: small arial; WHITE-SPACE: normal; ORPHANS: 2; LETTER-SPACING: normal; COLOR: rgb(0,0,0); WORD-SPACING: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px">In 
August, the Netherlands Medicines Evaluation Board decided not to approve an MAA 
for the product.<wbr> The MAA was submitted under the EU’s decentralized procedure, 
with the Netherlands acting as the reference member state.<wbr> Ferring has rights to 
the product from Cosmo outside of the U.<wbr>S.<wbr> and Japan.<wbr></DIV> </div><div><DIV style="WIDOWS: 2; TEXT-TRANSFORM: none; TEXT-INDENT: 0px; FONT: small arial; WHITE-SPACE: normal; ORPHANS: 2; LETTER-SPACING: normal; COLOR: rgb(0,0,0); WORD-SPACING: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px">Source: 
<a href="http://www.santarus.com" class="defaultlink" title="www.santarus.com">santarus.com</a> </DIV> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20130431&edate=20130101&rec=1872">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-01-21T12:54:14+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-01-21T12:54:14+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category gastroenterology > <![CDATA[gastroenterology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Bavarian Nordic's Prostate Cancer Vaccine Strategy</title>
	<pubDate>2013-01-21T12:22:15+01:00</pubDate>
	<wp:post_id>4216</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment:  </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"><P align="left"><STRONG><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8738_2_ScreenCapture2.jpg"></STRONG></P> </div><div style="margin-bottom: 10px;"><P align="left"><STRONG><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8738_3_ScreenCapture3.jpg"></STRONG></P> </div><div style="margin-bottom: 10px;"><P align="left"><STRONG><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8738_4_ScreenCapture4.jpg"></STRONG></P> </div><div style="margin-bottom: 10px;"><P align="left"><STRONG><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8738_5_ScreenCapture5.jpg"></STRONG></P> </div><div style="margin-bottom: 10px;"><P align="left"><STRONG><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8738_6_ScreenCapture6.jpg"></STRONG></P> </div><div style="margin-bottom: 10px;"><P align="left"><STRONG><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8738_7_ScreenCapture7.jpg"></STRONG></P> </div><div style="margin-bottom: 10px;"><P align="left"><STRONG><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8738_8_ScreenCapture8.jpg"></STRONG></P> </div><div style="margin-bottom: 10px;"><P align="left"><STRONG><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8738_9_ScreenCapture9.jpg"></STRONG></P> </div><div style="margin-bottom: 10px;"><P align="left"><STRONG><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8738_10_ScreenCapture10.jpg"></STRONG></P> </div><div style="margin-bottom: 10px;"><P align="left"><STRONG><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8738_11_ScreenCapture11.jpg"></STRONG></P> </div><div style="margin-bottom: 10px;"><P align="left"><STRONG><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8738_12_ScreenCapture12.jpg"></STRONG></P> </div><div style="margin-bottom: 10px;"><P align="left"><STRONG><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8738_15_ScreenCapture15.jpg"></STRONG></P> </div><div style="margin-bottom: 10px;"><P align="left"><STRONG>Company Profile/<wbr> Financial Position</STRONG></P> </div><div style="margin-bottom: 10px;"><P align="left"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8738_16_ScreenCapture16.jpg"></P> </div><div style="margin-bottom: 10px;"><P align="left"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8738_13_ScreenCapture13.jpg"></P> </div><div style="margin-bottom: 10px;"><P align="left"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8738_14_ScreenCapture14.jpg"></P> </div><div><P align="left">Source: <A href="http://www.bavarian-nordic.com">www.<wbr>bavarian-nordic.<wbr>com</A></P> </div><!-- Comment details --><a name="oncology8738attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8738_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(118,4 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8738_2_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(81,5 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8738_3_ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(102,8 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8738_4_ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(94,6 KB)<br>&nbsp;&nbsp;5.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8738_5_ScreenCapture5.jpg">ScreenCapture5.jpg</a>&nbsp;&nbsp;(118,7 KB)<br>&nbsp;&nbsp;6.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8738_6_ScreenCapture6.jpg">ScreenCapture6.jpg</a>&nbsp;&nbsp;(81,5 KB)<br>&nbsp;&nbsp;7.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8738_7_ScreenCapture7.jpg">ScreenCapture7.jpg</a>&nbsp;&nbsp;(110,2 KB)<br>&nbsp;&nbsp;8.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8738_8_ScreenCapture8.jpg">ScreenCapture8.jpg</a>&nbsp;&nbsp;(118,3 KB)<br>&nbsp;&nbsp;9.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8738_9_ScreenCapture9.jpg">ScreenCapture9.jpg</a>&nbsp;&nbsp;(114,1 KB)<br>&nbsp;&nbsp;10.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8738_10_ScreenCapture10.jpg">ScreenCapture10.jpg</a>&nbsp;&nbsp;(110,6 KB)<br>&nbsp;&nbsp;11.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8738_11_ScreenCapture11.jpg">ScreenCapture11.jpg</a>&nbsp;&nbsp;(121,7 KB)<br>&nbsp;&nbsp;12.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8738_12_ScreenCapture12.jpg">ScreenCapture12.jpg</a>&nbsp;&nbsp;(69,6 KB)<br>&nbsp;&nbsp;13.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8738_13_ScreenCapture13.jpg">ScreenCapture13.jpg</a>&nbsp;&nbsp;(94,8 KB)<br>&nbsp;&nbsp;14.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8738_14_ScreenCapture14.jpg">ScreenCapture14.jpg</a>&nbsp;&nbsp;(114,8 KB)<br>&nbsp;&nbsp;15.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8738_15_ScreenCapture15.jpg">ScreenCapture15.jpg</a>&nbsp;&nbsp;(116,7 KB)<br>&nbsp;&nbsp;16.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8738_16_ScreenCapture16.jpg">ScreenCapture16.jpg</a>&nbsp;&nbsp;(208,1 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20130431&edate=20130101&rec=8738">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-01-21T12:22:15+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-01-21T12:22:15+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Biscayne Pharm. Closes $1.5M Financing to Develop GHRH Drugs</title>
	<pubDate>2013-01-21T11:35:47+01:00</pubDate>
	<wp:post_id>4217</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Biscayne Pharmaceuticals, a privately biopharm.<wbr> company discoverig and developing novel therapies based on GHRH analogs, is developing novel GHRH drugs based on recent discoveries by Dr.<wbr> Andrew Schally.<wbr> The company has exclusively licensed IP from the U.<wbr> of Miami that includes WW rights to the Schally GHRH technology, including GHRH antagonists and GHRH agonists.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Biscayne's lead GHRH antagonist is in PC development, initially for CRPC.<wbr> </div><div style="margin-bottom: 10px;">The company's GHRH agonists have demonstrated capacity to repair the heart following ischemic injury.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">The Reich Group, based in Miami Beach (Floria), led the financing.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">HQ: Miami, FL.<wbr> </div><div style="margin-bottom: 10px;">CEO: Samuel Reich, managing partner of the Reich Group.<wbr> </div><div>The company's technology stems from the discoveries of Dr.<wbr> A.<wbr> V.<wbr> Schally </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20130431&edate=20130101&rec=8735">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-01-21T11:35:47+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-01-21T11:35:47+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>FDA Approves Botox For iOAB as Allergan Launches New PhIII trial</title>
	<pubDate>2013-01-21T10:35:58+01:00</pubDate>
	<wp:post_id>4218</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: On Friday Allergan received FDA approval to expand Botox's label to include patients with idiopathic overactive bladder who do not repond to existing medications.<wbr> The timing is in line with expectations and follows European approval in December.<wbr> </div><div style="margin-bottom: 10px;">to be more specific the agency has said that Botox can be used to treat symptoms of overactive bladder including urinary incontinence, feeling a sudden and urgent need to urinate and frequent urination in patients who can't use or don't respond adequately to anticholinergic medications.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Launch of New Study</STRONG> </div><div style="margin-bottom: 10px;">Coinciding with this approval, Allergan has launched a new phIII study to evaluate the efficacy and safety of Botox in combination with solifenacin in patients with overactive bladder and urinary incontinence.<wbr> See <a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20130431&edate=20130101&rec=6751" class="defaultlink">Neurology6751: Botox and Solifenacin in Patients With OAB and Urinary Incontinence</a>.<wbr> </div><div style="margin-bottom: 10px;">The randomised 345 patient study will evaluate the number of episodes of urinary incontinence and percentage of patients who are 100% dry over a 12 week period.<wbr> The study is scheduled to complete in December 2014.<wbr> </div><div style="margin-bottom: 10px;">Including this indicatrion Botox is now approved for 26 different indications in more than 85 countries </div><div>Source: <A href="http://www.allergan.com/">www.<wbr>allergan.<wbr>com</A> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20130431&edate=20130101&rec=6758">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-01-21T10:35:58+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-01-21T10:35:58+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Merz's Extended Version 2011/12 Annual Report</title>
	<pubDate>2013-01-18T18:41:18+01:00</pubDate>
	<wp:post_id>4219</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: In its extended 2011/<wbr>12 annual report which has just been released, Merz suggests that it is likely to face more litigation in the US market in the coming year (2012/<wbr>13) relating to botulinum toxins and aesthetics particularly with regard to trade secrets.<wbr> </div><div style="margin-bottom: 10px;">Management assumes that the injunction improsed by the ruling about alleged abuse of business secrets by Merz US companiesIt "should not last beyond 2013 and that its products should be able to be marketed without further restriction from thereon.<wbr>" We believe its comments relate to fiscal 12/<wbr>13 which extends to June 2013.<wbr> </div><div style="margin-bottom: 10px;">With regard to Xeomin it notes that Merz Pharma will further build on its position as a specialist provider in the field of Neurology with Xeomin for the indication dystonia and spasticity.<wbr> In the US it claims that it will continue to invest heavily in successfully positioning Xeomin on the market after its market launch.<wbr> For further growth it notes that it willl be particuarly important to obtain expanded approvals in the US, Canada and Brazil as planned.<wbr> </div><div style="margin-bottom: 10px;">It suggests that the full potential of botulinum toxin has yet to be captured in manneurology.<wbr> Its stated objective is to broaden the range of indicationy aresa of specials It notes that it also improved its market share during the year particularly in Germany where its share of the market rose from 25% to 29%.<wbr> due to the size of the global market it claims to expect substantial growth in future years </div><div style="margin-bottom: 10px;">The company notes that one of the most important growth driver for the company is its aesthetic business and that building up this business has been one of its prime goals during the last reporting year.<wbr> </div><div>Source: Merz 2011/<wbr>12 Annual Report </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20130431&edate=20130101&rec=6755">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-01-18T18:41:18+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-01-18T18:41:18+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>New Migraine Treatment Gets The Nod - Partnership Now The Priority</title>
	<pubDate>2013-01-18T17:36:08+01:00</pubDate>
	<wp:post_id>4220</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: <SPAN style="WIDOWS: 2; TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; DISPLAY: inline !important; FONT: 12px arial, sans-serif; WHITE-SPACE: normal; ORPHANS: 2; FLOAT: none; LETTER-SPACING: normal; COLOR: rgb(34,34,34); WORD-SPACING: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px">NuPathe 
at last had something to celebrate yesterday, with the US approval of its 
battery-powered sumatriptan patch, Zecuity, for the acute treatment of migraine 
with or without aura in adults.<wbr></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="WIDOWS: 2; TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; DISPLAY: inline !important; FONT: 12px arial, sans-serif; WHITE-SPACE: normal; ORPHANS: 2; FLOAT: none; LETTER-SPACING: normal; COLOR: rgb(34,34,34); WORD-SPACING: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px">The 
company’s rock-bottom valuation had risesn by 15% ahead of the approval and 
yesterday soared by another 40%.<wbr></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="WIDOWS: 2; TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; DISPLAY: inline !important; FONT: 12px arial, sans-serif; WHITE-SPACE: normal; ORPHANS: 2; FLOAT: none; LETTER-SPACING: normal; COLOR: rgb(34,34,34); WORD-SPACING: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px">Given 
NuPathe’s limited cash and no immediate plans actually to launch Zecuity, its 
top priority now must be to sign a licensing deal.<wbr></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="WIDOWS: 2; TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; DISPLAY: inline !important; FONT: 12px arial, sans-serif; WHITE-SPACE: normal; ORPHANS: 2; FLOAT: none; LETTER-SPACING: normal; COLOR: rgb(34,34,34); WORD-SPACING: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6754_1_ScreenCapture1.jpg"></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="WIDOWS: 2; TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; DISPLAY: inline !important; FONT: 12px arial, sans-serif; WHITE-SPACE: normal; ORPHANS: 2; FLOAT: none; LETTER-SPACING: normal; COLOR: rgb(34,34,34); WORD-SPACING: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6754_2_ScreenCapture2.jpg"></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="WIDOWS: 2; TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; DISPLAY: inline !important; FONT: 12px arial, sans-serif; WHITE-SPACE: normal; ORPHANS: 2; FLOAT: none; LETTER-SPACING: normal; COLOR: rgb(34,34,34); WORD-SPACING: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6754_3_ScreenCapture3.jpg"></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="WIDOWS: 2; TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; DISPLAY: inline !important; FONT: 12px arial, sans-serif; WHITE-SPACE: normal; ORPHANS: 2; FLOAT: none; LETTER-SPACING: normal; COLOR: rgb(34,34,34); WORD-SPACING: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6754_4_ScreenCapture4.jpg"></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="WIDOWS: 2; TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; DISPLAY: inline !important; FONT: 12px arial, sans-serif; WHITE-SPACE: normal; ORPHANS: 2; FLOAT: none; LETTER-SPACING: normal; COLOR: rgb(34,34,34); WORD-SPACING: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6754_5_ScreenCapture5.jpg"></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="WIDOWS: 2; TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; DISPLAY: inline !important; FONT: 12px arial, sans-serif; WHITE-SPACE: normal; ORPHANS: 2; FLOAT: none; LETTER-SPACING: normal; COLOR: rgb(34,34,34); WORD-SPACING: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px">The 
Market</SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="WIDOWS: 2; TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; DISPLAY: inline !important; FONT: 12px arial, sans-serif; WHITE-SPACE: normal; ORPHANS: 2; FLOAT: none; LETTER-SPACING: normal; COLOR: rgb(34,34,34); WORD-SPACING: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6754_6_ScreenCapture6.jpg"></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="WIDOWS: 2; TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; DISPLAY: inline !important; FONT: 12px arial, sans-serif; WHITE-SPACE: normal; ORPHANS: 2; FLOAT: none; LETTER-SPACING: normal; COLOR: rgb(34,34,34); WORD-SPACING: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6754_7_ScreenCapture7.jpg"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6754_8_ScreenCapture8.jpg"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6754_9_ScreenCapture9.jpg"></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="WIDOWS: 2; TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; DISPLAY: inline !important; FONT: 12px arial, sans-serif; WHITE-SPACE: normal; ORPHANS: 2; FLOAT: none; LETTER-SPACING: normal; COLOR: rgb(34,34,34); WORD-SPACING: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6754_10_ScreenCapture10.jpg"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6754_11_ScreenCapture11.jpg"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6754_12_ScreenCapture12.jpg"></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="WIDOWS: 2; TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; DISPLAY: inline !important; FONT: 12px arial, sans-serif; WHITE-SPACE: normal; ORPHANS: 2; FLOAT: none; LETTER-SPACING: normal; COLOR: rgb(34,34,34); WORD-SPACING: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px">Finances</SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="WIDOWS: 2; TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; DISPLAY: inline !important; FONT: 12px arial, sans-serif; WHITE-SPACE: normal; ORPHANS: 2; FLOAT: none; LETTER-SPACING: normal; COLOR: rgb(34,34,34); WORD-SPACING: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6754_13_ScreenCapture13.jpg"></SPAN> </div><div><SPAN style="WIDOWS: 2; TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; DISPLAY: inline !important; FONT: 12px arial, sans-serif; WHITE-SPACE: normal; ORPHANS: 2; FLOAT: none; LETTER-SPACING: normal; COLOR: rgb(34,34,34); WORD-SPACING: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px">Source: 
<A href="http://www.nupathe.com">www.<wbr>nupathe.<wbr>com</A></SPAN> </div><!-- Comment details --><a name="neurology6754attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6754_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(99,5 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6754_2_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(88,9 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6754_3_ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(92,7 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6754_4_ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(96,6 KB)<br>&nbsp;&nbsp;5.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6754_5_ScreenCapture5.jpg">ScreenCapture5.jpg</a>&nbsp;&nbsp;(112,1 KB)<br>&nbsp;&nbsp;6.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6754_6_ScreenCapture6.jpg">ScreenCapture6.jpg</a>&nbsp;&nbsp;(85,2 KB)<br>&nbsp;&nbsp;7.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6754_7_ScreenCapture7.jpg">ScreenCapture7.jpg</a>&nbsp;&nbsp;(103 KB)<br>&nbsp;&nbsp;8.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6754_8_ScreenCapture8.jpg">ScreenCapture8.jpg</a>&nbsp;&nbsp;(116,7 KB)<br>&nbsp;&nbsp;9.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6754_9_ScreenCapture9.jpg">ScreenCapture9.jpg</a>&nbsp;&nbsp;(99,1 KB)<br>&nbsp;&nbsp;10.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6754_10_ScreenCapture10.jpg">ScreenCapture10.jpg</a>&nbsp;&nbsp;(112,1 KB)<br>&nbsp;&nbsp;11.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6754_11_ScreenCapture11.jpg">ScreenCapture11.jpg</a>&nbsp;&nbsp;(110,2 KB)<br>&nbsp;&nbsp;12.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6754_12_ScreenCapture12.jpg">ScreenCapture12.jpg</a>&nbsp;&nbsp;(83 KB)<br>&nbsp;&nbsp;13.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6754_13_ScreenCapture13.jpg">ScreenCapture13.jpg</a>&nbsp;&nbsp;(61,7 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20130431&edate=20130101&rec=6754">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-01-18T17:36:08+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-01-18T17:36:08+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>The European Medicines Agency (EMA) is seeking views on proposed changes to the way it assesses cancer drugs</title>
	<pubDate>2013-01-17T12:58:00+01:00</pubDate>
	<wp:post_id>4221</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment : The European Medicines Agency released early January a new guideline aiming to provide guidance on the development of medicinal products for use in anti-cancer indications.<wbr> It <SPAN style="display: inline! important; float: none; word-spacing: 0px; font: small arial; text-transform: none; color: #000000; text-indent: 0px; white-space: normal; letter-spacing: normal; orphans: 2; widows: 2; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;">underlines the importance of exploratory studies to properly define the most appropriate target population and puts further emphasis on the role of biomarkers.<wbr> <SPAN style="display: inline! important; float: none; word-spacing: 0px; font: small arial; text-transform: none; color: #000000; text-indent: 0px; white-space: normal; letter-spacing: normal; orphans: 2; widows: 2; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;">The draft guideline also covers companion diagnostics, and says their development should be considered early in clinical development, maximising the clinical application of the technology.<wbr></SPAN></SPAN> </div><div style="margin-bottom: 10px;">The guideline, adopted by the EMA during the <A href="http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2011/12/news_detail_001401.jsp&amp;mid=WC0b01ac058004d5c1" target="_blank">15 December 2011 meeting</A> of the Committee for Medicinal Products for Human Use (CHMP), aims to provide guidance on the development of medicinal products for use in anti-cancer indications.<wbr> More specifically, the guideline provides clarity on: </div><div style="margin-bottom: 10px;"><UL><LI>proper dosing of anticancer products
</LI>
<LI>proper scheduling of anticancer products
</LI>
<LI>optimizing the benefit of a product to patients by identifying the optimal target population
</LI>
<LI>conducting studies on combination therapies
</LI>
</UL> </div><div style="margin-bottom: 10px;">
It provides condition specific guidance for non-small cell lung cancer, <STRONG>prostate cancer</STRONG>, chronic myeloid leukemia, myelodysplastic syndromes, and hematopoietic stem cell transplantation.<wbr> </div><div style="margin-bottom: 10px;">The guideline was released with an accompanying appendix, titled, <EM><A href="http://www.ema.europa.eu/ema/doc_index.jsp?curl=pages/includes/document/document_detail.jsp?webContentId=WC500119965&amp;murl=menus/document_library/document_library.jsp&amp;mid=0b01ac058009a3dc" target="_blank">Methodological consideration for using progression-free survival (PFS) or disease-free survival (DFS) in confirmatory trials</A></EM>, which provides guidance on endpoint definitions, frequency and methods of assessment, ascertainment bias, handling of deviations and missing data, and radiology  review.<wbr><BR>From both a clinical and a methodological perspective, the most persuasive outcome of a clinical trial is the demonstration of favorable effects on overall survival.<wbr> Prolonged progression-free survival and disease-free survival are also considered to be of benefit to the patient.<wbr> </div><div style="margin-bottom: 10px;">Consultations are due by 31 May, 2012.<wbr> The guideline <SPAN style="display: inline! important; float: none; word-spacing: 0px; font: 12px Arial, Helvetica, sans-serif; text-transform: none; color: #222222; text-indent: 0px; white-space: normal; letter-spacing: normal; background-color: #ffffff; orphans: 2; widows: 2; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;">will come into effect on 1 July.<wbr></SPAN> </div><div style="margin-bottom: 10px;">Sources : Scrip 16 January and Regulatory Focus 5 January </div><div style="margin-bottom: 10px;">See : </div><div><UL><LI><A href="http://www.ema.europa.eu/ema/doc_index.jsp?curl=pages/includes/document/document_detail.jsp?webContentId=WC500119966&amp;murl=menus/document_library/document_library.jsp&amp;mid=0b01ac058009a3dc" target="_blank">EMA - Guideline on the evaluation of anticancer medicinal products in man</A>
</LI>
<LI><A href="http://www.ema.europa.eu/ema/doc_index.jsp?curl=pages/includes/document/document_detail.jsp?webContentId=WC500119965&amp;murl=menus/document_library/document_library.jsp&amp;mid=0b01ac058009a3dc" target="_blank">EMA - Appendix 1 to the guideline on the evaluation of anticancer medicinal products in man</A>
</LI>
</UL> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20130431&edate=20130101&rec=8733">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-01-17T12:58:00+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-01-17T12:58:00+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>re: Kinex' Src kinase inhibitor Enter Ph2 in Patients with Prostate Cancer</title>
	<pubDate>2013-01-17T12:45:12+01:00</pubDate>
	<wp:post_id>4222</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="border-left: 2px solid #8B1010; padding: 0px 0px 5px 12px; margin-bottom: 3px;"><span style="font-weight: bold; font-size: 14px;">Kinex' Src kinase inhibitor Enter Ph2 in Patients with Prostate Cancer</span>&nbsp;<br><span style="font-size: 12px;">Comment: The Ph2 trial will assess the safety and efficacy of KX2-391 in patients with bone-metastatic, castrate-resistant prostate cancer (CRPC).<wbr></span>&nbsp;&nbsp;<a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20130431&edate=20130101&rec=6058">...</a><br></div><div style="margin-bottom: 10px;">KX2-391 dosed at 40 mg twice-daily lacks antitumor activity in men with CRPC, but has modest effects on bone turnover markers.<wbr> Because a C (max) of &ge;142 ng/<wbr>mL is required for tubulin polymerization inhibition (defined from preclinical studies), higher once-daily dosing will be used in future trials.<wbr> </div><div style="margin-bottom: 10px;"><H4><STRONG>METHODS: We treated 31 patients with oral KX2-391 (40 mg twice-daily) until disease progression or unacceptable toxicity.<wbr> The primary endpoint was 24-week progression-free survival (PFS); a 50 % success rate was pre-defined as clinically significant.<wbr> Secondary endpoints included PSA progression-free survival (PPFS) and PSA response rates.<wbr> Exploratory outcomes included pharmacokinetic studies, circulating tumor cell (CTC) enumeration, and analysis of markers of bone resorption [urinary N-telopeptide (uNTx); C-telopeptide (CTx)] and formation [bone alkaline phosphatase (BAP); osteocalcin].<wbr></STRONG></H4> </div><div style="margin-bottom: 10px;"><H4>RESULTS: The trial closed early after accrual of 31 patients, due to a pre-specified futility rule.<wbr> PFS at 24 weeks was 8 %, and median PFS was 18.<wbr>6 weeks.<wbr> The PSA response rate (&ge;30 % decline) was 10 %, and median PPFS was 5.<wbr>0 weeks.<wbr> Additionally, 18 % of men with unfavorable (&ge;5) CTCs at baseline converted to favorable (&lt;5) CTCs with treatment.<wbr> The proportion of men with declines in bone turnover markers was 32 % for uNTx, 21 % for CTx, 10 % for BAP, and 25 % for osteocalcin.<wbr> In pharmacokinetic studies, median C (max) was 61 (range 16-129) ng/<wbr>mL, and median AUC was 156 (35-348) ng h/<wbr>mL.<wbr> Common toxicities included hepatic derangements, myelosuppression, fatigue, nausea, and constipation.<wbr></H4> </div><div style="margin-bottom: 10px;"><DIV class="cit"><A href="http://www.ncbi.nlm.nih.gov/pubmed/23314737?dopt=Abstract" title="Cancer chemotherapy and pharmacology.">Cancer Chemother Pharmacol.<wbr></A> 2013 Jan 13.<wbr> [Epub ahead of print]</DIV> </div><div style="margin-bottom: 10px;"><H1>A phase 2 study of KX2-391, an oral inhibitor of Src kinase and tubulin polymerization, in men with bone-metastatic castration-resistant prostate cancer.<wbr></H1> </div><div style="margin-bottom: 10px;"><DIV class="auths"><A href="http://www.ncbi.nlm.nih.gov/pubmed?term=Antonarakis%20ES%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=23314737">Antonarakis ES</A>, <A href="http://www.ncbi.nlm.nih.gov/pubmed?term=Heath%20EI%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=23314737">Heath EI</A>, <A href="http://www.ncbi.nlm.nih.gov/pubmed?term=Posadas%20EM%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=23314737">Posadas EM</A>, <A href="http://www.ncbi.nlm.nih.gov/pubmed?term=Yu%20EY%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=23314737">Yu EY</A>, <A href="http://www.ncbi.nlm.nih.gov/pubmed?term=Harrison%20MR%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=23314737">Harrison MR</A>, <A href="http://www.ncbi.nlm.nih.gov/pubmed?term=Bruce%20JY%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=23314737">Bruce JY</A>, <A href="http://www.ncbi.nlm.nih.gov/pubmed?term=Cho%20SY%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=23314737">Cho SY</A>, <A href="http://www.ncbi.nlm.nih.gov/pubmed?term=Wilding%20GE%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=23314737">Wilding GE</A>, <A href="http://www.ncbi.nlm.nih.gov/pubmed?term=Fetterly%20GJ%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=23314737">Fetterly GJ</A>, <A href="http://www.ncbi.nlm.nih.gov/pubmed?term=Hangauer%20DG%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=23314737">Hangauer DG</A>, <A href="http://www.ncbi.nlm.nih.gov/pubmed?term=Kwan%20MF%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=23314737">Kwan MF</A>, <A href="http://www.ncbi.nlm.nih.gov/pubmed?term=Dyster%20LM%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=23314737">Dyster LM</A>, <A href="http://www.ncbi.nlm.nih.gov/pubmed?term=Carducci%20MA%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=23314737">Carducci MA</A>.<wbr></DIV> </div><div><DIV class="aff">
<H3 class="label">Source : Prostate Cancer Research Program, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, 1650 Orleans Street, CRB1-1M45, Baltimore, MD, 21231-1000, USA, <A href="mailto:eantona1@jhmi.edu">eantona1@jhmi.<wbr>edu</A>.<wbr></H3>
</DIV> </div><!-- Comment details --><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20130431&edate=20130101&rec=8732">Add a Comment on this Article</a><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology6058">View thread  Oncology6058: Kinex' Src kinase inhibitor Enter Ph2 in Patients with Prostate Cancer</a>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-01-17T12:45:12+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-01-17T12:45:12+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Alternative to Animal Testing Available for Licensing or Collaboration</title>
	<pubDate>2013-01-17T11:56:53+01:00</pubDate>
	<wp:post_id>4223</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: The method, invented at ETH Zurich, uses functionalized liposomes to determine the toxin's activity under physiological conditions.<wbr> The invention will avoid the use of mouse LD50 tests for toxicity testing.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">The Swiss Federal Institute of Technology offers researchers and students a comprehensive education as one of the leading international universities for technology and the natural sciences.<wbr> </div><div>Press Release (in German) attached <a href="http://ci.beaufour-ipsen.com/traction?type=np&proj=*&sdate=20130431&edate=20130101&rs=/link%20Neurology6753%401" class="defaultlink">@1</a>.<wbr> </div><!-- Comment details --><a name="neurology6752attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6752_1_ETH%255fliposomen%255fersetzen%255ftierversuch.pdf">ETH_liposomen_ersetzen_tierversuch.pdf</a>&nbsp;&nbsp;(36,3 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20130431&edate=20130101&rec=6752">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-01-17T11:56:53+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-01-17T11:56:53+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Leupromer (Iranian Formulated LHRH agonist) and Eligard in Patients with Metastatic Prostate Cancer</title>
	<pubDate>2013-01-16T18:23:08+01:00</pubDate>
	<wp:post_id>4224</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: The Iranian Registry of Clinical Trials is listing a new Ph2/<wbr>Ph3 comparison study in approx.<wbr> 98 men with metastatic prostate cancer.<wbr> Primary outcome will assess ratio of serum PSA level 28, 56 and 84 days after beginning of treatment.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><A href="http://variandarou.com/">Varian Darou Pazhoh </A>privately owned pharma company founded in 2009.<wbr> </div><div style="margin-bottom: 10px;"><U>Product Range includes</U> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_dkphybrids_216_1_ScreenCapture1.jpg"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Matthieu Raimbault will be trying to learn more about this company/<wbr>trial/<wbr>product when travelling to Iran next week for a Uro-Onco congress.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">IRCT registration number : IRCT201206131030N10 </div><div style="margin-bottom: 10px;"><U>Start date</U>: Nov.<wbr> 2012 - Completion date: May 2013 </div><div style="margin-bottom: 10px;"><U>Design</U> </div><div style="margin-bottom: 10px;">Randomized: placebo not used </div><div style="margin-bottom: 10px;"><U>Intervention</U> </div><div style="margin-bottom: 10px;">Drug Leupromer 7.<wbr>5mg ev 28 days for 3 times </div><div style="margin-bottom: 10px;">Drug Eligard 7.<wbr>5mg ev 28 day for 3 times </div><div>Location: Shohadaye Tajrish Urology Clinic (Teheran) </div><!-- Comment details --><a name="dkphybrids216attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_dkphybrids_216_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(38,7 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_dkphybrids_216_2_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(62,7 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=DKPHybrids&sdate=20130431&edate=20130101&rec=216">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-01-16T18:23:08+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-01-16T18:23:08+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category dkphybrids > <![CDATA[dkphybrids]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Versartis Closed $25M Series C Financing</title>
	<pubDate>2013-01-16T08:24:23+01:00</pubDate>
	<wp:post_id>4225</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: The primary use of the proceeds will be to fund clinical trials of VRS-317 (monthly form of rhGH), currently in Ph1b/<wbr>Ph2a for growth hormone deficiency in paediatric patients.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">See <a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20130431&edate=20130101&rec=7142" class="defaultlink">Endocrinology7142: First Pediatric Trial with Versartis' Once-Monthly rhGH</a>.<wbr> </div><div style="margin-bottom: 10px;">In October 2012 the company started its first pediatric clinical trial of VRS-317 in pre-pubertal children with Growth Hormone Deficiency (GHD).<wbr> </div><div style="margin-bottom: 10px;">The <U>Ver</U>sartis <U>T</U>rial <U>I</U>n <U>C</U>hildren to <U>A</U>ssess <U>L</U>ong-Acting Growth Hormone (VERTICAL) study is being conducted in approx.<wbr> 30 sites in the US, and was initiated following the successful completion of a Ph1 study in adults with GHD.<wbr> </div><div style="margin-bottom: 10px;">The VERTICAL study is designed in 2 stages: </div><div><UL><LI>the first stage (Ph1b) utilizes an ascending-dose design to evaluate the safety and tolerability of up-to-four dosing levels of a single subcutaneous (SC) dose of VRS-317.<wbr>  </LI>
<LI>the second stage (Ph2a) will further study these patients to determine the efficacy of VRS-317 as defined by an increase in height velocity over six months of treatment.<wbr></LI>
</UL> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20130431&edate=20130101&rec=7238">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-01-16T08:24:23+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-01-16T08:24:23+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category endocrinology > <![CDATA[Endocrinology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Astellas' ASP-1707 (GnRH Antagonist) Now in Ph2 for Endometriosis Associated Pain</title>
	<pubDate>2013-01-15T17:53:18+01:00</pubDate>
	<wp:post_id>4226</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: The Ph2 trial will recruit approx.<wbr> 600 pre-menopausal women, with confirmed length and regular menstrual cycle, surgically diagnosed endometriosis and moderate-to-severe endometriosis related pain.<wbr> Primary endpoint will assess change from baseline to the end of 12 weeks treatment of pain score.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8729_1_ScreenCapture1.jpg"> </div><div style="margin-bottom: 10px;">Abbott's Elagolix is the most advanced (NDA filing/<wbr>Launch planned in 2016).<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG><A href="http://clinicaltrials.gov/ct2/show/NCT01767090?recr=Open&amp;no_unk=Y&amp;phase=012&amp;fund=2&amp;rcv_s=12%2F15%2F2012&amp;rank=150"><STRONG></STRONG></A> </div><div style="margin-bottom: 10px;"><STRONG>Title</STRONG>: A Randomized, Double-blind, Placebo-controlled, Phase 2 Study to Assess the Efficacy, Safety, and Dose-Response Relationship of ASP1707 in Subjects With Endometriosis Associated Pelvic Pain for 12 Weeks, Followed by a 12-Week Double-blind Extension Without Placebo Control, Including a 24-Week Open-Label Leuprorelin Acetate Treatment Group for Bone Mineral Density Assessment.<wbr> </div><div style="margin-bottom: 10px;">Completion dates: June 2014 </div><div>Location: Japan </div><!-- Comment details --><a name="oncology8729attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8729_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(53,4 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20130431&edate=20130101&rec=8729">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-01-15T17:53:18+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-01-15T17:53:18+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Botox and Solifenacin in Patients With OAB and Urinary Incontinence</title>
	<pubDate>2013-01-15T17:37:19+01:00</pubDate>
	<wp:post_id>4227</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Clinicaltrials.<wbr>gov is listing a new Ph3, which will be starting next month and assessing number of episodes of urinary incontinence and percentage of participants who are 100% incontinence-free/<wbr>dry as primary endpoints.<wbr> Locations of the trial include US, Belgium, Canada, Czech Rep.<wbr>, France, Germany, Poland and the UK.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG><A href="http://clinicaltrials.gov/ct2/show/NCT01767519?recr=Open&amp;no_unk=Y&amp;phase=012&amp;fund=2&amp;rcv_s=12%2F15%2F2012&amp;rank=43"><STRONG></STRONG></A> </div><div style="margin-bottom: 10px;">Recruitment: approx.<wbr> 345 participants, with: </div><div style="margin-bottom: 10px;"><UL style="MARGIN-TOP: 1ex; MARGIN-BOTTOM: 1ex"><LI class="color-bullet" style="MARGIN-TOP: 0.7ex">Symptoms of Overactive Bladder (OAB) (frequency/<wbr>urgency) with urinary incontinence for at least 6 months</LI>
<LI class="color-bullet" style="MARGIN-TOP: 0.7ex">Inadequate response or limiting side effects with anticholinergics for the treatment of OAB</LI>
</UL> </div><div style="margin-bottom: 10px;">
Completion dates: Dec 2014 /<wbr> June 2015 </div><div>Protocol : 3-arms (Botox; solifenacin, placebo).<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20130431&edate=20130101&rec=6751">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-01-15T17:37:19+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-01-15T17:37:19+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>New Senior Executive Team Structure at AstraZeneca</title>
	<pubDate>2013-01-15T16:11:35+01:00</pubDate>
	<wp:post_id>4228</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: The new, expanded membership of AstraZeneca’s Senior Executive Team, includes increased representation of the company’s scientific expertise, key products and key markets.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">• Three senior R&amp;D roles responsible for discovery and early stage development in small molecules; discovery and early stage development in biologics; and late stage development.<wbr><BR>• Three roles representing the commercial regions: North America, Europe and International.<wbr><BR>• A role responsible for global portfolio and product strategy, bridging between the R&amp;D and sales organisation.<wbr><BR> </div><div style="margin-bottom: 10px;">As a result of the changes, two senior roles – President of Research and Development, held by Martin Mackay, and Executive Vice President, Global Commercial, held by Tony Zook – have been eliminated.<wbr> Martin Mackay and Tony Zook will leave the company at the end of January.<wbr> </div><div style="margin-bottom: 10px;">The full Senior Executive Team is as follows: </div><div style="margin-bottom: 10px;">•Pascal Soriot Chief Executive Officer and Executive Director<BR>•Simon Lowth Chief Financial Officer and Executive Director<BR>•Mene Pangalos Executive Vice President, Innovative Medicines<BR>•Bahija Jallal Executive Vice President, MedImmune<BR>•Briggs Morrison Executive Vice President, Global Medicines Development<BR>•Paul Hudson Executive Vice President, North America<BR>•Ruud Dobber Executive Vice President, Europe<BR>•Mark Mallon Executive Vice President, International<BR>•David Smith Executive Vice President, Operations &amp; IS<BR>•Lynn Tetrault Executive Vice President, Human Resources &amp; Corporate Affairs<BR>•Katarina Ageborg Chief Compliance Officer<BR>•Jeff Pott General Counsel<BR> </div><div>Source: PharmaLive </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20130431&edate=20130101&rec=10290">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-01-15T16:11:35+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-01-15T16:11:35+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category pharma-news > <![CDATA[Pharma News]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Expanded Chemonaive Label For Zytiga In The EU</title>
	<pubDate>2013-01-15T11:04:47+01:00</pubDate>
	<wp:post_id>4229</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: J&amp;J has announced that last Friday the European Commission 
granted expanded approval to Zytiga for use in combination with prednisone for 
the treatment of metastatic CRPC who are asymptomatic or mildly symptomatic 
after failure of ADT in whom chemotherapy is not indicated.<wbr> </div><div style="margin-bottom: 10px;">This approval has been expected within this timeframe.<wbr> Previously the product 
has only been approved in Europe to treat men with CRPC whose disease has 
progressed on or after docetaxexl-based therapy.<wbr> This indication was approved in 
the US late last year.<wbr> </div><div style="margin-bottom: 10px;">The basis for approval was the results from the phIII COU-AA-302 study which 
showed a statistically signficant improvement in PFS, a trend towards improved 
overall suvival and significant improvements in a number of secondary 
endpoints.<wbr> </div><div>source: <a href="http://www.jnj.com" class="defaultlink" title="www.jnj.com">jnj.com</a> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20130431&edate=20130101&rec=8728">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-01-15T11:04:47+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-01-15T11:04:47+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Roche Hires Leading U.S Academic to Head pRED</title>
	<pubDate>2013-01-15T09:59:41+01:00</pubDate>
	<wp:post_id>4230</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: John C.<wbr> Reed, Chief Executive at Stanford-Burnham Research Intitute in California will take over as Head of Roche's Pharma Research and Early Development (pRED).<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">John C.<wbr> Reed (54), who is an American citizen, earned his M.<wbr>D.<wbr> and Ph.<wbr>D.<wbr> at the School of Medicine of the University of Pennsylvania.<wbr> </div><div style="margin-bottom: 10px;">Prior to joining Roche he has been CEO at Sanford-Burnham Medical Research Institute in La Jolla, California.<wbr> He is one of the world’s leading biomedical researchers with a focus on cancer, neuroprotection, autoimmunity, and other diseases.<wbr> John Reed has authored several hundred medical research publications and is among the world’s most highly cited scientists for his research contributions.<wbr> </div><div>He is an inventor of more than one hundred patents, a member of multiple scientific journal editorial boards, and the founder or co-founder of a number of biotechnology companies.<wbr> He has also served on the Boards of Directors of several public biopharmaceutical and biotechnology companies.<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20130431&edate=20130101&rec=10288">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-01-15T09:59:41+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-01-15T09:59:41+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category pharma-news > <![CDATA[Pharma News]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>re: The Toxin Aesthetic Landscape</title>
	<pubDate>2013-01-15T09:29:16+01:00</pubDate>
	<wp:post_id>4231</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="border-left: 2px solid #8B1010; padding: 0px 0px 5px 12px; margin-bottom: 3px;"><span style="font-weight: bold; font-size: 14px;">The Toxin Aesthetic Landscape</span>&nbsp;<br><span style="font-size: 12px;">Comment: You will find attached an overview of the competitive landscape compiled by the CI department in close collaboration with the Neurology Aesthetic Franchise.<wbr> We hope you will find this a useful tool and feel more inclined to contribute to our internal knowledge of the toxin aesthetic area.<wbr> By keeping us informed of developments in your countries, we can build our internal knowledge base, and together leverage the utility of the tool for everybody's benefit.<wbr> Highlighted below is a small selection of some of the slides from the attached presentation.<wbr></span>&nbsp;&nbsp;<a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20130431&edate=20130101&rec=6658">...</a><br></div><div>To respond one of the KIQs, PhII study demonstrated that Purtox has &gt; 30-60 days longer duration than Botox with the optimal dose of Purtox 30U vs.<wbr> Botox 20U (source Dr MAAS lecture at Toxins 2012).<wbr> </div><!-- Comment details --><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20130431&edate=20130101&rec=6749">Add a Comment on this Article</a><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology6658">View thread  Neurology6658: The Toxin Aesthetic Landscape</a>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-01-15T09:29:16+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-01-15T09:29:16+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Abiraterone + BEZ235 in mCRPC</title>
	<pubDate>2013-01-14T17:24:18+01:00</pubDate>
	<wp:post_id>4232</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Recently listed in clinicaltrials.<wbr>gov, this Ph1/<wbr>Ph2 study designed in collaboration with Novartis and Stand Up to Cancer is to start this month.<wbr> Primary endpoints will assess number of reported DLT of the combination, anti-tumour responses and response proportion as defined by a decline in PSA of &gt;50%.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG><A href="http://clinicaltrials.gov/ct2/show/NCT01717898?term=prostate&amp;recr=Open&amp;no_unk=Y&amp;phase=012&amp;fund=2&amp;rank=107"><STRONG></STRONG></A> </div><div style="margin-bottom: 10px;"><U>Recruitment</U>: approx.<wbr> 74 </div><div style="margin-bottom: 10px;"><U>Design</U> </div><div style="margin-bottom: 10px;"><DIV class="body3">
<UL style="MARGIN-TOP: 1ex; MARGIN-BOTTOM: 1ex"><LI class="color-bullet" style="MARGIN-TOP: 0.7ex">Phase 1: This part of the study will determine what dose of BEZ235 is safe to give with a standard dose of abiraterone acetate and prednisone by administering different doses of BEZ235.<wbr> This will help to find out what effects, good and/<wbr>or bad, this combination has on CRPC.<wbr></LI>
<LI class="color-bullet" style="MARGIN-TOP: 0.7ex">Phase 2: This part of the study will measure the treatment effect of the combination of BEZ235 and abiraterone acetate/<wbr>prednisone on CRPC.<wbr></LI>
</UL></DIV> </div><div style="margin-bottom: 10px;">Completion dates: Jan 2015 /<wbr> Jan 2016.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">BEZ235 is a potent pan-class I PI3K and mammalian target of rapamycin (mTOR) inhibitor belonging to the class of imidazoquinoline derivatives.<wbr> </div><div>Location: USA </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20130431&edate=20130101&rec=8727">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-01-14T17:24:18+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-01-14T17:24:18+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Dendreon Shares Jump As Bernstein Upgrades Stock To Outperform</title>
	<pubDate>2013-01-14T16:41:44+01:00</pubDate>
	<wp:post_id>4233</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Bernstein analysts have signalled that they believe Dendreon's shares could be one of the best performing stocks in 2013 as they believe the prostate cancer vaccine PROVENGE will return to modest but steady growth.<wbr> </div><div style="margin-bottom: 10px;">Dendreon's shares lost 60% of their value last year due to disappointing sales of PROVENGE launched in April 2010.<wbr> However, the analysts suggest the competitive environment is stabilizin, citing feedback from a survey with urologists who prescrive PROVENGE.<wbr> </div><div style="margin-bottom: 10px;">It is reported:- </div><div style="margin-bottom: 10px;">"Our interviews all suggested steady increases in expected uses among busy community urology practices: none of the physicians expected to reduce their usage and most expected to use PROVENGE in combination with Xtandi in the future and saw little threat from Zytiga".<wbr> </div><div style="margin-bottom: 10px;">The brokers forecast growth for 2013 peak revenue of $799m for PROVENGE by 2017 and 13% sales.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">See <a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20130431&edate=20130101&rec=8707" class="defaultlink">Oncology8707: Key Takeaways from Dendreon Preliminary Q4:12</a>.<wbr> </div><div>Source; <A href="http://www.reuters.com/">www.<wbr>reuters.<wbr>com</A> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20130431&edate=20130101&rec=8724">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-01-14T16:41:44+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-01-14T16:41:44+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>1st In Class SGLT2 Inhibitor Recommended For US Approval</title>
	<pubDate>2013-01-14T12:21:21+01:00</pubDate>
	<wp:post_id>4234</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment:J&amp;J announced last week that the Endocrinology &amp; Metabolic 
Advisory Comittee of the FDA recommended 10-5 in favour of approval of its SGLT2 
inhibitor canagliflozin for the treatment of type 2 diabetes.<wbr> This represents a 
key development for other companies, most notably for Lexicon 
Pharmaceuticals.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Novel MOA</STRONG> </div><div style="margin-bottom: 10px;">The SGLT2 class of agents is unique in that they block the reabsorption of 
glucose by the kidney, increasing its excretion and lowering blood glucose 
levels.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Scope of PhIII Programme &amp; Key Findings</STRONG> </div><div style="margin-bottom: 10px;">Data supporting the approval came from a comprehensice phIII programme which 
enrolled 10,285 patients in nine study, the largest late-stage development 
programme every undertaken for a diabetes product.<wbr> The results of the studies 
shown that in addition to lowering blood glucose canagliflozin was also 
associated with reductions in weight loss and reductions in blood pressure.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Safety Issues</STRONG> </div><div style="margin-bottom: 10px;">The drug has some specific safety issues such as genital 
mycotic infections and urinary tract infections which reportedly can be 
well managed by physicians.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Implications For Other Companies</STRONG> </div><div style="margin-bottom: 10px;">At one time there was some scepticism about whether this class of agents 
would ever be approved.<wbr> Possible hurdles now seem to have been overcome which is 
good news for other companies developing such agents such as GSK and Lexicon 
Pharmaceuticals and for the potential outlicensing of Lexicon's drug which 
appears as though it could be best-in-class.<wbr> </div><div>Source: <A href="http://www.jnj.com">www.<wbr>jnj.<wbr>com</A> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20130431&edate=20130101&rec=7237">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-01-14T12:21:21+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-01-14T12:21:21+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category endocrinology > <![CDATA[Endocrinology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Disappointment For Eisai in Ovarian Cancer</title>
	<pubDate>2013-01-14T12:07:57+01:00</pubDate>
	<wp:post_id>4235</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Eisai announced on Friday the preliminary results of its global 
phIII study with its folate antagonists farletuzumab which regretably 
failed to meet its pre-specified endpoint of improvement in PFS in patieents 
with platinum sensitive epithelial ovarian cancer in first relapse.<wbr> The company 
appears committed to further development in possible disease sub-sets.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Study Design</STRONG> </div><div style="margin-bottom: 10px;">The study was a multicentre randomised double-blind placebo controlled 
parallel group study undertaken in 1,100 patients.<wbr> The patients received 
standard of care therapy (carboplatin and a taxane) in combination with doses of 
either 1.<wbr>25mg/<wbr>kg or 2.<wbr>5mg/<wbr>kg or farletuzumab or placebo.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Key Findings</STRONG> </div><div style="margin-bottom: 10px;">Whilst the primary endpoint was not met the post hoc exploratory analysis has 
showed a trend towards improved PFS in some patient sub-sets and further 
analysis of this data is ongoing.<wbr> Once this is available the company will 
determine a new development strategy based on discussions with external experts 
and the relevant health authorities.<wbr> </div><div>Source: <A href="http://www.eisai.com">www.<wbr>eisai.<wbr>com</A> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20130431&edate=20130101&rec=8723">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-01-14T12:07:57+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-01-14T12:07:57+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>re: Gattex for Short Bowel Syndrome at the Center of NPS' Presentation</title>
	<pubDate>2013-01-11T20:05:51+01:00</pubDate>
	<wp:post_id>4236</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="border-left: 2px solid #8B1010; padding: 0px 0px 5px 12px; margin-bottom: 3px;"><span style="font-weight: bold; font-size: 14px;">Gattex for Short Bowel Syndrome at the Center of NPS' Presentation</span>&nbsp;<br><span style="font-size: 12px;">Comment: At the J.<wbr>P Morgan Conference, François Nader (President and CEO) highlighted high unmet medical need, burden of illness, clincial value and ultra-orphan status as key value framework for Gattex (the first and only analog of GLP-2 proven to increase absorption of remaining bowel and decrease or eliminate the need for parenteral support).<wbr></span>&nbsp;&nbsp;<a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20130431&edate=20130101&rec=7230">...</a><br></div><div style="margin-bottom: 10px;"><P class="Body"><STRONG>SBS is perceived by physicians as one of the highest unmet needs in the field of GI conditions.<wbr> This NPS assessment could directly benefit to SSAs including Somatuline.<wbr></STRONG></P> </div><div style="margin-bottom: 10px;"><P class="Body"> If less than 1 meter of ileum is remaining after surgery, chronic intestinal failure is installed,  making the patient dependent on parenteral nutrition for life.<wbr></P> </div><div style="margin-bottom: 10px;"><P class="Body"> Several clinical aspects must attract our interest:</P> </div><div style="margin-bottom: 10px;"><P class="Body">-          Despite they are malabsorptive, SBS patients are not &ldquo;nil per os&rdquo;.<wbr> They could even ingest very large amounts of energy and liquids;</P> </div><div style="margin-bottom: 10px;"><P class="Body">-          Depending of patients GI functional capacities and for answering to nutritional needs, parenteral nutrition could be administered either to fulfill daily needs or just a part of these needs.<wbr> Because of these different situations and related to respecting a &ldquo;physiological&rdquo; slow rate of infusion, patients could be fed all day long and every day , or &ldquo;only&rdquo; some days per week  and/<wbr>or some hours per days (in a cycling way, at night).<wbr></P> </div><div style="margin-bottom: 10px;"><P class="Body">-          So improving SBS is not only reducing the number of parenterally fed patients, but this could be also preserving for each patient, number of days or hours of freedom with no &ldquo;line-attachment&rdquo; or no infusion (meaning improving Quality of Life).<wbr></P> </div><div style="margin-bottom: 10px;"><P class="Body">-           Because SBS is a chronic condition, PN is given at home ( &ldquo;HPN&rdquo;) and today , there are registries for HPN patients in almost all EU countries.<wbr> However it is important to take into consideration that the major part of HPN patients are not recorded in registries and this &ldquo;hidden&rdquo; part of SBS /<wbr> HPN patients are postoperative patients suffering of digestive cancer.<wbr> So the real number of SBS patients is in practice significantly larger than registered patients (but this actual number is unknown).<wbr></P> </div><div><P class="Body">Taking as a whole, reducing fluid secretion, means improving SBS patient quality of life: patients can receive oral food, their transit and enterostomy fluid outputs can be reduced and parenteral nutrition and rehydration regimen as well as their potential risks (infection and metabolic) can be diminished.<wbr> The main medical field is cancer.<wbr></P> </div><!-- Comment details --><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20130431&edate=20130101&rec=7236">Add a Comment on this Article</a><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7230">View thread  Endocrinology7230: Gattex for Short Bowel Syndrome at the Center of NPS' Presentation</a>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-01-11T20:05:51+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-01-11T20:05:51+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category endocrinology > <![CDATA[Endocrinology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>re: Aspireo Starts Ph2a Study with Somatoprim for Acromegaly</title>
	<pubDate>2013-01-11T19:39:07+01:00</pubDate>
	<wp:post_id>4237</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="border-left: 2px solid #8B1010; padding: 0px 0px 5px 12px; margin-bottom: 3px;"><span style="font-weight: bold; font-size: 14px;">Aspireo Starts Ph2a Study with Somatoprim for Acromegaly</span>&nbsp;<br><span style="font-size: 12px;">Comment: The Israeli biopharm company has enrolled its first patient in a Ph2a study designed to assess the safety, tolerability and efficacy of its drug in untreated acromegaly patients.<wbr> Initial data from this study is expected to be available in the first quarter of 2013.<wbr> Aspireo has been looking to partner this product for some while but has so far been unsuccessful, most probably because of the short patent life that remains.<wbr></span>&nbsp;&nbsp;<a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20130431&edate=20130101&rec=7158">...</a><br></div><div style="margin-bottom: 10px;"><STRONG>Besides Novartis SSAs ( Octreotide and Pasireotide) do we have a new competitor to Somatuline to consider ?</STRONG> </div><div style="margin-bottom: 10px;">Somatoprim (DG3173) is a SSA developed by the Israeli biopharm company Aspireo (Project Focused Company ; <A href="http://www.aspireopharma.com/">www.<wbr>aspireopharma.<wbr>com</A>).<wbr> </div><div style="margin-bottom: 10px;"><STRONG> </STRONG>As mentioned by Brigitte, Aspireo is looking for partnership, their only one current investor is TVM Capital.<wbr> </div><div style="margin-bottom: 10px;">Looking at Pubmed, there are currently only 3 referenced publications with a main one reporting a recent German in vitro study.<wbr> ( Pl&ouml;ckinger et al, 2012 Charit&eacute; Hosp, Berlin).<wbr> </div><div style="margin-bottom: 10px;">Regarding the results of this preclinical study and also a clinical Phase I single ascending dose study in HV, Somatoprim is described as follows </div><div style="margin-bottom: 10px;"><SPAN style="text-decoration: underline;"> From International Journal of Endocrinology, 2012</SPAN> : A recently developed somatostatin multireceptor ligand, Somatoprim, may be at least as potent, as Octreotide, but without a negative effect on glucose metabolism.<wbr> This molecule has a GH suppressing effect but a very low insulin-suppressing action in vitro.<wbr> If these in vitro data are confirmed in vivo in acromegalic patients, Somatoprim will be a valuable alternative to other SRL.<wbr> </div><div style="margin-bottom: 10px;"><SPAN style="text-decoration: underline;">From Nature Review Endocrinology</SPAN> : Somatoprim causes greater GH suppression than octreotide when applied to primary cell cultures of somatotroph adenomas according to a German Study.<wbr> In contrast to octreotide, somatoprim has a high affinity for SSTR3, in addition to SSTR2 and SSTR5.<wbr> All analyzed adenomas highly exptessed SSTR3, the activation of which might have been responsible for the higher number of tumors responsive to somatoprim compared to octreotide.<wbr> Previous studies have shown a very low insulin-suppressing effect of somatoprim (NB: leading to less risk of hyperglycemia), which is an advantage vs Pasireotide and Octrotide.<wbr> </div><div style="margin-bottom: 10px;"><SPAN style="text-decoration: underline;"> Prof Ursula Pl&ouml;ckinger</SPAN> : &ldquo;If clinical trials confirm the in vitro data, we feel that the drug may well become the treatment of choice for medical therapy in acromegaly owing its high efficacy, potential for tumor shrinkage and its negligible effect on insulin secretion&rdquo;.<wbr> </div><div style="margin-bottom: 10px;"><SPAN style="text-decoration: underline;">Concerning the results of the clinical Phase I study</SPAN>: it is indicated that Somatoprim had an excellent tolerability profile at all doses administered.<wbr> An exploratory analysis of plasma growth hormone levels was consistent with a suppression of growth hormone release thus indicating that Somatoprim is able to suppress growth hormone release in humans.<wbr> </div><div style="margin-bottom: 10px;">Finally, Somatoprim is also expected to enter in phase II for its development in GEP-NET.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Main Bibliographic References</STRONG> </div><div style="margin-bottom: 10px;">U.<wbr> Ploeckinger, U.<wbr> Hoffmann, M.<wbr> Geese et al.<wbr>, &ldquo;DG3173 (Somatoprim), a unique Somatostatin receptor subtype 2-, 4- and 5-selective analogue, effectively reduces GH-secretion in human growth hormone secreting pituitary adenomas even in Octreotide non-responsive tumours,&rdquo; <EM>European Journal of Endocrinology</EM>, vol.<wbr> 166, no.<wbr> 2, pp.<wbr> 223&ndash;234, 2012.<wbr> </div><div>Shimon I,  Rubinek T,  Hadani M, and Alhadef N, &ldquo;PTR- 3173 (Somatoprim), a novel somatostatin analog with affinity for somatostatin receptors 2, 4 and 5 is a potent inhibitor of human GH secretion,&rdquo; <EM>Journal of Endocrinological Investigation</EM>, vol.<wbr> 27, no.<wbr> 8, pp.<wbr> 721&ndash;727, 2004.<wbr> </div><!-- Comment details --><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20130431&edate=20130101&rec=7235">Add a Comment on this Article</a><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7158">View thread  Endocrinology7158: Aspireo Starts Ph2a Study with Somatoprim for Acromegaly</a>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-01-11T19:39:07+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-01-11T19:39:07+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category endocrinology > <![CDATA[Endocrinology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Xiaflex's Uptake For Dupuytren's Contracture & Extended LifreCycle Management Opportunities In Urology & Aesthetics</title>
	<pubDate>2013-01-11T17:25:09+01:00</pubDate>
	<wp:post_id>4238</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: At the JP Morgan H/<wbr>C Conference this week Auxillium gave a detailed account of its commercialisation activities with Xiaflex for Dupuytren's Contracture and development prospects for other indications such as peyrone's disease, frozen shoulder and cellulitis.<wbr> Some key comments about the termination of its relationship with Pfizer in Europe were also made particularly in relationship to the strategic flexibility this now gives ahead of the submission for peyrone's disease in Europe by the end of the year.<wbr> </div><div style="margin-bottom: 10px;">Highlighted below are some of the key slides that were presented.<wbr>and some of theCEO's  key comments made during the breakout session with regard to pricing in Europe and the mutual termination of its partnership with Pfizer in Europe covering Xiaflex.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6746_1_ScreenCapture1.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6746_2_ScreenCapture2.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6746_3_ScreenCapture3.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6746_4_ScreenCapture4.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6746_5_ScreenCapture5.jpg"> </div><div style="margin-bottom: 10px;">During the breakout session an interesting question was posed about Xiaflex's pricing in Europe which prompted both a response about European pricing and Auxilium's relationship with Pfizer.<wbr> </div><div style="margin-bottom: 10px;"><P class="pwrapper firstP">Q: Why are you selling XIAFLEX in Europe at about half the price of the U.<wbr>S.<wbr> and then still, you have to give a discount to Pfizer? That's one question.<wbr> And the other question is German government has rejected your application for XIAFLEX under the grounds that it is not the newest technology.<wbr> What do you do to still try to get into this basically most important market in Europe?</P> </div><div style="margin-bottom: 10px;"><P class="pwrapper firstP">Adiran Adams CEO responded:-</P> </div><div style="margin-bottom: 10px;"><P class="pwrapper firstP">"Yes, I think, I mean, there's a lot of, kind of, points to note in there.<wbr> As it relates to price, I think &ndash; I don't think it would be wrong of me to say that it is not uncommon in a lot of different disease areas for the pricing, kind of broad structure in Europe to be quite different from the pricing structure within the United States.<wbr>"</P> </div><div style="margin-bottom: 10px;"><P class="pwrapper firstP">"So, I think, obviously, decision making in relation to pricing, et cetera, was done obviously in concert with our partner , Pfizer n Europe for XIAFLEX.<wbr> As you well know, I think we announced the mutual termination of the agreement wit h Pfizer in Europe.<wbr> And we're having discussions with them in terms of a transition perspective ahead of the termination which is at the &ndash; towards the end of April of this year.<wbr>"</P> </div><div style="margin-bottom: 10px;"><P class="pwrapper">"Now, you are absolutely correct that everyone looks broadly across Europe, and particularly in the Scandinavian countries, a number of other countries, we've actually seen some good progress with XIAFLEX.<wbr> But in some of the key markets of Germany and France, there have been some challenges in relation to securing the right reimbursement levels.<wbr> And I think that is not in any way reflective of lack of focus by Pfizer"</P> </div><div style="margin-bottom: 10px;"><P class="pwrapper">"It's just that, as you well know, across a large number of products, not just specific to Auxilium and <SPAN id="highlight" style="background-color: #ffff00; color: black;">Pfizer</SPAN> and XIAFLEX, I think changing the goalpost in terms of what's needed to get to reimbursement approvals, et cetera, and putting in place certain challenges in relation to demonstrating difference versus current available treatment options, I think, is very challenging.<wbr> And clearly, I think where we are right now with the mutual termination of the agreement with Pfizeris we see this as an opportunity, I think.<wbr>"</P> </div><div style="margin-bottom: 10px;"><P class="pwrapper firstP">"We see this as an opportunity.<wbr> We have the strategic flexibility now to either, one, consider whether there is a cost-effective, shareholder-friendly way of commercializing and distributing ourselves; or to assess whether or not there are other partners that we could work with.<wbr> And certainly, we had a number of inbound interest calls in that area, which we're assessing at this particular point in time.<wbr>"</P> </div><div style="margin-bottom: 10px;"><P class="pwrapper">"We want to make sure that the decisions we make are the right, appropriate decisions.<wbr> And I think we certainly see continued opportunity in Dupuytren's.<wbr> And more certainly, I think, there is nothing impacting the momentum in relation to moving towards submitting the Peyronie's application in Europe towards the end of this year.<wbr> So, I think from our perspective, particular with the corporate evolution here in the United States, we're happy to have the strategic flexibility in Europe that is now afforded.<wbr>"</P> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6746_6_ScreenCapture6.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6746_7_ScreenCapture7.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6746_8_ScreenCapture8.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6746_9_ScreenCapture9.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6746_10_ScreenCapture10.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6746_11_ScreenCapture11.jpg"> </div><div><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6746_12_ScreenCapture12.jpg"> </div><!-- Comment details --><a name="neurology6746attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6746_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(58,5 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6746_2_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(65,2 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6746_3_ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(66,6 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6746_4_ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(65,4 KB)<br>&nbsp;&nbsp;5.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6746_5_ScreenCapture5.jpg">ScreenCapture5.jpg</a>&nbsp;&nbsp;(71,2 KB)<br>&nbsp;&nbsp;6.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6746_6_ScreenCapture6.jpg">ScreenCapture6.jpg</a>&nbsp;&nbsp;(83 KB)<br>&nbsp;&nbsp;7.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6746_7_ScreenCapture7.jpg">ScreenCapture7.jpg</a>&nbsp;&nbsp;(77,1 KB)<br>&nbsp;&nbsp;8.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6746_8_ScreenCapture8.jpg">ScreenCapture8.jpg</a>&nbsp;&nbsp;(66,2 KB)<br>&nbsp;&nbsp;9.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6746_9_ScreenCapture9.jpg">ScreenCapture9.jpg</a>&nbsp;&nbsp;(75,3 KB)<br>&nbsp;&nbsp;10.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6746_10_ScreenCapture10.jpg">ScreenCapture10.jpg</a>&nbsp;&nbsp;(61 KB)<br>&nbsp;&nbsp;11.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6746_11_ScreenCapture11.jpg">ScreenCapture11.jpg</a>&nbsp;&nbsp;(59,5 KB)<br>&nbsp;&nbsp;12.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6746_12_ScreenCapture12.jpg">ScreenCapture12.jpg</a>&nbsp;&nbsp;(71,3 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20130431&edate=20130101&rec=6746">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-01-11T17:25:09+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-01-11T17:25:09+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Efficacy of Octreotide LAR and Cabergoline in Japanese Patients with Acromegaly</title>
	<pubDate>2013-01-11T12:56:08+01:00</pubDate>
	<wp:post_id>4239</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Conclusion indicates that <SPAN style="TEXT-ALIGN: left; WIDOWS: 2; TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; DISPLAY: inline !important; FONT: 13px/17px arial, helvetica, clean, sans-serif; WHITE-SPACE: normal; ORPHANS: 2; FLOAT: none; LETTER-SPACING: normal; COLOR: rgb(0,0,0); WORD-SPACING: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="TEXT-ALIGN: left; WIDOWS: 2; TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; DISPLAY: inline !important; FONT: 13px/17px arial, helvetica, clean, sans-serif; WHITE-SPACE: normal; ORPHANS: 2; FLOAT: none; LETTER-SPACING: normal; COLOR: rgb(0,0,0); WORD-SPACING: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"></SPAN> </div><div style="margin-bottom: 10px;"><H1 style="BORDER-BOTTOM: 0px; TEXT-ALIGN: left; BORDER-LEFT: 0px; PADDING-BOTTOM: 0px; WIDOWS: 2; TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; MARGIN: 0.37em 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; FONT: bold 1.23em/1.12em arial, helvetica, clean, sans-serif; WHITE-SPACE: normal; ORPHANS: 2; LETTER-SPACING: normal; COLOR: rgb(0,0,0); VERTICAL-ALIGN: baseline; BORDER-TOP: 0px; BORDER-RIGHT: 0px; WORD-SPACING: 0px; PADDING-TOP: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px">Efficacy of combined octreotide and cabergoline treatment in patients with acromegaly: a retrospective clinical study and review of the literature.<wbr></H1> </div><div style="margin-bottom: 10px;"><DIV class="auths" style="BORDER-BOTTOM: 0px; TEXT-ALIGN: left; BORDER-LEFT: 0px; PADDING-BOTTOM: 0px; WIDOWS: 2; TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(255,255,255); FONT-VARIANT: normal; FONT-STYLE: normal; TEXT-INDENT: 0px; MARGIN: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; FONT-FAMILY: arial, helvetica, clean, sans-serif; WHITE-SPACE: normal; ORPHANS: 2; LETTER-SPACING: normal; COLOR: rgb(0,0,0); FONT-SIZE: 0.92em; VERTICAL-ALIGN: baseline; BORDER-TOP: 0px; FONT-WEIGHT: normal; BORDER-RIGHT: 0px; WORD-SPACING: 0px; PADDING-TOP: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"><A href="http://www.ncbi.nlm.nih.gov/pubmed?term=Suda%20K%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=23291436" style="BORDER-BOTTOM: 0px; BORDER-LEFT: 0px; PADDING-BOTTOM: 0px; MARGIN: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; COLOR: rgb(102,0,102); FONT-SIZE: 12px; VERTICAL-ALIGN: baseline; BORDER-TOP: 0px; BORDER-RIGHT: 0px; TEXT-DECORATION: underline; PADDING-TOP: 0px">Suda K</A>, <A href="http://www.ncbi.nlm.nih.gov/pubmed?term=Inoshita%20N%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=23291436" style="BORDER-BOTTOM: 0px; BORDER-LEFT: 0px; PADDING-BOTTOM: 0px; MARGIN: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; COLOR: rgb(102,0,102); FONT-SIZE: 12px; VERTICAL-ALIGN: baseline; BORDER-TOP: 0px; BORDER-RIGHT: 0px; TEXT-DECORATION: underline; PADDING-TOP: 0px">Inoshita N</A>, <A href="http://www.ncbi.nlm.nih.gov/pubmed?term=Iguchi%20G%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=23291436" style="BORDER-BOTTOM: 0px; BORDER-LEFT: 0px; PADDING-BOTTOM: 0px; MARGIN: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; COLOR: rgb(102,0,102); FONT-SIZE: 12px; VERTICAL-ALIGN: baseline; BORDER-TOP: 0px; BORDER-RIGHT: 0px; TEXT-DECORATION: underline; PADDING-TOP: 0px">Iguchi G</A>, <A href="http://www.ncbi.nlm.nih.gov/pubmed?term=Fukuoka%20H%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=23291436" style="BORDER-BOTTOM: 0px; BORDER-LEFT: 0px; PADDING-BOTTOM: 0px; MARGIN: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; COLOR: rgb(102,0,102); FONT-SIZE: 12px; VERTICAL-ALIGN: baseline; BORDER-TOP: 0px; BORDER-RIGHT: 0px; TEXT-DECORATION: underline; PADDING-TOP: 0px">Fukuoka H</A>, <A href="http://www.ncbi.nlm.nih.gov/pubmed?term=Takahashi%20M%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=23291436" style="BORDER-BOTTOM: 0px; BORDER-LEFT: 0px; PADDING-BOTTOM: 0px; MARGIN: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; COLOR: rgb(102,0,102); FONT-SIZE: 12px; VERTICAL-ALIGN: baseline; BORDER-TOP: 0px; BORDER-RIGHT: 0px; TEXT-DECORATION: underline; PADDING-TOP: 0px">Takahashi M</A>, <A href="http://www.ncbi.nlm.nih.gov/pubmed?term=Nishizawa%20H%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=23291436" style="BORDER-BOTTOM: 0px; BORDER-LEFT: 0px; PADDING-BOTTOM: 0px; MARGIN: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; COLOR: rgb(102,0,102); FONT-SIZE: 12px; VERTICAL-ALIGN: baseline; BORDER-TOP: 0px; BORDER-RIGHT: 0px; TEXT-DECORATION: underline; PADDING-TOP: 0px">Nishizawa H</A>, <A href="http://www.ncbi.nlm.nih.gov/pubmed?term=Yamamoto%20M%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=23291436" style="BORDER-BOTTOM: 0px; BORDER-LEFT: 0px; PADDING-BOTTOM: 0px; MARGIN: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; COLOR: rgb(102,0,102); FONT-SIZE: 12px; VERTICAL-ALIGN: baseline; BORDER-TOP: 0px; BORDER-RIGHT: 0px; TEXT-DECORATION: underline; PADDING-TOP: 0px">Yamamoto M</A>, <A href="http://www.ncbi.nlm.nih.gov/pubmed?term=Yamada%20S%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=23291436" style="BORDER-BOTTOM: 0px; BORDER-LEFT: 0px; PADDING-BOTTOM: 0px; MARGIN: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; COLOR: rgb(102,0,102); FONT-SIZE: 12px; VERTICAL-ALIGN: baseline; BORDER-TOP: 0px; BORDER-RIGHT: 0px; TEXT-DECORATION: underline; PADDING-TOP: 0px">Yamada S</A>, <A href="http://www.ncbi.nlm.nih.gov/pubmed?term=Takahashi%20Y%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=23291436" style="BORDER-BOTTOM: 0px; BORDER-LEFT: 0px; PADDING-BOTTOM: 0px; MARGIN: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; COLOR: rgb(102,0,102); FONT-SIZE: 12px; VERTICAL-ALIGN: baseline; BORDER-TOP: 0px; BORDER-RIGHT: 0px; TEXT-DECORATION: underline; PADDING-TOP: 0px">Takahashi Y</A>.<wbr></DIV> </div><div style="margin-bottom: 10px;"><DIV class="aff" style="BORDER-BOTTOM: 0px; TEXT-ALIGN: left; BORDER-LEFT: 0px; PADDING-BOTTOM: 0px; WIDOWS: 2; TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; MARGIN: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; FONT: 0.84em/1.09em arial, helvetica, clean, sans-serif; WHITE-SPACE: normal; ORPHANS: 2; LETTER-SPACING: normal; COLOR: rgb(0,0,0); VERTICAL-ALIGN: baseline; BORDER-TOP: 0px; BORDER-RIGHT: 0px; WORD-SPACING: 0px; PADDING-TOP: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px">
<H3 class="label" style="BORDER-BOTTOM: 0px; POSITION: absolute; BORDER-LEFT: 0px; PADDING-BOTTOM: 0px; LINE-HEIGHT: 1.2857; MARGIN: 1.28em 0px 0.64em; PADDING-LEFT: 0px; WIDTH: 1px; PADDING-RIGHT: 0px; HEIGHT: 1px; COLOR: rgb(114,65,40); FONT-SIZE: 1.07em; VERTICAL-ALIGN: baseline; OVERFLOW: hidden; BORDER-TOP: 0px; TOP: auto; FONT-WEIGHT: bold; BORDER-RIGHT: 0px; PADDING-TOP: 0px; LEFT: -10000px">Source</H3>
<P style="BORDER-BOTTOM: 0px; BORDER-LEFT: 0px; PADDING-BOTTOM: 0px; MARGIN: 0.5em 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; FONT-SIZE: 11px; VERTICAL-ALIGN: baseline; BORDER-TOP: 0px; BORDER-RIGHT: 0px; PADDING-TOP: 0px">Division of Diabetes and Endocrinology, Department of Internal Medicine, Kobe University Graduate School of Medicine, Kobe 650-0017, Japan.<wbr></P></DIV> </div><div style="margin-bottom: 10px;"><SPAN style="TEXT-ALIGN: left; WIDOWS: 2; TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; DISPLAY: inline !important; FONT: 13px/17px arial, helvetica, clean, sans-serif; WHITE-SPACE: normal; ORPHANS: 2; FLOAT: none; LETTER-SPACING: normal; COLOR: rgb(0,0,0); WORD-SPACING: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="TEXT-ALIGN: left; WIDOWS: 2; TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; DISPLAY: inline !important; FONT: 13px/17px arial, helvetica, clean, sans-serif; WHITE-SPACE: normal; ORPHANS: 2; FLOAT: none; LETTER-SPACING: normal; COLOR: rgb(0,0,0); WORD-SPACING: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"></SPAN> </div><div><SPAN style="TEXT-ALIGN: left; WIDOWS: 2; TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; DISPLAY: inline !important; FONT: 13px/17px arial, helvetica, clean, sans-serif; WHITE-SPACE: normal; ORPHANS: 2; FLOAT: none; LETTER-SPACING: normal; COLOR: rgb(0,0,0); WORD-SPACING: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"></SPAN> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20130431&edate=20130101&rec=7231">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-01-11T12:56:08+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-01-11T12:56:08+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category endocrinology > <![CDATA[Endocrinology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Astellas Strengthens its UroOnco Position with EU Approval of Mirabegron for OAB</title>
	<pubDate>2013-01-11T10:57:30+01:00</pubDate>
	<wp:post_id>4240</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: BETMIGA has received EU approval for the treatment of OAB symptoms in adults (data on file).<wbr> The drug will offer doctors an alternative to antimuscarinic agents (the only class of approved oral treatment previously available).<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><U>Different Mechanism of Action</U> </div><div style="margin-bottom: 10px;">Mirabegron improves the storage capacity of the bladder without inhibiting bladder voiding, thereby prolonging the time between trips to the toilet for the patient ().<wbr> </div><div style="margin-bottom: 10px;"><U>Quality of Life</U> </div><div style="margin-bottom: 10px;">Patients with OAB who received mirabegron reported significant improvements in treatment satisfaction, symptom bother, disease perception and quality of life, in comparison to placebo ().<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"> </div><div><DIV id="contents">
<DIV class="area_h2"><STRONG></STRONG></DIV>
<DIV class="area_h2">Phase III study in China, Korea, Taiwan, and India recently completed.<wbr></DIV>
<DIV class="area_h2">Source: ASTELLAS</DIV></DIV> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20130431&edate=20130101&rec=8718">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-01-11T10:57:30+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-01-11T10:57:30+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Allergan to Advance Bimatoprost in Ph3 for Eyebrow Hypotrichosis</title>
	<pubDate>2013-01-10T18:23:39+01:00</pubDate>
	<wp:post_id>4241</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: The randomized trial will start in March 2013, and assess the safety and efficacy of the drug compared with placebo.<wbr> Primary endpoint will measure percentage of participants with at least a 1-grade increase in the 4-point Global Eyebrow Assessment (GEBA) scale.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Completion date: Oct 2014 /<wbr> Nov 2014 </div><div style="margin-bottom: 10px;">Recruitment: approx 348 </div><div style="margin-bottom: 10px;">Location: USA (1); Canada (1) </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div>Please see <a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20130431&edate=20130101&rec=6641" class="defaultlink">Neurology6641: Allergan Progresses with Bimatoprost for Increasing Eyelash Growth</a>.<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20130431&edate=20130101&rec=6745">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-01-10T18:23:39+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-01-10T18:23:39+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Norwegian Directorate of Health Recommends Zytiga for National Cancer Treatment Guidelines</title>
	<pubDate>2013-01-10T14:43:09+01:00</pubDate>
	<wp:post_id>4242</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: The advisory group of Norway's Directorate of Health recommended yesterday (9 January) to insert Yervoy (ipilimumab; BMS, US) and Zytiga (abiraterone; J&amp;J, US) into the national guidelines for cancer treatment.<wbr> The advisory group has indicated the drugs for their beneficial effects in the treatment of specific cancer types.<wbr> The experts have taken into consideration results of clinical trials that have demonstrated that Zytiga was found to prolong patients' life and improves overall patients' QoL in individuals suffering from prostate cancer.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">According to the Directorate, the cost estimate of both drugs is between NOK750,000 (USD134,152) and NOK850,000 per quality-adjusted life year (QALY).<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">A final decision on the willingness of the community to pay for these drugs will be taken by the National Council for quality and prioritisation in health services.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">The Directorate of Health requested in September 2012 that the NMA ascertain the cost-effectiveness of Zytiga for patients affected by prostate cancer.<wbr> The recommendations issued by the advisory group need to now be examined by the Directorate for a final decision on admission of the two drugs on the national guidelines.<wbr> A final decision of the regulatory body in favour of the insertion of Yervoy and Zytiga on the Norwegian cancer guidelines will clearly represent a major opportunity for BMS and J&amp;J to further penetrate the Norwegian pharmaceutical market.<wbr> </div><div>Source: Global Insight </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20130431&edate=20130101&rec=8716">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-01-10T14:43:09+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-01-10T14:43:09+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Amgen and BIND Biosciences Sign $180M Nanomedicine Deal</title>
	<pubDate>2013-01-10T11:49:06+01:00</pubDate>
	<wp:post_id>4243</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: BIND's lead product candidate contains the chemotherapy docetaxel.<wbr> Data from the ongoing Ph1, presented at AACR 2012, demonstrated safety and tolerability.<wbr> The clinical-stage biopharmaceutical company plans to initiate Ph2 clinical trials in multiple solid tumor indications in 2013.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">- <STRONG>Terms</STRONG>: W/<wbr>W collaboration agreement to develop and commercialize a kinase inhibitor nanomedicine for treating a range of solid tumors.<wbr> </div><div style="margin-bottom: 10px;">- <STRONG>Financial</STRONG>: BIND could receive upfront and development fees of $46.<wbr>5M, and &gt; an additional $134M in regulatory and sales milestone payments for the 1st therapeutic indication.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">- <A href="http://www.bindbio.com/content/pages/technology/index.jsp">Accurin Platform</A> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8714_1_ScreenCapture1.jpg"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">- employs a combination of a targeted biodegradable nanoparticle and docetaxel </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div>- <SPAN style="FONT-FAMILY: 'Times New Roman', 'serif'"></SPAN> </div><!-- Comment details --><a name="oncology8714attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8714_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(139,2 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20130431&edate=20130101&rec=8714">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-01-10T11:49:06+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-01-10T11:49:06+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Sarepta Look To Exploit New Regulatory Framework For Rare Debilitating Diseases</title>
	<pubDate>2013-01-10T10:48:45+01:00</pubDate>
	<wp:post_id>4244</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Sarepta's presentation at the JP Morgan H/<wbr>C Conference highlighted both the new regulatory framework that exists for companies trying to obtain expedited approval for rare diseases beyond HIV/<wbr>AIDS that could be applicable to Eteplirsen and the commercial potential for its Duchenne Muscular Dystrophy drug, based on its positive phII data.<wbr> </div><div style="margin-bottom: 10px;">The results of Sarepta's phII data with Eteplirsen have been summarised previously (see <a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20130431&edate=20130101&rec=6656" class="defaultlink">Neurology6656: Sarepta Seeks Ex-US Partner For Its Duchenne Drug</a>) however, in summary the company''s position with the drug is shown below.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6741_1_ScreenCapture1.jpg"> </div><div style="margin-bottom: 10px;">What was interesting in terms of Sarepta's presentation was its focus on the new regulatory climate that exists for drugs like eteplirsen which the company is hoping to exploit in order to gain accelerated approval for Eteplirsen based on its strong phII data.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6741_2_ScreenCapture2.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6741_3_ScreenCapture3.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6741_4_ScreenCapture4.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6741_5_ScreenCapture5.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6741_6_ScreenCapture6.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6741_7_ScreenCapture7.jpg"> </div><div style="margin-bottom: 10px;"><STRONG>Commercial Potential In Duchenne Muscular Dystrophy Market</STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6741_8_ScreenCapture8.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6741_9_ScreenCapture9.jpg"> </div><div style="margin-bottom: 10px;"><STRONG>Next Steps</STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6741_10_ScreenCapture10.jpg"> </div><div style="margin-bottom: 10px;"><STRONG>Competitive Outlook</STRONG> </div><div style="margin-bottom: 10px;">Interestingly, Biocentury's reveiw of the approval outlook for 2013 included in its focus drugs for Duchenne Musuclar Dystrophy.<wbr> It was noted that multiple programmes are maturing including those being undertaken by Sarepta Therapeutics Inc.<wbr> <STRONG><STRONG></STRONG></STRONG>Therapeutics Inc.<wbr> </div><div style="margin-bottom: 10px;"><P align="left">Apparently, Sarepta was one of the leading gainers in 2012, with its share price up more than 450%.<wbr> In October, the company's market cap peaked at $1 billion after reporting additional data from a Phase IIb trial of its lead program eteplirsen, PTC Therapeutic's ataluren is under review in Europe for nonsense mutation DMD.<wbr> This quarter, the company expects to start a confirmatory Phase III trial of the small molecule, which facilitates complete translation of proteins containing nonsense mutations for DMD.<wbr></P> </div><div style="margin-bottom: 10px;"><P align="left">Both companies will be competing against drisapersen (GSK2402968,PRO051) from <STRONG></STRONG>GlaxoSmithKline plc oligonucleotide that induces exon 51 skipping on the dystrophin gene is in Phase III testing.<wbr></P> </div><div>Source:www.<wbr>sarepta.<wbr>com </div><!-- Comment details --><a name="neurology6741attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6741_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(73,6 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6741_2_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(63 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6741_3_ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(69,9 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6741_4_ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(45 KB)<br>&nbsp;&nbsp;5.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6741_5_ScreenCapture5.jpg">ScreenCapture5.jpg</a>&nbsp;&nbsp;(63,4 KB)<br>&nbsp;&nbsp;6.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6741_6_ScreenCapture6.jpg">ScreenCapture6.jpg</a>&nbsp;&nbsp;(49,5 KB)<br>&nbsp;&nbsp;7.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6741_7_ScreenCapture7.jpg">ScreenCapture7.jpg</a>&nbsp;&nbsp;(74,5 KB)<br>&nbsp;&nbsp;8.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6741_8_ScreenCapture8.jpg">ScreenCapture8.jpg</a>&nbsp;&nbsp;(62,3 KB)<br>&nbsp;&nbsp;9.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6741_9_ScreenCapture9.jpg">ScreenCapture9.jpg</a>&nbsp;&nbsp;(59 KB)<br>&nbsp;&nbsp;10.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6741_10_ScreenCapture10.jpg">ScreenCapture10.jpg</a>&nbsp;&nbsp;(84,8 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20130431&edate=20130101&rec=6741">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-01-10T10:48:45+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-01-10T10:48:45+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Exelixis - Key Takeaways From JP Morgan H/C Conference</title>
	<pubDate>2013-01-10T10:00:41+01:00</pubDate>
	<wp:post_id>4245</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Exelixis's presentation focused on its commercialisation plans for COMETRIQ (cabozantinib) in medullary thyroid cancer and its expanded lifecycle development plan for the drug which is aimed at creating a major oncology franchise with an initial focus on prostate cancer.<wbr> Top-line phIII data is expected in 2014.<wbr> </div><div style="margin-bottom: 10px;">Micahel Morrissey Exelixis's CEO emphasised the company's belief that cabozantinib is a unique compound especially in today&rsquo;s age of researchers making single molecules targeting driver mutations in oncology for a single subset of a single indication with high-efficacy, but also a very narrow, Commercially.<wbr> he believes Cabozantinib has the opportunity, of being a broadly active compound based upon existing Phase 2 data such as Taxotere or Avastin.<wbr> MTC is just the start for the company with the bigger opportunities lying behind.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8711_1_ScreenCapture1.jpg"> </div><div style="margin-bottom: 10px;"><STRONG>Commercialisation For MTC</STRONG> </div><div style="margin-bottom: 10px;">The company has adopted a unique selling process for its first approved indication as shown below.<wbr> The drug will be sold as a capsule configuration with three different doses that are flat priced at $9900 per 28-day supply.<wbr> Commercial launch will take place in the very near future.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8711_3_ScreenCapture3.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8711_4_ScreenCapture4.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8711_5_ScreenCapture5.jpg"> </div><div style="margin-bottom: 10px;">In terms of the prostate development programme top-line data is expected in 2014.<wbr> Meanwhile, there is an interest in the company in terms of conducting combination trials with abiraterone and enzalutamide.<wbr>in post and pre-chemo settings.<wbr> Exelixis claims to have some early data from an IST and Dana Farber, which highlights the potential there and so it is devising a plan to conduct company sponsored randomized trials in that space.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8711_6_ScreenCapture6.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8711_7_ScreenCapture7.jpg"> </div><div>Source:www.<wbr>exelixis.<wbr>com </div><!-- Comment details --><a name="oncology8711attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8711_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(76,7 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8711_2_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(51,3 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8711_3_ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(54,8 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8711_4_ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(53,6 KB)<br>&nbsp;&nbsp;5.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8711_5_ScreenCapture5.jpg">ScreenCapture5.jpg</a>&nbsp;&nbsp;(54,7 KB)<br>&nbsp;&nbsp;6.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8711_6_ScreenCapture6.jpg">ScreenCapture6.jpg</a>&nbsp;&nbsp;(68,7 KB)<br>&nbsp;&nbsp;7.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8711_7_ScreenCapture7.jpg">ScreenCapture7.jpg</a>&nbsp;&nbsp;(76,7 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20130431&edate=20130101&rec=8711">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-01-10T10:00:41+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-01-10T10:00:41+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Gattex for Short Bowel Syndrome at the Center of NPS' Presentation</title>
	<pubDate>2013-01-09T18:25:24+01:00</pubDate>
	<wp:post_id>4246</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: At the J.<wbr>P Morgan Conference, François Nader (President and CEO) highlighted high unmet medical need, burden of illness, clincial value and ultra-orphan status as key value framework for Gattex (the first and only analog of GLP-2 proven to increase absorption of remaining bowel and decrease or eliminate the need for parenteral support).<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">See <a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20130431&edate=20130101&rec=7210" class="defaultlink">Endocrinology7210: NPS Sets Price for Newly Approved Gattex</a>.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7230_1_ScreenCapture1.jpg"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7230_2_ScreenCapture2.jpg"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7230_3_ScreenCapture3.jpg"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7230_4_ScreenCapture4.jpg"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7230_5_ScreenCapture5.jpg"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7230_6_ScreenCapture6.jpg"> </div><!-- Comment details --><span style="font-weight: bold; font-style: italic;"><br>Comments</span><a name="Endocrinology7236c"></a><br><div style="border: 1px solid #AAA; background-color: #FFF; margin-left: 10px; padding: 5px;"><div style="margin-bottom: 10px;"><P class="Body"><STRONG>SBS is perceived by physicians as one of the highest unmet needs in the field of GI conditions.<wbr> This NPS assessment could directly benefit to SSAs including Somatuline.<wbr></STRONG></P> </div><div style="margin-bottom: 10px;"><P class="Body"> If less than 1 meter of ileum is remaining after surgery, chronic intestinal failure is installed,  making the patient dependent on parenteral nutrition for life.<wbr></P> </div><div style="margin-bottom: 10px;"><P class="Body"> Several clinical aspects must attract our interest:</P> </div><div style="margin-bottom: 10px;"><P class="Body">-          Despite they are malabsorptive, SBS patients are not &ldquo;nil per os&rdquo;.<wbr> They could even ingest very large amounts of energy and liquids;</P> </div><div style="margin-bottom: 10px;"><P class="Body">-          Depending of patients GI functional capacities and for answering to nutritional needs, parenteral nutrition could be administered either to fulfill daily needs or just a part of these needs.<wbr> Because of these different situations and related to respecting a &ldquo;physiological&rdquo; slow rate of infusion, patients could be fed all day long and every day , or &ldquo;only&rdquo; some days per week  and/<wbr>or some hours per days (in a cycling way, at night).<wbr></P> </div><div style="margin-bottom: 10px;"><P class="Body">-          So improving SBS is not only reducing the number of parenterally fed patients, but this could be also preserving for each patient, number of days or hours of freedom with no &ldquo;line-attachment&rdquo; or no infusion (meaning improving Quality of Life).<wbr></P> </div><div style="margin-bottom: 10px;"><P class="Body">-           Because SBS is a chronic condition, PN is given at home ( &ldquo;HPN&rdquo;) and today , there are registries for HPN patients in almost all EU countries.<wbr> However it is important to take into consideration that the major part of HPN patients are not recorded in registries and this &ldquo;hidden&rdquo; part of SBS /<wbr> HPN patients are postoperative patients suffering of digestive cancer.<wbr> So the real number of SBS patients is in practice significantly larger than registered patients (but this actual number is unknown).<wbr></P> </div><div><P class="Body">Taking as a whole, reducing fluid secretion, means improving SBS patient quality of life: patients can receive oral food, their transit and enterostomy fluid outputs can be reduced and parenteral nutrition and rehydration regimen as well as their potential risks (infection and metabolic) can be diminished.<wbr> The main medical field is cancer.<wbr></P> </div></div><a name="endocrinology7230attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7230_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(92 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7230_2_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(44,8 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7230_3_ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(68,8 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7230_4_ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(75,8 KB)<br>&nbsp;&nbsp;5.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7230_5_ScreenCapture5.jpg">ScreenCapture5.jpg</a>&nbsp;&nbsp;(82,7 KB)<br>&nbsp;&nbsp;6.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7230_6_ScreenCapture6.jpg">ScreenCapture6.jpg</a>&nbsp;&nbsp;(66 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20130431&edate=20130101&rec=7230">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-01-09T18:25:24+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-01-09T18:25:24+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category endocrinology > <![CDATA[Endocrinology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Merz Re-enters US Toxin Market</title>
	<pubDate>2013-01-09T15:08:48+01:00</pubDate>
	<wp:post_id>4247</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Merz North America has announced that effective today, the court ordered injunction has been lifted and patients and physicians now have access to " a broader range of treatment options in aesthetic medicine, dermatology and neurology".<wbr> </div><div style="margin-bottom: 10px;"><STRONG>The press release states that:-</STRONG> </div><div style="margin-bottom: 10px;">"The violations that led to this injunction were directly attributable to the acts of several individuals, and were entirely incompatible with Merz's culture.<wbr> We accepted the injunction as a challenge to us to reinforce compliance training throughout the company and to re-imagine a company-wide compliance program.<wbr> Last summer we directed all our efforts and resources toward the remediation process, and were pleased when the court agreed to a partial lift of the injunction in November 2012,&rdquo; said Katrina Church, Vice President - Chief Compliance Officer of Merz, Inc.<wbr> &ldquo;We believe that compliance policies are an investment in our company's future.<wbr>&rdquo; </div><div style="margin-bottom: 10px;">Merz North America is now permitted to sell and promote its entire portfolio of FDA-approved products, including XEOMIN<SUP>&reg;</SUP> (incobotulinumtoxinA), BELOTERO BALANCE<SUP>&reg; </SUP>Dermal Filler, and Radiesse<SUP>&reg;</SUP> Volumizing Filler, in the U.<wbr>S.<wbr> with no restrictions imposed by the court order.<wbr> </div><div>Source:<A href="http://www.merz.com/">www.<wbr>merz.<wbr>com</A> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20130431&edate=20130101&rec=6738">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-01-09T15:08:48+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-01-09T15:08:48+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>A Newly Formed Big Cap Pharma Highlights Its Strategic Ambitions</title>
	<pubDate>2013-01-09T10:22:23+01:00</pubDate>
	<wp:post_id>4248</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: The newly formed Abbvie, the  pharmaceutical business spun out 
of Abbott gave its first presentation at the JP Morgan H/<wbr>C conference yesterday.<wbr> 
Hiighlighting were the key areas of product growth which includes a 
focus on endometriosis, uterine fibroids and Parkinson's disease.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10280_1_ScreenCapture1.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10280_2_ScreenCapture2.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10280_3_ScreenCapture3.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10280_4_ScreenCapture4.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10280_5_ScreenCapture5.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10280_6_ScreenCapture6.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10280_7_ScreenCapture7.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10280_8_ScreenCapture8.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10280_9_ScreenCapture9.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10280_10_ScreenCapture10.jpg"> </div><div>Source: <A href="http://www.abbvie.com">www.<wbr>abbvie.<wbr>com</A> </div><!-- Comment details --><a name="pharmaworld10280attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10280_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(61,1 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10280_2_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(47,2 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10280_3_ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(78,7 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10280_4_ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(58,5 KB)<br>&nbsp;&nbsp;5.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10280_5_ScreenCapture5.jpg">ScreenCapture5.jpg</a>&nbsp;&nbsp;(45 KB)<br>&nbsp;&nbsp;6.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10280_6_ScreenCapture6.jpg">ScreenCapture6.jpg</a>&nbsp;&nbsp;(77,8 KB)<br>&nbsp;&nbsp;7.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10280_7_ScreenCapture7.jpg">ScreenCapture7.jpg</a>&nbsp;&nbsp;(69,9 KB)<br>&nbsp;&nbsp;8.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10280_8_ScreenCapture8.jpg">ScreenCapture8.jpg</a>&nbsp;&nbsp;(79,6 KB)<br>&nbsp;&nbsp;9.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10280_9_ScreenCapture9.jpg">ScreenCapture9.jpg</a>&nbsp;&nbsp;(79,4 KB)<br>&nbsp;&nbsp;10.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10280_10_ScreenCapture10.jpg">ScreenCapture10.jpg</a>&nbsp;&nbsp;(67,3 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20130431&edate=20130101&rec=10280">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-01-09T10:22:23+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-01-09T10:22:23+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category pharma-news > <![CDATA[Pharma News]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Telormedix granted IND for Phase II Bladder Cancer Study</title>
	<pubDate>2013-01-09T09:47:43+01:00</pubDate>
	<wp:post_id>4249</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Telormedix, a clinical stage biopharmaceutical company focused on 
TLR7 agonists has received FDA authorisation for Phase II trial of its 
lead product TMX-101, a TLR-7 agonist, in CIS (carcinoma in situ) in the 
bladder.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Next Steps</STRONG> </div><div style="margin-bottom: 10px;">The planned Phase II study is due to commence in March 2013 and will involve 
a small number of CIS patients recruited from private urology clinics in the USA 
to examine at the efficacy of TMX-101 over six doses.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Supportive Data</STRONG> </div><div style="margin-bottom: 10px;">Dr Johanna Holldack, CEO of Telormedix, commenting in the company's press 
release notes that:-<BR>“Our recently completed safety trial of TMX-101 showed 
it induced a strong disease-modifying cytokine response in patients with 
non-muscle invasive bladder cancer (NMIBC).<wbr> We have high hopes that this means 
TMX-101 will demonstrate disease modifying efficacy in CIS.<wbr> “ </div><div style="margin-bottom: 10px;">Dr Stuart Holden, a prominent practicing uro-oncologist and Telormedix board 
member, added:<BR>“We have known for many years that CIS patients respond well 
to immunotherapeutic interventions such as BCG.<wbr> So there are already good 
reasons to be optimistic that TLR-7 mediated treatments such as TMX-101 will 
offer a new and effective clinical tool in the treatment of this aggressive 
carcinoma.<wbr>” </div><div style="margin-bottom: 10px;"><STRONG>Company Profile</STRONG> </div><div style="margin-bottom: 10px;">Telormedix was founded in October 2007, is a biopharmaceutical company 
focused on targeted immunity and modulation of the innate immune system for 
treating cancer and autoimmune diseases.<wbr> The Company’s lead product 
is TMX-101, In addition, Telormedix is developing novel TLR7-targeted 
agonists.<wbr> One of these molecules, TMX-202, has recently been selected for 
preclinical study for the topical treatment of skin cancers and other 
indications.<wbr> Telormedix also has a pipeline of programs for inflammatory and 
autoimmune diseases, which includes TMX-302, a TLR7-binding small molecule 
showing anti-inflammatory properties in vivo.<wbr> </div><div style="margin-bottom: 10px;">Located in Switzerland, 
Telormedix is led by a highly experienced management team and backed by an 
international consortium of venture capitalists including Aravis Venture (Basel, 
Switzerland) and Proquest Investments (Princeton-San Diego, USA).<wbr> </div><div>Source: <A href="http://www.telormedix.com">www.<wbr>telormedix.<wbr>com</A> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20130431&edate=20130101&rec=8710">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-01-09T09:47:43+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-01-09T09:47:43+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Efficacy of Using Umbilical Cord Blood for Cerebral Palsy (CP)</title>
	<pubDate>2013-01-08T17:51:53+01:00</pubDate>
	<wp:post_id>4250</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Cryo-Cell first results of a Ph2 study have been published in <EM>Stem Cells</EM> and conclude that umbilical cord blood (UCB) treatment ameliorated motor and cognitive dysfunction in children with CP undergoing active rehabilitation, accompanied by structural and metabolic changes in the brain.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">- Recruitment: 96 children were treated (between the ages of 10 months and 10 years).<wbr> </div><div style="margin-bottom: 10px;">- Protocol: Patients were divided into 3 groups: those treated with HLA-matched cord blood from unrelated donor along with EPO - those treated with placebo + EPO - those treated with placebo alone.<wbr> </div><div style="margin-bottom: 10px;">- See full paper attached <a href="http://ci.beaufour-ipsen.com/traction?type=np&proj=*&sdate=20130431&edate=20130101&rs=/link%20Neurology6737%401" class="defaultlink">@1</a> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Founded in 1989 </div><div style="margin-bottom: 10px;">Location: Tampa Bay Area in Florida (USA) </div><div>Became the first private cord blood bank in the world to separate and store stem cells </div><!-- Comment details --><a name="neurology6736attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6736_1_Stem%20Cells%255fAbstract.pdf">Stem Cells_Abstract.pdf</a>&nbsp;&nbsp;(1,1 MB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20130431&edate=20130101&rec=6736">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-01-08T17:51:53+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-01-08T17:51:53+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Novartis Strategy for Future Growth</title>
	<pubDate>2013-01-08T14:41:57+01:00</pubDate>
	<wp:post_id>4251</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: At the J.<wbr>P Morgan H/<wbr>C Conference, Joseph Jimenez (CEO) outlined that '2013 will be a year of two halves'.<wbr> The first one to be significantly impacted by the Diovan patent expiration.<wbr> The second half begins the next growth phase, driven by launch products, emerging growth markets and lower impact of generics after 2013.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7227_1_ScreenCapture1.jpg"> </div><div style="margin-bottom: 10px;">In terms of <U>innovation</U>, Novartis received 17 key approvals across its divisions and 9 positive Ph3 trials.<wbr> </div><div style="margin-bottom: 10px;"><UL dir="ltr" style="MARGIN-RIGHT: 0px"><LI>Afinitor in advanced breast cancer was approved in Europe and the US.<wbr> Management believes that this will be a significant new indication for Afinitor and have pegged it over $1 billion for that one indication alone.<wbr></LI>
</UL> </div><div style="margin-bottom: 10px;">In terms of <U>growth</U>, newly launched products accounted for almost 30% of total group sales through the first three quarters.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7227_2_ScreenCapture2.jpg"> </div><div style="margin-bottom: 10px;"><STRONG><U>Key Products</U></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7227_3_ScreenCapture3.jpg"> </div><div style="margin-bottom: 10px;">In terms of <U>productivity</U>, Novartis generated $900M in procurement savings, reduced marketing and sales as percent of sales.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7227_4_ScreenCapture4.jpg"> </div><div><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7227_5_ScreenCapture5.jpg"> </div><!-- Comment details --><a name="endocrinology7227attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7227_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(58,3 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7227_2_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(27,4 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7227_3_ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(36,8 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7227_4_ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(32,5 KB)<br>&nbsp;&nbsp;5.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7227_5_ScreenCapture5.jpg">ScreenCapture5.jpg</a>&nbsp;&nbsp;(28,4 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20130431&edate=20130101&rec=7227">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-01-08T14:41:57+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-01-08T14:41:57+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category endocrinology > <![CDATA[Endocrinology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Valeant's New Financial Guidance & Strategic Ambitions</title>
	<pubDate>2013-01-08T13:47:34+01:00</pubDate>
	<wp:post_id>4252</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Valeant hosted a call with analysts on Friday to provide better guidance on the outlook for the new entity post the acquisition of Medicis.<wbr> Top-line guidance seems to have been below consensus but cost synergies from the acquisition higher than anticipated.<wbr> Management also appears to have floated the idea of a potential merger with a larger peer that could allow Valeant to maintain control as well as its tax rate.<wbr> </div><div style="margin-bottom: 10px;">CEO Mike Pearson envisions transforming Valeant from a $4.<wbr>6bn company in 2013 to a $10-20bn revenue company "in the foreseeable future".<wbr> While current leverage may preclude a transformative cash deal over the near term, Pearson believe that a merger of equals may allow for signficant value creation and deleveraging.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10276_4_ScreenCapture4.jpg"> </div><div><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10276_1_ScreenCapture1.jpg"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10276_2_ScreenCapture2.jpg"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10276_3_ScreenCapture3.jpg"> </div><!-- Comment details --><a name="pharmaworld10276attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10276_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(150,8 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10276_2_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(91,7 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10276_3_ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(89,2 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10276_4_ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(135 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20130431&edate=20130101&rec=10276">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-01-08T13:47:34+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-01-08T13:47:34+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category pharma-news > <![CDATA[Pharma News]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>ASCO-GU Upcoming Data Of Significance</title>
	<pubDate>2013-01-08T12:05:05+01:00</pubDate>
	<wp:post_id>4253</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Yesterday at the JP Morgan H/<wbr>C Conference, Medivation confirmed that data from its phII hormone-naive trial with Xtandi (enzalutamide) will be presented for the first time at ASCO GU in February.<wbr> This will be an important congress for prostate cancer data as additionally there will be CPRC data released from two phIII studies.<wbr> One with Aflibercept (Zaltrap Sanofi) which is known not to have reached its primary endpoint and the other with dastinib (BMS) results of which are eagerly awaited.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Medivation Data</STRONG> </div><div style="margin-bottom: 10px;">Medivation's Phase 2 hormone-na&iuml;ve trial completed enrollment in January 2011.<wbr> This trial enrolled 67 patients who are first-line (prior to even Lupron therapy).<wbr> The primary endpoint is PSA response and the dose of enzalutamide being tested is 160 mg given once-a-day.<wbr> The goal of this trial is to explore the use of enzalutamide in first-line patients.<wbr> </div><div style="margin-bottom: 10px;">The other new indication that Medivation is exploring in a phII setting is as a neadjuvant prior to prostatectomy.<wbr> A phII trial in 50 patients started in this setting in June 2012.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>BMS Data</STRONG> </div><div style="margin-bottom: 10px;">Dasatinib (Sprycel, Bristol-Myers Squibb), approved for treatment of adults with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML), demonstrated some encouraging results in a phase I-II study in 46 patients with CRPC.<wbr> Dasatinib targets both the tumor and bone microenvironment in CRPC via the Src pathway, <BR><BR>In the phase I-II study, 18 of 30 patients with measurable disease had a partial PSA response.<wbr>1 Treatment with dasatinib also resulted in improvement in bone markers, with 87% of patients experiencing decreases in urinary N-telopeptide and 76% showing a decrease in bone-specific alkaline phosphatase levels.<wbr> The combination of dasatinib and docetaxel was generally well tolerated; 28% of patients had grade 3-4 toxicity.<wbr> </div><div style="margin-bottom: 10px;">The results led to the development of a phase III trial of docetaxel with and without dasatinib in 1500 patients with metastatic CRPC with evidence of progression.<wbr>  The trial&rsquo;s primary endpoint is overall survival.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Sanofi Data</STRONG> </div><div style="margin-bottom: 10px;">Sanofi will report in more detail the results of the VENICE trial at ASCO GU.<wbr> This was a phIII trial that evaluated the effect of the angiogenic drug aflibercept (VEGF-trap) in first-line combination with docetaxel in 1,224 CRPC patients.<wbr> Sanofi reported back in April 2012 that the study did not meet its primary endpoint in terms of efficacy i.<wbr>e.<wbr> an improvement in overall survival.<wbr> </div><div style="margin-bottom: 10px;">VEGF Trap, is an angiogenesis inhibitor with a unique mechanism of action.<wbr>  The fusion protein binds multiple forms of Vascular Endothelial Growth Factor-A (VEGF-A), as well as VEGF-B and placental growth factor (PIGF), additional angiogenic growth factors that appear to play a role in tumor angiogenesis and inflammation.<wbr> </div><div style="margin-bottom: 10px;">The results of this trial provide yet further evidence of the lack of benefit obtained with pure anti-angiogenic agents in the CRPC setting, with similar phIII trials undertaken with sunitinib and bevacizumab also having failed to demonstrate efficacy in CRPC patients.<wbr> </div><div>Source: <A href="http://www.medivation.com">www.<wbr>medivation.<wbr>com</A> and ASCO GU programme </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20130431&edate=20130101&rec=8708">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-01-08T12:05:05+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-01-08T12:05:05+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Allergan Strengthens European Communications Team</title>
	<pubDate>2013-01-08T11:42:53+01:00</pubDate>
	<wp:post_id>4254</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Julia Kendrick and Bahar Turkoglu have joined Allergan from the Chandler Chicco Agency.<wbr> </div><div style="margin-bottom: 10px;">These two newly created roles will be based in the UK and will report to EMEA corporate affairs and PR director Janet Kettles as Allergan focuses on its medical aesthetics, neurosciences and ophthalmology business units.<wbr> </div><div style="margin-bottom: 10px;">Kendrick will handle corporate affairs and PR for Allergan&rsquo;s medical aesthetics business, which includes Botox and dermal filler products, across the EMEA region.<wbr> </div><div style="margin-bottom: 10px;">Turkoglu will manage corporate affairs and PR for the firm&rsquo;s neuroscience and ophthalmology business, including chronic migraine and overactive bladder conditions throughout the EMEA region.<wbr> </div><div>Source: PR Week 8 January 2013 </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20130431&edate=20130101&rec=6735">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-01-08T11:42:53+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-01-08T11:42:53+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Key Takeaways from Dendreon Preliminary Q4:12</title>
	<pubDate>2013-01-08T11:19:09+01:00</pubDate>
	<wp:post_id>4255</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: At the J.<wbr>P Morgan H/<wbr>C Conference, John J.<wbr> Johnson (President &amp; CEO) highlighted increasing utilization of PROVENGE, reducing COGS and cost structure and expanding pipeline as key areas of focus to drive shareholder value.<wbr> Of note, Management expects a regulatory decision of PROVENGE in EU in mid-2013, and has plans to start enzalutamide sequencing trial soon.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8707_2_ScreenCapture2.jpg"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8707_3_ScreenCapture3.jpg"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8707_4_ScreenCapture4.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8707_5_ScreenCapture5.jpg"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8707_6_ScreenCapture6.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8707_7_ScreenCapture7.jpg"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Supporting sequencing through clinical research </div><div><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8707_8_ScreenCapture8.jpg"> </div><!-- Comment details --><a name="oncology8707attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8707_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(81,5 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8707_2_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(76,2 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8707_3_ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(50,1 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8707_4_ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(53,1 KB)<br>&nbsp;&nbsp;5.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8707_5_ScreenCapture5.jpg">ScreenCapture5.jpg</a>&nbsp;&nbsp;(54,6 KB)<br>&nbsp;&nbsp;6.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8707_6_ScreenCapture6.jpg">ScreenCapture6.jpg</a>&nbsp;&nbsp;(67,3 KB)<br>&nbsp;&nbsp;7.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8707_7_ScreenCapture7.jpg">ScreenCapture7.jpg</a>&nbsp;&nbsp;(53,4 KB)<br>&nbsp;&nbsp;8.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_8707_8_ScreenCapture8.jpg">ScreenCapture8.jpg</a>&nbsp;&nbsp;(60,4 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20130431&edate=20130101&rec=8707">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-01-08T11:19:09+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-01-08T11:19:09+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Aspireo Reports Somatoprim Phase I b Interim Data</title>
	<pubDate>2013-01-08T11:07:40+01:00</pubDate>
	<wp:post_id>4256</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: The preliminary data confirms the safety profile of Somatoprim, with the maximum tolerated dose not reached.<wbr> No serious adverse events were reported.<wbr> </div><div style="margin-bottom: 10px;">The single centre study is investigating the safety, side effect profile, as well as pharmacokinetic and pharmacodynamic profile of multiple ascending doses of Somatoprim in healthy male volunteers, when administered alone and in combination with octreotide.<wbr> </div><div style="margin-bottom: 10px;">Somatoprim also demonstrated a dose-dependent lowering effect on growth hormone, as shown by an analysis of the pharmacodynamic effect on hGH, when stimulated by growth hormone releasing hormone.<wbr> </div><div style="margin-bottom: 10px;">Aspireo expects final data to be available in Q2 2013.<wbr> </div><div style="margin-bottom: 10px;">See also <a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20130431&edate=20130101&rec=7158" class="defaultlink">Endocrinology7158: Aspireo Starts Ph2a Study with Somatoprim for Acromegaly</a> </div><div>Source: Aspireo Pharmaceuticals 7 January 2013 </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20130431&edate=20130101&rec=7226">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-01-08T11:07:40+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-01-08T11:07:40+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category endocrinology > <![CDATA[Endocrinology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Key Messages from Merck's Presentation at J.P Morgan H/C Conference</title>
	<pubDate>2013-01-08T10:38:40+01:00</pubDate>
	<wp:post_id>4257</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Matthias Zachert (CFO) and Stefan Oschmann (CEO Merck Serono) presented an update of the company business.<wbr> YTD Sept.<wbr> 2012 sales in Europe and Emerging markets represented 37% and 34% respectively.<wbr> Portfolio strategy is to not divest until 2014, and sign deals before 2014.<wbr> Fertility and Endocrinology franchises continued to support the business.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7225_1_ScreenCapture1.jpg"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7225_2_ScreenCapture2.jpg"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7225_3_ScreenCapture3.jpg"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7225_4_ScreenCapture4.jpg"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7225_5_ScreenCapture5.jpg"> </div><div>Source: Merck (JPM conference) </div><!-- Comment details --><a name="endocrinology7225attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7225_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(68,7 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7225_2_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(50,6 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7225_3_ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(60,7 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7225_4_ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(70,7 KB)<br>&nbsp;&nbsp;5.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7225_5_ScreenCapture5.jpg">ScreenCapture5.jpg</a>&nbsp;&nbsp;(106,9 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20130431&edate=20130101&rec=7225">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-01-08T10:38:40+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-01-08T10:38:40+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category endocrinology > <![CDATA[Endocrinology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>New Friedreich Ataxia Drug Moves Into PhIIb</title>
	<pubDate>2013-01-07T17:57:08+01:00</pubDate>
	<wp:post_id>4258</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Pricate company Edison Pharmaceuticals Inc has announced the 
initiation of a phIIb study entitled "Safety and efficacy of EPO-743 on visual 
function in patients with Friedreich's  Ataxia </div><div style="margin-bottom: 10px;"><STRONG>Study Design</STRONG> </div><div style="margin-bottom: 10px;">The trial is a placebo-controlled study lasting six months, followed by an 
extension phase in which all subjects will receive EPI-743.<wbr> </div><div style="margin-bottom: 10px;">The primary endpoint of the trial is visual function, with sedonary endpoint 
including neurological and neuromuscular function.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Trial Logistics</STRONG> </div><div style="margin-bottom: 10px;">The trial is being conducted with the assistance of investigators from the 
Friedreich's Ataxia Research Alliance (FARA) Clinical Research Network and 
FARA's Patient registry.<wbr> Three clinical trial sites have been  selected in 
the US: University of South Florida, Children's Hospital of Philadelphia and the 
University of California </div><div style="margin-bottom: 10px;">What is EPI-743 </div><div style="margin-bottom: 10px;">It is an orally bioavailable small molecule which is a member of the 
para-benzoquinone class of drugs.<wbr> It acts as a cofactor for a new drug target 
NADPH quinone oxidase.<wbr> The drug augments endogenous glutathione biosynthesis - a 
process essential for the control of oxidative stress.<wbr> </div><div><a href="http://www.edspharma.com" class="defaultlink" title="www.edspharma.com">edspharma.com</a> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20130431&edate=20130101&rec=6734">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-01-07T17:57:08+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-01-07T17:57:08+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>New US Patent for PROLOR</title>
	<pubDate>2013-01-07T14:44:33+01:00</pubDate>
	<wp:post_id>4259</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: The company has received a notice of allowance from the U.<wbr>S.<wbr> Patent and Trademark Office.<wbr> The allowed claims cover manufacturing methods for CTP-modified compositions of a wide array of classes of therapeutic proteins, including hormones.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">This new U.<wbr>S.<wbr> patent is expected to be issued in the next few months.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>References in Traction CI</STRONG> </div><div>See <a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20130431&edate=20130101&rec=7169" class="defaultlink">Endocrinology7169: New Patent Covering PROLOR's Reversible-Pegylation Platform</a>.<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20130431&edate=20130101&rec=7218">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-01-07T14:44:33+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-01-07T14:44:33+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category endocrinology > <![CDATA[Endocrinology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Study: Cost Utility Analysis of Primary Treatments for Clinically Localised Prostate Cancer</title>
	<pubDate>2013-01-07T11:31:24+01:00</pubDate>
	<wp:post_id>4260</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Analysis of 232 papers published in the last decade that report results from clinical studies following patients with low-, intermediate- and high-risk forms of prostate cancer who were treated with one or more of the standard treatments.<wbr> Costs were determined from the USA payer perspective.<wbr> </div><div style="margin-bottom: 10px;">Overall, the analysis showed small differences in outcomes and substantial differences in payer and patient costs across treatment alternatives.<wbr> </div><div style="margin-bottom: 10px;">The analysis shows that for people with low-risk prostate cancer, the various forms of treatment vary only slightly in terms of survival, but the cost of radiation therapy is significantly more expensive than surgery.<wbr> For intermediate- and high-risk cancers, both survival and cost generally favored surgery over other forms of treatment -- although combination external-beam radiation and brachytherapy together were comparable in terms of quality of life-adjusted survival for high-risk prostate cancer.<wbr> </div><div style="margin-bottom: 10px;">Link to full text (Ipsen subscription) <a href="http://onlinelibrary.wiley.com/doi/10.1111/j.1464-410X.2012.11597.x/pdf" class="defaultlink" title="http://onlinelibrary.wiley.com/doi/10.1111/j.1464-410X.2012.11597.x/pdf">onlinelibrary.wil&hellip;</a> </div><div>Source: BJU International 28 December 2012 </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20130431&edate=20130101&rec=8704">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-01-07T11:31:24+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-01-07T11:31:24+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Addex Reports Progress with its GABA-BR PAM Compound</title>
	<pubDate>2013-01-07T11:27:10+01:00</pubDate>
	<wp:post_id>4261</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: The company has announced achievement of a positive PoC in a validated model of Charcot-Marie-Tooth 1A.<wbr> Ph1 testing is planned for H1:13, initially for the treatment of spasticity associated with MS.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><SPAN lang="EN-US" style="FONT-FAMILY: 'arial'"></SPAN> </div><div style="margin-bottom: 10px;"><SPAN lang="EN-US" style="FONT-FAMILY: 'arial'"><STRONG></STRONG></SPAN> </div><div style="margin-bottom: 10px;"><SPAN lang="EN-US" style="FONT-FAMILY: 'arial'"></SPAN> </div><div><SPAN lang="EN-US" style="FONT-FAMILY: 'arial'"></SPAN> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20130431&edate=20130101&rec=6733">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-01-07T11:27:10+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-01-07T11:27:10+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>re: LRRK2 Gene Reseach Receives Significant Funding</title>
	<pubDate>2013-01-07T11:18:18+01:00</pubDate>
	<wp:post_id>4262</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="border-left: 2px solid #8B1010; padding: 0px 0px 5px 12px; margin-bottom: 3px;"><span style="font-weight: bold; font-size: 14px;">LRRK2 Gene Reseach Receives Significant Funding</span>&nbsp;<br><span style="font-size: 12px;">Comment: The Michael J.<wbr> Fox Foundation for Parkinson's Research has agreed to fund to the tune of $3.<wbr>5m nine research studies aiming to advance understanding of the LRRK2 gene, a promising new therapeutic target for Parkinson's disease.<wbr></span>&nbsp;&nbsp;<a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20130431&edate=20130101&rec=4833">...</a><br></div><div><P align="left">Vernalis has reported that it is to  receive a &pound;750,000 ($1.<wbr>2 million) milestone payment from Lundbeck under a December 2010 deal to identify inhibitors of leucine-rich repeat kinase 2 (LRRK2) for neurodegenerative diseases using Vernalis&rsquo; fragment and structure-based discovery platform.<wbr> The milestone, which was triggered by an undisclosed event, is the third under the deal.<wbr></P> </div><!-- Comment details --><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20130431&edate=20130101&rec=6732">Add a Comment on this Article</a><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology4833">View thread  Neurology4833: LRRK2 Gene Reseach Receives Significant Funding</a>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-01-07T11:18:18+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-01-07T11:18:18+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Repros Updates on Proellex-V for UF</title>
	<pubDate>2013-01-04T13:30:15+01:00</pubDate>
	<wp:post_id>4263</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Topline analysis of Ph2 suggests 12mg vaginal dose effective after 4 months of treatment, and well tolerated.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">- Repros to request end of Ph2 meeting with Fda during Q1:13.<wbr> </div><div style="margin-bottom: 10px;">- Repros has put in place an extension study to begin to build the 1 year exposure safety database that will be required for an eventual NDA submission (to date 15 of the 40 participants have elected to enroll in this extension study).<wbr> </div><div>Source: ThonsonOne; Repros </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20130431&edate=20130101&rec=7217">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-01-04T13:30:15+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-01-04T13:30:15+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category endocrinology > <![CDATA[Endocrinology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Valeant Adds L.D Kornwasser to its Senior Management Team</title>
	<pubDate>2013-01-04T12:46:02+01:00</pubDate>
	<wp:post_id>4264</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Laizer D.<wbr> Kornwasser will assume the role of Executive VP/<wbr>Company Group Chairman where he will be responsible for Valeant's Operations in Canada, US Neurology effecitve Feb.<wbr> 1, 2013.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Was Senior Executive @ Medco Health (prior to its acquisition by Express Scripts).<wbr> </div><div style="margin-bottom: 10px;">Prior to joining Medco, he held positions @ Merrill Lynch and Coopers &amp; Lybrand.<wbr> </div><div style="margin-bottom: 10px;">Has an MBA from Harvard Business School and a BS in Accounting from Yeshiva U.<wbr> </div><div><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6730_1_ScreenCapture1.jpg"> </div><!-- Comment details --><a name="neurology6730attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6730_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(57,8 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20130431&edate=20130101&rec=6730">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-01-04T12:46:02+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-01-04T12:46:02+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Subgroup Analysis of RADIANT-2 in Advanced Colorectal NETs</title>
	<pubDate>2013-01-04T12:31:04+01:00</pubDate>
	<wp:post_id>4265</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: <SPAN style="TEXT-ALIGN: left; WIDOWS: 2; TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; DISPLAY: inline !important; FONT: 13px/17px arial, helvetica, clean, sans-serif; WHITE-SPACE: normal; ORPHANS: 2; FLOAT: none; LETTER-SPACING: normal; COLOR: rgb(0,0,0); WORD-SPACING: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px">.<wbr></SPAN> </div><div style="margin-bottom: 10px;"><H1 style="BORDER-BOTTOM: 0px; TEXT-ALIGN: left; BORDER-LEFT: 0px; PADDING-BOTTOM: 0px; WIDOWS: 2; TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; MARGIN: 0.37em 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; FONT: bold 1.23em/1.12em arial, helvetica, clean, sans-serif; WHITE-SPACE: normal; ORPHANS: 2; LETTER-SPACING: normal; COLOR: rgb(0,0,0); VERTICAL-ALIGN: baseline; BORDER-TOP: 0px; BORDER-RIGHT: 0px; WORD-SPACING: 0px; PADDING-TOP: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"></H1> </div><div style="margin-bottom: 10px;"><DIV class="auths" style="BORDER-BOTTOM: 0px; TEXT-ALIGN: left; BORDER-LEFT: 0px; PADDING-BOTTOM: 0px; WIDOWS: 2; TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(255,255,255); FONT-VARIANT: normal; FONT-STYLE: normal; TEXT-INDENT: 0px; MARGIN: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; FONT-FAMILY: arial, helvetica, clean, sans-serif; WHITE-SPACE: normal; ORPHANS: 2; LETTER-SPACING: normal; COLOR: rgb(0,0,0); FONT-SIZE: 0.92em; VERTICAL-ALIGN: baseline; BORDER-TOP: 0px; FONT-WEIGHT: normal; BORDER-RIGHT: 0px; WORD-SPACING: 0px; PADDING-TOP: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"></DIV> </div><div style="margin-bottom: 10px;"><DIV class="aff" style="BORDER-BOTTOM: 0px; TEXT-ALIGN: left; BORDER-LEFT: 0px; PADDING-BOTTOM: 0px; WIDOWS: 2; TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; MARGIN: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; FONT: 0.84em/1.09em arial, helvetica, clean, sans-serif; WHITE-SPACE: normal; ORPHANS: 2; LETTER-SPACING: normal; COLOR: rgb(0,0,0); VERTICAL-ALIGN: baseline; BORDER-TOP: 0px; BORDER-RIGHT: 0px; WORD-SPACING: 0px; PADDING-TOP: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px">
<H3 class="label" style="BORDER-BOTTOM: 0px; POSITION: absolute; BORDER-LEFT: 0px; PADDING-BOTTOM: 0px; LINE-HEIGHT: 1.2857; MARGIN: 1.28em 0px 0.64em; PADDING-LEFT: 0px; WIDTH: 1px; PADDING-RIGHT: 0px; HEIGHT: 1px; COLOR: rgb(114,65,40); FONT-SIZE: 1.07em; VERTICAL-ALIGN: baseline; OVERFLOW: hidden; BORDER-TOP: 0px; TOP: auto; FONT-WEIGHT: bold; BORDER-RIGHT: 0px; PADDING-TOP: 0px; LEFT: -10000px"></H3>
<P style="BORDER-BOTTOM: 0px; BORDER-LEFT: 0px; PADDING-BOTTOM: 0px; MARGIN: 0.5em 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; FONT-SIZE: 11px; VERTICAL-ALIGN: baseline; BORDER-TOP: 0px; BORDER-RIGHT: 0px; PADDING-TOP: 0px"></P></DIV> </div><div style="margin-bottom: 10px;"><DIV class="abstr" style="BORDER-BOTTOM: 0px; TEXT-ALIGN: left; BORDER-LEFT: 0px; PADDING-BOTTOM: 0px; WIDOWS: 2; TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; MARGIN: 1.2em auto auto; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; FONT: 13px/17px arial, helvetica, clean, sans-serif; WHITE-SPACE: normal; ORPHANS: 2; LETTER-SPACING: normal; COLOR: rgb(0,0,0); VERTICAL-ALIGN: baseline; BORDER-TOP: 0px; BORDER-RIGHT: 0px; WORD-SPACING: 0px; PADDING-TOP: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px">
<P style="BORDER-BOTTOM: 0px; BORDER-LEFT: 0px; PADDING-BOTTOM: 0px; MARGIN: 0px 0px 0.5em; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; FONT-SIZE: 13px; VERTICAL-ALIGN: baseline; BORDER-TOP: 0px; BORDER-RIGHT: 0px; PADDING-TOP: 0px"></P>
<P style="BORDER-BOTTOM: 0px; BORDER-LEFT: 0px; PADDING-BOTTOM: 0px; MARGIN: 0px 0px 0.5em; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; FONT-SIZE: 13px; VERTICAL-ALIGN: baseline; BORDER-TOP: 0px; BORDER-RIGHT: 0px; PADDING-TOP: 0px"></P>
<P style="BORDER-BOTTOM: 0px; BORDER-LEFT: 0px; PADDING-BOTTOM: 0px; MARGIN: 0px 0px 0.5em; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; FONT-SIZE: 13px; VERTICAL-ALIGN: baseline; BORDER-TOP: 0px; BORDER-RIGHT: 0px; PADDING-TOP: 0px"></P>
<P style="BORDER-BOTTOM: 0px; BORDER-LEFT: 0px; PADDING-BOTTOM: 0px; MARGIN: 0px 0px 0.5em; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; FONT-SIZE: 13px; VERTICAL-ALIGN: baseline; BORDER-TOP: 0px; BORDER-RIGHT: 0px; PADDING-TOP: 0px"></P>
<P style="BORDER-BOTTOM: 0px; BORDER-LEFT: 0px; PADDING-BOTTOM: 0px; MARGIN: 0px 0px 0.5em; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; FONT-SIZE: 13px; VERTICAL-ALIGN: baseline; BORDER-TOP: 0px; BORDER-RIGHT: 0px; PADDING-TOP: 0px"></P>
<P style="BORDER-BOTTOM: 0px; BORDER-LEFT: 0px; PADDING-BOTTOM: 0px; MARGIN: 0px 0px 0.5em; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; FONT-SIZE: 13px; VERTICAL-ALIGN: baseline; BORDER-TOP: 0px; BORDER-RIGHT: 0px; PADDING-TOP: 0px"></P></DIV> </div><div><SPAN style="TEXT-ALIGN: left; WIDOWS: 2; TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; DISPLAY: inline !important; FONT: 13px/17px arial, helvetica, clean, sans-serif; WHITE-SPACE: normal; ORPHANS: 2; FLOAT: none; LETTER-SPACING: normal; COLOR: rgb(0,0,0); WORD-SPACING: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"></SPAN> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20130431&edate=20130101&rec=7215">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-01-04T12:31:04+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-01-04T12:31:04+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category endocrinology > <![CDATA[Endocrinology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>New OAB Drug May Overcome Some Of The Limitations Of Existing Products</title>
	<pubDate>2013-01-04T12:20:54+01:00</pubDate>
	<wp:post_id>4266</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Theravida has announced positive results from a phII trial of its lead combination product (Tolenix) for iOAB.<wbr> Tolerix is a twice daily combination of tolteridine, a muscarinic antagonist commonly used to treat iOAB and pilocarpine, a muscarinic agonist approved to treat dry mouth, a common side-effect experienced with many existing OAB drugs.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Study Design &amp; Key Findings</STRONG> </div><div style="margin-bottom: 10px;">Patient receiving Tolenix (2mg tolterodine plus 9mg pilocarpine) experienced significant improvement in their OAB and urge incontinence symptoms compared to placebo.<wbr> Efficacy was similar in magnitude to Detrol (2mg tolterodine) administered alone.<wbr> However, patients receiving Tolenix exhibited no significant safety issues and clinically meaningful improvements in their saliva and dry mouth side effeccts compared to active control Detrol.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Potential For Greater Efficacy Associated With Higher Doses</STRONG> </div><div style="margin-bottom: 10px;">The phII study also demonstrated a favourable therapeutic index, which may enable higher dosing of Tolenix.<wbr> A higher dose study in a 12-week open label extension period demonstrated the ability to provide greater bladder control with minimal dry mouth side-effects.<wbr> </div><div>Tolenix is a new, patent-protected therapeutic combination that utilises a proprietary combination drug delivery technology.<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20130431&edate=20130101&rec=6729">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-01-04T12:20:54+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-01-04T12:20:54+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>re: Review - Novel Pathway for Somatostatin Analogs in Patients with Acromegaly</title>
	<pubDate>2013-01-04T10:30:23+01:00</pubDate>
	<wp:post_id>4267</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="border-left: 2px solid #8B1010; padding: 0px 0px 5px 12px; margin-bottom: 3px;"><span style="font-weight: bold; font-size: 14px;">re: Review - Novel Pathway for Somatostatin Analogs in Patients with Acromegaly</span>&nbsp;<br><span style="font-size: 12px;">Very interesting insights into MOA of SSA resistance and why patients with germline mutations in AIP are usually poorly-responsive to SSA therapy.<wbr> One of the authors (MK) very interested in exploring this further in ESS work that maybe worth following-up; potentially interesting research link too between Europe and Intercontinental medical personnel.<wbr></span>&nbsp;&nbsp;<a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20130431&edate=20130101&rec=7212">...</a><br></div><div>We are reviewing this area in research at the moment.<wbr> I caution against any approaches to MK at the present time.<wbr> </div><!-- Comment details --><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20130431&edate=20130101&rec=7214">Add a Comment on this Article</a><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7209">View thread  Endocrinology7209: Review - Novel Pathway for Somatostatin Analogs in Patients with Acromegaly</a>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-01-04T10:30:23+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-01-04T10:30:23+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category endocrinology > <![CDATA[Endocrinology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Promotion of AZ's Zoladex in France</title>
	<pubDate>2013-01-03T17:42:42+01:00</pubDate>
	<wp:post_id>4268</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Last week Pierre Fabre signed a 3-year agreement with AZ to exclusively promote Zoladex(R) in France.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">To leverage its uro-onco portfolio, and complement Permixon (for BPH), Ormandyl (similar to Casodex) and Javlor (for bladder cancer).<wbr> </div><div>Source: Pierre Fabre </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20130431&edate=20130101&rec=8703">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-01-03T17:42:42+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-01-03T17:42:42+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Biogen-Idec Drug Fails In PhIII ALS Study</title>
	<pubDate>2013-01-03T17:30:40+01:00</pubDate>
	<wp:post_id>4269</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Dexapramipexole, viewed as a potentially promising new approach for 
the debilitating neurological disorder ALS, failed to meet its primary endpoint 
in the PhIII EMPOWER study.<wbr> </div><div style="margin-bottom: 10px;">EMPOWER was a randomized, double-blind, placebo-controlled Phase 3 trial 
which enrolled 943 people with ALS at 81 sites in 11 countries.<wbr> Patients were 
randomized on a one-to-one basis to receive either dexpramipexole or placebo.<wbr> </div><div style="margin-bottom: 10px;">The trial did not meet its primary endpoint, a joint rank analysis of 
function and survival, and no efficacy was seen in the individual components of 
function or survival.<wbr> The trial also failed to show efficacy in its key 
secondary endpoints.<wbr> Additional analyses of multiple subpopulations failed to 
demonstrate any efficacy among these groups.<wbr> Based on these results, Biogen Idec 
will discontinue development of dexpramipexole in ALS.<wbr> </div><div style="margin-bottom: 10px;">Biogen in-licensed dexpramipexole from Knopp BioSciences in August 2010 
in a deal at the time worth $345m.<wbr> To date, we believe it has paid out $80, $60m 
in stock plus a $20m upfront payment.<wbr> The drug was poised to enter phIII at this 
point.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Biogen-Idec's Ongoing Commitment To ALS</STRONG> </div><div style="margin-bottom: 10px;">Biogen Idec has several programs underway in ALS.<wbr> The company recently 
entered into a research collaboration with <ORG>Duke University</ORG> and 
HudsonAlpha Institute to sequence the genomes of up to 1,000 people with ALS 
over the next five years in an effort to gain a deeper understanding about the 
fundamental genetic causes of the disease.<wbr> <ORG>Duke</ORG> and HudsonAlpha will 
work with several world-class researchers who have deep expertise and experience 
with ALS and the genes associated with the disease.<wbr> </div><div style="margin-bottom: 10px;">Biogen Idec recently created a research consortium in collaboration 
with several leading academic research centers to identify new approaches to 
treating ALS.<wbr> Each of the centers involved in this consortium brings different 
scientific and technical expertise and a shared goal of improving the 
understanding of ALS from a basic science perspective.<wbr> </div><div style="margin-bottom: 10px;">In addition, <ORG value="NASDAQ-NMS:BIIB">Biogen 
Idec</ORG> has committed significant funds to the <ORG>University of 
Massachusetts Medical School</ORG> ALS Champion Fund.<wbr> The funding will drive 
awareness of ALS and support basic and clinical science research into potential 
treatments for ALS and other neurodegenerative diseases </div><div>Source: <A href="http://www.biogenidec.com/">www.<wbr>biogenidec.<wbr>com</A> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20130431&edate=20130101&rec=6728">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-01-03T17:30:40+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-01-03T17:30:40+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Nexavar Meets Primary Endpoint In PhIII Thyroid Cancer Study</title>
	<pubDate>2013-01-03T17:10:41+01:00</pubDate>
	<wp:post_id>4270</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><U></U><U></U><U></U><U></U><U></U><U></U><U></U><U></U> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG><BR> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div>Source: <A href="http://www.bayer.com">www.<wbr>bayer.<wbr>com</A> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20130431&edate=20130101&rec=8701">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-01-03T17:10:41+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-01-03T17:10:41+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>re: Dicerna Achieves POP With Previously Non Druggable Target</title>
	<pubDate>2013-01-03T16:52:42+01:00</pubDate>
	<wp:post_id>4271</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="border-left: 2px solid #8B1010; padding: 0px 0px 5px 12px; margin-bottom: 3px;"><span style="font-weight: bold; font-size: 14px;">Dicerna Achieves POP With Previously Non Druggable Target</span>&nbsp;<br><span style="font-size: 12px;">Comment: Kyowa Hakko has agreed to advance its first oncology therapeutic candidate from basic research into development studies, triggering a $5 million milestone payment to its siRNA partner Dicerna.<wbr></span>&nbsp;&nbsp;<a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20130431&edate=20130101&rec=7970">...</a><br></div><div style="margin-bottom: 10px;">Kyowa Hakko Kirin Co.<wbr>, Ltd.<wbr> has elected to advance the 2nd therapeutic oncology candidate from the research to development stage.<wbr> The achievement of this milestone triggers a $5 million payment from KHK to Dicerna.<wbr> </div><div style="margin-bottom: 10px;">"The speed with which this second oncology program has moved from concept to development candidate is impressive.<wbr> Highly active DsiRNAs combined with KHK's proprietary lipid nanoparticle delivery technology can be validated <EM>in vivo</EM> in less than a year.<wbr>&rdquo; said Etsuo Ohshima, Ph.<wbr>D.<wbr>, managing officer and vice president, head, research division at KHK.<wbr> </div><div style="margin-bottom: 10px;">Along with Dicerna's own hepatocellular carcinoma program, the company now has 3 oncology candidates, all utilizing Dicerna's Dicer Substrate Technology&trade; (see <a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20130431&edate=20130101&rec=8476" class="defaultlink">Oncology8476: Dicerna Presents Positive HCC Preclinical Data At the ILCA Meeting</a>).<wbr> </div><div>Source: Dicerna </div><!-- Comment details --><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20130431&edate=20130101&rec=8700">Add a Comment on this Article</a><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology7970">View thread  Oncology7970: Dicerna Achieves POP With Previously Non Druggable Target</a>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-01-03T16:52:42+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-01-03T16:52:42+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>re: Review - Novel Pathway for Somatostatin Analogs in Patients with Acromegaly</title>
	<pubDate>2013-01-03T16:31:24+01:00</pubDate>
	<wp:post_id>4272</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="border-left: 2px solid #8B1010; padding: 0px 0px 5px 12px; margin-bottom: 3px;"><span style="font-weight: bold; font-size: 14px;">Review - Novel Pathway for Somatostatin Analogs in Patients with Acromegaly</span>&nbsp;<br><span style="font-size: 12px;">Comment: In a considerable percentage of patients with acromegaly, disease activity cannot be fully controlled with somatostatin analogs.<wbr> The mechanisms involved in SSA resistance are not completely understood.<wbr></span>&nbsp;&nbsp;<a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20130431&edate=20130101&rec=7209">...</a><br></div><div style="margin-bottom: 10px;">Very interesting insights into MOA of SSA resistance and why patients with germline mutations in AIP are usually poorly-responsive to SSA therapy.<wbr> One of the authors (MK) very interested in exploring this further in ESS work that maybe worth following-up; potentially interesting research link too between Europe and Intercontinental medical personnel.<wbr> </div><div style="margin-bottom: 10px;">In the meantime, proposal to retroactively examine samples collected in the Ipsen-sponsored Primary Medical Treatment Study (-207) for patients' AIP gene status and T2 MRI imaging currently under consideration.<wbr> </div><div>I wonder too if the emerging ZAC1 story in acromegaly suggests this disease could be an interesting target in the wider development programme for TASQ.<wbr> </div><!-- Comment details --><br><span style="font-weight: bold; font-style: italic;"><br>Comments</span><a name="Endocrinology7214c"></a><br><div style="border: 1px solid #AAA; background-color: #FFF; margin-left: 10px; padding: 5px;"><div>We are reviewing this area in research at the moment.<wbr> I caution against any approaches to MK at the present time.<wbr> </div></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20130431&edate=20130101&rec=7212">Add a Comment on this Article</a><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7209">View thread  Endocrinology7209: Review - Novel Pathway for Somatostatin Analogs in Patients with Acromegaly</a>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-01-03T16:31:24+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-01-03T16:31:24+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category endocrinology > <![CDATA[Endocrinology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Pfizer to Advance Repligen's Spinal Muscular Atrophy (SMA) Program</title>
	<pubDate>2013-01-03T16:31:06+01:00</pubDate>
	<wp:post_id>4273</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: The program includes RG3039, a small molecule in clinical development for SMA as well as backup compounds, and enabling technologies.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><STRONG>Financial</STRONG> </div><div style="margin-bottom: 10px;">Repligen is to receive &gt;$70M from Pfizer, commencing with an upfront payment of $5M </div><div style="margin-bottom: 10px;">Total potential future milestone payments &gt;$65M </div><div style="margin-bottom: 10px;"><STRONG>Drug Development</STRONG> </div><div style="margin-bottom: 10px;">Repligen is responsible for completing the first two cohorts of a Ph1 study evaluating RG3039 in healthy volunteers in Q1:13.<wbr> </div><div style="margin-bottom: 10px;">Families of SMA, a patient organization dedicated to funding research to advance therapies for SMA, funded and directed the PC development of RG3039 with an investment of more than $13M.<wbr> This was the first drug discovery program ever conducted specifically for SMA.<wbr> Repligen’s research and clinical efforts, including the current Ph1b trial, have been partially supported by a $1.<wbr>4M grant from the Muscular Dystrophy Association.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">RG3039 received US Orphan Drug and Fast Track designations for SMA as well as Orphan Medicinal Poduct designation in the EU.<wbr> </div><div>Source: Repligen </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20130431&edate=20130101&rec=6726">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-01-03T16:31:06+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-01-03T16:31:06+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>re: Endo Discontinues Second Ph3 Trial with Urocidin for Non-muscle Invasive Bladder Cancer</title>
	<pubDate>2013-01-03T14:53:50+01:00</pubDate>
	<wp:post_id>4274</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="border-left: 2px solid #8B1010; padding: 0px 0px 5px 12px; margin-bottom: 3px;"><span style="font-weight: bold; font-size: 14px;">Endo Discontinues Second Ph3 Trial with Urocidin for Non-muscle Invasive Bladder Cancer</span>&nbsp;<br><span style="font-size: 12px;">Comment: The trial, being run by Endo Pharm.<wbr>, has not been recruiting at the expected rate.<wbr> Endo and Bioniche are jointly considering potential next steps for the program in order to build on the outome of the first Ph3 and to continue to work toward regulatory approval.<wbr></span>&nbsp;&nbsp;<a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20130431&edate=20130101&rec=8572">...</a><br></div><div style="margin-bottom: 10px;"><SPAN style="widows: 2; text-transform: none; background-color: #ffffff; text-indent: 0px; display: inline !important; font: 14px/22px Helvetica, Arial, sans-serif; white-space: normal; orphans: 2; float: none; letter-spacing: normal; color: #1a1a1a; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;">Last week, Bioniche and Endo </SPAN><SPAN style="widows: 2; text-transform: none; background-color: #ffffff; text-indent: 0px; display: inline !important; font: 14px/22px Helvetica, Arial, sans-serif; white-space: normal; orphans: 2; float: none; letter-spacing: normal; color: #1a1a1a; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;">came to an agreement that a mutually favourable path forward for the product is to return global rights to Bioniche.<wbr> In exchange for this agreement, Endo will receive a royalty on future revenue.<wbr></SPAN> </div><div><SPAN style="widows: 2; text-transform: none; background-color: #ffffff; text-indent: 0px; display: inline !important; font: 14px/22px Helvetica, Arial, sans-serif; white-space: normal; orphans: 2; float: none; letter-spacing: normal; color: #1a1a1a; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;"><SPAN style="widows: 2; text-transform: none; background-color: #316632; text-indent: 0px; display: inline !important; font: 14px/22px Helvetica, Arial, sans-serif; white-space: normal; orphans: 2; float: none; letter-spacing: normal; color: #1a1a1a; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;"><SPAN style="background-color: #ffffff;">Bioniche now has the opportunity to seek alternate partnership arrangements, which would be expected to generate income to offset the costs of any additional clinical trial work required.<wbr></SPAN></SPAN></SPAN> </div><!-- Comment details --><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20130431&edate=20130101&rec=8699">Add a Comment on this Article</a><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology8572">View thread  Oncology8572: Endo Discontinues Second Ph3 Trial with Urocidin for Non-muscle Invasive Bladder Cancer</a>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-01-03T14:53:50+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-01-03T14:53:50+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>New Study Concludes Botox Induces Remission in Depression</title>
	<pubDate>2013-01-03T14:18:55+01:00</pubDate>
	<wp:post_id>4275</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: This second of Dr Finzi's studies comes to the conclusion that Botox relieved symptoms in more than a quarter of patients, compared to just 7% of those receiving placebo.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Recruitment: 84 people with severe depression (&gt; than an average of 2 years, and who had not fully responded to treatment with antidepressants).<wbr> </div><div style="margin-bottom: 10px;">Treatment: 29U of Botox to smooth frown lines or a placebo injection into the same facial region.<wbr> </div><div style="margin-bottom: 10px;">Assessment: at 3 weeks and at 6 weeks </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">In 2006 Dr Finzi and Dr Wasserman recruited 10 women (between 36 and 63) with a medical history of depression.<wbr> </div><div style="margin-bottom: 10px;">Patient description: Average period of depression was 3.<wbr>5 years although 1 patient had been ill for 17 years and had not responded well to conventional treatments.<wbr> </div><div style="margin-bottom: 10px;">7/<wbr>10 had been on anti-depressants, but continued to be dogged by severe depression before taking part in the trial.<wbr> </div><div style="margin-bottom: 10px;">Findings: 9/<wbr>10 were no longer clinical depressed and the one who still was reported a significant improvement in symptoms.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div>Dr Finzi is Medical Director at the Chevy Chase Cosmetic Cneter, in Maryland (USA).<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20130431&edate=20130101&rec=6725">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-01-03T14:18:55+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-01-03T14:18:55+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Novel Pathway May Promote Metastatic CRPC Through AR Signalling</title>
	<pubDate>2013-01-03T12:24:55+01:00</pubDate>
	<wp:post_id>4276</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;"><P style="TEXT-ALIGN: left; PADDING-BOTTOM: 5px; WIDOWS: 2; TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; MARGIN: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; FONT: 13px/15px Arial, Helvetica, sans-serif; WHITE-SPACE: normal; ORPHANS: 2; LETTER-SPACING: normal; COLOR: rgb(0,0,0); WORD-SPACING: 0px; PADDING-TOP: 5px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"></P> </div><div style="margin-bottom: 10px;"><P style="TEXT-ALIGN: left; PADDING-BOTTOM: 5px; WIDOWS: 2; TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; MARGIN: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; FONT: 13px/15px Arial, Helvetica, sans-serif; WHITE-SPACE: normal; ORPHANS: 2; LETTER-SPACING: normal; COLOR: rgb(0,0,0); WORD-SPACING: 0px; PADDING-TOP: 5px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"></P> </div><div style="margin-bottom: 10px;"><P style="TEXT-ALIGN: left; PADDING-BOTTOM: 5px; WIDOWS: 2; TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; MARGIN: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; FONT: 13px/15px Arial, Helvetica, sans-serif; WHITE-SPACE: normal; ORPHANS: 2; LETTER-SPACING: normal; COLOR: rgb(0,0,0); WORD-SPACING: 0px; PADDING-TOP: 5px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"></P> </div><div style="margin-bottom: 10px;"><P style="TEXT-ALIGN: left; PADDING-BOTTOM: 5px; WIDOWS: 2; TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; MARGIN: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; FONT: 13px/15px Arial, Helvetica, sans-serif; WHITE-SPACE: normal; ORPHANS: 2; LETTER-SPACING: normal; COLOR: rgb(0,0,0); WORD-SPACING: 0px; PADDING-TOP: 5px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"></P> </div><div style="margin-bottom: 10px;"><P style="TEXT-ALIGN: left; PADDING-BOTTOM: 5px; WIDOWS: 2; TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; MARGIN: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; FONT: 13px/15px Arial, Helvetica, sans-serif; WHITE-SPACE: normal; ORPHANS: 2; LETTER-SPACING: normal; COLOR: rgb(0,0,0); WORD-SPACING: 0px; PADDING-TOP: 5px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"></P> </div><div style="margin-bottom: 10px;"><P style="TEXT-ALIGN: left; PADDING-BOTTOM: 5px; WIDOWS: 2; TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; MARGIN: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; FONT: 13px/15px Arial, Helvetica, sans-serif; WHITE-SPACE: normal; ORPHANS: 2; LETTER-SPACING: normal; COLOR: rgb(0,0,0); WORD-SPACING: 0px; PADDING-TOP: 5px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"></P> </div><div style="margin-bottom: 10px;"><P style="TEXT-ALIGN: left; PADDING-BOTTOM: 5px; WIDOWS: 2; TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; MARGIN: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; FONT: 13px/15px Arial, Helvetica, sans-serif; WHITE-SPACE: normal; ORPHANS: 2; LETTER-SPACING: normal; COLOR: rgb(0,0,0); WORD-SPACING: 0px; PADDING-TOP: 5px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"></P> </div><div style="margin-bottom: 10px;"><P style="TEXT-ALIGN: left; PADDING-BOTTOM: 5px; WIDOWS: 2; TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; MARGIN: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; FONT: 13px/15px Arial, Helvetica, sans-serif; WHITE-SPACE: normal; ORPHANS: 2; LETTER-SPACING: normal; COLOR: rgb(0,0,0); WORD-SPACING: 0px; PADDING-TOP: 5px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"></P> </div><div><P style="TEXT-ALIGN: left; PADDING-BOTTOM: 5px; WIDOWS: 2; TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; MARGIN: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; FONT: 13px/15px Arial, Helvetica, sans-serif; WHITE-SPACE: normal; ORPHANS: 2; LETTER-SPACING: normal; COLOR: rgb(0,0,0); WORD-SPACING: 0px; PADDING-TOP: 5px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"></P> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20130431&edate=20130101&rec=8693">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-01-03T12:24:55+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-01-03T12:24:55+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>MedyTox' Growth Drivers for 2013</title>
	<pubDate>2013-01-03T12:14:57+01:00</pubDate>
	<wp:post_id>4277</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: A recent report from Woorin investment outlines that exports of Meditoxin (for cosmetic use) to Russia is likely to emerge in Q2:13.<wbr> Ph2 trial of next generation Meditoxin was completed on December 14th in Australia.<wbr> The company may plan to either pursue a licensing out deal with multinational pharmas based in the US and EU or opt to internally carry out the Ph3 trials.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Exports to Brazil and Japan and increasing exports to Thailand and Hong Kong to increase 47,7%.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Domestic and Export Sales Trend</STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6723_1_ScreenCapture1.jpg"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Analysts expect the company to sign technology export contracts with "a combined 4 drug makers in the US and EU".<wbr> </div><div>Anticipating commissions and royalty payments, MedyTox is to experience strong earnings in H1:13.<wbr> </div><!-- Comment details --><a name="neurology6723attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_6723_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(31,4 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20130431&edate=20130101&rec=6723">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-01-03T12:14:57+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-01-03T12:14:57+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>NPS Sets Price for Newly Approved Gattex</title>
	<pubDate>2013-01-03T11:45:07+01:00</pubDate>
	<wp:post_id>4278</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;"><SPAN style="WIDOWS: 2; TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; DISPLAY: inline !important; FONT: 13px arial, sans-serif; WHITE-SPACE: normal; ORPHANS: 2; FLOAT: none; LETTER-SPACING: normal; COLOR: rgb(34,34,34); WORD-SPACING: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px">Comment: 
NPS has set the annual list price for its short bowel syndrome (SBS) 
drug </SPAN>Gattex<SPAN style="WIDOWS: 2; TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; DISPLAY: inline !important; FONT: 13px arial, sans-serif; WHITE-SPACE: normal; ORPHANS: 2; FLOAT: none; LETTER-SPACING: normal; COLOR: rgb(34,34,34); WORD-SPACING: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"> teduglutide at $295,000 (well in excess 
of consensus).<wbr> The company, which plans to launch the Orphan drug in February, 
said it has identified more than 1,000 patients who are eligible for Gattex and 
expects to have 200-300 patients on the drug by the end of 2013.<wbr> </SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="WIDOWS: 2; TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; DISPLAY: inline !important; FONT: 13px arial, sans-serif; WHITE-SPACE: normal; ORPHANS: 2; FLOAT: none; LETTER-SPACING: normal; COLOR: rgb(34,34,34); WORD-SPACING: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px">NPS's 
estimates of prevalence of 3000-5000 patients is lower than some previous 
estimates of 10-15,000 but its price is considerably higher.<wbr> It 
expects payers to provide broad access to Gattex" and now estimates peak 
revenues will be "well in excess of" its previous estimate of $350 million.<wbr> In 
late December, FDA approved the analog of </SPAN>glucagon-like peptide-2 
(GLP-2)<SPAN style="WIDOWS: 2; TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; DISPLAY: inline !important; FONT: 13px arial, sans-serif; WHITE-SPACE: normal; ORPHANS: 2; FLOAT: none; LETTER-SPACING: normal; COLOR: rgb(34,34,34); WORD-SPACING: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"> to treat adults with SBS who are 
dependent on parenteral support.<wbr> </SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="WIDOWS: 2; TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; DISPLAY: inline !important; FONT: 13px arial, sans-serif; WHITE-SPACE: normal; ORPHANS: 2; FLOAT: none; LETTER-SPACING: normal; COLOR: rgb(34,34,34); WORD-SPACING: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"><STRONG>Sales 
Expectations</STRONG></SPAN> </div><div style="margin-bottom: 10px;">Analysts expect the launch take-off to be gradual as patients who are stably 
treated with home parenteral nutrition typically see a gastroenterologists 
annually, along with reimbursement approval typically taking 90-120 days and a 
requirement for a colonoscopy prior to the start of Gattex therapy, </div><div style="margin-bottom: 10px;">Accordingly Wedbush securties has adjusted its revenue estimated to $15.<wbr>2m, 
$97M, $212m and $312m in years 2013-2016 from $21.<wbr>6m, $68m, $145m and $211m.<wbr>.<wbr> It 
has modeled the launch on a similar ultra-rare orphan drug launch such as 
Myozyme.<wbr> </div><div style="margin-bottom: 10px;">Tedglutide ia already approved in Europe and will be marketed in this region 
by Takeda that gained access to the drug through its acquisition of Nycomed.<wbr> </div><div><SPAN style="WIDOWS: 2; TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; DISPLAY: inline !important; FONT: 13px arial, sans-serif; WHITE-SPACE: normal; ORPHANS: 2; FLOAT: none; LETTER-SPACING: normal; COLOR: rgb(34,34,34); WORD-SPACING: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px">Source: 
<A href="http://www.nps.com/">www.<wbr>nps.<wbr>com</A></SPAN> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20130431&edate=20130101&rec=7210">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-01-03T11:45:07+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-01-03T11:45:07+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category endocrinology > <![CDATA[Endocrinology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>New Formulation of Dr Falk 's Mesalazine for Ulcerative Colitis</title>
	<pubDate>2013-01-02T17:37:39+01:00</pubDate>
	<wp:post_id>4279</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Clinicaltrials.<wbr>gov is listing a new Ph3 study to assess whether TID 1000mg mesalazine is non-inferior to TID 2x500mg for acute UC.<wbr> Primary endpoint will evaluate rate of clinical remission at 8 wks compared to baseline.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG><A href="http://clinicaltrials.gov/ct2/show/NCT01745770?recr=Open&amp;no_unk=Y&amp;phase=012&amp;fund=2&amp;rcv_s=12%2F02%2F2012&amp;rank=107"><STRONG></STRONG></A> </div><div style="margin-bottom: 10px;">Recruitment: approx.<wbr> 400 </div><div style="margin-bottom: 10px;">Start date: Dec 2012 - Completion: June 2014 </div><div style="margin-bottom: 10px;">PI: Axel Dignass, Prof.<wbr> Dr.<wbr> </div><div>Location: Germany (1) </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20130431&edate=20130101&rec=1869">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-01-02T17:37:39+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-01-02T17:37:39+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category gastroenterology > <![CDATA[gastroenterology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>POC Trial of Zytiga (Abiraterone) in Japan for CRPC</title>
	<pubDate>2013-01-02T17:30:25+01:00</pubDate>
	<wp:post_id>4280</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Clinicaltrials.<wbr>gov is listing a Ph2 study evaluating safety and efficacy of abiraterone in Japanse patients with mCRPC, and who have not received prior chemotherapy.<wbr> Primary endpoint will assess percentage of participants achieving PSA response up to 12wks.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG><A href="http://clinicaltrials.gov/ct2/show/NCT01756638?recr=Open&amp;no_unk=Y&amp;phase=012&amp;fund=2&amp;rcv_s=12%2F02%2F2012&amp;rank=73"><STRONG></STRONG></A> </div><div style="margin-bottom: 10px;">Recruitment: approx.<wbr> 45 </div><div style="margin-bottom: 10px;">Completion date: Sept 2014 </div><div style="margin-bottom: 10px;">Location: &gt;20 sites (Jpn) </div><div style="margin-bottom: 10px;">The study consists of 3 phases: </div><div><UL><LI>Screening phase (consists of 14 days before study commences on Day -1); </LI>
<LI>Treatment phase (consists of 28-daily dosing cycles wherein abiraterone 1000 milligram [mg] once daily along with 5 mg prednisolone twice daily will be given until disease progression or unacceptable toxicity is observed); </LI>
<LI>Follow-up phase (up to 5 years or until survival after the first dose of study drug).<wbr></LI>
</UL> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20130431&edate=20130101&rec=8690">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-01-02T17:30:25+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-01-02T17:30:25+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Swedish TLV and Janssen-Cilag Reach Risk-Sharing Agreement for Zytiga</title>
	<pubDate>2013-01-02T17:15:58+01:00</pubDate>
	<wp:post_id>4281</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;">.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20130431&edate=20130101&rec=8689">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-01-02T17:15:58+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-01-02T17:15:58+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Review - Novel Pathway for Somatostatin Analogs in Patients with Acromegaly</title>
	<pubDate>2013-01-02T16:47:31+01:00</pubDate>
	<wp:post_id>4282</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: In a considerable percentage of patients with acromegaly, disease activity cannot be fully controlled with somatostatin analogs.<wbr> The mechanisms involved in SSA resistance are not completely understood.<wbr> </div><div style="margin-bottom: 10px;">Patients with <EM>AIP</EM> germline mutations or patients with somatotropinomas with low AIP protein expression typically show a poor response to SSA therapy.<wbr> SSAs increase AIP and ZAC1 mRNA and protein expression.<wbr> These data suggest that AIP and ZAC1 play important roles in the SSTRs signaling cascade.<wbr> Further deciphering these molecular pathways, including studies with novel SSAs such as pasireotide, which exhibit a different affinity profile for the SSTRs, will provide a better understanding of the mechanism of action of this class of drugs, and will have important therapeutic implications.<wbr> </div><div style="margin-bottom: 10px;">Link to full text: (Ipsen subscription) <a href="http://www.sciencedirect.com/science/article/pii/S1043276012002172" class="defaultlink" title="http://www.sciencedirect.com/science/article/pii/S1043276012002172">sciencedirect.com&hellip;</a> </div><div>Source:  <A href="http://www.ncbi.nlm.nih.gov/pubmed/23270713?dopt=Abstract" title="Trends in endocrinology and metabolism: TEM."><SPAN style="color: #000000;">Trends Endocrinol Metab</SPAN>.<wbr></A> 2012 Dec 25 </div><!-- Comment details --><span style="font-weight: bold; font-style: italic;"><br>Comments</span><a name="Endocrinology7212c"></a><br><div style="border: 1px solid #AAA; background-color: #FFF; margin-left: 10px; padding: 5px;"><div style="margin-bottom: 10px;">Very interesting insights into MOA of SSA resistance and why patients with germline mutations in AIP are usually poorly-responsive to SSA therapy.<wbr> One of the authors (MK) very interested in exploring this further in ESS work that maybe worth following-up; potentially interesting research link too between Europe and Intercontinental medical personnel.<wbr> </div><div style="margin-bottom: 10px;">In the meantime, proposal to retroactively examine samples collected in the Ipsen-sponsored Primary Medical Treatment Study (-207) for patients' AIP gene status and T2 MRI imaging currently under consideration.<wbr> </div><div>I wonder too if the emerging ZAC1 story in acromegaly suggests this disease could be an interesting target in the wider development programme for TASQ.<wbr> </div><span style="font-weight: bold; font-style: italic;"></span><a name="Endocrinology7214c"></a><br><div style="border: 1px solid #AAA; background-color: #FFF; margin-left: 10px; padding: 5px;"><div>We are reviewing this area in research at the moment.<wbr> I caution against any approaches to MK at the present time.<wbr> </div></div></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20130431&edate=20130101&rec=7209">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-01-02T16:47:31+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-01-02T16:47:31+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category endocrinology > <![CDATA[Endocrinology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>re: Proteologics Reports Progress in Research Collaboration with Teva</title>
	<pubDate>2013-01-02T13:37:06+01:00</pubDate>
	<wp:post_id>4283</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="border-left: 2px solid #8B1010; padding: 0px 0px 5px 12px; margin-bottom: 3px;"><span style="font-weight: bold; font-size: 14px;">Proteologics Reports Progress in Research Collaboration with Teva</span>&nbsp;<br><span style="font-size: 12px;"> 
Comment: Proteologics and Teva partner in two independent, yet complementary projects, focusing on specific components of the <U>ubiquitin system</U>.<wbr> Specific components of the ubiqutin pathway, such as E3's, are believed to offer novel targets for cancer, viral diseases, and CNS related pathologies</span>&nbsp;&nbsp;<a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20130431&edate=20130101&rec=3042">...</a><br></div><div style="margin-bottom: 10px;">Following Teva's decision to refocus R&amp;D on branded specialty drugs for CNS and respiratory diseases as well ascomplex and combination generics called new therapeutic entities (NTEs), the company will return rights to 3 compounds in PC development for cancer and inflammation to Proteologics.<wbr> </div><div>Last November, Teva sold its 31.<wbr>5% stake in Proteologics.<wbr> </div><!-- Comment details --><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20130431&edate=20130101&rec=8688">Add a Comment on this Article</a><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology3042">View thread  Oncology3042: Proteologics Reports Progress in Research Collaboration with Teva</a>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-01-02T13:37:06+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-01-02T13:37:06+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>re: Novel medicines approved in 2012</title>
	<pubDate>2013-01-02T08:54:18+01:00</pubDate>
	<wp:post_id>4284</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="border-left: 2px solid #8B1010; padding: 0px 0px 5px 12px; margin-bottom: 3px;"><span style="font-weight: bold; font-size: 14px;">Novel medicines approved in 2012</span>&nbsp;<br><span style="font-size: 12px;">Comment : in a recent report issued by the Food and Drug Administration (FDA) &ldquo;<A href="http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Reports/UCM330859.pdf">Fiscal Year 2012 Innovative Drug Approvals</A>,&rdquo; the agency highlighted 35 new drug approvals.<wbr>  This marks the second year in a row where FDA has issued 35 approvals and continues the trend of more annual approvals than in years past.<wbr></span>&nbsp;&nbsp;<a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20130431&edate=20130101&rec=10267">...</a><br></div><div style="margin-bottom: 10px;">I just put a focus in Oncology.<wbr> FDA uses a range of tools to expedite the development, review, and approval of the most promising new therapies.<wbr> These tools include Fast Track, Priority Review, and Accelerated Approval.<wbr> For 2012, in oncology, 8 drugs (listed below) were approved as Fast Track drugs.<wbr> </div><div><OL start="1"><LI>Erivedge (vismodegib)for late-stage skin cancer            Hedgehog inhibitor
</LI>
<LI>Xtandi (enzalutamide) for late-stage prostate cancer   Androgen inhibitor
</LI>
<LI>Jakafi (ruxolitinib) for myelofibrosis                                      Janus Associated Kinase (JAK) inhibitor
</LI>
<LI>Voraxaze (glucarpidase) to lower toxic levels of the chemotherapy drug methotrexate
</LI>
<LI>Erwinaze (asparaginase erwinia chrysthemi) for acute leukemia
</LI>
<LI>Stivarga (reborafenib) for late-stage colorectal cancer A multi-kinase inhibitor
</LI>
<LI>Perjeta (pertuzumab) for late-stage breast cancer        Anti HER2 inhibitor
</LI>
<LI>Bosulif (bosutinib) for chronic leukemia
</LI>
</OL> </div><!-- Comment details --><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20130431&edate=20130101&rec=10269">Add a Comment on this Article</a><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10267">View thread  PharmaWorld10267: Novel medicines approved in 2012</a>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-01-02T08:54:18+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-01-02T08:54:18+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category pharma-news > <![CDATA[Pharma News]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	

</channel>
</rss>
